
<html lang="en"     class="pb-page"  data-request-id="f9242d9f-745d-4cf8-a691-58fc2dd2c9b9"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/jm8010542;issue:issue:10.1021/jmcmar.2009.52.issue-6"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies" /></meta><meta name="dc.Creator" content="Jack A.  Bikker" /></meta><meta name="dc.Creator" content="Natasja  Brooijmans" /></meta><meta name="dc.Creator" content="Allan  Wissner" /></meta><meta name="dc.Creator" content="Tarek S.  Mansour" /></meta><meta name="dc.Publisher" content=" American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 24, 2009" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm8010542" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2009 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm8010542" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm8010542" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm8010542" /></link>
        
    
    

<title>Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm8010542" /></meta><meta property="og:title" content="Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies" /></meta><meta property="og:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta property="og:description" content="" /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm8010542"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm8010542">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm8010542&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm8010542&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm8010542&amp;href=/doi/10.1021/jm8010542" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2009</span><span class="cit-fg-volume">, 52</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 1493-1509</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/52/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm801627a" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jack+A.++Bikker">Jack A. Bikker</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Natasja++Brooijmans">Natasja Brooijmans</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Allan++Wissner">Allan Wissner</a></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tarek+S.++Mansour">Tarek S. Mansour</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info"><span class="aff-text">Chemical Sciences, Wyeth Research, 401 North Middletown Road, Pearl River, New York 10965</span></div><div class="corresp-info"><strong>*</strong> To whom correspondence should be addressed. Telephone: 845 602 8819. Facsimile: 845 602 5682. E-mail: <a href="/cdn-cgi/l/email-protection#23414a484846514963545a46574b0d404c4e"><span class="__cf_email__" data-cfemail="ddbfb4b6b6b8afb79daaa4b8a9b5f3beb2b0">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm8010542&amp;href=/doi/10.1021%2Fjm8010542" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2009</span></span><span class="cit-volume">, 52</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 1493â1509</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 24, 2009</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 August 2008</li><li><span class="item_label"><b>Published</b> online</span>24 February 2009</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 March 2009</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm8010542" title="DOI URL">https://doi.org/10.1021/jm8010542</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2009 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1493%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJack%2BA.%2BBikker%252C%2BNatasja%2BBrooijmans%252C%2BAllan%2BWissner%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D52%26issueNum%3D6%26contentID%3Djm8010542%26title%3DKinase%2BDomain%2BMutations%2Bin%2BCancer%253A%2BImplications%2Bfor%2BSmall%2BMolecule%2BDrug%2BDesign%2BStrategies%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1509%26publicationDate%3DMarch%2B2009">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm8010542"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">7485</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">124</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm8010542" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jack&quot;,&quot;last_name&quot;:&quot;A. Bikker&quot;},{&quot;first_name&quot;:&quot;Natasja&quot;,&quot;last_name&quot;:&quot;Brooijmans&quot;},{&quot;first_name&quot;:&quot;Allan&quot;,&quot;last_name&quot;:&quot;Wissner&quot;},{&quot;first_name&quot;:&quot;Tarek&quot;,&quot;last_name&quot;:&quot;S. Mansour&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2009&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;52&quot;,&quot;pages&quot;:&quot;1493-1509&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm8010542&quot;},&quot;abstract&quot;:&quot;&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm8010542&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm8010542" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm8010542&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm8010542" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm8010542&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm8010542" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm8010542&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm8010542&amp;href=/doi/10.1021/jm8010542" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm8010542" /></input><a href="/doi/pdf/10.1021/jm8010542" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DBikker%26date%3D2009%26atitle%3DKinase%2BDomain%2BMutations%2Bin%2BCancer%253A%2BImplications%2Bfor%2BSmall%2BMolecule%2BDrug%2BDesign%2BStrategies%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D52%26issue%3D6%26spage%3D1493%26epage%3D1509%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/52/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction to Kinases and Kinase Inhibition</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07440" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07440" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Kinases have emerged as ubiquitous but highly challenging targets for drug discovery. The human genome has 518 kinases<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and many of these play critical roles in cell growth and apoptosis, making them interesting drug targets for oncology. Kinase targets including epidermal growth factor receptor (EGFR<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a>), <div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: Abl, Abelson kinase; AML, Acute Myeloid Leukemia; AMP-PNP, 5â²-adenylyl-Î²,Î³-imidodiphosphate; ATP, adenosine triphosphate; Bcr-Abl, breakpoint cluster regionâAbelson kinase; EGF(R), epidermal growth factor (receptor); CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CMPD, chronic myeloproliferative disorders; DFSP, dermatofibrossarcoma protruberans; Erb-B1/2/3/4, erythroblastic leukemia viral oncogene homologue 1/2/3/4; Erb-B1 is synonymous with EGFR and HER-1; GIST, gastroInstestinal stromal tumor; HER-1/2/3/4, human EGF receptor-1/2/3/4; HES, hypereosinophilic syndrome; NSCLC, non-small-cell lung cancer; PDGF(R), platelet derived growth factor (receptor); PKA, protein kinase A; SMCD, systemic mast cell disease; VEGF(R), vascular endothelial growth factor (receptor); WT, wild type.</p></div> Raf, Src, and breakpoint cluster regionâAbelsonâs kinase (bcr-Abl) emerged early in the study of oncogenic proteins.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Despite years of effort involving a compelling breadth of accumulated preclinical design experience (reviewed extensively by Liao and Andrews<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a>) and clinical experience (reviewed by LaRusso and Eder <a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a>), relatively few kinase inhibitors have been approved (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). As an additional complication, clinical use of these inhibitors has led to the emergence of drug resistant tumors.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5-8)</a> In many patients, response to small molecule kinase inhibitors has been followed by tumor resurgence, which rendered these inhibitors less effective than expected. This resistance has been linked to a number of mechanisms that include the amplification of the oncogenic kinase gene<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and alternative signaling pathways or plasticity in signaling.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, in many instances, resistance has been traced to individual or groups of mutations in the drug targets that make the tumors unresponsive in the clinic. These mutants alter the binding properties of the drugs as shown by in vitro studies.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> When viewed across multiple cancer targets, the location of these mutations forms a compelling pattern with a number of common mechanisms elucidated with reference to this pattern. Significantly, recent characterization of mutations in the EGFR kinase has included structural and kinetic studies that have challenged assumptions about how individual drug resistance mutants are understood and to what extent mechanisms can be generalized across kinases by homology alone. This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clinical mutations, and review the emerging understanding of their impact based on sequence homology, protein crystal complexes, and biochemical/biophysical information. Underlying this discussion is our appreciation that the current clinical arsenal of small molecule kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Kinase Inhibitors Approved for Use in the U.S. as of August 2008</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead valign="bottom"><tr valign="top"><th align="left" valign="bottom">U.S. brand name</th><th align="left" valign="bottom">year approved</th><th align="left" valign="bottom">generic name</th><th align="left" valign="bottom">U.S. FDA-approved indications</th><th align="left" valign="bottom">company</th><th align="left" valign="bottom">target kinases</th></tr></thead><tbody><tr valign="top"><td align="left">Gleevec</td><td align="left">2001</td><td align="left">imatinib mesylate</td><td align="left">chronic myeloid leukemia (CML)</td><td align="left">Novartis</td><td align="left">Abl, c-Kit, PDGFRa, PDGFRb</td></tr><tr valign="top"><td align="left">Iressa</td><td align="left">2003</td><td align="left">gefitinib</td><td align="left">oncology, non-small-cell lung cancers (NSCLC)</td><td align="left">AstraZeneca</td><td align="left">EGFR</td></tr><tr valign="top"><td align="left">Tarceva</td><td align="left">2004</td><td align="left">erlotinib</td><td align="left">NSCLC, pancreatic cancers</td><td align="left">Genentech, OSIP</td><td align="left">EGFR</td></tr><tr valign="top"><td align="left">Nexavar</td><td align="left">2005</td><td align="left">sorafenib tosylate</td><td align="left">hepatocellular carcinoma, renal cell carcinoma</td><td align="left">Bayer and Onyx</td><td align="left">Raf, VEGFR2, VEGFR3, c-Kit, PDFGRb</td></tr><tr valign="top"><td align="left">Sutent</td><td align="left">2006</td><td align="left">sunitinib malate</td><td align="left">gastrointestinal stromal tumor (GIST),ârenal cell carcinoma</td><td align="left">Pfizer</td><td align="left">c-Kit, VEGFR, PDGFR, FLT3</td></tr><tr valign="top"><td align="left">Sprycel</td><td align="left">2006</td><td align="left">dasatinib</td><td align="left">CML (especially imatinib-resistant)</td><td align="left">Bristol-Myers Squibb</td><td align="left">Abl, c-Kit, PDGFR, Src</td></tr><tr valign="top"><td align="left">Tasigna</td><td align="left">2007</td><td align="left">nilotinib</td><td align="left">CML (imatinib resistant and intolerant)</td><td align="left">Novartis</td><td align="left">Abl, c-Kit, PDGFRb, Src, Ephthrin</td></tr><tr valign="top"><td align="left">Tykerb</td><td align="left">2007</td><td align="left">lapatinib</td><td align="left">breast cancer</td><td align="left">GlaxoSmithKline</td><td align="left">EGFR, Her-2</td></tr></tbody></table></div></div><div class="NLM_p">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> provides a list of kinase inhibitors approved to date for various cancer indications within the U.S. Since 2001, eight inhibitors targeted to the kinase catalytic domain have been approved for clinical use led by imatinib mesylate for chronic myeloid leukemia (CML).<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> CML has been traced to the effect of a characteristic mutation in which part of the breakpoint cluster region (BCR) gene was spliced into the Abelson kinase (Abl) gene creating a hybrid BCR-Abl gene. Known as the âPhiladelphia chromosomeâ, the splice occurs upstream of the kinase domain. Nevertheless, pathway inhibition, by imatinib treatment (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), provides a significant benefit to patients until the emergence of resistant tumor strains. Gene sequencing efforts on the resulting resistant tumors identified a number of mutations, many in the kinase domain, which reduced the effectiveness of imatinib. Two additional drugs, nilotinib and dasatinib, have since been approved specifically for imatinib-resistant or unresponsive tumors in CML. The history of the development and spectrum of the activity of current inhibitors, including those now in clinical trials, have been the subject of several recent reviews.<a onclick="showRef(event, 'ref11 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref11 ref13 ref14 ref15">(11, 13-15)</a></div><figure id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of kinase inhibitors marketed in the U.S. as of August 2008.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second and third kinase inhibitors to be approved for clinical use were gefitinib and erlotinib, two inhibitors of EGFR kinase (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). These drugs worked remarkably well in a subpopulation of patients with non-small-cell lung cancer (NSCLC) harboring activating mutations.<a onclick="showRef(event, 'ref7 ref16 ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref7 ref16 ref17 ref18 ref19 ref20 ref21 ref22">(7, 16-22)</a> Unfortunately, drug resistant tumors often emerged within a year or so of initiating treatment. In 2007, a third inhibitor, lapatinib (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), was approved for use in breast cancer in combination with a cytotoxic agent; lapatinib is a dual inhibitor of both EGFR and human EGF receptor-2(HER-2) kinases.</div><div class="NLM_p">The other class of clinically approved inhibitors targets multiple kinases associated with angiogenesis and has a broader spectrum of inhibition against such tyrosine kinases (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Sorafenib inhibits multiple vascular endothelial growth factor (VEGF) receptor kinases, platelet derived growth factor (PDGF) receptor kinases, the mast-stem cell growth factor receptor (c-KIT) kinase, and the proto-oncogene c-Raf kinase at clinically relevant concentrations. Sunitinib inhibits VEGF and PDGF receptor kinases, as well as c-Kit and FL tyrosine kinase 3 (Flt3). These drugs are expected to be effective by arresting the development of blood supplies to the growing tumors, in addition to specifically blocking an oncogenic kinase within a tumor type (e.g., c-Kit).<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23-25)</a></div><div class="NLM_p">The story of the development of these kinase inhibitors is partly the story of the discovery and progressive exploitation of multiple conformational states of the kinases. Early on, selectivity was identified as a challenge when designing inhibitors that bound at the adenosine triphosphate (ATP) pocket. Since ATP is a cofactor that is essential to kinase function, evolutionary pressure has been exerted to maintain a general common shape and chemical similarity to its binding site in different kinases. Because of this, drug design efforts have sought to exploit regions of the active site that are not directly involved in ATP binding, or conformations of the kinase that show greater structural and chemical heterogeneity. The opportunity to exploit conformational heterogeneity is a consequence of the activation and inactivation mechanisms of kinases. As the inactive form of the kinase does not have to obey the requirement of binding to the common substrate ATP, greater structural variation has been observed in the inactive states of kinases. Notably, imatinib, the first kinase inhibitor to make it to market, binds to an inactive form of the Abl, c-Kit, and PDGF kinases.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">The clinical experiences with the kinase inhibitors, particularly in terms of patient response and resistance to drugs, have stimulated vigorous efforts in search of solutions that will aid in the design of the next generation of inhibitors. Resistance to inhibitors is expected to occur because of several mechanisms including gene amplification<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> or mutations in the kinase domain, which include specific mutations in amino acid residues or deletions of certain sequences. From a technical drug design perspective, this aspect represents a remarkable opportunity to design compounds with enhanced biological properties, but its complexity from a practical point of view is substantial. Underlying this complexity are the effects of mutations in the kinase domain on ATP affinity, catalytic activity, and (global) dynamic effects on kinase structures (active vs inactive forms) in addition to effects on the binding site character, (local) movement of amino acid residues, and nature of key interactions with the protein. Chemists have to integrate multidimensional information from various sources to develop design strategies for the next generation of drugs having enhanced properties over current compounds.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Kinase Activation Relevant to the Design of Clinical Inhibitors: DFG Motif Dynamics</h3><div class="NLM_p">Kinases control and amplify intracellular signals by the selective phosphorylation of residues on other proteins, often other kinases, or even the same kinase. Upon activation, the kinase binds ATP and the terminal phosphate group of ATP is abstracted and subsequently transferred to the substrate. Kinases share a characteristic ATP-binding structure shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. The kinase or catalytic domain consists of an N-terminal lobe, which consists mainly of Î² strands but contains one Î± helix, helix C. The C-terminal lobe is mainly Î±-helical in nature, and a short strand termed the hinge region connects the two lobes. The ATP binding site is sandwiched between the lobes where ATP forms critical hydrogen bonding interactions to the hinge region. The P-loop (or phosphate-binding loop or glycine-rich loop), with the sequence of G-X-G-X-X-G, plays a large role in the dynamics of the kinase domain where its conformation is a determining factor in the shape of the ATP-binding site (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). In the active kinase, a characteristic Asp-Phe-Gly motif (DFG motif), which is located immediately before the activation loop, adopts a conformation with the Asp and Phe both oriented toward the binding site (DFG-in) (Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>a).</div><figure id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of Abl in the active form bound to dasatinib (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GQG">2GQG</a>.pdb) in ribbon depiction. The top part, mostly in white, is the N-terminal lobe. The C-terminal lobe at the bottom is shown in yellow. The hinge region connecting the two lobes is colored orange, and dashed yellow lines show the hydrogen-bonding interactions of dasatinib to the hinge region. Also shown is the hydrogen bond of the inhibitor to the gatekeeper residue Thr315 (magenta carbons). Helix C at the back of the binding site is colored green, and the P loop is shown in purple. The activation loop (pink) and the DFG motif (red) are fully resolved in this structure. The catalytic lysine (cyan carbons) is in proximity to the glutamic acid (white carbons) from helix C, allowing the formation of a salt bridge, as expected in the active form.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding site comparisons of active and inactive forms of different kinases. (a) The Abl active form in complex with dasatinib (2GQG.pdb). The phenylalanine of the DFG motif (green carbons) is shown to point away from the binding site and is buried in the interior of the protein. (b) The Abl DFG-out inactive form in complex with imatinib (1IEP.pdb). The phenylalanine of the DFG motif is shown in pink carbons and points into the binding pocket. (c) Rotation of â¼90 degrees of (b) to highlight the depth of the DFG-out pocket (surface representation). (d) Helix-C-out inactive form of EGFR (1XKK.pdb). The catalytic lysine (cyan carbons) is far removed from Helix Câs glutamic acid (white carbons). (e) Helix-C movement from active (cyan helix) to inactive form (green helix) from an overlay of the Abl (2GQG.pdb, helix in) and EGFR (1XKK.pdb, helix out). (a)â(c) show the catalytic lysine (cyan carbons) and the salt bridge formed with the glutamic acid from Helix C (white carbons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Whereas the active form of the kinase catalytic domain is fairly homogeneous structurally, determined by the requirement to be able to bind ATP, the inactive forms are less so. Different inactive states have been identified, which can be related to the mechanism of activation of the kinase.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> One of these states is often called the âDFG-outâ state and is associated with kinases that activate by phosphorylation of residues on the activation loop. In the DFG-out state, the phenylalanine of the DFG motif is positioned in the ATP-binding site so that it effectively blocks ATP access to its binding site (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>b). Phosphorylation of tyrosine, threonine, or serine residues of the activation loop by another kinase is incompatible with this conformation and subsequently leads to activation. Phosphorylation can occur because the activation loop can act as a substrate to other kinases or can even be phosphorylated autocatalytically.</div><div class="NLM_p">Crystal structures of kinases in the DFG-out conformation have been solved for Abl, c-Kit, IRK, Flt3, CSK, Raf, and P38.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> This state is a key target of drug design for these kinases. Kinase inhibitors that bind to the active form of the kinase are often called type I inhibitors, and those that bind to the inactive form of the kinase are called type II inhibitors.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> According to this classification, dasatinib is a type I inhibitor and imatinib and nilotinib are clinical type II inhibitors.</div><div class="NLM_p">In the past year, several NMR studies of kinase catalytic domains have been reported in the literature. Studies of protein kinase A (PKA) with addition of the nonhydrolyzable ATP analogue AMP-PNP and a peptide substrate highlighted the areas that undergo conformational changes upon binding of ATP and substrate. Interestingly, it was shown that the DFG region accesses multiple conformational states, presumably âflippingâ from DFG-in to DFG-out, in the presence of AMP-PNP and with both AMP-PNP and peptide substrate bound. X-ray crystallography studies of PKA showed a single conformation for this region.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> NMR studies of Abl in complex with type I and type II inhibitors highlighted conformational differences in the DFG region and the activation loop in complex with these different types of inhibitors. The mechanism of inhibition of imatinib and nilotinib (type II) and dasatinib (type I) could be assigned unambiguously on the basis of the NMR data.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In contrast to the PKA NMR studies highlighted above,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> the DFG region was fully resolved in all three Abl complexes and thus resides in a single conformation.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The Abl NMR studies with PD-180970<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> (<b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), a type I inhibitor, highlight that X-ray crystallography can trap protein conformations that are not highly populated in solution.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig6" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Preclinical and clinical phase inhibitors of bcr-Abl.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Kinase Activation Relevant to the Design of Clinical Inhibitors: C-Helix Dynamics</h3><div class="NLM_p">A second inactive form of the kinase, most commonly associated with EGFR, retains the general DFG-in form but leads to inactivation by rotating and shifting the C-helix out (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>dâe).<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> Different activation mechanisms have been associated with the helix-C-out inactive conformation. In c-Src, activation is effected by phosphorylation of a tyrosine in the activation loop, in much the same way as phosphorylation of Abl destabilized the DFG-out inactive form. In CDK2, binding of the protein cyclin to the kinase appears to be the key event effecting activation. In EGFR, the formation of an asymmetric kinase domain homo- or heterodimer upon the extracellular binding of EGF leads to kinase activation.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> Although EGFR family kinases have a tyrosine in the activation loop that gets phosphorylated, this does not appear to be necessary for activation.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The C-helix-out form of the kinase has been shown to bind lapatinib<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and the clinical candidate <b>8</b> (neratinib, HKI-272, Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><figure id="fig8" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Preclinical and clinical investigational inhibitors of EGFR kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The C-helix-out inactive form can alter the nature of the ATP binding site. Upon rotation of helix C in EGFR, a conserved glutamic acid points toward solvent rather than toward the ATP binding site (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>d). This conformation disrupts a salt bridge between the glutamic acid and the conserved catalytic lysine residue. This salt bridge is key in positioning the Î± and Î² phosphate groups of ATP and is thus critical for catalytic activity. The C-helix motion also appears to draw the P-loop down to further close the ATP binding cleft (compare Figures <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). Key structural changes associated with the movement from C-helix-out inactive form to the active form are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>d and Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>e. Crystal structures of EGFR bound to ATP analogues in the DFG-in/C-helix-out conformation have been solved for EGFR.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This opens the possibility that this state may be ATP-bound under normal conditions.</div><figure id="fig9" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Protein crystallographic complex of EGFR in the active form with gefitinib (<a href="https://" class="ext-link">2ITY</a>.pdb). The central ring interacts with Met 793 of the hinge (gray carbons) with a single hydrogen bond. The DFG motif is shown in pink carbons. The locations of key mutant residues are shown. Glycine 719 (green carbons) lies in the P-loop, and Thr 790 (gatekeeper, magenta carbons) forms part of the binding pocket. Leu 858, which is part of the activation loop (cyan carbons), does not interact with the inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A number of recent studies have suggested that these inactive states may not be mutually exclusive. A C-helix-out conformation of an inhibitor bound to Abl has been solved.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Conversely, a crystal structure of c-Src bound to a close analogue of imatinib in a DFG-out inactive conformation has also been solved.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The authors of this latter study, however, note that achieving this conformation appears to come at a substantial thermodynamic penalty, reflected in inhibitor potency, that cannot be attributed to the effect of individual amino acid changes. Overall, these observations provide insight into the dynamics of kinases. The value of different structural forms from a drug design perspective is unknown, as the thermodynamic penalties associated with these atypical states could be substantial and might therefore not be effective targets for inhibition.</div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Emergence of Drug Resistance</h3><div class="NLM_p">The emergence of drug resistant tumors was an unwelcome addition to the already substantial challenges to kinase drug discovery. Kinases were expected to be difficult targets partly because the conservation of shape and character of the ATP binding site posed a selectivity issue and partly because the high endogenous concentration of ATP suggested that inhibitors would have to be very potent to succeed clinically. Notably, after the first kinase inhibitors were used clinically, it became clear that various amino acid mutations, some in the kinase domain, could lead to drug resistance.<a onclick="showRef(event, 'ref5 ref18 ref19 ref38'); return false;" href="javascript:void(0);" class="ref ref5 ref18 ref19 ref38">(5, 18, 19, 38)</a> Since then, overcoming drug resistance has become a defining challenge of kinase drug discovery to existing targets. Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> shows an alignment of parts of the sequences of kinases that are relevant to the action of kinase inhibitors in clinical use and onto which the location of key mutations have been mapped. Repeating patterns of mutations appear at the activation loop, at the P-loop, and at the âgatekeeperâ residue within the ATP binding sites. Individual kinases have additional mutations that appear at unique locations, most of which can result in alterations of ligand binding or kinase activation. The emergence of crystallographic data for complexes of key proteinâligand pairs with mutations in Abl<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39-41)</a> and EGFR<a onclick="showRef(event, 'ref33 ref42'); return false;" href="javascript:void(0);" class="ref ref33 ref42">(33, 42)</a> has helped interpretation of the consequences of these mutants.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0001.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinase domain mutations identified in EGFR, ABL, and PDGF and c-Kit. Mutants that activate the kinase or cause resistance by activating the kinase are shown in magenta. Mutants that lead to resistance either directly or in conjunction with an activating mutant are shown in bold blue. Although not directly linked to resistance mutations, activating mutations of b-Raf are also shown emphasizing the patterns arising in the resistance mutants.<a onclick="showRef(event, 'ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref114 ref115">(114, 115)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Some general trends are evident. Mutations in the P-loop and activation loop destabilize inactive forms of the kinases in favor of active states. In this way, they reduce or eliminate binding of inhibitors targeted at the inactive forms of the kinases. This mechanism of drug resistance is equivalent to the effect of oncogenic activating mutations (cf. c-Kit<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and PDGFR <a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a>). The effects of a number of mutations can also be rationalized by their direct action on ligand binding within the ATP-binding cleft or occupation of additional accessible space in the inactive form of the kinase. Most notable of this type of mutation is that of the gatekeeper threonine in Bcr-Abl and c-Kit, which confer resistance to imatinib. This has been rationalized as a direct loss of a critical hydrogen bond to the ligand (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>b). An intriguing exception to this pattern occurs in EGFR kinase, in which mutation of the gatekeeper residue appears to restore ATP affinity lost because of co-occurring activating mutations.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">2 Protein Structural Interpretation of Drug Resistant Mutations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85226" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85226" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">How much do we now understand about the key mutations in various kinases? In this section, the key resistance mutations of the kinase targets relevant to the current clinical drugs will be described. Where possible, the effect of the mutation on ligand binding will be discussed on the basis of crystallography and, if available, biochemical studies. Important clinical candidates that appear to overcome known resistant mutants will also be identified. Together, this information points toward strategies that might overcome known resistant mutants and anticipated resistance mutations that could emerge for new inhibitors and targets as a consequence of clinical use.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> BCR-Abl</h3><div class="NLM_p">The approval of imatinib (Gleevec, STI-571) in 2001 was a major breakthrough not only in the treatment of CML but also for cancer therapeutics in general. Imatinib was the first targeted cancer therapy to enter the clinic that specifically inhibited the kinase domain of the BCR-Abl oncogene. Despite the initial success of imatinib treatment, most patients will eventually develop resistance. Dozens of clinical mutations in the kinase domain of this enzyme have been described.<a onclick="showRef(event, 'ref46 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref48 ref49">(46-49)</a> The most commonly observed mutations are T315I, E255K, and M351T, which account for more than 60% of the cases (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).<a onclick="showRef(event, 'ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref49 ref50 ref51">(49-51)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Partial List of Observed Resistance Mutations, Their Location, and the Mechanism of Resistance in Bcr-Abl, cKIT, PDGFR, and EGFR</div></div></div><div class="scrollable-table-wrap"><table class="table frame_topbot"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead valign="middle"><tr valign="top"><th align="left" valign="middle">Â </th><th align="left" valign="middle">mechanism</th><th align="left" valign="middle">Bcr-Abl</th><th align="left" valign="middle">cKIT</th><th align="left" valign="middle">PDGFR</th><th align="left" valign="middle">EGFR</th></tr></thead><tbody><tr valign="top"><td align="left" valign="top">P-loop</td><td align="left" valign="top">activating</td><td align="left" valign="top">L248V/R, G250E, Q252H/R,âââââY253H/F, E255K/V</td><td align="left" valign="top">Â </td><td align="left" valign="top">Â </td><td align="left" valign="top">G719S</td></tr><tr valign="top"><td align="left" valign="top">gatekeeper</td><td align="left" valign="top">direct except for EGFR</td><td align="left" valign="top">T315I/F/D/N</td><td align="left" valign="top">T670I/E</td><td align="left" valign="top">T674I</td><td align="left" valign="top">T790M</td></tr><tr valign="top"><td align="left" valign="top">binding site</td><td align="left" valign="top">direct</td><td align="left" valign="top">F317L, G321W</td><td align="left" valign="top">V654A</td><td align="left" valign="top">Â </td><td align="left" valign="top">Â </td></tr><tr valign="top"><td align="left" valign="top">hydrophobic pocket</td><td align="left" valign="top">direct</td><td align="left" valign="top">M351T, F359V</td><td align="left" valign="top">Â </td><td align="left" valign="top">Â </td><td align="left" valign="top">Â </td></tr><tr valign="top"><td align="left" valign="top">activation loop</td><td align="left" valign="top">activating</td><td align="left" valign="top">L387M, H396P/R</td><td align="left" valign="top">D816E, D820Y/E,âââââN822Y/K, Y823D</td><td align="left" valign="top">D842V, D846Y</td><td align="left" valign="top">L858R</td></tr><tr valign="top"><td align="left" valign="top">deletion mutationsâââââaround helix C</td><td align="left" valign="top">activating</td><td align="left" valign="top">Â </td><td align="left" valign="top">Â </td><td align="left" valign="top">Â </td><td align="left" valign="top">E746, L747, R748, E749,âââââA750, T751, S752</td></tr></tbody></table></div></div><div class="NLM_p">Imatinib was shown by X-ray crystallography to inhibit Abl kinase by binding to the DFG-out form of the kinase domain.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The observed relapse of CML patients undergoing treatment with imatinib can be ascribed to two main groups of mutations, namely, those that directly affect binding of imatinib to Abl and those that have an indirect binding effect. The latter mutations are thought to change the dynamics of the kinase domain in such a manner that the inactive, DFG-out, form is destabilized, resulting in a loss of affinity of imatinib for Abl (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>a).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Close-up of binding site of Abl bound to imatinib (<a href="https://" class="ext-link">1IEP</a>.pdb). Hydrogen bonding interactions of imatinib to the hinge region (Met 318 in gray carbons) and T315 (magenta carbons) are indicated. Several drug-resistant mutation sites are shown. Gly321, in the front of the binding, is shown in purple carbons, and the P-loop residue L248 is shown in orange carbons. Also shown is Glu255 (cyan carbons) and its proximity to Lys247 (magenta carbons) and Tyr 257 (white carbons). (b) Close-up of the hydrophobic enclosure of imatinib (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>.pdb). The hinge-region hydrogen bond to Met 318 is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> BCR-Abl Mutations That Affect the Gatekeeper and Hydrophobic Region</h4><div class="NLM_p">Mutations that directly affect the affinity of imatinib for Abl are the T315I/D/N, F317L, and G321W mutations. Mutations of Tyr 253 and Phe 359 probably have both a direct and an indirect effect on imatinib binding to Abl.</div><div class="NLM_p">The residue Thr 315 in Abl is the so-called gatekeeper residue. The size of the residue at this position in kinases determines how easily the hydrophobic pocket behind it can be accessed, especially in the active form (DFG-in). In the case of imatinib binding, the hydroxyl group of Thr 315 forms a hydrogen bond to the amine linker between the pyrimidine and phenyl rings of imatinib. Mutation of the threonine thus results in a loss of this hydrogen bonding interaction, while the larger sizes of the residues at this position (isoleucine, aspartic acid, and asparagine) also result in steric clashes, preventing imatinib from binding to mutant Abl strutures (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>a). Recent mutagenesis studies showed that gatekeeper mutations in Abl, PDGFRA, PDGFRB, EGFR, and Src have increased activity and can transform BaF3 cells to become independent of IL-3 signaling for survival.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The increased activity is attributed to a strengthening of the âhydrophobic spineâ, which is a conserved feature of active kinases and is disrupted in inactive kinases.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The increase in activity can clearly further contribute to drug resistance.</div><div class="NLM_p">The side chain of Phe 317, which is part of the hinge region, effectively forms the roof of the ATP binding site near the hinge region in the area where the critical hydrogen bonding interactions to the hinge region backbone are formed. The side chain shields the hinge region from solvent. This can be illustrated using the hydrophobic enclosure term of the Glide XP scoring function as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>b.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The role of this residue in forming a hydrophobic environment around the hinge region is further supported by an analysis of residue conservation at this position in â¼480 kinases (alignments available at <a href="http://kinase.com" class="extLink">kinase.com</a>). In â¼300 kinases, an aromatic residue (Tyr, Phe, His, Trp) can be found at this position (62%) while small hydrophobic residues such as Ala, Ile, and Val are only found â¼15 times (3%). Leucine is found in 25% of the kinases at this position, indicating that its packing properties are similar to those of tyrosine and phenylalanine in the context of the hinge region.</div><div class="NLM_p">Similarly, Phe 359 forms the back of the DFG-out binding pocket and mutating it to a smaller, hydrophobic residue could also influence binding although the distance between Phe 359 and the inhibitor is beyond the van der Waals interaction sphere (â¼4.5 Ã). It is possible that a mutation at this position also influences the dynamics of the region.</div><div class="NLM_p">The CÎ± atom of Gly 321 in wild type (WT) Abl is 3.8 Ã removed from the pyridine ring of imatinib (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>a). Mutation to a larger residue such as tryptophan (G321W) would thus result in a direct clash with imatinib, resulting in loss of binding of imatinib to this mutant.</div><div class="NLM_p">Tyrosine 253 in WT Abl presents a polar hydroxyl group to a region with a backbone-NH and an asparagine residue (distances 3.6 and 3.2 Ã, respectively). The aromatic ring is 3.5â4.5 Ã removed from the pyridineâpyrimidine rings of imatinib, possibly forming ÏâÏ interactions. Both of these features likely play a role in binding, as mutations to phenylalanine result in loss of binding, as does mutation to histidine. In addition, this residue is part of the glycine-rich loop and the changes in the dynamics of the glycine-rich loop may play a significant role in the dynamics of the protein and the accessibility of the DFG-out vs DFG-in conformation of the catalytic domain.</div><div class="NLM_p">Additional P-loop mutations have been observed at Gly 250, Gln 252, and Tyr 253. These are likely to affect the dynamics of the loop considerably, resulting in a different equilibrium between the active and inactive forms of the protein.</div><div class="NLM_p">Leucine 248 in resistant tumors has been mutated to both a smaller residue (valine) and a larger one (arginine). The smaller residue may result in loss of binding due to a loss of van der Waals interactions with imatinib, while the larger residue will result in a significant clash with the pyridine ring (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>a).</div><div class="NLM_p">The E255K/V mutation probably influences the dynamics of the kinase catalytic domain. This residue is located directly after the glycine-rich loop. The glutamic acid side chain is placed within hydrogen-bonding distance of a hydroxyl group (from Tyr 257) and a charged nitrogen atom (from Lys 247). Mutating this residue to a lysine or valine will surely disrupt this network of hydrogen bonds (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>a).</div><div class="NLM_p last">In summary, a large number of clinical mutations have been observed in response to imatinib treatment in CML. Some of these mutations appear to directly affect the binding of imatinib to Abl. However, most of these mutations decrease the occupation of the DFG-out form of the protein, which is the conformation of the protein that imatinib preferentially binds to. The shift of equilibrium away from this state is believed to be the key determinant of the loss in binding.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> BCR-Abl Recent Clinical Candidates Demonstrating Drug Design Concepts To Circumvent Resistance</h4><div class="NLM_p">Since the development of imatinib, several new drugs have been developed that target Abl. The main goal of developing these additional drugs was to obtain greater efficacy, especially against the observed clinical mutations that confer resistance. Various mutant kinases can still bind imatinib with only a moderate loss in affinity of 10- to 30-fold, namely, those with Q252H, Y253F, M351T, F359V, or H396P mutations. The E255K mutation more severely affects imatinib inhibition of Abl, with a change in IC<sub>50</sub> of 50-fold. The most severe losses in drug affinity are observed with the gatekeeper mutations T315I (3000-fold loss) and T315N (IC<sub>50</sub> > 10 Î¼M).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Not surprisingly, the mutations with the greatest losses in potency have also been observed most frequently in patients who developed drug resistance on imatinib treatment.</div><div class="NLM_p">Dasatinib maintains potent inhibition against most clinical mutations that are resistant to imatinib inhibition. This is possibly a consequence of the fact that it inhibits the DFG-in, or active, form of the Abl kinase, and many of the mutations are thought to destabilize the inactive form in favor of the active form of the kinase. Unfortunately, dasatinib is also highly sensitive to mutations of the gatekeeper residue, resulting in 80-fold (T315N) and 1200-fold (T315I) losses in potency, respectively.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Upon examination of the structure of dasatinib in complex with Abl the loss in potency upon gatekeeper residue mutation is not very surprising, as the inhibitor forms a hydrogen-bonding interaction with the threonine hydroxyl group (Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>a).</div><div class="NLM_p">Nilotinib is structurally related to imatinib but is 30 times more potent than imatinib against cell lines expressing wild type Abl and mutated Abl.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57, 58)</a> Nilotinib forms the same hydrogen bonding interaction with the gatekeeper residue as imatinib and consequently shares its susceptibility to the T315I mutation. Significantly, this is the only imatinib-resistant mutant that is not inhibited by nilotinib.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57, 58)</a></div><div class="NLM_p">Although the marketed Abl inhibitors target different structural forms of the enzyme, none of them are able to inhibit the T315I mutant form of the enzyme, and thus, drug resistance is still a problem for CML patients. Current Abl inhibitors all form a hydrogen-bonding interaction with the threonine side chain of the gatekeeper residue, and thus, an obvious strategy to overcome resistance would be to develop inhibitors that do not interact with the gatekeeper residue at all. Early proof-of-concept was provided by modifying <b>2 (</b>AP23464, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) and removing the substituent that interacts with the region near the gatekeeper residue.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Although AP23846 (<b>3</b>) was less potent at inhibiting WT Abl, it did retain activity against the T315I mutant while <b>2</b> lost potency by more than 100-fold.</div><div class="NLM_p">Further evidence of this strategy is provided by <b>4</b> (SGX70393 or SGX393;<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> undisclosed structure), which was described to have inhibitory activity against the T315I and other imatinib-resistant mutations in vitro and in mouse xenograft models. In addition, combination of <b>4</b> with nilotinib or dastinib completely repressed the emergence of known resistant clones in vitro.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Some insight into the binding is offered by cocrystal structures of <b>5</b> (PPY-A, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) available with both WT and T315I Abl. <a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> This compound has been identified as an analogue of <b>4</b>. These structures show that the compound is 3 Ã or more removed from the gatekeeper residue in either WT or the T315 mutant (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). Similarly, VX-680 (or MK-0457, <b>6</b>), originally developed as an Aurora kinase inhibitor,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> also does not interact with the gatekeeper residue of Abl and has been shown in vitro<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> and clinically<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> to maintain activity against the imatinib-resistant T315I mutant.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Crystal structure of an analogue of <b>4</b> in complex with Abl, highlighting its distance from the gatekeeper residue T315 (magenta carbons, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QOH">2QOH</a>.pdb) and the Ile 315 mutant (cyan carbons, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z60">2Z60</a>.pdb).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">An alternative strategy to overcome drug resistance would be the development of non-ATP competitive Abl inhibitors. ON012380 (<b>7</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) has been described to inhibit 16 imatinib-resistant mutants in an in vitro setting.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> No loss in potency was observed for inhibition of any of the mutant enzymes compared to the WT enzyme. Further experiments showed that this compound is not-ATP competitive but rather substrate competitive.</div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> c-Kit</h3><div class="NLM_p">Expression of c-Kit, a receptor tyrosine kinase, occurs in 90% of gastrointestinal stromal tumors (GISTs).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> In most cases of GIST, c-Kit exhibits activating mutations.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Until recently, the only treatment option was surgery, as GISTs do not respond to chemotherapy or radiation therapy. Upon identification of c-Kit as a molecular target of imatinib, the effect of imatinib on GIST was tested and a positive response was shown.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Subsequent clinical trials<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67, 68)</a> led to FDA approval of imatinib in unresectable and/or metastatic GISTs.</div><div class="NLM_p">X-ray crystallographic studies have shown that imatinib inhibits c-Kit by interacting with the DFG-out, inactive, form of the kinase. This is analogous to the mode of inhibition observed for imatinib with Abl.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> As observed with CML patients, patients undergoing imatinib treatment for GIST eventually become resistant because of secondary mutations in c-Kit.</div><div class="NLM_p">Over 10 imatinib-resistant mutations of 6 residues in the kinase domain have been described so far (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).<a onclick="showRef(event, 'ref70 ref71 ref72 ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref70 ref71 ref72 ref73 ref74">(70-74)</a> Two of the observed mutations correspond to similar resistance mutants in Abl (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Only two of the mutations in c-Kit are in proximity to the inhibitor and can influence the binding affinity directly, namely, T670I/E and V654A. Threonine 670 (Thr 315 in Abl) is the gatekeeper residue and forms a hydrogen bond with imatinib, which is lost upon mutation. As in Abl, this gatekeeper mutation leads to a complete loss of inhibition by imatinib.<a onclick="showRef(event, 'ref56 ref75'); return false;" href="javascript:void(0);" class="ref ref56 ref75">(56, 75)</a> Another common mutation in c-Kit is V654A, which is conserved in Abl (V299) but has not been observed to be mutated in imatinib-resistant CML. The valine side chain is â¼4 Ã from imatinib, and mutation to alanine possibly leads to a less snug fit of the inhibitor resulting in resistance.</div><div class="NLM_p">Other mutations mainly occur in the activation loop (D816E/H, D820V/Y/E, N822Y/K, Y823D) and are likely to increase the propensity of the enzyme to reside in the active form. The activation loop mutation at position 816 has a counterpart in Abl (Leu 387 in Abl). Both D816E and D816H are activating mutations, which have been linked to being the molecular cause of cancers such as acute myelogenous leukemia (AML)<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and systemic mast cell disease (SMCD).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Mutation of Tyr 823 is possibly activating as well, as this is the tyrosine that is phosphorylated upon activation.</div><div class="NLM_p last">Similar to observations in Abl, dasatinib is more potent in WT c-Kit and several of the imatinib-resistant mutations. However, 1000-fold in potency is lost in the gatekeeper T670I mutant.<a onclick="showRef(event, 'ref56 ref75'); return false;" href="javascript:void(0);" class="ref ref56 ref75">(56, 75)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> PDGFR</h3><div class="NLM_p">While PDGFR plays a role in the development and maintenance of cancer because of its role in blood vessel growth, the validity of PDGFR as a drug target itself is unclear, as it is not usually the main factor in tumor development. However, there are several cancers that are more closely linked to up-regulation of PDGFR, namely, chronic myelomonocytic leukemia (CMML), GIST (when c-Kit mutations have not been observed), AML, chronic myeloproliferative disorders (CMPD), and dermatofibrossarcoma protruberans (DFSP), a soft tissue sarcoma. In some of these cancers, imatinib treatment has been successful, as it was shown that imatinib inhibits PDGFR at low-nanomolar concentrations.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77, 78)</a></div><div class="NLM_p">Different PDFGR fusion proteins are the underlying cause of DFSP<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79, 80)</a> and CMML.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81, 82)</a> Clinical application of imatinib in patients with these cancers has resulted in responses that validate PDFGR as a target in these diseases and other cancers that are PDGFR-driven.<a onclick="showRef(event, 'ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref83 ref84 ref85">(83-85)</a></div><div class="NLM_p">While imatinib is effective in certain PDGFR-driven cancers, several known oncogenic mutations are resistant to imatinib treatment. The observed PDGFR mutations D842V and D846Y are equivalent to the cKIT D816E/H and D820V/Y mutations. These mutations are in the activation loop of the catalytic domain and lead to constitutively active kinases.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> This suggests that imatinib inhibits PDGFR by the same mechanism as it inhibits Abl, namely, by binding to the inactive form of the kinase. To this date, no crystal structures of PDGFR have appeared in the public domain.</div><div class="NLM_p last">Targeted therapies such as imatinib can also be used to help further the understanding of cancers for which the molecular basis is unknown. For example, patients with hypereosinophilic syndrome (HES) showed dramatic clinical responses to imatinib treatment.<a onclick="showRef(event, 'ref86 ref87 ref88 ref89 ref90 ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref86 ref87 ref88 ref89 ref90 ref91 ref92">(86-92)</a> Later it was shown that a PDGFRÎ± fusion protein underlies HES and that the fusion protein is indeed inhibited by imatinib.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Patients who developed resistance were shown to carry a mutation at T674I, which is equivalent to the T315I mutation in Abl.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> EGFR</h3><div class="NLM_p">The EGFR receptors have been oncology targets since the early days of kinase drug discovery. The epidermal growth factor (EGF) controls a pathway that is linked to cell proliferation, migration, and differentiation. The EGFR family of receptors contains four known members: EGFR-1 (later referred to as EGFR; also known as erythroblastic leukemia viral oncogene homologue 1, Erb-B1, or human EGF receptor HER-1), HER-2 (Erb-B2, also neurogliobastoma neu), HER-3 (Erb-B3), and HER-4 (Erb-B4). Of these, HER-2 lacks a known endogenous ligand and HER-3 lacks kinase activity.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Aberrant activity, either by overexpression or constitutive activation, has been linked to a number of cancers, including lung, breast (especially HER-2/neu), and prostate cancers. Over the past decade extensive research, recently aided by inhibitors and crystallographic information, has progressively built a model of how the EGF signaling cascade operates.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Two drugs (erlotinib and gefitinib) have been approved for clinical use, both of which are designed to interact with the active form of the kinase. In 2007, lapatinib, a highly selective inhibitor of EGFR and HER-2, which binds the C-helix-out inactive form, was approved for breast cancer. Another generation of inhibitors, currently undergoing clinical trials, includes neratinib (<b>8</b>), pelitinib (<b>9</b>), canertinib (<b>10</b>), and BIBW-2992 (<b>11</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>).</div><div id="sec2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Clinical Mutations Affecting Inhibitor Binding</h4><div class="NLM_p">During clinical trials of getitinib and erlotinib for NSCLC, it was apparent that only a subset of the patient population with tumors showed a significant response to these drugs.<a onclick="showRef(event, 'ref7 ref8 ref17 ref18 ref19 ref21 ref22 ref38 ref95'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref17 ref18 ref19 ref21 ref22 ref38 ref95">(7, 8, 17-19, 21, 22, 38, 95)</a> In one study with gefitinib, tumors from 119 patients with NSCLC were sequenced.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Two point mutations in the kinase domain, G719S and L858R, located in the P-loop and activation loop, respectively, were observed (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The somatic origin of these mutations was confirmed by sequencing normal lung tissue from the same patients. In addition, a number of deletion mutations in the region of residues 746â759 of the kinase domain were found. Analysis of the clinical data suggested that these mutations are activating, and patients harboring these mutations were more likely to respond to treatment with gefitinib. Similar conclusions were obtained in an analogous study.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Significantly, the enzymes with the L858R and G719S substitution mutations are both catalytically competent and are actually more active than the wild-type enzyme by 50- and 20-fold, respectively.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p">The activating mutations, G719S and L858R, occur in the kinase domain regions that are critical to the binding of inhibitors. Kinetic parameters for ATP and a peptide substrate (poly-Glu<sub>4</sub>Tyr<sub>1</sub>) were measured in several assays for these mutants and the wild type enzyme. A comparison of the catalytic rate constants <i>k</i><sub>cat</sub> indicated that the L858R mutant is approximately 50-fold more active than the WT enzyme and that the G719S mutant is about 10-fold more active than WT. This greater activity of both the L858R and G719S mutants suggests a role of these activating mutations in shifting the conformation of the enzyme toward the active form.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Despite the enhancement of enzymatic activity of the L858R mutant, its apparent affinity for ATP as measured by the MichaelisâMenten constant <i>K</i><sub>m</sub> is reduced about 28-fold in comparison to the WT enzyme. This finding suggests that the L858R mutant is more easily inhibited by ATP-competitive inhibitors.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Thus, erlotinib and gefitinib succeed because the affinity for ATP is compromised by these mutations.</div><div class="NLM_p">While substantial efforts have focused on understanding the relationship between ATP affinity and activity of mutant enzymes, kinetic data on mutant enzymes with peptide substrates have been limited to the L858R and G719S mutants. It is not surprising that the <i>K</i><sub>m</sub> value (443 Î¼M) for the peptide substrate in the L858R mutant is about half that of the WT enzyme, since this residue lies in proximity to the peptide substrate binding site.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In contrast the substrate <i>K</i><sub>m</sub> value for the G719S mutant is similar to that of the WT enzyme.</div><div class="NLM_p">In addition to the activating mutations discovered during clinical trials, another substitution mutation was uncovered by analysis of biopsies taken from NSCLC patients who initially responded to treatment with gefitinib or erlotinib but who later developed drug resistance.<a onclick="showRef(event, 'ref7 ref96'); return false;" href="javascript:void(0);" class="ref ref7 ref96">(7, 96)</a> Sequencing of the EGFR gene showed drug resistance was the result of the additional mutation of the gatekeeper threonine at position 790 to methionine (T790M). This mutation has been observed to occur concurrently with either the activating deletion mutants<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> or the substitution L858R mutation.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><div class="NLM_p">The role of the T790M secondary mutation in drug resistance was elucidated on the basis of enzyme kinetics measurements complementing structural findings with inhibitors.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In this case, the <i>K</i><sub>m</sub> value for the T790M mutant does not significantly affect ATP affinity but activates the kinase about 5-fold in comparison to the WT enzyme.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> These findings regarding ATP affinity and catalytic competency of the T790M mutant are in contrast to those of the L858R mutant and do not suggest any preference for the active or inactive conformation of the kinase. Indeed, two reported cocrystal structures of <b>12</b> (AEE788, Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>)<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and <b>8</b><a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> bound to the T790M mutant were found in the active and inactive forms, respectively, supporting this conclusion. The <i>K</i><sub>m</sub> values for ATP in the WT (5.2 Î¼M) and in the drug-resistant L858R/T790M double mutant (8.4 Î¼M) are somewhat similar. However, the <i>K</i><sub>m</sub> value in the double mutant is 17-fold lower than in the single L858R mutant (148 Î¼M). These data suggest a key role for the T790M mutation in restoring the ATP affinity back to the WT enzyme. Of interest is that the L858R/T790M mutant is also 10-fold more active than the WT enzyme and â¼5-fold more active than the L858R mutant based on a comparison of the specificity constant <i>k</i><sub>cat</sub>/<i>K</i><sub>m</sub> values.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p last">The sensitivity of kinases to reversible TKIs is greatly influenced by the affinity of the inhibitors for the enzyme, since these inhibitors must compete with high concentrations of ATP for binding in the cell. The binding of gefitinib to the L858R mutant (<i>K</i><sub>d</sub> = 2.4 nM) is 15-fold stronger than its binding to WT enzyme (<i>K</i><sub>d</sub> = 35.3 nM). Gefitinib also retains good binding affinity to the L858R/T790M double mutant (<i>K</i><sub>d</sub> = 10.9 nM). These data suggest that the clinically observed resistance of the L858R/T790M mutant is largely due to its enhanced affinity for ATP.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> EGFR Crystallography and Modeling</h4><div class="NLM_p">Considerable insight into the structural effect of mutations on the binding of inhibitors and ATP-like molecules has been provided by research undertaken by the Kuriyan<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> and Eck<a onclick="showRef(event, 'ref7 ref33 ref42'); return false;" href="javascript:void(0);" class="ref ref7 ref33 ref42">(7, 33, 42)</a> laboratories, which has recently been reviewed. <a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><div class="NLM_p">Crystal structures of EGFR in complex with the marketed drugs erlotinib<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> and gefitinib<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> both show the kinase in its active form. Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a> shows the location of bound gefitinib, as well as the relative disposition of the residues that confers resistance or oncogenic mutations. The inhibitor binds in the ATP cleft and accepts a key hydrogen bond from the backbone NH of Met 793. The 3-chloro-4-fluorophenyl group extends to a region adjacent to the catalytic lysine, making what appears to be van der Waals contacts to adjacent residues. With minor variations, other noncovalent inhibitors (such as erlotinib and <b>12</b>) share the same binding mode, location, and interactions, including the hydrogen bond to the bridging water.</div><div class="NLM_p">Lapatinib binds to the C-helix-out inactive form of the kinase (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In this inactive form, Leu 858 is oriented into the binding cleft and forms part of the binding site. The C-helix shifts outward, opening additional space that is filled by the extended benzyloxy group on the inhibitor. The P-loop also moves closer to the binding site and forms additional contacts to the inhibitor. A crystal structure of this inactive form that binds ATP conjugated with a peptide in the substrate pocket has also been solved,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and this structure is essentially identical to the complex with lapatinib.</div><figure id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Lapatinib bound to the C-helix-out inactive form of EGFR kinase (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>.pdb). Threonine 790 (magenta carbons) makes a favorable interaction with the fluorophenyl group of the inhibitor. The DFG motif is shown in pink carbons. Glycine 719 (green carbons) lies in the P-loop and forms part of the binding cleft. The significant change in conformation of the DFG motif (compare to Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>) causes Leu 858 (cyan carbons) to be directed toward the binding region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Gly 719 lies in the P-loop that forms part of the ATP binding cleft. Crystal structures have been obtained with the G719S mutant bound to gefitinib and other inhibitors.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> For gefitinib, this mutation does not appear to affect the binding mode. The mutation occurs in the region of, but not in contact with, the solubilizing morpholine group of the inhibitor. The effect of the G719S mutation is more interpretable when viewed in the context of the inactive form of the kinase. In this form, the conformation of the backbone of Gly 719 is one that is unique to glycine and inaccessible to other amino acids; mutation to serine or any other residue would lead to significant strain of this conformation and bias the P-loop to adopt another conformation (e.g., that of the active form).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><div class="NLM_p">Gefitinib and other inhibitors have also been cocrystallized with the L858R mutant protein.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The observed binding modes are essentially unchanged compared to those obtained with the wild type enzyme. This is understandable because Leu 858 is located well away from the ATP binding site when in the active conformation.</div><div class="NLM_p">The crystal structures of the inactive form of the kinase provide considerable insight into the mechanism of the activating mutation L858R. In this form of the kinase, Leu 858 is closely packed against several hydrophobic residues, including Leu 862, Met 766, Leu 777, Leu 788, and Leu 747. The L858R mutation would cause significant disruption of the inactive state due to steric clashes leading to changes in the shape of the binding site and by a severe mismatch of chemical properties.</div><div class="NLM_p">Although crystallographic data for complexes of the deletion mutants are not available, some sense of their disposition with respect to the ATP site can be surmised. Residues preceding the C-helix that are the site of the oncogenic deletion mutations do not appear to be in contact with the inhibitors. The region from Glu 746 to Ser 752 is in a loop that traces an arc from the P-loop to the start of the C-helix. Truncation of three to five residues is likely to remove a turn from the C-helix while generally maintaining contacts as they are in the wild type enzyme.</div><div class="NLM_p">Examination of the inactive form of the kinases provides additional insight into how the deletion mutants of the loop preceding the C-helix might disrupt the inactive state. Because the C-helix is shifted out compared to the orientation in the active form, this loop is drawn taut. The C-helix also contains one turn less than in the active form of the kinase. Truncation of this loop would lead to an even more strained system, probably leading to the unwinding of an additional turn of the C-helix. This could lead to a loss of interactions between secondary structural subunits, which understandably could destabilize the C-helix-out, inactive conformation.</div><div class="NLM_p last">Only one cocrystal structure of the T790M mutant in the active form is available, but it is remarkably informative.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> When the T790M mutation was first identified as a resistance mutation, a number of authors attributed the resistance to a loss of binding affinity of the inhibitors due to direct steric interference and/or the possible loss of a bridging water interaction.<a onclick="showRef(event, 'ref7 ref100'); return false;" href="javascript:void(0);" class="ref ref7 ref100">(7, 100)</a> However, the structure of the <b>12</b> complex demonstrates that the mutated methionine can move to accommodate an inhibitor bound in the active form of the kinase.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Comparisons between this structure and the bound forms of gefitinib and erlotinib suggest that these compounds could also be accommodated in the T790M binding site. This is consistent with the observation that irreversible inhibitors, which otherwise are structurally similar to erlotinib and gefitinib, are able to inhibit the T790M mutant in conjunction with activating mutants.<a onclick="showRef(event, 'ref97 ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref97 ref101 ref102">(97, 101, 102)</a></div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Irreversible Inhibitors</h4><div class="NLM_p">Relatively early on in researching inhibitors of EGFR kinase, two groups, at Wyeth and Parke-Davis, working independently pursued irreversible binding inhibitors of the enzyme.<a onclick="showRef(event, 'ref101 ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref101 ref103 ref104">(101, 103, 104)</a> A number of factors motivated these researchers to investigate inhibitors of this type. Among these was the expectation that such compounds might show a longer duration of action. Additionally, since it was expected that the major component of the inhibitory activity would be due to the covalent interaction, only those kinases that formed the covalent bond with the inhibitors should be significantly inhibited. This could result in an improvement in selectivity. A further motivation for designing these irreversible inhibitors was the thought that it would be difficult for a conventional reversibly binding inhibitor to compete with the high endogenous concentration of ATP within the cell for the extended time needed to exert effective antitumor activity. An irreversible inhibitor would be, in effect, noncompetitive with ATP and should thereby overcome this problem. While it turned out that reversible-binding inhibitors of EGFR could become useful drugs, the ability of these compounds to compete with ATP is a very important factor when considering the activity of inhibitors toward the mutant forms of the enzyme.</div><div class="NLM_p">A number of these irreversible inhibitors have been or are still in clinical trials targeting EGFR and/or HER-2 dependent cancers. Some of these compounds are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>. These compounds fall into two related series, either 4-anilinoquinazolines or 4-anilino-3-cyanoquinolines. The latter series was designed on the basis of the former to replace a predicted (and later observed) water-mediated hydrogen bond between the 3-N atom of a quinazoline inhibitor and the protein by a direct hydrogen bond to the protein with the 3-cyano group.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> These compounds function as irreversible inhibitors by forming a covalent interaction with a cysteine residue conserved within the ErbB kinase family. The covalent bond is the result of a Michael addition reaction between the inhibitor and the sulfhydryl group of Cys 797 in EGFR(or Cys 773, using the alternative EGFR numbering scheme that excludes a signal sequence) or Cys 805 in HER-2. The crystal structure of <b>8</b> was solved in complex with the T790M mutant and clearly showed the covalent bond between the reactive cysteine and the Michael acceptor (Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>).</div><figure id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <b>8</b> bound to the T790M mutant of EGFR (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV">2JIV</a>.pdb). Cysteine 797 (green carbons) forms a covalent bond to the inhibitor (purple carbons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A particular advantage of these irreversible inhibitors over the first generation of EGFR inhibitors such as erlotinib and gefitinib is their ability to retain inhibitory efficacy against cancers that have mutated and become resistant to the first generation of drugs. This has become evident from both studies in cell culture and from some interim results of ongoing clinical trials. For example, in cells with the activating L747-S752 deletion mutation and those with the L747-S752 deletion plus T790M mutation, the irreversible inhibitor EKI-785 (<b>13</b>) showed significant inhibitory activity against both cells lines while erlotinib was ineffective against the cell line having the double mutation.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Similarly, in cell lines having the L858R/T790M double mutation, <b>8</b>â<b>11</b> showed potent inhibitory activity, whereas gefitinib and erlotinib were ineffective.<a onclick="showRef(event, 'ref5 ref97 ref106'); return false;" href="javascript:void(0);" class="ref ref5 ref97 ref106">(5, 97, 106)</a> Most significantly, irreversible inhibitors such as <b>8</b> have shown efficacy during clinical trials in treating NSCLC patients with disease that has become resistant to conventional ATP-competitive inhibitors.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><div class="NLM_p">The activity of gefitinib, erlotinib, and <b>8</b> was evaluated in Ba/F3 cells transformed with the L858R and L858R/T790M mutations. In cells transformed with L858R mutants, gefitinib, erlotinib, and <b>8</b> maintain their sensitivity (IC<sub>50</sub> values of 10.8, 12.5, and 3.5 nM, respectively); however, cells transformed with the double mutant are not inhibited by gefitinib or erlotinib but retain sensitivity to <b>8</b> (IC<sub>50</sub> = 180 nM).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Moreover, in a mouse lung model that is dependent on activated EGFR signaling, erlotinib and <b>8</b>, as well as the humanized anti-hEGFR antibody cetuximab, led to dramatic tumor regression.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> It is noted that while the irreversible inhibitors such as <b>8</b> can overcome primary resistance mutations by forming a covalent interaction with an active site cysteine, such drugs could conceivably induce a secondary resistance by mutation of this cysteine. At this time, clinical experience with these inhibitors is limited and it remains to be seen if this additional resistance mechanism will emerge.</div><div class="NLM_p last">An X-ray crystal structure of the clinical candidate <b>8</b> in complex with the T790M single mutant kinase has recently been disclosed.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a><b>8</b> interacts with the C-helix-out inactive form in a binding mode that is similar to that of lapatinib except for the addition of a covalent bond with Cys 797. Consistent with the observations arising from the kinetics of mutant receptors, the side chain of mutant Met 790 adopted a conformation that did not perturb the binding of <b>8</b>. In doing so, it makes hydrophobic contacts with Cys 775 and Leu 777. Presumably, these additional hydrophobic contacts may lead to some restoration of wild-type affinity for ATP when introduced into a kinase with an activating mutant.<a onclick="showRef(event, 'ref33 ref98'); return false;" href="javascript:void(0);" class="ref ref33 ref98">(33, 98)</a> Much as with lapatinib complex, the additional 2-pyridylmethoxy group extends into the space created by the outward movement of the C-helix. The incompatibility of the active state with <b>8</b> binding coupled with <b>8</b>âs persistent ability to inhibit kinases with the L858R/T790M double mutation implies that a conformation of the kinase similar to the C-helix-out form is available in the double mutant. However, this remains speculative because it is not clear by how much the L858R or the deletion mutants (e.g., del 746â750) disrupt the inactive state.</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">3 Drug Design Strategies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our current knowledge about kinase domain mutations and the need to overcome drug resistance due to these mutations is a compelling driver for drug discovery within oncology. The preceding section has identified several strategies that have led to the next generation of kinase inhibitors. Some of these inhibitors have been shown to have better efficacy against known mutants and/or better risk profiles against the emergence of new mutant strains. In this section, we will review the key strategies needed to develop drugs that overcome drug resistance, highlighting both what has already been achieved and the remaining issues.</div><div class="NLM_p">Clearly, the simplest and most important strategy to overcome resistance is to increase the potency of the inhibitors toward their target proteins. Many of the resistance mutations reduce drug-binding affinity and therefore drug inhibitory activity sufficiently to allow continued cancer growth. Although in absolute terms this represents a challenge for a given drug, in relative terms, the effect on ligand binding for most mutations is not as severe as might be anticipated, often only 10- to 30-fold. Therefore, a more potent analogue of a clinical drug may overcome many clinical resistant mutations. This is illustrated by nilotinib, which was designed as a successor to imatinib and demonstrates 10-fold more potent binding to the wild type enzyme. This is responsible for its effectiveness against all but the T315I mutation in BCR-Abl. For any given chemical class, the ability to increase in vivo potency involves a balance of factors, namely, changing the molecule to increase or improve molecular interactions with the kinase while maintaining or improving physicochemical and pharmacokinetic properties. While reaching this strategic objective may not be successful in a parent series of inhibitors, identifying a new chemical series or making significant structural changes to an existing series (with its attendant risks and uncertainties) may be necessary.</div><div class="NLM_p">As the development of <b>8</b>â<b>11</b> have demonstrated, irreversible inhibitors that form a covalent interaction with an active site cysteine residue are viable drug candidates. Effectively, this can be considered as a special case of increasing the potency of the drug. Yun et al. estimated that the potency of a covalent inhibitor is equivalent to a 0.2 nM inhibitor.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Additionally, irreversible inhibition requires receptor cycling to regenerate active enzyme. This could result in sustained inhibitory activity for this class of compounds. Importantly, irreversible inhibitors do not compete with high ATP concentrations in the cell and are additionally unaffected by changes in the ATP binding affinity that can occur with mutant forms of the enzyme. It is hoped that concerns about toxicity caused by nonspecific reactivity will be mitigated provided that the reactive moiety can be tuned to have an appropriate degree of reactivity and orientation with respect to the target residue. Assuming that the clinical experience to date continues through FDA approval resulting in clinical utility, the key limit to this strategy is opportunity. While there are only 10 kinases including EGFR with a homologous cysteine, other kinases have cysteines at other locations in the binding site. These appear to function as small hydrophobic residues and can serve as targets for irreversible inhibitors. A recent analysis suggested that there were over 200 kinases with cysteines accessible to drug targeting.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Still, the irreducible minimum for this strategy to succeed is the presence of a binding site cysteine.</div><div class="NLM_p">Another strategy to overcome resistance is to rationally design inhibitors to avoid or co-opt specific mutations. Clearly, in Bcr-Abl, the gatekeeper threonine makes a direct and important hydrogen bond to imatinib and nilotinib. Upon mutation, this bond is lost, essentially leading to a complete loss of drug potency. The design of inhibitors that avoid a direct interaction with the gatekeeper or avoid sterically clashing with the gatekeeper upon mutation has been shown to be a viable strategy. Sunitinib has recently been shown to be, surprisingly, a type II inhibitor, with its continued effectiveness in cells with the gatekeeper mutation T670I due to a lack of interaction with Thr 670.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> In preclinical studies, compounds with this property such as <b>6</b> have been identified by directed screening of mutant kinases.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Similarly, <b>4</b> was the result of a discovery effort with this strategy in mind from the beginning.</div><div class="NLM_p">The realization that the resistance effects of the gatekeeper mutation in EGFR are not solely due to direct interactions with the ligand but are the result of enhancing the binding affinity for ATP argues against adopting this uncritically as a universal strategy. Indeed, it is this property of the L858R/T790M double mutation of EGFR kinase that is primarily responsible for the resistance. In contrast, in Abl the gatekeeper mutation leads to a direct loss of inhibitor potency due to the loss of a hydrogen bonding interaction. The fact that seemingly similar mutations in Abl and EGFR result in different mechanisms of drug resistance highlights the need to fully characterize the mutant enzymes both kinetically and structurally to be able to identify an appropriate drug design strategy to overcome resistance.</div><div class="NLM_p">Where there is clear clinical evidence of mutations, there is also the opportunity to rationally design inhibitors of the mutant enzymes. This could involve exploiting a significant change in the shape or character of the binding site. The means by which a ligand could be designed in this way are numerous: (a) a focused screening effort could be developed to identify templates that preferentially bind to the mutant rather than the native enzyme;<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (b) a known template could be rationally modified with substituents that exploit the novel shape or character of the binding pocket; or (c) fragment screening might be employed to identify moieties that uniquely bind to the novel pocket. An emerging opportunity to support this strategy is the identification of potential mutations in vitro early in the drug design process.<a onclick="showRef(event, 'ref110 ref111 ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref110 ref111 ref112 ref113">(110-113)</a></div><div class="NLM_p">Another strategy is to rationally design inhibitors for the different structural states of a kinase. As we have highlighted, a number of the known resistance mutations bias the structures of the Abl and c-Kit enzymes from the inactive to the active state, thereby reducing the binding affinity of those inhibitors, such as imatinib, that prefer the inactive form of the enzyme. Dasatinib, which binds to the active state of the kinase, appears to be less sensitive to such mutations for that reason. Similarly, gefitinib and erlotinib appear to be uniquely effective against mutant EGFR kinases that favor the active state.</div><div class="NLM_p">A clinical treatment strategy to prevent or slow the occurrence of drug resistance could be to administer two drugs having different mechanisms of action simultaneously. At least in an in vitro setting this seems like a promising avenue.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><div class="NLM_p last">Crystallographic knowledge derived from multiple crystal structures in various conformational states of EGFR, Abl, cKIT, and other kinases is a valuable asset for optimal inhibitor design. The value of such an asset is amplified when kinetic analyses of mutant enzymes specifically in relation to ATP affinity and catalytic competence are revealed. Such knowledge complements that obtained by crystallography at the molecular level and should pave the road for designing inhibitors with desired profiles.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">4 Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53051" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53051" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The identification of kinase domain mutations in the clinic has stimulated basic research efforts to relate structure and function as reviewed in this Perspective. The specific properties of these mutations can influence the structural states, binding site character, and affinity for ATP of the kinases. Understanding these aspects in combination will be pivotal for any drug design program with the goal of identification of a small molecule inhibitor that can overcome resistance mechanisms. Protein structural information obtained from multiple crystal structures in various conformational states is a valuable asset for optimal inhibitor design. This information can be further enhanced by kinetic analyses of mutant enzymes with respect to ATP affinity and catalytic competence. The clinical need and preclinical complexity of the design challenge both point to adopting the most integrated approach available when designing the next generation of inhibitors.</div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jack A. Bikker</span> - <span class="hlFld-Affiliation affiliation">Chemical Sciences, Wyeth Research, 401 North Middletown Road, Pearl River, New York 10965</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e2808b8989879088a2959b87968acc818d8f"><span class="__cf_email__" data-cfemail="aac8c3c1c1cfd8c0eaddd3cfdec284c9c5c7">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natasja Brooijmans</span> - <span class="hlFld-Affiliation affiliation">Chemical Sciences, Wyeth Research, 401 North Middletown Road, Pearl River, New York 10965</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Allan Wissner</span> - <span class="hlFld-Affiliation affiliation">Chemical Sciences, Wyeth Research, 401 North Middletown Road, Pearl River, New York 10965</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tarek S. Mansour</span> - <span class="hlFld-Affiliation affiliation">Chemical Sciences, Wyeth Research, 401 North Middletown Road, Pearl River, New York 10965</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm8010542" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18240" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18240" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Jack A. Bikker</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jack A. Bikker</b> obtained a B.Sc. degree Queenâs University in Canada, followed by a Ph.D. in Medicinal Chemistry from the same institution under the supervision of Prof. Donald Weaver in 1993. He was a postdoctoral fellow at Parke Davis Pharmaceuticals in Ann Arbor, MI, from 1993 to 1996, working with Dr. Christine Humblet, and did further postdoctoral training with Dr. Andy Vinter at Cambridge University, U.K. He joined the Parke Davis Neuroscience Research Centre in Cambridge, England, in 1997 and moved within the company to Ann Arbor, MI, in 1998. He held various scientific and management positions within the Parke Davis and later Pfizer organizations in Ann Arbor, MI, until Discovery Research was discontinued at the site in 2007. He joined Wyeth in 2007, where he is currently a Principal Research Scientist III working in the Chemical Sciences division.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Natasja Brooijmans</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Natasja Brooijmans</b> obtained an M.Pharm. degree from the Utrecht University, The Netherlands, and performed her thesis research with Barry Honig at Columbia University, NY. She received a Ph.D. in Chemistry and Chemical Biology from the University of California, San Francisco, under the supervision of Prof. Peter Kollman and Prof. Irwin âTackâ Kuntz in 2003. After a brief postdoc with Tack Kuntz, she joined Wyeth Research in Pearl River in 2004. She is currently a Principal Research Scientist I working in the Chemical Sciences division. She has contributed to research projects in disease areas including oncology, immunology, and cardiovascular research, with considerable focus on kinases.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Allan Wissner</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Allan Wissner</b> obtained a B.S. degree in Chemistry from Long Island University, NY, and his Ph.D. in Organic Chemistry from the University of Pennsylvania under the supervision of Prof. Bryan W. Roberts in 1971. He was an NIH postdoctoral fellow from 1972 to 1974 working in the laboratory of Prof. Jerrold Meinwald at Cornell University, NY. In 1974, he joined the Oncology and Immunology Research Section of Lederle Laboratories, the pharmaceutical division of American Cyanamid Co. where he achieved the position of Group Leader. He continued in his employment after this company was acquired by Wyeth-Ayerst in 1995. He is currently a Principal Research Scientist IV working in the Chemical Sciences division of Wyeth. He has led medicinal chemistry projects in the oncology, immunology, and metabolic disease research areas.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Tarek S. Mansour</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tarek S. Mansour</b> received a B.S. degree in Chemistry from the American University of Beirut, Lebanon (1977), M.Sc. in Chemistry from the University of Manchester Institute of Science and Technology, U.K. (1979), a Ph.D. degree from the University of Missouri-Columbia, MO (1982), under the supervision of Prof. E. M. Kaiser, and a diploma in Applied Management from McGill University, Canada (1993). Following postdoctoral tenure with Professor R. R. Fraser at the University of Ottawa, Ontario, Canada, Dr. Mansour moved to McGill University, Montreal, Canada, as a Research Associate in the immunomedicinal chemistry chair headed by Professor B. Belleau. In 1989, Dr. Mansour moved to BioChem Pharma and assumed various leadership positions. Subsequently, he joined Wyeth Research in 1997. He presently holds the position of Vice PresidentâMedicinal Chemistry, with medicinal chemistry efforts responsibility in several therapeutic areas.</p></figure></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74242" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74242" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Christine Humblet and Diane Boschelli for critical readings of this manuscript and many colleagues within Wyeth Research for informative discussions and insights over many years.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22327" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22327" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 115 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x"> (</span><span class="NLM_issue">5600</span><span class="NLM_x">) </span> <span class="NLM_fpage">1912</span><span class="NLM_x">â</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&issue=5600&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0lg_-ih_IaSpWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26issue%3D5600%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">LaRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eder, J. P.</span><span> </span><span class="NLM_article-title">Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1013</span><span class="NLM_x">â</span> <span class="NLM_lpage">1028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1013-1028&issue=7&author=P.+M.+LaRussoauthor=J.+P.+Eder&title=Therapeutic+potential+of+novel+selective-spectrum+kinase+inhibitors+in+oncology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaRusso%26aufirst%3DP.%2BM.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26atitle%3DTherapeutic%2520potential%2520of%2520novel%2520selective-spectrum%2520kinase%2520inhibitors%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26issue%3D7%26spage%3D1013%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Liao, J. J.-L.</span><span> </span><span class="NLM_article-title">Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">409</span><span class="NLM_x">â</span> <span class="NLM_lpage">424</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0608107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=409-424&issue=3&author=J.+J.-L.+Liao&title=Molecular+recognition+of+protein+kinase+binding+pockets+for+design+of+potent+and+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many kinase inhibitors have failed in preclin. or clin. development because of the lack of such selectivity that induces intolerable side effects, mostly because the catalytic cleft is highly conserved in sequence and conformation.  Systematic anal. of the crystal structures of protein kinases can offer insight into the design of highly selective kinase inhibitors to overcome these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDTl2SBUfbbVg90H21EOLACvtfcHk0lg_-ih_IaSpWw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D&md5=77542d3ba589bd834a0d2b97a24eea05</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm0608107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608107%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.-L.%26atitle%3DMolecular%2520recognition%2520of%2520protein%2520kinase%2520binding%2520pockets%2520for%2520design%2520of%2520potent%2520and%2520selective%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D3%26spage%3D409%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Liao, J. J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, R. C.</span><span> </span><span class="NLM_article-title">Targeting protein multiple conformations: a structure-based strategy for kinase drug design</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">â</span> <span class="NLM_lpage">1407</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.2174%2F156802607781696783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17692028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1394-1407&author=J.+J.-L.+Liaoauthor=R.+C.+Andrews&title=Targeting+protein+multiple+conformations%3A+a+structure-based+strategy+for+kinase+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein multiple conformations: a structure-based strategy for kinase drug design</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou; Andrews, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1394-1407</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Multiple conformations of a protein kinase target offer an opportunity to design small-mol. inhibitors with distinct but clin. useful profiles.  This article analyzes and classifies the binding pockets in the kinase catalytic cleft in different conformational states.  Targeting kinase multiple conformations as an emerging strategy in the field is exemplified with important small-mol. agents in the clinic.  The structure-based anal. in the paper provides a rationale for thwarting the development of drug-resistant mutations in antikinase therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWOkJq0JBN2rVg90H21EOLACvtfcHk0lirsQd4k4WgeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrF&md5=db6aa8c76bf20857cfe31c71625ffa9e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F156802607781696783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607781696783%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.-L.%26aulast%3DAndrews%26aufirst%3DR.%2BC.%26atitle%3DTargeting%2520protein%2520multiple%2520conformations%253A%2520a%2520structure-based%2520strategy%2520for%2520kinase%2520drug%2520design%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1394%26epage%3D1407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paetel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">11011</span><span class="NLM_x">â</span> <span class="NLM_lpage">11016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&issue=31&author=T.+A.+Carterauthor=L.+M.+Dodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=W.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrfardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Paetelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DDodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrfard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPaetel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26issue%3D31%26spage%3D11011%26epage%3D11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Strategies to overcome resistance to targeted protein kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1001</span><span class="NLM_x">â</span> <span class="NLM_lpage">1010</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1001-1010&issue=12&author=H.+Daubauthor=K.+Spechtauthor=A.+Ullrich&title=Strategies+to+overcome+resistance+to+targeted+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DSpecht%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DStrategies%2520to%2520overcome%2520resistance%2520to%2520targeted%2520protein%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D12%26spage%3D1001%26epage%3D1010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resitance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">786</span><span class="NLM_x">â</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&issue=8&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resitance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lirsQd4k4WgeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resitance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D8%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Dowell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">Chasing mutations in the epidermal growth factor in lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">830</span><span class="NLM_x">â</span> <span class="NLM_lpage">832</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMe058033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15728818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFChsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=830-832&issue=8&author=J.+E.+Dowellauthor=J.+D.+Minna&title=Chasing+mutations+in+the+epidermal+growth+factor+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Chasing mutations in the epidermal growth factor in lung cancer</span></div><div class="casAuthors">Dowell, Jonathan E.; Minna, John D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">830-832</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDSz54eHP5KbVg90H21EOLACvtfcHk0liuE6UsJB-3cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFChsrk%253D&md5=4f73d92d2b699d0ad2004e0b60ca78e7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMe058033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe058033%26sid%3Dliteratum%253Aachs%26aulast%3DDowell%26aufirst%3DJ.%2BE.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DChasing%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520in%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D8%26spage%3D830%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">293</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">â</span> <span class="NLM_lpage">880</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=876-880&author=M.+E.+Gorreauthor=M.+Mohammedauthor=K.+Ellwoodauthor=N.+Hsuauthor=R.+L.+Paquetteauthor=P.+N.+Raoauthor=C.+L.+Sawyers&title=Clinical+resistance+to+STI-571+cancer+therapy+caused+by+BCR-ABL+gene+mutation+or+amplification"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DMohammed%26aufirst%3DM.%26aulast%3DEllwood%26aufirst%3DK.%26aulast%3DHsu%26aufirst%3DN.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DRao%26aufirst%3DP.%2BN.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DClinical%2520resistance%2520to%2520STI-571%2520cancer%2520therapy%2520caused%2520by%2520BCR-ABL%2520gene%2520mutation%2520or%2520amplification%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D876%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A., J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x"> (</span><span class="NLM_issue">5827</span><span class="NLM_x">) </span> <span class="NLM_fpage">1039</span><span class="NLM_x">â</span> <span class="NLM_lpage">1043</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&issue=5827&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Misudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.-M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.%2C+J+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+Janne&title=MET+amplification+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB3+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMisudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%252C%2BJ%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplification%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB3%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26issue%3D5827%26spage%3D1039%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">4392</span><span class="NLM_x">â</span> <span class="NLM_lpage">4399</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1158%2F1078-0432.CCR-08-0117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18628453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4392-4399&issue=14&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Therapeutic+options+against+BCR-ABL1+T315I-positive+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4399</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease.  Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib.  Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid.  This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket.  To expedite the identification of strategies to override the resistance imposed by the T315I mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1.  Recent insights gained regarding the structural biol. of T315I have led to the development of a variety of compds. against this mutant.  We herein summarize the most clin. promising anti-T315I therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplJ8bpmJXGkrVg90H21EOLACvtfcHk0liuE6UsJB-3cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D&md5=01688b0795daf1ca29c7ad4a98e3977b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0117%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DTherapeutic%2520options%2520against%2520BCR-ABL1%2520T315I-positive%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D14%26spage%3D4392%26epage%3D4399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamaru, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">â</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnm0596-561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=8616716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&author=B.+J.+Drukerauthor=S.+Tamaruauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span></div><div class="casAuthors">Druker, Brian J.; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shane; Zimmermann, Jurg; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">The Bcr-Abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease.  A compd., designed to inhibit the Abl protein tyrosine kinase (CGP 57148), was evaluated for its effects on cells contg. the Bcr-Abl fusion protein.  Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compd.  In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the no. of Bcr-Abl colonies formed but no inhibition of normal colony formation.  This compd. may be useful in the treatment of Bcr-Abl-pos. leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzXj-25AHOrVg90H21EOLACvtfcHk0liuE6UsJB-3cw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D&md5=1dc111cc883a1ed29964ae2c88c88cb9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnm0596-561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0596-561%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamaru%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Boschelli, D. H.</span><span> </span><span class="NLM_article-title">Bcr-Abl kinase inhibitors</span> <span class="citation_source-journal">Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">â</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1007%2F7355_2006_008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=407-444&author=D.+H.+Boschelli&title=Bcr-Abl+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2F7355_2006_008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7355_2006_008%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26atitle%3DBcr-Abl%2520kinase%2520inhibitors%26jtitle%3DTop.%2520Med.%2520Chem.%26date%3D2007%26volume%3D1%26spage%3D407%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebansky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, S. S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, B.</span><span> </span><span class="NLM_article-title">Inhibitors of ABL and the ABL-T315I mutation</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">â</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.2174%2F156802608784911635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18673174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=905-921&author=G.+Noronhaauthor=J.+Caoauthor=C.+P.+Chowauthor=E.+Dneprovskaiaauthor=R.+M.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=B.+Klebanskyauthor=D.+Lohseauthor=C.+C.+Makauthor=A.+McPhersonauthor=S.+S.+P.+Moorthyauthor=V.+P.+Pathakauthor=J.+Renickauthor=R.+Sollauthor=B.+Zeng&title=Inhibitors+of+ABL+and+the+ABL-T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of ABL and the ABL-T315I mutation</span></div><div class="casAuthors">Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Fine, Richard M.; Hood, John; Kang, Xinshan; Klebansky, Boris; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Palanki, Moorthy S. S.; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) is a hematol. stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells.  Abelson tyrosine kinase (ABL) is a non-receptor tyrosine kinase involved in cell growth and proliferation and is usually under tight control.  However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.  This Philadelphia chromosome is responsible for the prodn. of BCR-ABL, a constitutively active tyrosine kinase that causes uncontrolled cellular proliferation.  An ABL inhibitor, imatinib, was approved by the FDA for the treatment of CML, and is currently used as first line therapy.  However, a high percentage of clin. relapse has been obsd. due to long term treatment with imatinib.  A majority of these relapsed patients have several point mutations at and around the ATP binding pocket of the ABL kinase domain in BCR-ABL.  To address the resistance of mutated BCR-ABL to imatinib, 2nd generation inhibitors such as dasatinib, and nilotinib were developed.  These compds. were approved for the treatment of CML patients who are resistant to imatinib.  All of the BCR-ABL mutants are inhibited by the 2nd generation inhibitors with the exception of the T3151 mutant.  Several 3rd generation inhibitors such as AP24534, VX-680 (MK-0457), PHA-739358, PPY-A, XL-228, SGX-70393, FTY720 and TG101113 are being developed to target the T3151 mutation.  The early results from these compds. are encouraging and it is anticipated that physicians will have addnl. drugs at their disposal for the treatment of patients with the mutated BCR-ABL-T315I.  The success of these inhibitors has greater implication not only in CML, but also in other diseases driven by kinases where the mutated gatekeeper residue plays a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCjbrW8rt8HbVg90H21EOLACvtfcHk0lgJbZlo7rIrxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D&md5=c61dc3941c9fd71ddd4ed02732e80998</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F156802608784911635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784911635%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DC.%2BP.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DR.%2BM.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DKlebansky%26aufirst%3DB.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DMoorthy%26aufirst%3DS.%2BS.%2BP.%26aulast%3DPathak%26aufirst%3DV.%2BP.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DB.%26atitle%3DInhibitors%2520of%2520ABL%2520and%2520the%2520ABL-T315I%2520mutation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarijian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Flying under the radar: the new wave of BCR-ABL inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">834</span><span class="NLM_x">â</span> <span class="NLM_lpage">848</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=834-848&issue=10&author=A.+Quintas-Cardamaauthor=H.+Kantarijianauthor=J.+Cortes&title=Flying+under+the+radar%3A+the+new+wave+of+BCR-ABL+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarijian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFlying%2520under%2520the%2520radar%253A%2520the%2520new%2520wave%2520of%2520BCR-ABL%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D10%26spage%3D834%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Chan, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullick, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M. E.</span><span> </span><span class="NLM_article-title">Mutations of the epidermal growth factor receptor in non-small cell lung cancerâsearch and destroy</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">â</span> <span class="NLM_lpage">23</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=17-23&author=S.+K.+Chanauthor=W.+J.+Gullickauthor=M.+E.+Hill&title=Mutations+of+the+epidermal+growth+factor+receptor+in+non-small+cell+lung+cancer%E2%80%94search+and+destroy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BK.%26aulast%3DGullick%26aufirst%3DW.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BE.%26atitle%3DMutations%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520non-small%2520cell%2520lung%2520cancer%25E2%2580%2594search%2520and%2520destroy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D17%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shigematsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">Mutations and addiction to EGFR: the Achilles âhealâ of lung cancers</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">481</span><span class="NLM_x">â</span> <span class="NLM_lpage">486</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=481-486&issue=10&author=A.+F.+Gazdarauthor=H.+Shigematsuauthor=J.+Herzauthor=J.+D.+Minna&title=Mutations+and+addiction+to+EGFR%3A+the+Achilles+%E2%80%9Cheal%E2%80%9D+of+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DShigematsu%26aufirst%3DH.%26aulast%3DHerz%26aufirst%3DJ.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DMutations%2520and%2520addiction%2520to%2520EGFR%253A%2520the%2520Achilles%2520%25E2%2580%259Cheal%25E2%2580%259D%2520of%2520lung%2520cancers%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2004%26volume%3D10%26issue%3D10%26spage%3D481%26epage%3D486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protopopov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glatt, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">7817</span><span class="NLM_x">â</span> <span class="NLM_lpage">7822</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=7817-7822&issue=20&author=H.+Jiauthor=X.+Zhaoauthor=Y.+Yuzaauthor=T.+Shimamuraauthor=D.+Liauthor=A.+Protopopovauthor=B.+L.+Jungauthor=K.+McNamaraauthor=H.+Xiaauthor=K.+A.+Glattauthor=R.+K.+Thomasauthor=H.+Sasakiauthor=J.+W.+Hornerauthor=M.+J.+Eckauthor=C.+M.+Discafaniauthor=E.+Maherauthor=G.+I.+Shapiroauthor=M.+Meyersonauthor=K.-K.+Wong&title=Epidermal+growth+factor+receptor+variant+III+mutations+in+lung+tumorigenesis+and+sensitivity+to+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DProtopopov%26aufirst%3DA.%26aulast%3DJung%26aufirst%3DB.%2BL.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DXia%26aufirst%3DH.%26aulast%3DGlatt%26aufirst%3DK.%2BA.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DHorner%26aufirst%3DJ.%2BW.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DMaher%26aufirst%3DE.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520variant%2520III%2520mutations%2520in%2520lung%2520tumorigenesis%2520and%2520sensitivity%2520to%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26issue%3D20%26spage%3D7817%26epage%3D7822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in patients with non-small cell lung cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7525</span><span class="NLM_x">â</span> <span class="NLM_lpage">7529</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=7525-7529&issue=17&author=B.+E.+Johnsonauthor=P.+Janne&title=Epidermal+growth+factor+receptor+mutations+in+patients+with+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DJanne%26aufirst%3DP.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D17%26spage%3D7525%26epage%3D7529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatual, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">2129</span><span class="NLM_x">â</span> <span class="NLM_lpage">2139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&issue=21&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatualauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lj1NqRETwyIvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatual%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26issue%3D21%26spage%3D2129%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">â</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lj1NqRETwyIvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reily, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from ânever smokersâ and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">â</span> <span class="NLM_lpage">13311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+I.+Reilyauthor=R.+Somwarauthor=M.+F.+Zakowski&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%9Cnever+smokers%E2%80%9D+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DReily%26aufirst%3DG.%2BI.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%259Cnever%2520smokers%25E2%2580%259D%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargent, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Molecular basis for sunitinib efficacy and future clinical development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">734</span><span class="NLM_x">â</span> <span class="NLM_lpage">745</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=734-745&issue=9&author=S.+Faivreauthor=G.+Demetriauthor=W.+Sargentauthor=E.+Raymond&title=Molecular+basis+for+sunitinib+efficacy+and+future+clinical+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DSargent%26aufirst%3DW.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DMolecular%2520basis%2520for%2520sunitinib%2520efficacy%2520and%2520future%2520clinical%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D9%26spage%3D734%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1116</span><span class="NLM_x">â</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&issue=7&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=T.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D7%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span> </span><span class="NLM_article-title">Design and discovery of small molecules targeting Raf-1 kinase</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">25</span><span class="NLM_x">) </span> <span class="NLM_fpage">2269</span><span class="NLM_x">â</span> <span class="NLM_lpage">2278</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.2174%2F1381612023393125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12369855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XnvVGntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=2269-2278&issue=25&author=T.+Lowingerauthor=B.+Riedlauthor=J.+Dumasauthor=R.+A.+Smith&title=Design+and+discovery+of+small+molecules+targeting+Raf-1+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design and discovery of small molecules targeting raf-1 kinase</span></div><div class="casAuthors">Lowinger, Timothy B.; Riedl, Bernd; Dumas, Jacques; Smith, Roger A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2269-2278</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Raf kinase, an enzyme which acts downstream in the Ras signaling pathway, is involved in cancerous cell proliferation.  Thus, small mol. inhibitors of Raf kinase activity may be important agents for the treatment of cancer.  A novel class of Raf-1 inhibitors was discovered, using a combination of medicinal and combinatorial chem. approaches.  This effort culminated in the identification of the clin. candidate BAY 43-9006, currently undergoing Phase I clin. trials.  The present review summarizes the medicinal chem. development of ureas as highly potent inhibitors of Raf-1 kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqviNIBK_IYW7Vg90H21EOLACvtfcHk0lgXE1k7sK_qHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnvVGntrk%253D&md5=a62445c3fb50083175ee4863ae84f6ce</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F1381612023393125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612023393125%26sid%3Dliteratum%253Aachs%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26atitle%3DDesign%2520and%2520discovery%2520of%2520small%2520molecules%2520targeting%2520Raf-1%2520kinase%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2002%26volume%3D8%26issue%3D25%26spage%3D2269%26epage%3D2278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Huse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">The conformational plasticity of protein kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">275</span><span class="NLM_x">â</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS0092-8674%2802%2900741-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12015977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=275-282&issue=3&author=M.+Huseauthor=J.+Kuriyan&title=The+conformational+plasticity+of+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The conformational plasticity of protein kinases</span></div><div class="casAuthors">Huse, Morgan; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-282</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 48 refs.  Protein kinases operate in a large no. of distinct signaling pathways, where the tight regulation of their catalytic activity is crucial to the development and maintenance of eukaryotic organisms.  The catalytic domains of different kinases adopt strikingly similar structures when they are active.  By contrast, crystal structures of inactive kinases have revealed a marked plasticity in the kinase domain that allows the adoption of distinct conformations in response to interactions with specific regulatory domains or proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJrn7F3h4ej7Vg90H21EOLACvtfcHk0lgXE1k7sK_qHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D&md5=cd56edae94ad239f2ce7a5d6c8930cbb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900741-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900741-9%26sid%3Dliteratum%253Aachs%26aulast%3DHuse%26aufirst%3DM.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DThe%2520conformational%2520plasticity%2520of%2520protein%2520kinases%26jtitle%3DCell%26date%3D2002%26volume%3D109%26issue%3D3%26spage%3D275%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">358</span><span class="NLM_x">â</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&issue=7&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lgXE1k7sK_qHw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26issue%3D7%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Masterson, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascioni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traaseth, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veglia, G.</span><span> </span><span class="NLM_article-title">Allosteric cooperativity in protein kinase A</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">506</span><span class="NLM_x">â</span> <span class="NLM_lpage">511</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=506-511&issue=2&author=L.+R.+Mastersonauthor=A.+Mascioniauthor=N.+J.+Traasethauthor=S.+S.+Taylorauthor=G.+Veglia&title=Allosteric+cooperativity+in+protein+kinase+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMasterson%26aufirst%3DL.%2BR.%26aulast%3DMascioni%26aufirst%3DA.%26aulast%3DTraaseth%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DVeglia%26aufirst%3DG.%26atitle%3DAllosteric%2520cooperativity%2520in%2520protein%2520kinase%2520A%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26issue%3D2%26spage%3D506%26epage%3D511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Vajpai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grzesiek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jahnke, W.</span><span> </span><span class="NLM_article-title">Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x"> (</span><span class="NLM_issue">26</span><span class="NLM_x">) </span> <span class="NLM_fpage">18292</span><span class="NLM_x">â</span> <span class="NLM_lpage">18302</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=18292-18302&issue=26&author=N.+Vajpaiauthor=A.+Straussauthor=G.+Fendrichauthor=S.+W.+Cowan-Jacobauthor=P.+W.+Manleyauthor=S.+Grzesiekauthor=W.+Jahnke&title=Solution+conformations+and+dynamics+of+ABL+kinase-inhibitor+complexes+determined+by+NMR+substantiate+the+different+binding+modes+of+imatinib%2Fnilotinib+and+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVajpai%26aufirst%3DN.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DGrzesiek%26aufirst%3DS.%26aulast%3DJahnke%26aufirst%3DW.%26atitle%3DSolution%2520conformations%2520and%2520dynamics%2520of%2520ABL%2520kinase-inhibitor%2520complexes%2520determined%2520by%2520NMR%2520substantiate%2520the%2520different%2520binding%2520modes%2520of%2520imatinib%252Fnilotinib%2520and%2520dasatinib%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D26%26spage%3D18292%26epage%3D18302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Dorsey, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jove, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span> </span><span class="NLM_article-title">The pyrido[2,3-<i>d</i>]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">3127</span><span class="NLM_x">â</span> <span class="NLM_lpage">3131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=3127-3131&issue=12&author=J.+F.+Dorseyauthor=R.+Joveauthor=A.+J.+Krakerauthor=J.+Wu&title=The+pyrido%5B2%2C3-d%5Dpyrimidine+derivative+PD180970+inhibits+p210Bcr-Abl+tyrosine+kinase+and+induces+apoptosis+of+K562+leukemic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DJ.%2BF.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DThe%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520derivative%2520PD180970%2520inhibits%2520p210Bcr-Abl%2520tyrosine%2520kinase%2520and%2520induces%2520apoptosis%2520of%2520K562%2520leukemic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26issue%3D12%26spage%3D3127%26epage%3D3131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C. W.</span><span> </span><span class="NLM_article-title">Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-<i>d</i>]pyrimidine tyrosine kinase inhibitors</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">885</span><span class="NLM_x">â</span> <span class="NLM_lpage">898</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=885-898&issue=7&author=A.+J.+Krakerauthor=B.+G.+Hartlauthor=A.+M.+Amarauthor=M.+R.+Barvianauthor=H.+D.+H.+Showalterauthor=C.+W.+Moore&title=Biochemical+and+cellular+effects+of+c-Src+kinase-selective+pyrido%5B2%2C3-d%5Dpyrimidine+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DHartl%26aufirst%3DB.%2BG.%26aulast%3DAmar%26aufirst%3DA.%2BM.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DMoore%26aufirst%3DC.%2BW.%26atitle%3DBiochemical%2520and%2520cellular%2520effects%2520of%2520c-Src%2520kinase-selective%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2000%26volume%3D60%26issue%3D7%26spage%3D885%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakcey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuck, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">66452</span><span class="NLM_x">â</span> <span class="NLM_lpage">66659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=66452-66659&author=E.+R.+Woodauthor=A.+T.+Tuesdaleauthor=O.+B.+McDonaldauthor=D.+Yanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lakceyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilbmerauthor=L.+Shewchuck&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTuesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLakcey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilbmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuck%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D66452%26epage%3D66659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">â</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljWLc-Hk6j1vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gureasko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">â</span> <span class="NLM_lpage">1149</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2Fj.cell.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=16777603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=1137-1149&author=X.+Zhangauthor=J.+Gureaskoauthor=H.+Shenauthor=P.+A.+Coleauthor=J.+Kuriyan&title=An+allosteric+mechanism+for+activation+of+the+kinase+domain+of+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span></div><div class="casAuthors">Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1137-1149</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition.  We find that the EGFR kinase domain can be activated by increasing its local concn. or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation.  This suggests that the kinase domain is intrinsically auto-inhibited, and an intermol. interaction promotes its activation.  Using further mutational anal. and crystallog. we demonstrate that the auto-inhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs).  EGFR activation results from the formation of an asym. dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes.  The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRAzLF-wK7Vg90H21EOLACvtfcHk0ljWLc-Hk6j1vg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D&md5=f7b6795851425346f588cbd682125c93</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGureasko%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DAn%2520allosteric%2520mechanism%2520for%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D1137%26epage%3D1149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickin, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">450</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">â</span> <span class="NLM_lpage">745</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnature05998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18046415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKmtbrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2007&pages=741-745&author=X.+Zhangauthor=K.+A.+Pickinauthor=R.+Boseauthor=N.+Juraauthor=P.+A.+Coleauthor=J.+Kuriyan&title=Inhibition+of+the+EGF+receptor+by+binding+of+MIG6+to+an+activating+kinase+domain+interface"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface</span></div><div class="casAuthors">Zhang, Xuewu; Pickin, Kerry A.; Bose, Ron; Jura, Natalia; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">7170</span>),
    <span class="NLM_cas:pages">741-744</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy.  Crit. for activation is the formation of an asym. dimer by the intracellular kinase domains, in which the carboxy-terminal lobe (C lobe) of one kinase domain induces an active conformation in the other.  The cytoplasmic protein MIG6 (mitogen-induced gene 6; also known as ERRFI1) interacts with and inhibits the kinase domains of EGFR and ERBB2 (refs).  Crystal structures of complexes between the EGFR kinase domain and a fragment of MIG6 show that a â¼25-residue epitope (segment 1) from MIG6 binds to the distal surface of the C lobe of the kinase domain.  Biochem. and cell-based analyses confirm that this interaction contributes to EGFR inhibition by blocking the formation of the activating dimer interface.  A longer MIG6 peptide that is extended C terminal to segment 1 has increased potency as an inhibitor of the activated EGFR kinase domain, while retaining a crit. dependence on segment 1.  We show that signaling by EGFR mols. that contain constitutively active kinase domains still requires formation of the asym. dimer, underscoring the importance of dimer interface blockage in MIG6-mediated inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2aM4ZGKQTr7Vg90H21EOLACvtfcHk0lho3ZrKIW_hSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKmtbrP&md5=788822e6303a35eddea3e032875c57d7</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnature05998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05998%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DPickin%26aufirst%3DK.%2BA.%26aulast%3DBose%26aufirst%3DR.%26aulast%3DJura%26aufirst%3DN.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520the%2520EGF%2520receptor%2520by%2520binding%2520of%2520MIG6%2520to%2520an%2520activating%2520kinase%2520domain%2520interface%26jtitle%3DNature%26date%3D2007%26volume%3D450%26spage%3D741%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Levinson, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchment, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koldobskiy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karplus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">A Src-like inactive conformation in the Abl tyrosine kinase domain</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">753</span><span class="NLM_x">â</span> <span class="NLM_lpage">767</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=753-767&issue=5&author=N.+M.+Levinsonauthor=O.+Kuchmentauthor=K.+Shenauthor=M.+A.+Youngauthor=M.+Koldobskiyauthor=M.+Karplusauthor=P.+A.+Coleauthor=J.+Kuriyan&title=A+Src-like+inactive+conformation+in+the+Abl+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevinson%26aufirst%3DN.%2BM.%26aulast%3DKuchment%26aufirst%3DO.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DKoldobskiy%26aufirst%3DM.%26aulast%3DKarplus%26aufirst%3DM.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DA%2520Src-like%2520inactive%2520conformation%2520in%2520the%2520Abl%2520tyrosine%2520kinase%2520domain%26jtitle%3DPLoS%2520Biol.%26date%3D2006%26volume%3D4%26issue%3D5%26spage%3D753%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coa, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">â</span> <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2Fj.str.2007.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17355866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=299-311&author=M.+A.+Seeligerauthor=B.+Nagarauthor=F.+Frankauthor=X.+Coaauthor=M.+N.+Hendersonauthor=J.+Kuriyan&title=c-Src+binds+to+the+cancer+drug+imatinib+with+an+inactive+Abl%2Fc-Kit+conformation+and+a+distributed+thermodynamic+penalty"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty</span></div><div class="casAuthors">Seeliger, Markus A.; Nagar, Bhushan; Frank, Filipp; Cao, Xiaoxian; Henderson, M. Nidanie; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-311</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor.  Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src.  The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Ablâ¢imatinib and c-Kitâ¢imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases.  Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodn. penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure.  Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2SQGjjXdg1LVg90H21EOLACvtfcHk0lho3ZrKIW_hSg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D&md5=ddfbcf06d91b408ca5fb25af9774c334</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2007.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2007.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DFrank%26aufirst%3DF.%26aulast%3DCoa%26aufirst%3DX.%26aulast%3DHenderson%26aufirst%3DM.%2BN.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3Dc-Src%2520binds%2520to%2520the%2520cancer%2520drug%2520imatinib%2520with%2520an%2520inactive%2520Abl%252Fc-Kit%2520conformation%2520and%2520a%2520distributed%2520thermodynamic%2520penalty%26jtitle%3DStructure%26date%3D2007%26volume%3D15%26spage%3D299%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayahshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Hashem, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronson, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">â</span> <span class="NLM_lpage">495</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=485-495&author=H.+Jiauthor=D.+Liauthor=L.+Chenauthor=T.+Shimamuraauthor=S.+Kobayahshiauthor=K.+McNamaraauthor=U.+Mahmoodauthor=A.+Mitchellauthor=Y.+Sunauthor=R.+Al-Hashemauthor=L.+R.+Chirieacauthor=R.+Paderaauthor=R.+T.+Bronsonauthor=W.+Kimauthor=P.+Janneauthor=G.+I.+Shapiroauthor=D.+G.+Tenenauthor=B.+E.+Johnsonauthor=R.+Weisslederauthor=N.+E.+Sharplessauthor=K.-K.+Wong&title=The+impact+of+human+EGFR+kinase+domain+mutations+on+lung+tumorigenesis+and+in+vivo+sensitivity+to+EGFR-targeted+therapies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKobayahshi%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DMahmood%26aufirst%3DU.%26aulast%3DMitchell%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAl-Hashem%26aufirst%3DR.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DJanne%26aufirst%3DP.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DSharpless%26aufirst%3DN.%2BE.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DThe%2520impact%2520of%2520human%2520EGFR%2520kinase%2520domain%2520mutations%2520on%2520lung%2520tumorigenesis%2520and%2520in%2520vivo%2520sensitivity%2520to%2520EGFR-targeted%2520therapies%26jtitle%3DCancer%2520Cell%26date%3D2006%26volume%3D9%26spage%3D485%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Modugno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soncini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosettani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I Abl mutant in complex with the Aurora kinase inhibitor PHA-739358</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7987</span><span class="NLM_x">â</span> <span class="NLM_lpage">7990</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=7987-7990&issue=17&author=M.+Modugnoauthor=E.+Casaleauthor=C.+Sonciniauthor=P.+Rosettaniauthor=R.+Colomboauthor=R.+Lupiauthor=L.+Rusconiauthor=D.+Fancelliauthor=P.+Carpinelliauthor=A.+D.+Cameronauthor=A.+Isacchiauthor=J.+Moll&title=Crystal+structure+of+the+T315I+Abl+mutant+in+complex+with+the+Aurora+kinase+inhibitor+PHA-739358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DModugno%26aufirst%3DM.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DRosettani%26aufirst%3DP.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DA.%2BD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520Abl%2520mutant%2520in%2520complex%2520with%2520the%2520Aurora%2520kinase%2520inhibitor%2520PHA-739358%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D17%26spage%3D7987%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Young, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">1007</span><span class="NLM_x">â</span> <span class="NLM_lpage">1014</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1007-1014&issue=2&author=M.+A.+Youngauthor=N.+P.+Shahauthor=L.+H.+Chaoauthor=M.+Seeligerauthor=Z.+V.+Milanovauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhartauthor=C.+L.+Sawyersauthor=J.+Kuriyan&title=Structure+of+the+kinase+domain+of+an+imatinib-resistant+Abl+mutant+in+complex+with+the+Aurora+kinase+inhibitor+VX-680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DChao%26aufirst%3DL.%2BH.%26aulast%3DSeeliger%26aufirst%3DM.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520kinase%2520domain%2520of%2520an%2520imatinib-resistant%2520Abl%2520mutant%2520in%2520complex%2520with%2520the%2520Aurora%2520kinase%2520inhibitor%2520VX-680%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D2%26spage%3D1007%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parillon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I mutant of Abl kinase</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">171</span><span class="NLM_x">â</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1111%2Fj.1747-0285.2007.00556.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17718712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=171-181&issue=3&author=T.+Zhouauthor=L.+Parillonauthor=F.+Liauthor=Y.+Wangauthor=J.+Keatsauthor=S.+Lamoreauthor=Q.+Xuauthor=W.+Shakespeareauthor=D.+Dalgarnoauthor=X.+Zhu&title=Crystal+structure+of+the+T315I+mutant+of+Abl+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the T315I mutant of Abl kinase</span></div><div class="casAuthors">Zhou, Tianjun; Parillon, Lois; Li, Feng; Wang, Yihan; Keats, Jeff; Lamore, Sarah; Xu, Qihong; Shakespeare, William; Dalgarno, David; Zhu, Xiaotian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a disease characterized by the presence of a constitutively activated chimeric tyrosine kinase protein Bcr-Abl.  However, drug resistance often occurs at later stages of the disease, principally because of the occurrence of mutations in the kinase domain.  Second generation Bcr-Abl inhibitors, such as dasatinib and nilotinib are capable of inhibiting many imatinib-resistant forms of the kinase but not the form in which threonine is mutated to isoleucine at the gatekeeper position (T315I).  In this study, we present the crystal structure of the kinase domain of the c-Abl T315I mutant, as well as the wild-type form, in complex with a pyrrolopyridine inhibitor, PPY-A.  The side chain of Ile315 is accommodated in the Abl T315I mutant structure without large conformational changes proximal to the site of mutation.  In contrast to other inhibitors, such as imatinib and dasatinib, PPY-A does not occupy the hydrophobic pocket behind the gate-keeper residue.  This binding mode, coupled with augmented contacts with the glycine-rich loop, appears to be crit. for its ability to override the T315I mutation.  The data presented here may provide structural guidance for the design of clin. useful inhibitors of Bcr-Abl T315I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcbSxFWWpadbVg90H21EOLACvtfcHk0lic1MDqCge9tw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F&md5=b15c60121b02e33d71783db3abd5ce72</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00556.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00556.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DLamore%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DShakespeare%26aufirst%3DW.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520mutant%2520of%2520Abl%2520kinase%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26issue%3D3%26spage%3D171%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">â</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lic1MDqCge9tw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Beghini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cairoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larizza, L.</span><span> </span><span class="NLM_article-title">In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation</span> <span class="citation_source-journal">Blood Cells, Mol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">262</span><span class="NLM_x">â</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1006%2Fbcmd.1998.0191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=9714703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADyaK1cXltl2ntbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1998&pages=262-270&issue=2&author=A.+Beghiniauthor=R.+Cairoliauthor=E.+Morraauthor=L.+Larizza&title=In+vivo+differentiation+of+mast+cells+from+acute+myeloid+leukemia+blasts+carrying+a+novel+activating+ligand-independent+C-kit+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation</span></div><div class="casAuthors">Beghini, Alessandro; Cairoli, Roberto; Morra, Enrica; Larizza, Lidia</div><div class="citationInfo"><span class="NLM_cas:title">Blood Cells, Molecules & Diseases</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">262-270</span>CODEN:
                <span class="NLM_cas:coden">BCMDFX</span>;
        ISSN:<span class="NLM_cas:issn">1079-9796</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The primary role of protooncogene c-kit in mast cell differentiation is supported by the development of mast cells from CD34+/CD117+ (c-kit) myeloid precursors.  Growth factor independence, neoplastic transformation and differentiation of mast cells were found in assocn. with c-kit activating mutations in both murine and human mastocytoma and mast cell diseases.  We have identified a novel c-kit mutation (D816Y) in peripheral blood mononuclear cells from a patient with AML (M2), massive presence of mast cells in bone marrow and rapid progression of the disease.  The mutation, a GâT transversion at nt 2467 of the c-kit gene resulting in Asp816âTyr substitution, corresponds to the D814Y and D817Y mutations identified and characterized in the murine P815 mastocytoma and the rat RBL-2H3 mast cell leukemia cell lines.  The absence of SCF transcripts that we found by RT-PCR in the patient's blasts indicates that, also in humans, this activating mutation leads to SCF independent growth.  The expression of the mutant allele on Kit signaling may by further enhanced by trisomy of chromosome 4 (carrying the c-kit gene) in the patient's blasts.  From these findings it is concluded that mast cells could be generated from a leukemic CD34/CD117-pos. clone, that combines the antigenic expression of mast cell precursor to the growth and differentiation factor-independence which was derived by the c-kit D816Y mutation.  (c) 1998 The Blood Cells Foundation, La Jolla, CA, USA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdKER3DbokJLVg90H21EOLACvtfcHk0lic1MDqCge9tw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltl2ntbo%253D&md5=e9c69dc1b7dcc192411a9f3612927274</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1006%2Fbcmd.1998.0191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbcmd.1998.0191%26sid%3Dliteratum%253Aachs%26aulast%3DBeghini%26aufirst%3DA.%26aulast%3DCairoli%26aufirst%3DR.%26aulast%3DMorra%26aufirst%3DE.%26aulast%3DLarizza%26aufirst%3DL.%26atitle%3DIn%2520vivo%2520differentiation%2520of%2520mast%2520cells%2520from%2520acute%2520myeloid%2520leukemia%2520blasts%2520carrying%2520a%2520novel%2520activating%2520ligand-independent%2520C-kit%2520mutation%26jtitle%3DBlood%2520Cells%252C%2520Mol.%2520Dis.%26date%3D1998%26volume%3D24%26issue%3D2%26spage%3D262%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Chompret, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannengiesser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrois, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tursz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenoir, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bressac-De Paillerets, B.</span><span> </span><span class="NLM_article-title">PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">318</span><span class="NLM_x">â</span> <span class="NLM_lpage">321</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=318-321&issue=1&author=A.+Chompretauthor=C.+Kannengiesserauthor=M.+Barroisauthor=P.+Terrierauthor=P.+Dahanauthor=T.+Turszauthor=G.+M.+Lenoirauthor=B.+Bressac-De+Paillerets&title=PDGFRA+germline+mutation+in+a+family+with+multiple+cases+of+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChompret%26aufirst%3DA.%26aulast%3DKannengiesser%26aufirst%3DC.%26aulast%3DBarrois%26aufirst%3DM.%26aulast%3DTerrier%26aufirst%3DP.%26aulast%3DDahan%26aufirst%3DP.%26aulast%3DTursz%26aufirst%3DT.%26aulast%3DLenoir%26aufirst%3DG.%2BM.%26aulast%3DBressac-De%2BPaillerets%26aufirst%3DB.%26atitle%3DPDGFRA%2520germline%2520mutation%2520in%2520a%2520family%2520with%2520multiple%2520cases%2520of%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DGastroenterology%26date%3D2004%26volume%3D126%26issue%3D1%26spage%3D318%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">PDGFRA activating mutations in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x"> (</span><span class="NLM_issue">5607</span><span class="NLM_x">) </span> <span class="NLM_fpage">708</span><span class="NLM_x">â</span> <span class="NLM_lpage">710</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=708-710&issue=5607&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=A.+Duensingauthor=L.+McGreeveyauthor=C.+J.+Chenauthor=N.+Josephauthor=S.+Singerauthor=D.+J.+Griffithauthor=A.+Haleyauthor=A.+Townauthor=G.+D.+Demetriauthor=C.+D.+Fletcherauthor=J.+A.+Fletcher&title=PDGFRA+activating+mutations+in+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGriffith%26aufirst%3DD.%2BJ.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DPDGFRA%2520activating%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D2003%26volume%3D299%26issue%3D5607%26spage%3D708%26epage%3D710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">9244</span><span class="NLM_x">â</span> <span class="NLM_lpage">9249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=9244-9249&issue=24&author=M.+Azamauthor=V.+Nardiauthor=W.+C.+Shakespeareauthor=C.+A.+Metcalfauthor=R.+S.+Bohacekauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=P.+Slizauthor=D.+R.+Veachauthor=W.+G.+Bornmannauthor=B.+Clarksonauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=G.+Q.+Daley&title=Activity+of+dual+SRC-ABL+inhibitors+highlights+the+role+of+BCR%2FABL+kinase+dynamics+in+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DNardi%26aufirst%3DV.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivity%2520of%2520dual%2520SRC-ABL%2520inhibitors%2520highlights%2520the%2520role%2520of%2520BCR%252FABL%2520kinase%2520dynamics%2520in%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26issue%3D24%26spage%3D9244%26epage%3D9249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Rosee, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahaye, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanfstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gschaidmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hehlmann, R.</span><span> </span><span class="NLM_article-title">Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2190</span><span class="NLM_x">â</span> <span class="NLM_lpage">2196</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=2190-2196&issue=11&author=A.+Hochhausauthor=S.+Kreilauthor=A.+S.+Corbinauthor=P.+La+Roseeauthor=M.+C.+Mullerauthor=T.+Lahayeauthor=B.+Hanfsteinauthor=C.+Schochauthor=N.+C.+Crossauthor=U.+Bergerauthor=H.+Gschaidmeierauthor=B.+J.+Drukerauthor=R.+Hehlmann&title=Molecular+and+chromosomal+mechanisms+of+resistance+to+imatinib+%28STI571%29+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DKreil%26aufirst%3DS.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DLa%2BRosee%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DM.%2BC.%26aulast%3DLahaye%26aufirst%3DT.%26aulast%3DHanfstein%26aufirst%3DB.%26aulast%3DSchoch%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DBerger%26aufirst%3DU.%26aulast%3DGschaidmeier%26aufirst%3DH.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DHehlmann%26aufirst%3DR.%26atitle%3DMolecular%2520and%2520chromosomal%2520mechanisms%2520of%2520resistance%2520to%2520imatinib%2520%2528STI571%2529%2520therapy%26jtitle%3DLeukemia%26date%3D2002%26volume%3D16%26issue%3D11%26spage%3D2190%26epage%3D2196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Roumiantsev, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasher, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span> </span><span class="NLM_article-title">Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x"> (</span><span class="NLM_issue">16</span><span class="NLM_x">) </span> <span class="NLM_fpage">10700</span><span class="NLM_x">â</span> <span class="NLM_lpage">10705</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=10700-10705&issue=16&author=S.+Roumiantsevauthor=N.+P.+Shahauthor=M.+E.+Gorreauthor=J.+Nicollauthor=B.+B.+Brasherauthor=C.+L.+Sawyersauthor=R.+A.+Van+Etten&title=Clinical+resistance+to+the+kinase+inhibitor+STI-571+in+chronic+myeloid+leukemia+by+mutation+of+Tyr-253+in+the+Abl+kinase+domain+P-loop"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoumiantsev%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DNicoll%26aufirst%3DJ.%26aulast%3DBrasher%26aufirst%3DB.%2BB.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26atitle%3DClinical%2520resistance%2520to%2520the%2520kinase%2520inhibitor%2520STI-571%2520in%2520chronic%2520myeloid%2520leukemia%2520by%2520mutation%2520of%2520Tyr-253%2520in%2520the%2520Abl%2520kinase%2520domain%2520P-loop%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2002%26volume%3D99%26issue%3D16%26spage%3D10700%26epage%3D10705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">117</span><span class="NLM_x">â</span> <span class="NLM_lpage">125</span><div class="note"><p class="first last">[Comment]</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&issue=2&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+kinase+domain+mutations+confer+polyclonal+resistance+to+the+tyrosine+kinase+inhibitor+imatinib+%28STI571%29+in+chronic+phase+and+blast+crisis+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520confer%2520polyclonal%2520resistance%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520%2528STI571%2529%2520in%2520chronic%2520phase%2520and%2520blast%2520crisis%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26issue%3D2%26spage%3D117%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">OâHare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia</span> <span class="citation_source-journal">Clin. Lymphoma Myeloma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S120</span><span class="NLM_x">â</span> <span class="NLM_lpage">S130</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=S120-S130&issue=Suppl.+3&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=M.+W.+Deininger&title=Bcr-Abl+kinase+domain+mutations+and+the+unsettled+problem+of+Bcr-AblT315I%3A+looking+into+the+future+of+controlling+drug+resistance+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DBcr-Abl%2520kinase%2520domain%2520mutations%2520and%2520the%2520unsettled%2520problem%2520of%2520Bcr-AblT315I%253A%2520looking%2520into%2520the%2520future%2520of%2520controlling%2520drug%2520resistance%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Lymphoma%2520Myeloma%26date%3D2007%26volume%3D7%26issue%3DSuppl.%25203%26spage%3DS120%26epage%3DS130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Soverini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colarossi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gnani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poerio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacobucci, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amabile, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abruzzese, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlandi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radaelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciccone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiribelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">di Lorenzo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caracciolo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izzo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pane, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leukemia, G. W. P. o. C. M.</span><span> </span><span class="NLM_article-title">Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">7374</span><span class="NLM_x">â</span> <span class="NLM_lpage">7379</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1158%2F1078-0432.CCR-06-1516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17189410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCrtr%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=7374-7379&issue=24&author=S.+Soveriniauthor=S.+Colarossiauthor=A.+Gnaniauthor=G.+Rostiauthor=F.+Castagnettiauthor=A.+Poerioauthor=I.+Iacobucciauthor=M.+Amabileauthor=E.+Abruzzeseauthor=E.+Orlandiauthor=F.+Radaelliauthor=F.+Cicconeauthor=M.+Tiribelliauthor=R.+di+Lorenzoauthor=C.+Caraccioloauthor=B.+Izzoauthor=F.+Paneauthor=G.+Saglioauthor=M.+Baccaraniauthor=G.+Martinelliauthor=G.+W.+P.+o.+C.+M.+Leukemia&title=Contribution+of+ABL+kinase+domain+mutations+to+imatinib+resistance+in+different+subsets+of+Philadelphia-positive+patients%3A+by+the+GIMEMA+Working+Party+on+Chronic+Myeloid+Leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia</span></div><div class="casAuthors">Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandra; Rosti, Gianantonio; Castagnetti, Fausto; Poerio, Angela; Iacobucci, Ilaria; Amabile, Marilina; Abruzzese, Elisabetta; Orlandi, Ester; Radaelli, Franca; Ciccone, Fabrizio; Tiribelli, Mario; di Lorenzo, Roberto; Caracciolo, Clementina; Izzo, Barbara; Pane, Fabrizio; Saglio, Giuseppe; Baccarani, Michele; Martinelli, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7374-7379</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-pos. (Ph+) leukemia patients.  Exptl. Design: Using denaturing high-performance liq. chromatog. and sequencing, we screened for ABL kinase domain mutations in 370 Ph+ patients with evidence of hematol. or cytogenetic resistance to imatinib.  Results: Mutations were found in 127 of 297 (43%) evaluable patients.  Mutations were found in 27% of chronic-phase patients (14% treated with imatinib frontline; 31% treated with imatinib post-IFN failure), 52% of accelerated-phase patients, 75% of myeloid blast crisis patients, and 83% of lymphoid blast crisis/Ph+ acute lymphoblastic leukemia (ALL) patients.  Mutations were assocd. in 30% of patients with primary resistance (44% hematol. and 28% cytogenetic) and in 57% of patients with acquired resistance (23% patients who lost cytogenetic response; 55% patients who lost hematol. response; and 87% patients who progressed to accelerated phase/blast crisis).  P-loop and T315I mutations were particularly frequent in advanced-phase chronic myeloid leukemia and Ph+ ALL patients, and often accompanied progression from chronic phase to accelerated phase/blast crisis.  Conclusions: We conclude that (a) amino acid substitutions at seven residues (M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V) account for 85% of all resistance-assocd. mutations; (b) the search for mutations is important both in case of imatinib failure and in case of loss of response at the hematol. or cytogenetic level; (c) advanced-phase chronic myeloid leukemia and Ph+ ALL patients have a higher likelihood of developing imatinib-resistant mutations; and (d) the presence of either P-loop or T315I mutations in imatinib-treated patients should warn the clinician to reconsider the therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSQP35u9vcXbVg90H21EOLACvtfcHk0limVOqlVDSV2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCrtr%252FK&md5=52440d8b2a968324b30fec90669cd442</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1516%26sid%3Dliteratum%253Aachs%26aulast%3DSoverini%26aufirst%3DS.%26aulast%3DColarossi%26aufirst%3DS.%26aulast%3DGnani%26aufirst%3DA.%26aulast%3DRosti%26aufirst%3DG.%26aulast%3DCastagnetti%26aufirst%3DF.%26aulast%3DPoerio%26aufirst%3DA.%26aulast%3DIacobucci%26aufirst%3DI.%26aulast%3DAmabile%26aufirst%3DM.%26aulast%3DAbruzzese%26aufirst%3DE.%26aulast%3DOrlandi%26aufirst%3DE.%26aulast%3DRadaelli%26aufirst%3DF.%26aulast%3DCiccone%26aufirst%3DF.%26aulast%3DTiribelli%26aufirst%3DM.%26aulast%3Ddi%2BLorenzo%26aufirst%3DR.%26aulast%3DCaracciolo%26aufirst%3DC.%26aulast%3DIzzo%26aufirst%3DB.%26aulast%3DPane%26aufirst%3DF.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DLeukemia%26aufirst%3DG.%2BW.%2BP.%2Bo.%2BC.%2BM.%26atitle%3DContribution%2520of%2520ABL%2520kinase%2520domain%2520mutations%2520to%2520imatinib%2520resistance%2520in%2520different%2520subsets%2520of%2520Philadelphia-positive%2520patients%253A%2520by%2520the%2520GIMEMA%2520Working%2520Party%2520on%2520Chronic%2520Myeloid%2520Leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26issue%3D24%26spage%3D7374%26epage%3D7379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4236</span><span class="NLM_x">â</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&issue=15&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0limVOqlVDSV2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26issue%3D15%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1109</span><span class="NLM_x">â</span> <span class="NLM_lpage">1118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnsmb.1486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18794843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1109-1118&issue=10&author=M.+Azamauthor=M.+A.+Seeligerauthor=N.+S.+Grayauthor=J.+Kuriyanauthor=G.+Q.+Daley&title=Activation+of+tyrosine+kinases+by+mutation+of+the+gatekeeper+threonine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span></div><div class="casAuthors">Azam, Mohammad; Seeliger, Markus A.; Gray, Nathanael S.; Kuriyan, John; Daley, George Q.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1109-1118</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinases targeted by small-mol. inhibitors develop resistance through mutation of the 'gatekeeper' threonine residue of the active site.  Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth factor receptor-Î± and -Î², and epidermal growth factor receptor activates the kinase and promotes malignant transformation of BaF3 cells.  Structural anal. reveals that a network of hydrophobic interactions - the hydrophobic spine - characteristic of the active kinase conformation is stabilized by the gatekeeper substitution.  Substitution of glycine for the residues constituting the spine disrupts the hydrophobic connectivity and inactivates the kinase.  Furthermore, a small-mol. inhibitor (compd. 14) that maximizes complementarity with the dismantled spine inhibits the gatekeeper mutation of BCR-ABL-T315I.  These results demonstrate that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases and provide structural insights to guide the development of next-generation inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEoZTY5SkbALVg90H21EOLACvtfcHk0limVOqlVDSV2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM&md5=4afc4e5a0850a4510ced3fa5fbda97fa</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1486%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivation%2520of%2520tyrosine%2520kinases%2520by%2520mutation%2520of%2520the%2520gatekeeper%2520threonine%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2008%26volume%3D15%26issue%3D10%26spage%3D1109%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haste, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyck, L. F.</span><span> </span><span class="NLM_article-title">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">17783</span><span class="NLM_x">â</span> <span class="NLM_lpage">17788</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1073%2Fpnas.0607656103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17095602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=17783-17788&author=A.+P.+Kornevauthor=N.+M.+Hasteauthor=S.+S.+Taylorauthor=L.+F.+Eyck&title=Surface+comparison+of+active+and+inactive+protein+kinases+identifies+a+conserved+activation+mechanism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span></div><div class="casAuthors">Kornev, Alexandr P.; Haste, Nina M.; Taylor, Susan S.; Ten Eyck, Lynn F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">17783-17788</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The surface comparison of different serine-threonine and tyrosine kinases reveals a set of 30 residues whose spatial positions are highly conserved.  The comparison between active and inactive conformations identified the residues whose positions are the most sensitive to activation.  Based on these results, we propose a model of protein kinase activation.  This model explains how the presence of a phosphate group in the activation loop dets. the position of the catalytically important aspartate in the Asp-Phe-Gly (DFG) motif.  According to the model, the most important feature of the activation is a "spine" formation that is dynamically assembled in all active kinases.  The spine is comprised of four hydrophobic residues that we detected in a set of 23 eukaryotic and prokaryotic kinases.  It spans the mol. and plays a coordinating role in activated kinases.  The spine is disordered in the inactive kinases and can explain how stabilization of the whole mol. is achieved upon phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwv4ByA5owH7Vg90H21EOLACvtfcHk0ljXEJhT91rIGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ&md5=f474acffd8b17d8352ac9f6fc9bbbf8f</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0607656103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0607656103%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DHaste%26aufirst%3DN.%2BM.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DEyck%26aufirst%3DL.%2BF.%26atitle%3DSurface%2520comparison%2520of%2520active%2520and%2520inactive%2520protein%2520kinases%2520identifies%2520a%2520conserved%2520activation%2520mechanism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D17783%26epage%3D17788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halgren, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanschagrin, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainz, D. T.</span><span> </span><span class="NLM_article-title">Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for proteinâligand complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">6177</span><span class="NLM_x">â</span> <span class="NLM_lpage">6196</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm051256o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6177-6196&issue=21&author=R.+A.+Friesnerauthor=R.+B.+Murphyauthor=M.+P.+Repaskyauthor=L.+L.+Fryeauthor=J.+R.+Greenwoodauthor=T.+A.+Halgrenauthor=P.+C.+Sanschagrinauthor=D.+T.+Mainz&title=Extra+precision+glide%3A+docking+and+scoring+incorporating+a+model+of+hydrophobic+enclosure+for+protein%E2%88%92ligand+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm051256o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051256o%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DSanschagrin%26aufirst%3DP.%2BC.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26atitle%3DExtra%2520precision%2520glide%253A%2520docking%2520and%2520scoring%2520incorporating%2520a%2520model%2520of%2520hydrophobic%2520enclosure%2520for%2520protein%25E2%2588%2592ligand%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D21%26spage%3D6177%26epage%3D6196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">11011</span><span class="NLM_x">â</span> <span class="NLM_lpage">11016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&issue=31&author=T.+A.+Carterauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=W.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Patelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26issue%3D31%26spage%3D11011%26epage%3D11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">OâHare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4500</span><span class="NLM_x">â</span> <span class="NLM_lpage">4505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4500-4505&issue=11&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=T.+Jiaauthor=P.+W.+Manleyauthor=J.+Mestanauthor=S.+W.+Cowan-Jacobauthor=F.+Y.+Leeauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=In+vitro+activity+of+Bcr-Abl+inhibitors+AMN107+and+BMS-354825+against+clinically+relevant+imatinib-resistant+Abl+kinase+domain+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DJia%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bcr-Abl%2520inhibitors%2520AMN107%2520and%2520BMS-354825%2520against%2520clinically%2520relevant%2520imatinib-resistant%2520Abl%2520kinase%2520domain%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D11%26spage%3D4500%26epage%3D4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">le Coutre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottmann, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gattermann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apperley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abruzzese, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâBrien, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuliczkowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahon, F.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobbi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">1834</span><span class="NLM_x">â</span> <span class="NLM_lpage">1839</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=1834-1839&issue=4&author=P.+le+Coutreauthor=O.+G.+Ottmannauthor=F.+Gilesauthor=D.-W.+Kimauthor=J.+Cortesauthor=N.+Gattermannauthor=J.+F.+Apperleyauthor=R.+A.+Larsonauthor=E.+Abruzzeseauthor=S.+G.+O%E2%80%99Brienauthor=K.+Kuliczkowskiauthor=A.+Hochhausauthor=F.-X.+Mahonauthor=G.+Saglioauthor=M.+Gobbiauthor=Y.-L.+Kwongauthor=M.+Baccaraniauthor=T.+Hughesauthor=G.+Martinelliauthor=J.+P.+Radichauthor=M.+Zhengauthor=Y.+Shouauthor=H.+Kantarjian&title=Nilotinib+%28formerly+AMN107%29%2C+a+highly+selective+BCR-ABL+tyrosine+kinase+inhibitor%2C+is+active+in+patients+with+imatinib-resistant+or+-intolerant+accelerated-phase+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dle%2BCoutre%26aufirst%3DP.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DGattermann%26aufirst%3DN.%26aulast%3DApperley%26aufirst%3DJ.%2BF.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DAbruzzese%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DKuliczkowski%26aufirst%3DK.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DMahon%26aufirst%3DF.-X.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DGobbi%26aufirst%3DM.%26aulast%3DKwong%26aufirst%3DY.-L.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DT.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DShou%26aufirst%3DY.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DNilotinib%2520%2528formerly%2520AMN107%2529%252C%2520a%2520highly%2520selective%2520BCR-ABL%2520tyrosine%2520kinase%2520inhibitor%252C%2520is%2520active%2520in%2520patients%2520with%2520imatinib-resistant%2520or%2520-intolerant%2520accelerated-phase%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26issue%3D4%26spage%3D1834%26epage%3D1839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">OâHare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holme, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burley, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">5507</span><span class="NLM_x">â</span> <span class="NLM_lpage">5512</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=5507-5512&issue=14&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=J.+W.+Tynerauthor=A.+S.+Corbinauthor=M.+J.+Wongauthor=S.+Buchananauthor=K.+Holmeauthor=K.+A.+Jessenauthor=C.+Tangauthor=H.+A.+Lewisauthor=R.+D.+Romeroauthor=S.+K.+Burleyauthor=M.+W.+Deininger&title=SGX393+inhibits+the+CML+mutant+Bcr-AblT315I+and+preempts+in+vitro+resistance+when+combined+with+nilotinib+or+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWong%26aufirst%3DM.%2BJ.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DHolme%26aufirst%3DK.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DRomero%26aufirst%3DR.%2BD.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DSGX393%2520inhibits%2520the%2520CML%2520mutant%2520Bcr-AblT315I%2520and%2520preempts%2520in%2520vitro%2520resistance%2520when%2520combined%2520with%2520nilotinib%2520or%2520dasatinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26issue%3D14%26spage%3D5507%26epage%3D5512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Harrington, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebbington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajose-Adeogun, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hercend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diu-Hercend, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golec, J. M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. M.</span><span> </span><span class="NLM_article-title">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">262</span><span class="NLM_x">â</span> <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnm1003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=14981513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=262-267&issue=3&author=E.+A.+Harringtonauthor=D.+Bebbingtonauthor=J.+Mooreauthor=R.+K.+Rasmussenauthor=A.+O.+Ajose-Adeogunauthor=T.+Nakayamaauthor=J.+A.+Grahamauthor=C.+Demurauthor=T.+Hercendauthor=A.+Diu-Hercendauthor=M.+Suauthor=J.+M.+C.+Golecauthor=K.+M.+Miller&title=VX-680%2C+a+potent+and+selective+small-molecule+inhibitor+of+the+Aurora+kinases%2C+suppresses+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span></div><div class="casAuthors">Harrington, Elizabeth A.; Bebbington, David; Moore, Jeff; Rasmussen, Richele K.; Ajose-Adeogun, Abi O.; Nakayama, Tomoko; Graham, Joanne A.; Demur, Cecile; Hercend, Thierry; Diu-Hercend, Anita; Su, Michael; Golec, Julian M. C.; Miller, Karen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-267</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis.  Aberrant expression and activity of these kinases occur in a wide range of human tumors, and lead to aneuploidy and tumorigenesis.  Here we report the discovery of a highly potent and selective small-mol. inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types.  This compd. causes profound inhibition of tumor growth in a variety of in vivo xenograft models, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses.  Our data indicate that Aurora kinase inhibition provides a new approach for the treatment of multiple human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgm1YUgqkWLVg90H21EOLACvtfcHk0ljlGi9dolVHFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D&md5=954ba274e280d8d08a7f2e331011432d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnm1003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1003%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DBebbington%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DJ.%26aulast%3DRasmussen%26aufirst%3DR.%2BK.%26aulast%3DAjose-Adeogun%26aufirst%3DA.%2BO.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DJ.%2BA.%26aulast%3DDemur%26aufirst%3DC.%26aulast%3DHercend%26aufirst%3DT.%26aulast%3DDiu-Hercend%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%2BC.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26atitle%3DVX-680%252C%2520a%2520potent%2520and%2520selective%2520small-molecule%2520inhibitor%2520of%2520the%2520Aurora%2520kinases%252C%2520suppresses%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26issue%3D3%26spage%3D262%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaggs, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branford, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2562</span><span class="NLM_x">â</span> <span class="NLM_lpage">2569</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=2562-2569&issue=9&author=N.+P.+Shahauthor=B.+J.+Skaggsauthor=S.+Branfordauthor=T.+P.+Hughesauthor=J.+M.+Nicollauthor=R.+L.+Paquetteauthor=C.+L.+Sawyers&title=Sequential+ABL+kinase+inhibitor+therapy+selects+for+compound+drug-resistant+BCR-ABL+mutations+with+altered+oncogenic+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DSkaggs%26aufirst%3DB.%2BJ.%26aulast%3DBranford%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DSequential%2520ABL%2520kinase%2520inhibitor%2520therapy%2520selects%2520for%2520compound%2520drug-resistant%2520BCR-ABL%2520mutations%2520with%2520altered%2520oncogenic%2520potency%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26issue%3D9%26spage%3D2562%26epage%3D2569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, S. J.</span><span> </span><span class="NLM_article-title">MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">500</span><span class="NLM_x">â</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=500-502&issue=2&author=F.+J.+Gilesauthor=J.+Cortesauthor=D.+Jonesauthor=D.+Bergstromauthor=H.+Kantarjianauthor=S.+J.+Freedman&title=MK-0457%2C+a+novel+kinase+inhibitor%2C+is+active+in+patients+with+chronic+myeloid+leukemia+or+acute+lymphocytic+leukemia+with+the+T315I+BCR-ABL+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DBergstrom%26aufirst%3DD.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFreedman%26aufirst%3DS.%2BJ.%26atitle%3DMK-0457%252C%2520a%2520novel%2520kinase%2520inhibitor%252C%2520is%2520active%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520or%2520acute%2520lymphocytic%2520leukemia%2520with%2520the%2520T315I%2520BCR-ABL%2520mutation%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26issue%3D2%26spage%3D500%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Gumireddy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1992</span><span class="NLM_x">â</span> <span class="NLM_lpage">1997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=1992-1997&issue=6&author=K.+Gumireddyauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=P.+Johnauthor=A.+D.+Kangauthor=K.+A.+Robellauthor=M.+V.+R.+Reddyauthor=E.+P.+Reddy&title=A+non-ATP-competitive+inhibitor+of+BCR-ABL+overrides+imatinib+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DJohn%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DA.%2BD.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520non-ATP-competitive%2520inhibitor%2520of%2520BCR-ABL%2520overrides%2520imatinib%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26issue%3D6%26spage%3D1992%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Miettinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlomo-Rikala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasota, J.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors: recent advances in understanding of their biology</span> <span class="citation_source-journal">Hum. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1213</span><span class="NLM_x">â</span> <span class="NLM_lpage">1220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS0046-8177%2899%2990040-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=10534170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FgtFOgtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1999&pages=1213-1220&issue=10&author=M.+Miettinenauthor=M.+Sarlomo-Rikalaauthor=J.+Lasota&title=Gastrointestinal+stromal+tumors%3A+recent+advances+in+understanding+of+their+biology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumors: recent advances in understanding of their biology</span></div><div class="casAuthors">Miettinen M; Sarlomo-Rikala M; Lasota J</div><div class="citationInfo"><span class="NLM_cas:title">Human pathology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1213-20</span>
        ISSN:<span class="NLM_cas:issn">0046-8177</span>.
    </div><div class="casAbstract">Gastrointestinal stromal tumor (GIST) is the preferred term for mesenchymal tumors specific for the gastrointestinal tract (60% in stomach, 30% small intestine, 10% elsewhere).  GISTs include most tumors previously designated as leiomyoma, cellular leiomyoma, leiomyoblastoma, and leiomyosarcoma.  However, in the esophagus, leiomyoma is the most common mesenchymal tumor.  GISTs are composed of spindle (70%) or epithelioid (30%) cells, and 10%-30% are malignant showing intra-abdominal spread or liver metastases.  They are immunohistochemically positive for c-kit (CD117), CD34, and sometimes for actin but are almost always negative for desmin and S100-protein.  The malignant GISTs especially show activating mutations in the c-kit gene.  GISTs and gastrointestinal autonomic nerve tumors (GANT) overlap.  The cell of origin is not fully understood, but resemblance to the interstitial cells of Cajal, expression of some smooth muscle markers, and occurrence outside of the GI-tract suggest origin from multipotential cells that can differentiate into Cajal and smooth muscle cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyWL-Bn3fJXO3MPKNEWB5RfW6udTcc2ea4bz0RgpSL4rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FgtFOgtQ%253D%253D&md5=694517ed6b6ea7e57bd91895fc5c1c6c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0046-8177%2899%2990040-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0046-8177%252899%252990040-0%26sid%3Dliteratum%253Aachs%26aulast%3DMiettinen%26aufirst%3DM.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DLasota%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors%253A%2520recent%2520advances%2520in%2520understanding%2520of%2520their%2520biology%26jtitle%3DHum.%2520Pathol.%26date%3D1999%26volume%3D30%26issue%3D10%26spage%3D1213%26epage%3D1220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiguro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhammad Tunio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x"> (</span><span class="NLM_issue">5350</span><span class="NLM_x">) </span> <span class="NLM_fpage">577</span><span class="NLM_x">â</span> <span class="NLM_lpage">580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&issue=5350&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+Muhammad+Tunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%2BTunio%26aufirst%3DG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26issue%3D5350%26spage%3D577%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlomo-Rikala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tervahartiala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">1052</span><span class="NLM_x">â</span> <span class="NLM_lpage">1056</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJM200104053441404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=11287975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1052-1056&issue=14&author=H.+Joensuuauthor=P.+J.+Robertsauthor=M.+Sarlomo-Rikalaauthor=L.+C.+Anderssonauthor=P.+Tervahartialaauthor=D.+Tuvesonauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=S.+Dimitrijevicauthor=B.+Drukerauthor=G.+D.+Demetri&title=Effect+of+the+tyrosine+kinase+inhibitor+STI571+in+a+patient+with+a+metastatic+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1052-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYZ86Vmj15i5otVjB3IRIyfW6udTcc2eZrM47JCUT4H7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D&md5=d361debf544b136b28889449118225e3</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441404%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DTervahartiala%26aufirst%3DP.%26aulast%3DTuveson%26aufirst%3DD.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEffect%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%2520STI571%2520in%2520a%2520patient%2520with%2520a%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26issue%3D14%26spage%3D1052%26epage%3D1056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeCesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogendoorn, P. C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertulli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x"> (</span><span class="NLM_issue">9440</span><span class="NLM_x">) </span> <span class="NLM_fpage">1127</span><span class="NLM_x">â</span> <span class="NLM_lpage">1134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=1127-1134&issue=9440&author=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=A.+LeCesneauthor=P.+Reichardtauthor=J.-Y.+Blayauthor=R.+Isselsauthor=A.+van+Oosteromauthor=P.+C.+W.+Hogendoornauthor=M.+Van+Glabbekeauthor=R.+Bertulliauthor=I.+Judson&title=Progression-free+survival+in+gastrointestinal+stromal+tumours+with+high-dose+imatinib%3A+randomised+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DLeCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%26aulast%3DHogendoorn%26aufirst%3DP.%2BC.%2BW.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DProgression-free%2520survival%2520in%2520gastrointestinal%2520stromal%2520tumours%2520with%2520high-dose%2520imatinib%253A%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26issue%3D9440%26spage%3D1127%26epage%3D1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span> </span><span class="NLM_article-title">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">472</span><span class="NLM_x">â</span> <span class="NLM_lpage">480</span><div class="note"><p class="first last">[see Comment]</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMoa020461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12181401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=472-480&issue=7&author=G.+D.+Demetriauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=A.+D.+Van+den+Abbeeleauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=M.+C.+Heinrichauthor=D.+A.+Tuvesonauthor=S.+Singerauthor=M.+Janicekauthor=J.+A.+Fletcherauthor=S.+G.+Silvermanauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=B.+Kieseauthor=B.+Pengauthor=S.+Dimitrijevicauthor=B.+J.+Drukerauthor=C.+Corlessauthor=C.+D.+Fletcherauthor=H.+Joensuu&title=Efficacy+and+safety+of+imatinib+mesylate+in+advanced+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span></div><div class="casAuthors">Demetri, George D.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D. M.; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Constitutive activation of KIT receptor tyrosine kinase is crit. in the pathogenesis of gastrointestinal stromal tumors.  Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclin. models and preliminary clin. studies to have activity against such tumors.  We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor.  We assessed antitumor response and the safety and tolerability of the drug.  Pharmacokinetics were assessed in a subgroup of patients.  A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily.  Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for tech. reasons, response could not be evaluated in 7 patients (4.8 percent).  No patient had a complete response to the treatment.  The median duration of response had not been reached after a median follow-up of 24 wk after the onset of response.  Early resistance to imatinib was noted in 20 patients (13.6 percent).  Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common.  Gastrointestinal or intraabdominal hemorrhage occurred in approx. 5 percent of patients.  There were no significant differences in toxic effects or response between the two doses.  Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.  Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.  Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVE0HpuuKXXrVg90H21EOLACvtfcHk0lhAvR-hSOVDMw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D&md5=95c9ea076dd2b0e053ae2061cb3f5d24</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020461%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DJanicek%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSilverman%26aufirst%3DS.%2BG.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520imatinib%2520mesylate%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26issue%3D7%26spage%3D472%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheibe, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. P.</span><span> </span><span class="NLM_article-title">Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x"> (</span><span class="NLM_issue">30</span><span class="NLM_x">) </span> <span class="NLM_fpage">31655</span><span class="NLM_x">â</span> <span class="NLM_lpage">31663</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1074%2Fjbc.M403319200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15123710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=31655-31663&issue=30&author=C.+D.+Molauthor=D.+R.+Douganauthor=T.+R.+Schneiderauthor=R.+J.+Skeneauthor=M.+L.+Krausauthor=D.+N.+Scheibeauthor=G.+P.+Snellauthor=H.+Zouauthor=B.-C.+Sangauthor=K.+P.+Wilson&title=Structural+basis+for+the+autoinhibition+and+STI-571+inhibition+of+c-Kit+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase</span></div><div class="casAuthors">Mol, Clifford D.; Dougan, Douglas R.; Schneider, Thomas R.; Skene, Robert J.; Kraus, Michelle L.; Scheibe, Daniel N.; Snell, Gyorgy P.; Zou, Hua; Sang, Bi-Ching; Wilson, Keith P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">31655-31663</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers.  The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known.  We report the 1.9-Ã resoln. crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase.  Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure.  A 1.6-Ã crystal structure of c-Kit in complex with STI-571 (Imatinib or Gleevec) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state.  Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWJsKx1IzXQbVg90H21EOLACvtfcHk0liyjfWtEk5e1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D&md5=df6065a62b44e4c2e6b020da0f797ab4</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403319200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403319200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKraus%26aufirst%3DM.%2BL.%26aulast%3DScheibe%26aufirst%3DD.%2BN.%26aulast%3DSnell%26aufirst%3DG.%2BP.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSang%26aufirst%3DB.-C.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520for%2520the%2520autoinhibition%2520and%2520STI-571%2520inhibition%2520of%2520c-Kit%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D30%26spage%3D31655%26epage%3D31663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Antonescu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koryotowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leversha, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desantis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span> </span><span class="NLM_article-title">Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4182</span><span class="NLM_x">â</span> <span class="NLM_lpage">4190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&issue=11&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singerauthor=M.+F.+Brennanauthor=R.+G.+Makiauthor=R.+P.+DeMatteo&title=Acquired+resistance+to+imatinib+in+gastrointestinal+stromal+tumor+occurs+through+secondary+gene+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0liyjfWtEk5e1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DAcquired%2520resistance%2520to%2520imatinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520occurs%2520through%2520secondary%2520gene%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26issue%3D11%26spage%3D4182%26epage%3D4190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Chen, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuller, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramdas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prieto, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyedeji, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feig, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macapinlac, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hittelman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier, M. L.</span><span> </span><span class="NLM_article-title">A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">5913</span><span class="NLM_x">â</span> <span class="NLM_lpage">5919</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=5913-5919&issue=17&author=L.+L.+Chenauthor=J.+C.+Trentauthor=E.+F.+Wuauthor=G.+N.+Fullerauthor=L.+Ramdasauthor=W.+Zhangauthor=A.+K.+Raymondauthor=V.+G.+Prietoauthor=C.+O.+Oyedejiauthor=K.+K.+Huntauthor=R.+E.+Pollockauthor=B.+W.+Feigauthor=K.+J.+Hayesauthor=H.+Choiauthor=H.+A.+Macapinlacauthor=W.+Hittelmanauthor=M.+A.+Velascoauthor=S.+Patelauthor=M.+A.+Burgessauthor=R.+S.+Benjaminauthor=M.+L.+Frazier&title=A+missense+mutation+in+KIT+kinase+domain+1+correlates+with+imatinib+resistance+in+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%2BL.%26aulast%3DTrent%26aufirst%3DJ.%2BC.%26aulast%3DWu%26aufirst%3DE.%2BF.%26aulast%3DFuller%26aufirst%3DG.%2BN.%26aulast%3DRamdas%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRaymond%26aufirst%3DA.%2BK.%26aulast%3DPrieto%26aufirst%3DV.%2BG.%26aulast%3DOyedeji%26aufirst%3DC.%2BO.%26aulast%3DHunt%26aufirst%3DK.%2BK.%26aulast%3DPollock%26aufirst%3DR.%2BE.%26aulast%3DFeig%26aufirst%3DB.%2BW.%26aulast%3DHayes%26aufirst%3DK.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%26aulast%3DMacapinlac%26aufirst%3DH.%2BA.%26aulast%3DHittelman%26aufirst%3DW.%26aulast%3DVelasco%26aufirst%3DM.%2BA.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DBurgess%26aufirst%3DM.%2BA.%26aulast%3DBenjamin%26aufirst%3DR.%2BS.%26aulast%3DFrazier%26aufirst%3DM.%2BL.%26atitle%3DA%2520missense%2520mutation%2520in%2520KIT%2520kinase%2520domain%25201%2520correlates%2520with%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26issue%3D17%26spage%3D5913%26epage%3D5919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishitani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirota, S.</span><span> </span><span class="NLM_article-title">Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">799</span><span class="NLM_x">â</span> <span class="NLM_lpage">804</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1111%2Fj.1349-7006.2008.00727.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18294292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsFyls7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2008&pages=799-804&issue=4&author=T.+Nishidaauthor=T.+Kandaauthor=A.+Nishitaniauthor=T.+Takahashiauthor=K.+Nakajimaauthor=T.+Ishikawaauthor=S.+Hirota&title=Secondary+mutations+in+the+kinase+domain+of+the+KIT+gene+are+predominant+in+imatinib-resistant+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor</span></div><div class="casAuthors">Nishida, Toshirou; Kanda, Tatsuo; Nishitani, Akiko; Takahashi, Tsuyoshi; Nakajima, Kiyokazu; Ishikawa, Takashi; Hirota, Seiichi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">799-804</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">Although imatinib showed high activity for advanced gastrointestinal stromal tumor (GIST) and improved the prognosis of GIST patients, resistance to the drug appears with prolonged use.  Mechanisms of acquired resistance are still under investigation.  In the present study, the authors carried out histol. and genetic anal. of 45 secondary resistant lesions obtained from 25 Japanese GIST patients treated with imatinib.  All resistant lesions showed viable tumor cells expressing KIT protein, whereas imatinib-sensitive lesions did not.  All pre-imatinib samples have KIT mutations either in exon 9 (n = 3) or exon 11 (n = 22), identified in the KIT gene of corresponding resistant tumors.  In addn. to primary mutations, 33 out of 45 tumors (73%) showed secondary KIT mutations in the kinase domain of the KIT gene.  Secondary mutations are missense mutations and are mostly located in the kinase domains of the same allele to the primary mutations (cis-position).  Resistant lesions showed monoclonal development of tumor cells.  Taken together, addnl. cis-positioned mutations in the kinase domains are a major cause of secondary resistance to imatinib in Japanese GIST patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7QYQriMQeU7Vg90H21EOLACvtfcHk0liyjfWtEk5e1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsFyls7w%253D&md5=5b18ed82560702b3b9b2111149d8e44a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.00727.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.00727.x%26sid%3Dliteratum%253Aachs%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DNishitani%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DNakajima%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DHirota%26aufirst%3DS.%26atitle%3DSecondary%2520mutations%2520in%2520the%2520kinase%2520domain%2520of%2520the%2520KIT%2520gene%2520are%2520predominant%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DCancer%2520Sci.%26date%3D2008%26volume%3D99%26issue%3D4%26spage%3D799%26epage%3D804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Wardelmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkelbach-Bruse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speidel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BÃ¼ttner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leutner, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinicke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span> </span><span class="NLM_article-title">Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">249</span><span class="NLM_x">â</span> <span class="NLM_lpage">251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS1470-2045%2805%2970097-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15811621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlWjtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=249-251&issue=4&author=E.+Wardelmannauthor=N.+Thomasauthor=S.+Merkelbach-Bruseauthor=K.+Paulsauthor=N.+Speidelauthor=R.+B%C3%BCttnerauthor=H.+Bihlauthor=C.+C.+Leutnerauthor=T.+Heinickeauthor=P.+Hohenberger&title=Acquired+resistance+to+imatinib+in+gastrointestinal+stromal+tumours+caused+by+multiple+KIT+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations</span></div><div class="casAuthors">Wardelmann, Eva; Thomas, Nadja; Merkelbach-Bruse, Sabine; Pauls, Katharina; Speidel, Nicola; Buettner, Reinhard; Bihl, Heiner; Leutner, Claudia C.; Heinicke, Thomas; Hohenberger, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">249-251</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The acquired imatinib resistance in two patients with gastrointestinal stromal tumors is discussed.  The study showed that imatinib treatment of gastrointestinal stromal tumors might lead to secondary resistance because of newly acquired KIT mutations affecting different synchronous codons and exons in different tumor manifestations of the same patient.  More studies on the heterogeneity of acquired KIT mutations are needed to improve understanding of the biol. of metastatic lesions of gastrointestinal stromal tumors during imatinib treatment.  Results might affect the development of alternate therapeutic strategies in patients with progressive gastrointestinal stromal tumors.  Strategies might include surgical resection of single, progressive lesions as well as introduction of new mol.-targeted substances such as SU11248, another multitargeted tyrosine kinase-inhibitor that might overcome imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnW8mBAlLQc7Vg90H21EOLACvtfcHk0ljNuC6p83gscA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlWjtLY%253D&md5=1d30e96167153da54cd9388ce440b9ba</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2805%2970097-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252805%252970097-8%26sid%3Dliteratum%253Aachs%26aulast%3DWardelmann%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DN.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DPauls%26aufirst%3DK.%26aulast%3DSpeidel%26aufirst%3DN.%26aulast%3DB%25C3%25BCttner%26aufirst%3DR.%26aulast%3DBihl%26aufirst%3DH.%26aulast%3DLeutner%26aufirst%3DC.%2BC.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DHohenberger%26aufirst%3DP.%26atitle%3DAcquired%2520resistance%2520to%2520imatinib%2520in%2520gastrointestinal%2520stromal%2520tumours%2520caused%2520by%2520multiple%2520KIT%2520mutations%26jtitle%3DLancet%2520Oncol.%26date%3D2005%26volume%3D6%26issue%3D4%26spage%3D249%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Bickenbach, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcox, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veerapong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindler, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posner, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noffsinger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggin, K. K.</span><span> </span><span class="NLM_article-title">A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy</span> <span class="citation_source-journal">J. Gastrointest. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">758</span><span class="NLM_x">â</span> <span class="NLM_lpage">766</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1007%2Fs11605-007-0150-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17417711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A280%3ADC%252BD2szkslOhsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=758-766&issue=6&author=K.+Bickenbachauthor=R.+Wilcoxauthor=J.+Veerapongauthor=H.+L.+Kindlerauthor=M.+C.+Posnerauthor=A.+Noffsingerauthor=K.+K.+Roggin&title=A+review+of+resistance+patterns+and+phenotypic+changes+in+gastrointestinal+stromal+tumors+following+imatinib+mesylate+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy</span></div><div class="casAuthors">Bickenbach Kai; Wilcox Rebecca; Veerapong Jula; Kindler Hedy Lee; Posner Mitchell C; Noffsinger Amy; Roggin Kevin King</div><div class="citationInfo"><span class="NLM_cas:title">Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">758-66</span>
        ISSN:<span class="NLM_cas:issn">1091-255X</span>.
    </div><div class="casAbstract">Gastrointestinal stromal tumors are neoplastic lesions that arise from the interstitial cells of Cajal and are associated with somatic mutations in the tyrosine kinase receptor, KIT.  The only known curative therapy is complete surgical resection.  Unfortunately, postsurgical recurrence rates exceed 50% and most tumors are resistant to standard chemotherapy and radiation.  Imatinib mesylate, a novel tyrosine kinase inhibitor, holds promise as a potential adjuvant therapy to prevent recurrence and improve long-term survival.  However, as resistance data emerge, it appears that a potential "escape pathway" may originate from secondary mutations in the KIT receptor.  This paper reviews the historical clinical experience with imatinib mesylate and discusses resistance patterns following targeted therapy.  We highlight this review with an interesting case report that illustrates unique phenotypic tumoral changes associated with imatinib mesylate resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsZ3-xUqAauq-9TkgmBqTqfW6udTcc2eYniJOjCSiZ2rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szkslOhsA%253D%253D&md5=1c343754f90366f8931ecab054ffcd28</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1007%2Fs11605-007-0150-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11605-007-0150-y%26sid%3Dliteratum%253Aachs%26aulast%3DBickenbach%26aufirst%3DK.%26aulast%3DWilcox%26aufirst%3DR.%26aulast%3DVeerapong%26aufirst%3DJ.%26aulast%3DKindler%26aufirst%3DH.%2BL.%26aulast%3DPosner%26aufirst%3DM.%2BC.%26aulast%3DNoffsinger%26aufirst%3DA.%26aulast%3DRoggin%26aufirst%3DK.%2BK.%26atitle%3DA%2520review%2520of%2520resistance%2520patterns%2520and%2520phenotypic%2520changes%2520in%2520gastrointestinal%2520stromal%2520tumors%2520following%2520imatinib%2520mesylate%2520therapy%26jtitle%3DJ.%2520Gastrointest.%2520Surg.%26date%3D2007%26volume%3D11%26issue%3D6%26spage%3D758%26epage%3D766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agaram, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAdamo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">16</span><span class="NLM_x">) </span> <span class="NLM_fpage">4874</span><span class="NLM_x">â</span> <span class="NLM_lpage">4881</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1158%2F1078-0432.CCR-07-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17699867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4874-4881&issue=16&author=T.+Guoauthor=N.+P.+Agaramauthor=G.+C.+Wongauthor=G.+Homauthor=D.+D%E2%80%99Adamoauthor=R.+G.+Makiauthor=G.+K.+Schwartzauthor=D.+Veachauthor=B.+D.+Clarksonauthor=S.+Singerauthor=R.+P.+DeMatteoauthor=P.+Besmerauthor=C.+R.+Antonescu&title=Sorafenib+inhibits+the+imatinib-resistant+KITT670I+gatekeeper+mutation+in+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor</span></div><div class="casAuthors">Guo, Tianhua; Agaram, Narasimhan P.; Wong, Grace C.; Hom, Glory; D'Adamo, David; Maki, Robert G.; Schwartz, Gary K.; Veach, Darren; Clarkson, Bayard D.; Singer, Samuel; DeMatteo, Ronald P.; Besmer, Peter; Antonescu, Cristina R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4874-4881</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinib mesylate, often due to the development of secondary mutations in the KIT kinase domain.  We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and nilotinib, against the commonly obsd. imatinib-resistant KIT mutations (KITV654A, KITT670I, KITD820Y, and KITN822K) expressed in the Ba/F3 cellular system.  EXPTL. DESIGN: In vitro drug screening of stable Ba/F3 KIT mutants recapitulating the genotype of imatinib-resistant patients harboring primary and secondary KIT mutations was investigated.  Comparison was made to imatinib-sensitive Ba/F3 KIT mutant cells as well as Ba/F3 cells expressing only secondary KIT mutations.  The efficacy of drug treatment was evaluated by proliferation and apoptosis assays, in addn. to biochem. inhibition of KIT activation.  RESULTS: Sorafenib was potent against all imatinib-resistant Ba/F3 KIT double mutants tested, including the gatekeeper secondary mutation KITWK557-8del/T670I, which was resistant to other kinase inhibitors.  Although all three drugs tested decreased cell proliferation and inhibited KIT activation against exon 13 (KITV560del/V654A) and exon 17 (KITV559D/D820Y) double mutants, nilotinib did so at lower concns.  CONCLUSIONS: Our results emphasize the need for tailored salvage therapy in imatinib-refractory gastrointestinal stromal tumors according to individual mol. mechanisms of resistance.  The Ba/F3 KITWK557-8del/T670I cells were sensitive only to sorafenib inhibition, whereas nilotinib was more potent on imatinib-resistant KITV560del/V654A and KITV559D/D820Y mutant cells than dasatinib and sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqllTJoDeevKbVg90H21EOLACvtfcHk0ljNuC6p83gscA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D&md5=f1643671ada85f1bcd05faa04cd88b52</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0484%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DAgaram%26aufirst%3DN.%2BP.%26aulast%3DWong%26aufirst%3DG.%2BC.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DClarkson%26aufirst%3DB.%2BD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DSorafenib%2520inhibits%2520the%2520imatinib-resistant%2520KITT670I%2520gatekeeper%2520mutation%2520in%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26issue%3D16%26spage%3D4874%26epage%3D4881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Nagata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worobec, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdhury, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannenbaum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, D. D.</span><span> </span><span class="NLM_article-title">Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">10560</span><span class="NLM_x">â</span> <span class="NLM_lpage">10564</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=10560-10564&issue=23&author=H.+Nagataauthor=A.+S.+Worobecauthor=C.+K.+Ohauthor=B.+A.+Chowdhuryauthor=S.+Tannenbaumauthor=Y.+Suzukiauthor=D.+D.+Metcalfe&title=Identification+of+a+point+mutation+in+the+catalytic+domain+of+the+protooncogene+c-kit+in+peripheral+blood+mononuclear+cells+of+patients+who+have+mastocytosis+with+an+associated+hematologic+disorder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagata%26aufirst%3DH.%26aulast%3DWorobec%26aufirst%3DA.%2BS.%26aulast%3DOh%26aufirst%3DC.%2BK.%26aulast%3DChowdhury%26aufirst%3DB.%2BA.%26aulast%3DTannenbaum%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26atitle%3DIdentification%2520of%2520a%2520point%2520mutation%2520in%2520the%2520catalytic%2520domain%2520of%2520the%2520protooncogene%2520c-kit%2520in%2520peripheral%2520blood%2520mononuclear%2520cells%2520of%2520patients%2520who%2520have%2520mastocytosis%2520with%2520an%2520associated%2520hematologic%2520disorder%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1995%26volume%3D92%26issue%3D23%26spage%3D10560%26epage%3D10564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">561</span><span class="NLM_x">â</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnm0596-561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=8616716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&issue=5&author=B.+J.+Drukerauthor=S.+Tamuraauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=S.+Fanningauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span></div><div class="casAuthors">Druker, Brian J.; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shane; Zimmermann, Jurg; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">The Bcr-Abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease.  A compd., designed to inhibit the Abl protein tyrosine kinase (CGP 57148), was evaluated for its effects on cells contg. the Bcr-Abl fusion protein.  Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compd.  In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the no. of Bcr-Abl colonies formed but no inhibition of normal colony formation.  This compd. may be useful in the treatment of Bcr-Abl-pos. leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzXj-25AHOrVg90H21EOLACvtfcHk0ljDiXdJxSAFqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D&md5=1dc111cc883a1ed29964ae2c88c88cb9</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnm0596-561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0596-561%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26issue%3D5%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cioffi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno-Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Abl proteinâtyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">139</span><span class="NLM_x">â</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=10991971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ygur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=139-145&issue=1&author=E.+Buchdungerauthor=C.+L.+Cioffiauthor=N.+Lawauthor=D.+Stoverauthor=S.+Ohno-Jonesauthor=B.+J.+Drukerauthor=N.+B.+Lydon&title=Abl+protein%E2%88%92tyrosine+kinase+inhibitor+STI571+inhibits+in+vitro+signal+transduction+mediated+by+c-kit+and+platelet-derived+growth+factor+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors</span></div><div class="casAuthors">Buchdunger, Elisabeth; Cioffi, Catherine L.; Law, Norman; Stover, David; Ohno-Jones, Sayuri; Druker, Brian J.; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">139-145</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">STI571 (formerly known as CGP 57148B) is a protein-tyrosine kinase inhibitor that is currently in clin. trials for the treatment of chronic myelogenous leukemia.  STI571 selectively inhibits the Abl and platelet-derived growth factor (PDGF) receptor tyrosine kinases in vitro and blocks cellular proliferation and tumor growth of Bcr-abl- or v-abl-expressing cells.  We have further investigated the profile of STI571 against related receptor tyrosine kinases.  STI571 was found to potently inhibit the kinase activity of the Î±- and Î²-PDGF receptors and the receptor for stem cell factor, but not the closely related c-Fms, Flt-3, Kdr, Flt-1, and Tek tyrosine kinases.  Addnl., no inhibition of c-Met or nonreceptor tyrosine kinases such as Src and Jak-2 has been obsd.  In cell-based assays, STI571 selectively inhibited PDGF and stem cell factor-mediated cellular signaling, including ligand-stimulated receptor autophosphorylation, inositol phosphate formation, and mitogen-activated protein kinase activation and proliferation.  These results expand the profile of STI571 and suggest that in addn. to chronic myelogenous leukemia, STI571 may have clin. potential in the treatment of diseases that involve abnormal activation of c-Kit or PDGF receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogymen0UOTarVg90H21EOLACvtfcHk0ljDiXdJxSAFqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ygur4%253D&md5=b15a49df360ae0d00c34f7cc5d3b0fe8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DLaw%26aufirst%3DN.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DOhno-Jones%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DAbl%2520protein%25E2%2588%2592tyrosine%2520kinase%2520inhibitor%2520STI571%2520inhibits%2520in%2520vitro%2520signal%2520transduction%2520mediated%2520by%2520c-kit%2520and%2520platelet-derived%2520growth%2520factor%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26issue%3D1%26spage%3D139%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Shimizu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâBrien, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjoblom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietras, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heldin, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumanski, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostman, A.</span><span> </span><span class="NLM_article-title">The dermatofibrosarcoma protuberans-associated collagen type IÎ±1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">3719</span><span class="NLM_x">â</span> <span class="NLM_lpage">3723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=3719-3723&issue=15&author=A.+Shimizuauthor=K.+P.+O%E2%80%99Brienauthor=T.+Sjoblomauthor=K.+Pietrasauthor=E.+Buchdungerauthor=V.+P.+Collinsauthor=C.-H.+Heldinauthor=J.+P.+Dumanskiauthor=A.+Ostman&title=The+dermatofibrosarcoma+protuberans-associated+collagen+type+I%CE%B11%2Fplatelet-derived+growth+factor+%28PDGF%29+B-chain+fusion+gene+generates+a+transforming+protein+that+is+processed+to+functional+PDGF-BB"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%2BP.%26aulast%3DSjoblom%26aufirst%3DT.%26aulast%3DPietras%26aufirst%3DK.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCollins%26aufirst%3DV.%2BP.%26aulast%3DHeldin%26aufirst%3DC.-H.%26aulast%3DDumanski%26aufirst%3DJ.%2BP.%26aulast%3DOstman%26aufirst%3DA.%26atitle%3DThe%2520dermatofibrosarcoma%2520protuberans-associated%2520collagen%2520type%2520I%25CE%25B11%252Fplatelet-derived%2520growth%2520factor%2520%2528PDGF%2529%2520B-chain%2520fusion%2520gene%2520generates%2520a%2520transforming%2520protein%2520that%2520is%2520processed%2520to%2520functional%2520PDGF-BB%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26issue%3D15%26spage%3D3719%26epage%3D3723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Simon, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedeutour, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirvent, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosgeorge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coindre, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrier-Lacombe, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandahl, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craver, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turc-Carel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâBrien, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kedra, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilbaud, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumanski, J. P.</span><span> </span><span class="NLM_article-title">Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">95</span><span class="NLM_x">â</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fng0197-95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=8988177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFGksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1997&pages=95-98&issue=1&author=M.+P.+Simonauthor=F.+Pedeutourauthor=N.+Sirventauthor=J.+Grosgeorgeauthor=F.+Minolettiauthor=J.+M.+Coindreauthor=M.+J.+Terrier-Lacombeauthor=N.+Mandahlauthor=R.+D.+Craverauthor=N.+Blinauthor=G.+Sozziauthor=C.+Turc-Carelauthor=K.+P.+O%E2%80%99Brienauthor=D.+Kedraauthor=I.+Franssonauthor=C.+Guilbaudauthor=J.+P.+Dumanski&title=Deregulation+of+the+platelet-derived+growth+factor+B-chain+gene+via+fusion+with+collagen+gene+COL1A1+in+dermatofibrosarcoma+protuberans+and+giant-cell+fibroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma</span></div><div class="casAuthors">Simon, Marie-Pierre; Pedeutour, Florence; Sirvent, Nicolas; Grosgeorge, Josiane; Minoletti, Fabiola; Coindre, Jean-Michel; Terrier-Lacombe, Marie-Jose; Mandahl, Nils; Craver, Randall D.; Blin, Nikolaus; Sozzi, Gabriella; Turc-Carel, Claude; O'Brien, Kevin P.; Kedra, Darek; Fransson, Ingegerd; Guilbaud, Cecille; Dumanski, Jan P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-98</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Dermatofibrosarcoma protuberans (DP), an infiltrative skin tumor of intermediate malignancy, presents specific features such as reciprocal translocations t(17;22)(q22;q13) and supernumerary ring chromosomes derived from the t(17;22).  In this report, the breakpoints from translocations and rings in DP and its juvenile form, giant cell fibroblastoma (GCF), were characterized on the genomic and RNA level.  These rearrangements fuse the platelet-derived growth factor B-chain (PDGFB, c-sis proto-oncogene) and the collagen type I Î±1 (COL1A1) genes.  PDGFB has transforming activity and is a potent mitogen for a no. of cell types, but its role in oncogenic processes is not fully understood.  COL1A1 is major constituent of the connective tissue matrix.  Neither PDGFB nor COL1A1 have so far been implicated in any tumor translocations.  These gene fusions delete exon 1 of PDGFB, and release this growth factor from its normal regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6UEUQtHNyobVg90H21EOLACvtfcHk0liQDbpR_-Gqkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFGksg%253D%253D&md5=72435d32b5bfc28567d91488f9c5767a</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fng0197-95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0197-95%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DM.%2BP.%26aulast%3DPedeutour%26aufirst%3DF.%26aulast%3DSirvent%26aufirst%3DN.%26aulast%3DGrosgeorge%26aufirst%3DJ.%26aulast%3DMinoletti%26aufirst%3DF.%26aulast%3DCoindre%26aufirst%3DJ.%2BM.%26aulast%3DTerrier-Lacombe%26aufirst%3DM.%2BJ.%26aulast%3DMandahl%26aufirst%3DN.%26aulast%3DCraver%26aufirst%3DR.%2BD.%26aulast%3DBlin%26aufirst%3DN.%26aulast%3DSozzi%26aufirst%3DG.%26aulast%3DTurc-Carel%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%2BP.%26aulast%3DKedra%26aufirst%3DD.%26aulast%3DFransson%26aufirst%3DI.%26aulast%3DGuilbaud%26aufirst%3DC.%26aulast%3DDumanski%26aufirst%3DJ.%2BP.%26atitle%3DDeregulation%2520of%2520the%2520platelet-derived%2520growth%2520factor%2520B-chain%2520gene%2520via%2520fusion%2520with%2520collagen%2520gene%2520COL1A1%2520in%2520dermatofibrosarcoma%2520protuberans%2520and%2520giant-cell%2520fibroblastoma%26jtitle%3DNat.%2520Genet.%26date%3D1997%26volume%3D15%26issue%3D1%26spage%3D95%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Sjoblom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boureux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronnstrand, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heldin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghysdael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostman, A.</span><span> </span><span class="NLM_article-title">Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">50</span><span class="NLM_x">) </span> <span class="NLM_fpage">7055</span><span class="NLM_x">â</span> <span class="NLM_lpage">7062</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=7055-7062&issue=50&author=T.+Sjoblomauthor=A.+Boureuxauthor=L.+Ronnstrandauthor=C.+H.+Heldinauthor=J.+Ghysdaelauthor=A.+Ostman&title=Characterization+of+the+chronic+myelomonocytic+leukemia+associated+TEL-PDGF+beta+R+fusion+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSjoblom%26aufirst%3DT.%26aulast%3DBoureux%26aufirst%3DA.%26aulast%3DRonnstrand%26aufirst%3DL.%26aulast%3DHeldin%26aufirst%3DC.%2BH.%26aulast%3DGhysdael%26aufirst%3DJ.%26aulast%3DOstman%26aufirst%3DA.%26atitle%3DCharacterization%2520of%2520the%2520chronic%2520myelomonocytic%2520leukemia%2520associated%2520TEL-PDGF%2520beta%2520R%2520fusion%2520protein%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26issue%3D50%26spage%3D7055%26epage%3D7062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Jousset, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boureux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quang, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oury, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusanter-Fourt, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghysdael, J.</span><span> </span><span class="NLM_article-title">A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">69</span><span class="NLM_x">â</span> <span class="NLM_lpage">82</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=69-82&issue=1&author=C.+Joussetauthor=C.+Carronauthor=A.+Boureuxauthor=C.+T.+Quangauthor=C.+Ouryauthor=I.+Dusanter-Fourtauthor=M.+Charonauthor=J.+Levinauthor=O.+Bernardauthor=J.+Ghysdael&title=A+domain+of+TEL+conserved+in+a+subset+of+ETS+proteins+defines+a+specific+oligomerization+interface+essential+to+the+mitogenic+properties+of+the+TEL-PDGFR+beta+oncoprotein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJousset%26aufirst%3DC.%26aulast%3DCarron%26aufirst%3DC.%26aulast%3DBoureux%26aufirst%3DA.%26aulast%3DQuang%26aufirst%3DC.%2BT.%26aulast%3DOury%26aufirst%3DC.%26aulast%3DDusanter-Fourt%26aufirst%3DI.%26aulast%3DCharon%26aufirst%3DM.%26aulast%3DLevin%26aufirst%3DJ.%26aulast%3DBernard%26aufirst%3DO.%26aulast%3DGhysdael%26aufirst%3DJ.%26atitle%3DA%2520domain%2520of%2520TEL%2520conserved%2520in%2520a%2520subset%2520of%2520ETS%2520proteins%2520defines%2520a%2520specific%2520oligomerization%2520interface%2520essential%2520to%2520the%2520mitogenic%2520properties%2520of%2520the%2520TEL-PDGFR%2520beta%2520oncoprotein%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26issue%3D1%26spage%3D69%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Apperley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardembas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melo, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell-Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessells, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearden, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahon, F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolova, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olavarria, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultheis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. M.</span><span> </span><span class="NLM_article-title">Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">481</span><span class="NLM_x">â</span> <span class="NLM_lpage">487</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMoa020150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12181402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=481-487&issue=7&author=J.+F.+Apperleyauthor=M.+Gardembasauthor=J.+V.+Meloauthor=R.+Russell-Jonesauthor=B.+J.+Bainauthor=E.+J.+Baxterauthor=A.+Chaseauthor=J.+M.+Chessellsauthor=M.+Colombatauthor=C.+E.+Deardenauthor=S.+Dimitrijevicauthor=F.+X.+Mahonauthor=D.+Marinauthor=Z.+Nikolovaauthor=E.+Olavarriaauthor=S.+Silbermanauthor=B.+Schultheisauthor=N.+C.+Crossauthor=J.+M.+Goldman&title=Response+to+imatinib+mesylate+in+patients+with+chronic+myeloproliferative+diseases+with+rearrangements+of+the+platelet-derived+growth+factor+receptor+beta"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta</span></div><div class="casAuthors">Apperley, Jane F.; Gardembas, Martine; Melo, Junia V.; Russell-Jones, Robin; Bain, Barbara J.; Baxter, E. Joanna; Chase, Andrew; Chessells, Judith M.; Colombat, Marie; Dearden, Claire E.; Dimitrijevic, Sasa; Mahon, Francois-X.; Marin, David; Nikolova, Zariana; Olavarria, Eduardo; Silberman, Sandra; Schultheis, Beate; Cross, Nicholas C. P.; Goldman, John M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">481-487</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A small proportion of patients with chronic myeloproliferative diseases have constitutive activation of the gene for platelet-derived growth factor receptor beta (PDGFRB), which encodes a receptor tyrosine kinase.  The gene is located on chromosome 5q33, and the activation is usually caused by a t(5;12)(q33;p13) translocation assocd. with an ETV6-PDGFRB fusion gene.  The tyrosine kinase inhibitor imatinib mesylate specifically inhibits ABL, PDGFR, and KIT kinases and has impressive clin. efficacy in BCR-ABL-pos. chronic myeloid leukemia.  We treated four patients who had chronic myeloproliferative diseases and chromosomal translocations involving 5q33 with imatinib mesylate (400 mg daily).  Three of the four patients presented with leukocytosis and eosinophilia; their leukemia cells carried the ETV6-PDGFRB fusion gene.  The fourth patient had leukocytosis, eosinophilia, and a t(5;12) translocation involving PDGFRB and an unknown partner gene; he also had extensive raised, ulcerated skin lesions that had been present for a long time.  In all four patients, a normal blood count was achieved within four weeks after treatment began.  In the patient with skin disease, the lesions began to resolve shortly after treatment began.  The t(5;12) translocation was undetectable by 12 wk in three patients and by 36 wk in the fourth patient.  In the three patients with the ETV6-PDGFRB fusion gene, the transcript level decreased, and in one patient, it became undetectable by 36 wk.  All responses were durable at 9 to 12 mo of follow-up.  Imatinib mesylate induces durable responses in patients with chronic myeloproliferative diseases assocd. with activation of PDGFRB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEEKR95RMc8bVg90H21EOLACvtfcHk0liQDbpR_-Gqkw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7g%253D&md5=2c03b388677f674f278544d6e9aa0698</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020150%26sid%3Dliteratum%253Aachs%26aulast%3DApperley%26aufirst%3DJ.%2BF.%26aulast%3DGardembas%26aufirst%3DM.%26aulast%3DMelo%26aufirst%3DJ.%2BV.%26aulast%3DRussell-Jones%26aufirst%3DR.%26aulast%3DBain%26aufirst%3DB.%2BJ.%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DChase%26aufirst%3DA.%26aulast%3DChessells%26aufirst%3DJ.%2BM.%26aulast%3DColombat%26aufirst%3DM.%26aulast%3DDearden%26aufirst%3DC.%2BE.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DMahon%26aufirst%3DF.%2BX.%26aulast%3DMarin%26aufirst%3DD.%26aulast%3DNikolova%26aufirst%3DZ.%26aulast%3DOlavarria%26aufirst%3DE.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DSchultheis%26aufirst%3DB.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DGoldman%26aufirst%3DJ.%2BM.%26atitle%3DResponse%2520to%2520imatinib%2520mesylate%2520in%2520patients%2520with%2520chronic%2520myeloproliferative%2520diseases%2520with%2520rearrangements%2520of%2520the%2520platelet-derived%2520growth%2520factor%2520receptor%2520beta%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26issue%3D7%26spage%3D481%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awan, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhanwar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">623</span><span class="NLM_x">â</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1002%2Fijc.10535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12209598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFKhu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=623-626&issue=6&author=R.+G.+Makiauthor=R.+A.+Awanauthor=R.+H.+Dixonauthor=S.+Jhanwarauthor=C.+R.+Antonescu&title=Differential+sensitivity+to+imatinib+of+2+patients+with+metastatic+sarcoma+arising+from+dermatofibrosarcoma+protuberans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans</span></div><div class="casAuthors">Maki, Robert G.; Awan, Rashid A.; Dixon, Richard H.; Jhanwar, Suresh; Antonescu, Cristina R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">623-626</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Dermatofibrosarcoma protuberans (DFSP) is a rare superficial sarcoma usually affecting the trunk, with significant risk of local recurrence.  It is characterized by the presence of ring chromosomes or chromosomal translocations fusing the promoter of the collagen gene COLIAI to the platelet-derived growth factor Î²-chain gene PDGFB, increasing the prodn. of PDGF locally and promoting autocrine or paracrine tumor growth.  Fewer than 5% of patients with DFSP develop metastatic sarcoma, with a poor subsequent prognosis.  Imatinib (STI-571) was developed as an inhibitor of the PDGF receptor tyrosine kinase and has proven clin. activity against chronic myelogenous leukemia (expressing bcr-abl) and gastrointestinal stromal tumors (expressing c-kit).  We describe 2 patients with metastatic and unresectable metastases from DFSP treated with imatinib.  After confirmation of neg. CD117 status of 2 sarcomas arising from DFSP, patients were given imatinib 400 mg po qd and assessed at regular intervals for their tolerance and response to therapy.  One patient had a transient response, then progressed rapidly and died of disease.  Another patient showed a partial response to therapy after 2 mo, with resoln. of superior vena cava syndrome and shrinking of metastatic lung lesions.  His response is ongoing after 6 mo of therapy.  These clin. data confirm findings from models of DFSP and support the use of imatinib in the rare setting of metastatic DFSP.  Imatinib may be useful for patients with locally advanced DFSP, when other options for local therapy are limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlU-Gnkx4EW7Vg90H21EOLACvtfcHk0ljQbFjd1yKisw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFKhu70%253D&md5=1efca6a46aa9fb897ad05997f8e41d55</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1002%2Fijc.10535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10535%26sid%3Dliteratum%253Aachs%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DAwan%26aufirst%3DR.%2BA.%26aulast%3DDixon%26aufirst%3DR.%2BH.%26aulast%3DJhanwar%26aufirst%3DS.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DDifferential%2520sensitivity%2520to%2520imatinib%2520of%25202%2520patients%2520with%2520metastatic%2520sarcoma%2520arising%2520from%2520dermatofibrosarcoma%2520protuberans%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D100%26issue%3D6%26spage%3D623%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Rubin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuetze, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eary, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norwood, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrad, E. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruckner, J. D.</span><span> </span><span class="NLM_article-title">Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">3586</span><span class="NLM_x">â</span> <span class="NLM_lpage">3591</span><div class="note"><p class="first last">[see Comment]</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1200%2FJCO.2002.01.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12202658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVynsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=3586-3591&issue=17&author=B.+P.+Rubinauthor=S.+M.+Schuetzeauthor=J.+F.+Earyauthor=T.+H.+Norwoodauthor=S.+Mirzaauthor=E.+U.+Conradauthor=J.+D.+Bruckner&title=Molecular+targeting+of+platelet-derived+growth+factor+B+by+imatinib+mesylate+in+a+patient+with+metastatic+dermatofibrosarcoma+protuberans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Targeting of Platelet-Derived Growth Factor B by Imatinib Mesylate in a Patient With Metastatic Dermatofibrosarcoma Protuberans</span></div><div class="casAuthors">Rubin, Brian P.; Schuetze, Scott M.; Eary, Janet F.; Norwood, Thomas H.; Mirza, Sohail; Conrad, Ernest U.; Bruckner, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3586-3591</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Dermatofibrosarcoma protuberans is caused by activation of the platelet-derived growth factor B (PDGFB) receptor, a transmembrane tyrosine kinase.  We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate.  A patient with unresectable, metastatic dermatofibrosarcoma protuberans received imatinib mesylate (400 mg bid).  Response to therapy was assessed by [18F]fluorodeoxyglucose (FDG) positron emission tomog., magnetic, resonance imaging, and histopathol. and immunohistochem. evaluation.  The patient was treated for 4 mo with imatinib mesylate.  The hypermetabolic uptake of FDG fell to background levels within 2 wk of treatment, and the tumor vol. shrank by over 75% during the 4 mo of therapy, allowing for resection of the mass.  There was no residual viable tumor in the resected specimen, indicating a complete histol. response to treatment with imatinib mesylate.  Thus, imatinib mesylate is highly active in dermatofibrosarcoma protuberans.  The dramatic response seen in this patient demonstrates that inhibition of PDGFB receptor tyrosine kinase activity can significantly impact viability of at least one type of solid tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTXFGgToc-cbVg90H21EOLACvtfcHk0ljQbFjd1yKisw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVynsr8%253D&md5=578d0d1487ba94e613492c71c0d70ad0</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.01.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.01.027%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DSchuetze%26aufirst%3DS.%2BM.%26aulast%3DEary%26aufirst%3DJ.%2BF.%26aulast%3DNorwood%26aufirst%3DT.%2BH.%26aulast%3DMirza%26aufirst%3DS.%26aulast%3DConrad%26aufirst%3DE.%2BU.%26aulast%3DBruckner%26aufirst%3DJ.%2BD.%26atitle%3DMolecular%2520targeting%2520of%2520platelet-derived%2520growth%2520factor%2520B%2520by%2520imatinib%2520mesylate%2520in%2520a%2520patient%2520with%2520metastatic%2520dermatofibrosarcoma%2520protuberans%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26issue%3D17%26spage%3D3586%26epage%3D3591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cilloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaviani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiribelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buccisano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testoni, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vivo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giugliano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacobucci, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soverini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astolfi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pane, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span> </span><span class="NLM_article-title">The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study</span> <span class="citation_source-journal">Haematologica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1173</span><span class="NLM_x">â</span> <span class="NLM_lpage">1179</span><div class="note"><p class="first last">[see Comment]</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2007&pages=1173-1179&issue=9&author=M.+Baccaraniauthor=D.+Cilloniauthor=M.+Rondoniauthor=E.+Ottavianiauthor=F.+Messaauthor=S.+Meranteauthor=M.+Tiribelliauthor=F.+Buccisanoauthor=N.+Testoniauthor=E.+Gottardiauthor=A.+de+Vivoauthor=E.+Giuglianoauthor=I.+Iacobucciauthor=S.+Paoliniauthor=S.+Soveriniauthor=G.+Rostiauthor=F.+Rancatiauthor=C.+Astolfiauthor=F.+Paneauthor=G.+Saglioauthor=G.+Martinelli&title=The+efficacy+of+imatinib+mesylate+in+patients+with+FIP1L1-PDGFRalpha-positive+hypereosinophilic+syndrome.+Results+of+a+multicenter+prospective+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DCilloni%26aufirst%3DD.%26aulast%3DRondoni%26aufirst%3DM.%26aulast%3DOttaviani%26aufirst%3DE.%26aulast%3DMessa%26aufirst%3DF.%26aulast%3DMerante%26aufirst%3DS.%26aulast%3DTiribelli%26aufirst%3DM.%26aulast%3DBuccisano%26aufirst%3DF.%26aulast%3DTestoni%26aufirst%3DN.%26aulast%3DGottardi%26aufirst%3DE.%26aulast%3Dde%2BVivo%26aufirst%3DA.%26aulast%3DGiugliano%26aufirst%3DE.%26aulast%3DIacobucci%26aufirst%3DI.%26aulast%3DPaolini%26aufirst%3DS.%26aulast%3DSoverini%26aufirst%3DS.%26aulast%3DRosti%26aufirst%3DG.%26aulast%3DRancati%26aufirst%3DF.%26aulast%3DAstolfi%26aufirst%3DC.%26aulast%3DPane%26aufirst%3DF.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DMartinelli%26aufirst%3DG.%26atitle%3DThe%2520efficacy%2520of%2520imatinib%2520mesylate%2520in%2520patients%2520with%2520FIP1L1-PDGFRalpha-positive%2520hypereosinophilic%2520syndrome.%2520Results%2520of%2520a%2520multicenter%2520prospective%2520study%26jtitle%3DHaematologica%26date%3D2007%26volume%3D92%26issue%3D9%26spage%3D1173%26epage%3D1179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Jovanovic, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Score, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waghorn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cilloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzgeroth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erben, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popp, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche-Lestienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preudhomme, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apperley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaviani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brito-Babapulle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hehlmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimwade, D.</span><span> </span><span class="NLM_article-title">Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4635</span><span class="NLM_x">â</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=4635-4640&issue=11&author=J.+V.+Jovanovicauthor=J.+Scoreauthor=K.+Waghornauthor=D.+Cilloniauthor=E.+Gottardiauthor=G.+Metzgerothauthor=P.+Erbenauthor=H.+Poppauthor=C.+Walzauthor=A.+Hochhausauthor=C.+Roche-Lestienneauthor=C.+Preudhommeauthor=E.+Solomonauthor=J.+Apperleyauthor=M.+Rondoniauthor=E.+Ottavianiauthor=G.+Martinelliauthor=F.+Brito-Babapulleauthor=G.+Saglioauthor=R.+Hehlmannauthor=N.+C.+Crossauthor=A.+Reiterauthor=D.+Grimwade&title=Low-dose+imatinib+mesylate+leads+to+rapid+induction+of+major+molecular+responses+and+achievement+of+complete+molecular+remission+in+FIP1L1-PDGFRA-positive+chronic+eosinophilic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJovanovic%26aufirst%3DJ.%2BV.%26aulast%3DScore%26aufirst%3DJ.%26aulast%3DWaghorn%26aufirst%3DK.%26aulast%3DCilloni%26aufirst%3DD.%26aulast%3DGottardi%26aufirst%3DE.%26aulast%3DMetzgeroth%26aufirst%3DG.%26aulast%3DErben%26aufirst%3DP.%26aulast%3DPopp%26aufirst%3DH.%26aulast%3DWalz%26aufirst%3DC.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DRoche-Lestienne%26aufirst%3DC.%26aulast%3DPreudhomme%26aufirst%3DC.%26aulast%3DSolomon%26aufirst%3DE.%26aulast%3DApperley%26aufirst%3DJ.%26aulast%3DRondoni%26aufirst%3DM.%26aulast%3DOttaviani%26aufirst%3DE.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DBrito-Babapulle%26aufirst%3DF.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DHehlmann%26aufirst%3DR.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DReiter%26aufirst%3DA.%26aulast%3DGrimwade%26aufirst%3DD.%26atitle%3DLow-dose%2520imatinib%2520mesylate%2520leads%2520to%2520rapid%2520induction%2520of%2520major%2520molecular%2520responses%2520and%2520achievement%2520of%2520complete%2520molecular%2520remission%2520in%2520FIP1L1-PDGFRA-positive%2520chronic%2520eosinophilic%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26issue%3D11%26spage%3D4635%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Antoniu, S. A.</span><span> </span><span class="NLM_article-title">Imatinib mesylate for the treatment of hypereosinophilic syndromes</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">980</span><span class="NLM_x">â</span> <span class="NLM_lpage">984</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17117585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlWhtLrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=980-984&issue=11&author=S.+A.+Antoniu&title=Imatinib+mesylate+for+the+treatment+of+hypereosinophilic+syndromes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib mesylate for the treatment of hypereosinophilic syndromes</span></div><div class="casAuthors">Antoniu, Sabina A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (Thomson Scientific)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">980-984</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Hypereosinophilic syndromes (HES) define several distinct entities, all of which show blood and tissue hypereosinophilia and end-organ secondary manifestations.  From a clin. and pathogenic perspective, the best characterized are the myeloproliferative and lymphoproliferative variants.  While there are several therapies available for the treatment of HES, such as corticosteroids, IFNÎ± and cytotoxic agents, there remains a high incidence of side effects and inconsistent efficacy.  Abnormal tyrosine kinase resulting from the FIP1L1-PDGFRA fusion gene is found in many patients with myeloproliferative variant, and is currently best targeted therapeutically with imatinib mesylate, a tyrosine kinase inhibitor.  However, complete hematol. remissions obtained with this compd. in patients without this defect suggest that it could be effective in other subtypes of HES.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp730dr9vDkDLVg90H21EOLACvtfcHk0lj8F1Mn5W6CUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlWhtLrN&md5=4c5bf1e609e1f85a37bb4a2632711f3b</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAntoniu%26aufirst%3DS.%2BA.%26atitle%3DImatinib%2520mesylate%2520for%2520the%2520treatment%2520of%2520hypereosinophilic%2520syndromes%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2006%26volume%3D7%26issue%3D11%26spage%3D980%26epage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ault, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrajoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierda, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rios, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letvak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaled, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">4714</span><span class="NLM_x">â</span> <span class="NLM_lpage">4716</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=4714-4716&issue=12&author=J.+Cortesauthor=P.+Aultauthor=C.+Kollerauthor=D.+Thomasauthor=A.+Ferrajoliauthor=W.+Wierdaauthor=M.+B.+Riosauthor=L.+Letvakauthor=E.+S.+Kaledauthor=H.+Kantarjian&title=Efficacy+of+imatinib+mesylate+in+the+treatment+of+idiopathic+hypereosinophilic+syndrome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DAult%26aufirst%3DP.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DWierda%26aufirst%3DW.%26aulast%3DRios%26aufirst%3DM.%2BB.%26aulast%3DLetvak%26aufirst%3DL.%26aulast%3DKaled%26aufirst%3DE.%2BS.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DEfficacy%2520of%2520imatinib%2520mesylate%2520in%2520the%2520treatment%2520of%2520idiopathic%2520hypereosinophilic%2520syndrome%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26issue%3D12%26spage%3D4714%26epage%3D4716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porrata, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tazelaar, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witzig, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">3391</span><span class="NLM_x">â</span> <span class="NLM_lpage">3397</span><div class="note"><p class="first last">[see Comment]</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3391-3397&issue=9&author=A.+Pardananiauthor=T.+Reederauthor=L.+F.+Porrataauthor=C.+Y.+Liauthor=H.+D.+Tazelaarauthor=E.+J.+Baxterauthor=T.+E.+Witzigauthor=N.+C.+Crossauthor=A.+Tefferi&title=Imatinib+therapy+for+hypereosinophilic+syndrome+and+other+eosinophilic+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DReeder%26aufirst%3DT.%26aulast%3DPorrata%26aufirst%3DL.%2BF.%26aulast%3DLi%26aufirst%3DC.%2BY.%26aulast%3DTazelaar%26aufirst%3DH.%2BD.%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DWitzig%26aufirst%3DT.%2BE.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DImatinib%2520therapy%2520for%2520hypereosinophilic%2520syndrome%2520and%2520other%2520eosinophilic%2520disorders%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26issue%3D9%26spage%3D3391%26epage%3D3397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Ault, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaled, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate</span> <span class="citation_source-journal">Leukemia Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">881</span><span class="NLM_x">â</span> <span class="NLM_lpage">884</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS0145-2126%2802%2900046-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12127565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsVOmsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=881-884&issue=9&author=P.+Aultauthor=J.+Cortesauthor=C.+Kollerauthor=E.+S.+Kaledauthor=H.+Kantarjian&title=Response+of+idiopathic+hypereosinophilic+syndrome+to+treatment+with+imatinib+mesylate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate</span></div><div class="casAuthors">Ault, Patricia; Cortes, Jorge; Koller, Charles; Kaled, Elizabeth S.; Kantarjian, Hagop</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">881-884</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Idiopathic hypereosinophilic syndrome (HES) is a rare hematol. disorder characterized by persistent eosinophilia with organ involvement.  Patients with HES have a poor prognosis, but the disease course can be heterogeneous.  Treatment of HES has included corticosteroids, chemotherapeutic agents such as cyclophosphamide, vincristine, hydroxyurea, and most recently interferon-Î± (IFN-Î±) which has shown long-term beneficial effects.  The authors herein report on a patient with HES who had disease resistant to steroids, and chemotherapy with 2-chlorodeoxyadenosine and cytarabine, but who had a significant response after only 8 days of treatment with imatinib mesylate 100 mg daily.  The possible mechanism of response is discussed.  This observation may lead to a better understanding of the pathophysiol. of HES, and may provide a new form of effective therapy for the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9MzLHL00PR7Vg90H21EOLACvtfcHk0lj8F1Mn5W6CUw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsVOmsb8%253D&md5=4893d0e27bbb4a3158d1b4de7e0aba6a</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0145-2126%2802%2900046-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0145-2126%252802%252900046-2%26sid%3Dliteratum%253Aachs%26aulast%3DAult%26aufirst%3DP.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DKaled%26aufirst%3DE.%2BS.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DResponse%2520of%2520idiopathic%2520hypereosinophilic%2520syndrome%2520to%2520treatment%2520with%2520imatinib%2520mesylate%26jtitle%3DLeukemia%2520Res.%26date%3D2002%26volume%3D26%26issue%3D9%26spage%3D881%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Gleich, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiferman, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterfield, J. H.</span><span> </span><span class="NLM_article-title">Treatment of hypereosinophilic syndrome with imatinib mesilate</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x"> (</span><span class="NLM_issue">9317</span><span class="NLM_x">) </span> <span class="NLM_fpage">1577</span><span class="NLM_x">â</span> <span class="NLM_lpage">1578</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2002&pages=1577-1578&issue=9317&author=G.+J.+Gleichauthor=K.+M.+Leifermanauthor=A.+Pardananiauthor=A.+Tefferiauthor=J.+H.+Butterfield&title=Treatment+of+hypereosinophilic+syndrome+with+imatinib+mesilate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGleich%26aufirst%3DG.%2BJ.%26aulast%3DLeiferman%26aufirst%3DK.%2BM.%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DButterfield%26aufirst%3DJ.%2BH.%26atitle%3DTreatment%2520of%2520hypereosinophilic%2520syndrome%2520with%2520imatinib%2520mesilate%26jtitle%3DLancet%26date%3D2002%26volume%3D359%26issue%3D9317%26spage%3D1577%26epage%3D1578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotlib, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legare, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutok, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrier, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenberghe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoef, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boogaerts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarska, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutre, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1201</span><span class="NLM_x">â</span> <span class="NLM_lpage">1214</span><div class="note"><p class="first last">[see Comment]</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMoa025217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12660384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVCqtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1201-1214&issue=13&author=J.+Coolsauthor=D.+J.+DeAngeloauthor=J.+Gotlibauthor=E.+H.+Stoverauthor=R.+D.+Legareauthor=J.+Cortesauthor=J.+Kutokauthor=J.+Clarkauthor=I.+Galinskyauthor=J.+D.+Griffinauthor=N.+C.+Crossauthor=A.+Tefferiauthor=J.+Maloneauthor=R.+Alamauthor=S.+L.+Schrierauthor=J.+Schmidauthor=M.+Roseauthor=P.+Vandenbergheauthor=G.+Verhoefauthor=M.+Boogaertsauthor=I.+Wlodarskaauthor=H.+Kantarjianauthor=P.+Marynenauthor=S.+E.+Coutreauthor=R.+Stoneauthor=D.+G.+Gilliland&title=A+tyrosine+kinase+created+by+fusion+of+the+PDGFRA+and+FIP1L1+genes+as+a+therapeutic+target+of+imatinib+in+idiopathic+hypereosinophilic+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome</span></div><div class="casAuthors">Cools, Jan; Daniel, Ph. D.; DeAngelo, J.; Gotlib, Jason; Stover, Elizabeth H.; Phil, M.; Legare, Robert D.; Cortes, Jorges; Lutok, Jeffrey; Clark, Jennifer; Galinsky, Ilene; Griffin, James D.; Cross, Nicholas, C. P.; Tefferi, Ayalew; Malone, James; Alam, Fafeul; Schrier, Stanley L.; Schmid, Janet; Rose, Michal; Vandenberghe, Peter; Verhoef, Gregor; Boogaerts, Marc; Wlodarska, Iwona; Kantarjian, Hagop; Marynen, Peter; Coutre, Steven E.; Stone, Richard; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1201-1214</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia assocd. with organ dysfunction.  It is of unknown cause.  Recent reports of responses to imatinib in patients with the syndrome suggested that an activated kinase such as ABL, platelet-derived growth factor receptor (PDGFR), or KIT, all of which are inhibited by imatinib, might be the cause.  We treated 11 patients with the hypereosinophilic syndrome with imatinib and identified the mol. basis for the response.  Nine of the 11 patients treated with imatinib had responses lasting more than three months in which the eosinophil count returned to normal.  One such patient had a complex chromosomal abnormality, leading to the identification of a fusion of the Fip1H-like 1 (FIP1L1) gene to the PDGFRÎ± (PDGFRA) gene generated by an interstitial deletion on chromosome 4q12.  FIP1L1-PDGFRÎ± is a constitutively activated tyrosine kinase that transforms hematopoietic cells and is inhibited by imatinib (50% inhibitory concn., 3.2 nM).  The FIP1L1-PDGFRA fusion gene was subsequently detected in 9 of 16 patients with the syndrome and in 5 of the 9 patients with responses to imatinib that lasted more than three months.  Relapse in one patient correlated with the appearance of a T674I mutation in PDGFRA that confers resistance to imatinib.  The hypereosinophilic syndrome may result from a novel fusion tyrosine kinase-FIP1L1-PDGFRÎ±-that is a consequence of an interstitial chromosomal deletion.  The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRÎ± is the target of imatinib.  Our data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ae4JFIom8LVg90H21EOLACvtfcHk0liR5zDE9f0GjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVCqtrY%253D&md5=1f0cc5760c701bf0ae35bcb7c0727d65</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa025217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa025217%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DGotlib%26aufirst%3DJ.%26aulast%3DStover%26aufirst%3DE.%2BH.%26aulast%3DLegare%26aufirst%3DR.%2BD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKutok%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DMalone%26aufirst%3DJ.%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DSchrier%26aufirst%3DS.%2BL.%26aulast%3DSchmid%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DM.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DVerhoef%26aufirst%3DG.%26aulast%3DBoogaerts%26aufirst%3DM.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DA%2520tyrosine%2520kinase%2520created%2520by%2520fusion%2520of%2520the%2520PDGFRA%2520and%2520FIP1L1%2520genes%2520as%2520a%2520therapeutic%2520target%2520of%2520imatinib%2520in%2520idiopathic%2520hypereosinophilic%2520syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26issue%3D13%26spage%3D1201%26epage%3D1214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ERBB receptors and cancer: the complexity of targeted inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">341</span><span class="NLM_x">â</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&issue=5&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0liR5zDE9f0GjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26issue%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Dowell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">Chasing mutations in the epidermal growth factor in lung cancer</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">830</span><span class="NLM_x">â</span> <span class="NLM_lpage">832</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMe058033" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2007&pages=830-832&author=J.+E.+Dowellauthor=J.+D.+Minna&title=Chasing+mutations+in+the+epidermal+growth+factor+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1056%2FNEJMe058033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe058033%26sid%3Dliteratum%253Aachs%26aulast%3DDowell%26aufirst%3DJ.%2BE.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DChasing%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520in%2520lung%2520cancer%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D352%26spage%3D830%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reily, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_elocation-id">e73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&issue=3&author=W.+Paoauthor=K.+A.+Politiauthor=G.+I.+Reilyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DReily%26aufirst%3DG.%2BI.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Nat. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">â</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1073%2Fpnas.0502860102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15897464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span></div><div class="casAuthors">Kwak, Eunice L.; Sordella, Raffaella; Bell, Daphne W.; Godin-Heymann, Nadia; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Driscoll, David R.; Fidias, Panos; Lynch, Thomas J.; Rabindran, Sridhar K.; McGinnis, John P.; Wissner, Allan; Sharma, Sreenath V.; Isselbacher, Kurt J.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7665-7670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva).  Some recurrent tumors have a common secondary mutation in the EGFR kinase domain, T790M, conferring drug resistance, but in other cases the mechanism underlying acquired resistance is unknown.  In studying multiple sites of recurrent NSCLCs, the authors detected T790M in only a small percentage of tumor cells.  To identify addnl. mechanisms of acquired resistance to gefitinib, the authors used NSCLC cells harboring an activating EGFR mutation to generate multiple resistant clones in vitro.  These drug-resistant cells demonstrate continued dependence on EGFR and ERBB2 signaling for their viability and have not acquired secondary EGFR mutations.  However, they display increased internalization of ligand-activated EGFR, consistent with altered receptor trafficking.  Although gefitinib-resistant clones are cross-resistant to related anilinoquinazolines, they demonstrate sensitivity to a class of irreversible inhibitors of EGFR.  These inhibitors also show effective inhibition of signaling by T790M-mutant EGFR and killing of NSCLC cells with the T790M mutation.  Both mechanisms of gefitinib resistance are therefore circumvented by irreversible tyrosine kinase inhibitors.  Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5BSM8yaZe7Vg90H21EOLACvtfcHk0li3SSebacUy2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D&md5=f3fb866c3673fd4dff8a3f0a8c9be65b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502860102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502860102%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Kumar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petri, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span> </span><span class="NLM_article-title">Structure and clinical relevance fo the epidermal growth factor receptor in human cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1742</span><span class="NLM_x">â</span> <span class="NLM_lpage">1751</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1200%2FJCO.2007.12.1178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18375904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWhs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1742-1751&issue=10&author=A.+Kumarauthor=E.+T.+Petriauthor=B.+Halmosauthor=T.+J.+Boggon&title=Structure+and+clinical+relevance+fo+the+epidermal+growth+factor+receptor+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and clinical relevance of the epidermal growth factor receptor in human cancer</span></div><div class="casAuthors">Kumar, Amit; Petri, Edward T.; Halmos, Balazs; Boggon, Titus J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1742-1751</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To review the recent advances in the at.-level understanding of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK).  We aim to highlight the current and future importance of these studies for the understanding and treatment of malignancies where EGFR-TK is improperly activated.  Methods: The anal. was conducted on published crystal structures deposited in the Protein Data Bank (www.pdb.org) using the program O.  Results: In this review we emphasize how recent EGFR kinase domain crystal structures can explain the mechanisms of activation for L858R and other EGFR-TK mutations, and compare these distinct activating mechanisms with those recently described for the wild-type EGFR.  We suggest an at.-level mechanism for the poor efficacy of lapatinib against tumors with activating EGFR kinase domain point mutations compared with the efficacy of gefitinib and erlotinib, and demonstrate how structural insights help our understanding of acquired resistance to these agents.  We also highlight how these new mol.-level structural data are expected to affect the development of EGFR-TK targeted small mol. kinase inhibitors.  Conclusion: There are now more crystal structures published for the EGFR-TK domain than for any other TK.  This wealth of crystallog. information is beginning to describe the mechanisms by which proper regulation of EGFR-TK is lost in disease.  These crystal structures are beginning to show how small mols. inhibit EGFR-TK activity and will aid development of EGFR-TK mutant targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7kmKpTtoyyLVg90H21EOLACvtfcHk0li3SSebacUy2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWhs7w%253D&md5=c0879a268b217c8d32573c36c08b9aa0</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.12.1178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.12.1178%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DPetri%26aufirst%3DE.%2BT.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26atitle%3DStructure%2520and%2520clinical%2520relevance%2520fo%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520human%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26issue%3D10%26spage%3D1742%26epage%3D1751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x"> (</span><span class="NLM_issue">48</span><span class="NLM_x">) </span> <span class="NLM_fpage">46265</span><span class="NLM_x">â</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&issue=48&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Ã resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0li3SSebacUy2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D48%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Michalczyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baviller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">3482</span><span class="NLM_x">â</span> <span class="NLM_lpage">3488</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3482-3488&issue=7&author=A.+Michalczykauthor=S.+Kluterauthor=H.+B.+Rodeauthor=J.+R.+Simardauthor=C.+Grutterauthor=M.+Bavillerauthor=D.+Rauh&title=Structural+insights+into+how+irreversible+inhibitors+can+overcome+drug+resistance+in+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichalczyk%26aufirst%3DA.%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DBaviller%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStructural%2520insights%2520into%2520how%2520irreversible%2520inhibitors%2520can%2520overcome%2520drug%2520resistance%2520in%2520EGFR%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26issue%3D7%26spage%3D3482%26epage%3D3488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">The development of HKI-272 and related compounds for the treatment of cancer</span> <span class="citation_source-journal">Arch. Pharm. Chem. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">â</span> <span class="NLM_lpage">477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1002%2Fardp.200800009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18493974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2008&pages=465-477&author=A.+Wissnerauthor=T.+S.+Mansour&title=The+development+of+HKI-272+and+related+compounds+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">The development of HKI-272 and related compounds for the treatment of cancer</span></div><div class="casAuthors">Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">465-477</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of HKI-272 and EKB-569 for the treatment of cancer is described.  These compds. function as irreversible inhibitors of some members of the ErbB family of receptor tyrosine kinases.  In particular, they target epidermal growth factor receptor (EGFR, also known as ErbB-1) and human epidermal growth factor receptor-2 (HER2, also known as ErbB-2).  Both, HKI-272 and EKB-569 are 4-anilino-3-cyano quinoline derivs. that contain a 4-(dimethylamino)crotonamide Michael-acceptor group at the 6-position.  These compds. inhibit the function of the target enzymes by forming a covalent interaction with a conserved cysteine residue located in the kinase domains of these proteins.  The potential advantages of using irreversible inhibitors for this purpose are discussed.  We summarize the recent findings concerning some somatic mutations in EGFR and their relevance with respect to the irreversible inhibitors.  In particular, we highlight the findings that these irreversible inhibitors retain activity against tumors that have acquired a resistance to the reversible binding inhibitors gefitinib and erlotinib.  The promising interim clin. trial results for HKI-272 and EKB-569 in treating colon, lung, and breast cancers are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSokM42ZhprVg90H21EOLACvtfcHk0liuNfJBVw6_HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E&md5=2e46d99ca74e297e6a7e860634bf096d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fardp.200800009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200800009%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DThe%2520development%2520of%2520HKI-272%2520and%2520related%2520compounds%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DArch.%2520Pharm.%2520Chem.%2520Life%2520Sci.%26date%3D2008%26volume%3D341%26spage%3D465%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">HKI-272 in non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4593</span><span class="NLM_x">â</span> <span class="NLM_lpage">4596</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1158%2F1078-0432.CCR-07-0369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17671147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlKjsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4593-4596&author=K.-K.+Wong&title=HKI-272+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">HKI-272 in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15, Pt. 2</span>),
    <span class="NLM_cas:pages">4593s-4596s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Somatic mutations in the kinase domain of the epidermal growth factor receptor (EGFR) gene are found in â¼10% of lung adenocarcinomas sequenced in the United States and in â¼30% sequenced in Asia.  These mutations are assocd. with sensitivity to the EGFR inhibitors gefitinib and erlotinib.  Many patients who initially respond to erlotinib or gefitinib subsequently relapse.  Studies have identified EGFR T790M mutations in tumors from patients who initially responded and then relapsed.  The T790M mutation, when combined in vitro with treatment-sensitizing EGFR mutations, permits the continued growth of tumor cells in the presence of erlotinib and gefitinib.  HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790M mutant cells in vitro in human lung cancer cell lines and in murine cells transfected with sensitizing EGFR mutations.  A phase I HKI-272 monotherapy trial in patients with solid tumors is close to completion.  Preliminary analyses of the trial, presented at the 2006 annual meeting of American Society of Clin. Oncol., showed that HKI-272 can achieve stable disease control for over 6 mo in some patients with non-small cell lung cancer that has progressed after treatment with gefitinib or erlotinib.  A phase II trial of HKI-272 in non-small cell lung cancer patients has been initiated.  HKI-272 might offer benefits to non-small cell lung cancer patients who have relapsed after an initial response to erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk5KWthnzz7LVg90H21EOLACvtfcHk0liuNfJBVw6_HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlKjsrw%253D&md5=24d09e44614f8286aa7b590ee86320e0</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0369%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DHKI-272%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4593%26epage%3D4596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS0163-7258%2802%2900194-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12191617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=253-261&author=W.+A.+Denny&title=Irreversible+inhibitors+of+the+erbB+family+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span></div><div class="casAuthors">Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">253-261</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The erbB family of transmembrane receptor tyrosine kinases initiates a large no. of cellular signaling pathways.  Their over-expression in human tumors correlates with poor prognosis, and they have become important targets for drug development.  The 4-anilinoquinazolines are potent and selective ATP site inhibitors of these enzymes, esp. erbB1 (epidermal growth factor receptor).  Structure-activity studies for binding at the ATP site are narrow, consistent with homol. and crystal structure-binding models.  Combinations of small lipophilic groups at the 3'-position of the aniline and electron-donating groups at the 6- or 7-positions of the quinazoline result in extremely potent (picomolar) reversible inhibitors, several of which are in clin. trial.  Observation that the erbB family of enzymes contains a unique Cys residue (Cys773) close to the ATP-binding site prompted the development of irreversible inhibitors, the most successful being 6-acrylamides and related butynamides, which show significantly improved in vivo antitumor activity compared with closely related reversibly binding compds.  Solubilizing side chains can be placed either at the terminus of the alkylating unit or at the quinazoline C-7, and examples of both types are in clin. trial.  Both reversible and irreversible inhibitors synergize with a variety of DNA-damaging anticancer drugs, and it is likely that the greatest impact of these agents will be in combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwN71GFZA09rVg90H21EOLACvtfcHk0liuNfJBVw6_HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D&md5=7937e2efbf606734ae781554e7c26d15</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900194-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900194-8%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520erbB%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D93%26spage%3D253%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Bridges, A. J.</span><span> </span><span class="NLM_article-title">The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">â</span> <span class="NLM_lpage">843</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFWqtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=825-843&author=A.+J.+Bridges&title=The+rationale+and+strategy+used+to+develop+a+series+of+highly+potent%2C+irreversible%2C+inhibitors+of+the+epidermal+growth+factor+receptor+family+of+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the Epidermal Growth Factor receptor family of tyrosine kinases</span></div><div class="casAuthors">Bridges, A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">825-843</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review with 122 refs.  The Epidermal Growth Factor receptor (EGFr) was one of the first oncogenes identified, and it, or its ligands Epidermal Growth Factor (EGF) and Transforming Growth Factor Î± (TGFÎ±) are overexpressed in most clin. tumors.  As EGF and TGFÎ± are potent mitogens, it appeared that inhibition of EGFr signaling would be a viable anti-proliferative strategy.  Screening found several classes of EGFr inhibitor, one of which, the indolinethiones was developed.  The SAR, in common with that of other first generation tyrosine kinase (TK) inhibitors was flat, and potency was poor.  Rescreening in presence of a thiol, to remove chem. reactive species, identified only two leads, a pyridopyrimidine and a quinazoline.  These were developed into a very broad class of EGFr inhibitors, with great potency and selectivity for EGFr, but poor physicochem. properties, and little if any in vivo anti-tumor activity.  Meanwhile the complex role of other members of the EGFr TK family in oncogenesis, was becoming apparent, suggesting that the whole EGFr family should be inhibited.  The difficulty of finding potent compds. with acceptable pharmacokinetics also suggested that irreversible inhibitors of the TK might produce better in vivo profiles.  Modeling suggested that the unusual Cys773 residue might be reached from the 6/7-positions of quinazoline and pyridopyrimidine inhibitors.  Inhibitors with acrylamides at these positions proved to be irreversible alkylating agents for both EGFr and erbB-2 with cellular inhibitory activities in the low nanomolar range, and very potent in vivo antitumor activity.  Optimized inhibitors had exceptionally potent oral antitumor activity, with negligible cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCfxlExE175LVg90H21EOLACvtfcHk0liuNfJBVw6_HQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFWqtb8%253D&md5=36f387aecf4c6e676591383bf25a10ca</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520rationale%2520and%2520strategy%2520used%2520to%2520develop%2520a%2520series%2520of%2520highly%2520potent%252C%2520irreversible%252C%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520family%2520of%2520tyrosine%2520kinases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D1999%26volume%3D6%26spage%3D825%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span> </span><span class="NLM_article-title">4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor (EGF-R) kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3244</span><span class="NLM_x">â</span> <span class="NLM_lpage">3256</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000206a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3244-3256&author=A.+Wissnerauthor=D.+M.+Bergerauthor=D.+H.+Boschelliauthor=M.+B.+J.+Floydauthor=L.+M.+Greenbergerauthor=B.+C.+Gruberauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=R.+Nilakantanauthor=M.+F.+Reichauthor=R.+Shenauthor=H.-R.+Tsouauthor=E.+Upeslacisauthor=Y.-F.+Wangauthor=B.+Wuauthor=F.+Yeauthor=N.+Zhang&title=4-Anilino-6%2C7-dialkoxyquinoline-3-carbonitrile+inhibitors+of+epidermal+growth+factor+receptor+%28EGF-R%29+kinase+and+their+bioisosteric+relationship+to+the+4-anilino-6%2C7-dialkoxyquinazoline+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fjm000206a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000206a%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DD.%2BM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%2BJ.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DUpeslacis%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DN.%26atitle%3D4-Anilino-6%252C7-dialkoxyquinoline-3-carbonitrile%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGF-R%2529%2520kinase%2520and%2520their%2520bioisosteric%2520relationship%2520to%2520the%25204-anilino-6%252C7-dialkoxyquinazoline%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3244%26epage%3D3256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">34</span><span class="NLM_x">) </span> <span class="NLM_fpage">4702</span><span class="NLM_x">â</span> <span class="NLM_lpage">4711</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&issue=34&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+G.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=M.+Solcaauthor=H.+Greulichauthor=K.-K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DM.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26issue%3D34%26spage%3D4702%26epage%3D4711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">2070</span><span class="NLM_x">â</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&issue=6&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lhRga8x4ipZxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26issue%3D6%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Chemical Approaches for Making âInactive-Conformationâ Kinase Inhibitors</span>. Presented at the 236th National Meeting of the American Chemical Society, Philadelphia, PA,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=N.+S.+Gray&title=Chemical+Approaches+for+Making+%E2%80%9CInactive-Conformation%E2%80%9D+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DChemical%2520Approaches%2520for%2520Making%2520%25E2%2580%259CInactive-Conformation%25E2%2580%259D%2520Kinase%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Gajiwala, K. S.; Wu, J.; Lunney, E.; Demetri, G.</span><span> </span><span class="NLM_article-title">Novel Mechanisms of Drug Resistance in KIT Mutants from Patients with Gastrointestinal Stromal Tumors: Structural Biology of Wild-Type and Mutated Proteins</span>. Presented at the 236th National Meeting of the American Chemical Society, Philadelphia, PA,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+S.+Gajiwala&author=J.+Wu&author=E.+Lunney&author=G.+Demetri&title=Novel+Mechanisms+of+Drug+Resistance+in+KIT+Mutants+from+Patients+with+Gastrointestinal+Stromal+Tumors%3A+Structural+Biology+of+Wild-Type+and+Mutated+Proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26atitle%3DNovel%2520Mechanisms%2520of%2520Drug%2520Resistance%2520in%2520KIT%2520Mutants%2520from%2520Patients%2520with%2520Gastrointestinal%2520Stromal%2520Tumors%253A%2520Structural%2520Biology%2520of%2520Wild-Type%2520and%2520Mutated%2520Proteins%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Zunder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houseman, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110alpha</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">â</span> <span class="NLM_lpage">192</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=180-192&author=E.+R.+Zunderauthor=Z.+A.+Knightauthor=B.+T.+Housemanauthor=B.+Apselauthor=K.+M.+Shokat&title=Discovery+of+drug-resistant+and+drug-sensitizing+mutations+in+the+oncogenic+PI3K+isoform+p110alpha"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DHouseman%26aufirst%3DB.%2BT.%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DDiscovery%2520of%2520drug-resistant%2520and%2520drug-sensitizing%2520mutations%2520in%2520the%2520oncogenic%2520PI3K%2520isoform%2520p110alpha%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D14%26spage%3D180%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latek, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR_ABL</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">831</span><span class="NLM_x">â</span> <span class="NLM_lpage">843</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2003&pages=831-843&author=M.+Azamauthor=R.+R.+Latekauthor=G.+Q.+Daley&title=Mechanisms+of+autoinhibition+and+STI-571%2Fimatinib+resistance+revealed+by+mutagenesis+of+BCR_ABL"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DLatek%26aufirst%3DR.%2BR.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DMechanisms%2520of%2520autoinhibition%2520and%2520STI-571%252Fimatinib%2520resistance%2520revealed%2520by%2520mutagenesis%2520of%2520BCR_ABL%26jtitle%3DCell%26date%3D2003%26volume%3D112%26spage%3D831%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">von Bubnoff, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Kuip, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulitzky, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sander, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seipel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peschel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duyster, J.</span><span> </span><span class="NLM_article-title">A cell-based screeen for resistance of Bcr-Abl-positive leukemia identieifs the mutation pattern for PD166326, an alternative Abl kinase inhibitor</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">1652</span><span class="NLM_x">â</span> <span class="NLM_lpage">1659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=1652-1659&author=N.+von+Bubnoffauthor=D.+R.+Veachauthor=H.+van+der+Kuipauthor=W.+E.+Aulitzkyauthor=J.+Sanderauthor=P.+Seipelauthor=W.+G.+Bornmannauthor=C.+Peschelauthor=B.+Clarksonauthor=J.+Duyster&title=A+cell-based+screeen+for+resistance+of+Bcr-Abl-positive+leukemia+identieifs+the+mutation+pattern+for+PD166326%2C+an+alternative+Abl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BBubnoff%26aufirst%3DN.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3Dvan%2Bder%2BKuip%26aufirst%3DH.%26aulast%3DAulitzky%26aufirst%3DW.%2BE.%26aulast%3DSander%26aufirst%3DJ.%26aulast%3DSeipel%26aufirst%3DP.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DDuyster%26aufirst%3DJ.%26atitle%3DA%2520cell-based%2520screeen%2520for%2520resistance%2520of%2520Bcr-Abl-positive%2520leukemia%2520identieifs%2520the%2520mutation%2520pattern%2520for%2520PD166326%252C%2520an%2520alternative%2520Abl%2520kinase%2520inhibitor%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D1652%26epage%3D1659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Girdler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sessa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patercoli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musacchoi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span> </span><span class="NLM_article-title">Molecular basis of drug resistance in Aurora kinases</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">552</span><span class="NLM_x">â</span> <span class="NLM_lpage">562</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2Fj.chembiol.2008.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18559266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1alurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=552-562&issue=6&author=F.+Girdlerauthor=F.+Sessaauthor=S.+Patercoliauthor=F.+Villaauthor=A.+Musacchoiauthor=S.+Taylor&title=Molecular+basis+of+drug+resistance+in+Aurora+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis of Drug Resistance in Aurora Kinases</span></div><div class="casAuthors">Girdler, Fiona; Sessa, Fabio; Patercoli, Simona; Villa, Fabrizio; Musacchio, Andrea; Taylor, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">552-562</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Aurora kinases have emerged as potential targets in cancer therapy, and several drugs are currently undergoing preclin. and clin. validation.  Whether clin. resistance to these drugs can arise is unclear.  The authors exploited a hypermutagenic cancer cell line to select mutations conferring resistance to a well-studied Aurora inhibitor, ZM447439.  All resistant clones contained dominant point mutations in Aurora B.  Three mutations map to residues in the ATP-binding pocket that are distinct from the "gatekeeper" residue.  The mutants retain wild-type catalytic activity and were resistant to all of the Aurora inhibitors tested.  The studies predict that drug-resistant Aurora B mutants are likely to arise during clin. treatment.  Furthermore, because the plasticity of the ATP-binding pocket renders Aurora B insensitive to multiple inhibitors, the observations indicate that the drug-resistant Aurora B mutants should be exploited as novel drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRp7zrCOdSOrVg90H21EOLACvtfcHk0liteGHS8JekGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1alurg%253D&md5=f272cd07a8371961b728c410ee987b1a</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DGirdler%26aufirst%3DF.%26aulast%3DSessa%26aufirst%3DF.%26aulast%3DPatercoli%26aufirst%3DS.%26aulast%3DVilla%26aufirst%3DF.%26aulast%3DMusacchoi%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DS.%26atitle%3DMolecular%2520basis%2520of%2520drug%2520resistance%2520in%2520Aurora%2520kinases%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26issue%3D6%26spage%3D552%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Project, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of b-Raf</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">â</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+G.+Projectauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+b-Raf"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0liteGHS8JekGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DProject%26aufirst%3DC.%2BG.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520b-Raf%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailtland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the BRAF gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">â</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Mailtlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0liteGHS8JekGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMailtland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 124 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yu-Qi Fang, <span class="NLM_string-name hlFld-ContribAuthor">Li Dang</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic Study of Domino Rearrangement-Promoted Meta CâH Activation in 2-Methyl-N-methoxyaniline via Cu(NHC)+: Motivation and Selectivity. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (23)
                                     , 9178-9183. <a href="https://doi.org/10.1021/acs.orglett.0c03004" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03004%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DMechanistic%252BStudy%252Bof%252BDomino%252BRearrangement-Promoted%252BMeta%252BC%2525E2%252580%252593H%252BActivation%252Bin%252B2-Methyl-N-methoxyaniline%252Bvia%252BCu%252528NHC%252529%25252B%25253A%252BMotivation%252Band%252BSelectivity%26aulast%3DFang%26aufirst%3DYu-Qi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D22092020%26date%3D16112020%26volume%3D22%26issue%3D23%26spage%3D9178%26epage%3D9183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jaya Krishna Koneru, Suman Sinha, <span class="NLM_string-name hlFld-ContribAuthor">Jagannath Mondal</span>. </span><span class="cited-content_cbyCitation_article-title">In Silico Reoptimization of Binding Affinity and Drug-Resistance Circumvention Ability in Kinase Inhibitors: A Case Study with RL-45 and Src Kinase. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2019,</strong> <em>123 </em>
                                    (31)
                                     , 6664-6672. <a href="https://doi.org/10.1021/acs.jpcb.9b02883" title="DOI URL">https://doi.org/10.1021/acs.jpcb.9b02883</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.9b02883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.9b02883%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DIn%252BSilico%252BReoptimization%252Bof%252BBinding%252BAffinity%252Band%252BDrug-Resistance%252BCircumvention%252BAbility%252Bin%252BKinase%252BInhibitors%25253A%252BA%252BCase%252BStudy%252Bwith%252BRL-45%252Band%252BSrc%252BKinase%26aulast%3DKoneru%26aufirst%3DJaya%2BKrishna%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27032019%26date%3D17062019%26date%3D30072019%26date%3D16072019%26volume%3D123%26issue%3D31%26spage%3D6664%26epage%3D6672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael
P. Agius, Kristin S. Ko, Taylor K. Johnson, Frank E. Kwarcinski, Sameer Phadke, Eric J. Lachacz, <span class="NLM_string-name hlFld-ContribAuthor">Matthew B. Soellner</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Proteolysis to Study the Global Conformation and Regulatory Mechanisms of c-Src Kinase. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (7)
                                     , 1556-1563. <a href="https://doi.org/10.1021/acschembio.9b00306" title="DOI URL">https://doi.org/10.1021/acschembio.9b00306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00306%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DSelective%252BProteolysis%252Bto%252BStudy%252Bthe%252BGlobal%252BConformation%252Band%252BRegulatory%252BMechanisms%252Bof%252Bc-Src%252BKinase%26aulast%3DAgius%26aufirst%3DMichael%2BP.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17042019%26date%3D25062019%26date%3D09072019%26date%3D25062019%26volume%3D14%26issue%3D7%26spage%3D1556%26epage%3D1563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ren-Jin Tang, Pascal Retailleau, Thierry Milcent, <span class="NLM_string-name hlFld-ContribAuthor">Benoit Crousse</span>. </span><span class="cited-content_cbyCitation_article-title">Direct Amination of Arenes with Azodicarboxylates Catalyzed by Bisulfate Salt/HFIP Association. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (5)
                                     , 8960-8966. <a href="https://doi.org/10.1021/acsomega.9b00781" title="DOI URL">https://doi.org/10.1021/acsomega.9b00781</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b00781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b00781%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DDirect%252BAmination%252Bof%252BArenes%252Bwith%252BAzodicarboxylates%252BCatalyzed%252Bby%252BBisulfate%252BSalt%25252FHFIP%252BAssociation%26aulast%3DTang%26aufirst%3DRen-Jin%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21032019%26date%3D10052019%26volume%3D4%26issue%3D5%26spage%3D8960%26epage%3D8966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mikhail O. Konev, T. Andrew McTeague, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey W. Johannes</span>. </span><span class="cited-content_cbyCitation_article-title">Nickel-Catalyzed Photoredox-Mediated Cross-Coupling of Aryl Electrophiles and Aryl Azides. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2018,</strong> <em>8 </em>
                                    (10)
                                     , 9120-9124. <a href="https://doi.org/10.1021/acscatal.8b02954" title="DOI URL">https://doi.org/10.1021/acscatal.8b02954</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.8b02954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.8b02954%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DNickel-Catalyzed%252BPhotoredox-Mediated%252BCross-Coupling%252Bof%252BAryl%252BElectrophiles%252Band%252BAryl%252BAzides%26aulast%3DKonev%26aufirst%3DMikhail%2BO.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26072018%26date%3D28082018%26date%3D04092018%26date%3D30082018%26volume%3D8%26issue%3D10%26spage%3D9120%26epage%3D9124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Siegfried R. Waldvogel, Sebastian Lips, Maximilian Selt, Barbara Riehl, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. Kampf</span>. </span><span class="cited-content_cbyCitation_article-title">Electrochemical Arylation Reaction. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2018,</strong> <em>118 </em>
                                    (14)
                                     , 6706-6765. <a href="https://doi.org/10.1021/acs.chemrev.8b00233" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00233%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DElectrochemical%252BArylation%252BReaction%26aulast%3DWaldvogel%26aufirst%3DSiegfried%2BR.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09042018%26date%3D02072018%26volume%3D118%26issue%3D14%26spage%3D6706%26epage%3D6765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Xie</span>, <span class="hlFld-ContribAuthor ">Yue-Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Lian-Wen  Qi</span>, and <span class="hlFld-ContribAuthor ">Bo  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Access to Aminated Saturated Oxygen Heterocycles via Copper-Catalyzed Aminooxygenation of Alkenes. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (5)
                                     , 1148-1151. <a href="https://doi.org/10.1021/acs.orglett.7b00182" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b00182</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b00182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b00182%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAccess%252Bto%252BAminated%252BSaturated%252BOxygen%252BHeterocycles%252Bvia%252BCopper-Catalyzed%252BAminooxygenation%252Bof%252BAlkenes%26aulast%3DXie%26aufirst%3DJian%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D19012017%26date%3D16022017%26date%3D03032017%26volume%3D19%26issue%3D5%26spage%3D1148%26epage%3D1151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jagannath  Mondal</span>, <span class="hlFld-ContribAuthor ">Pratyush  Tiwary</span>, and <span class="hlFld-ContribAuthor ">B. J.  Berne</span>  . </span><span class="cited-content_cbyCitation_article-title">How a Kinase Inhibitor Withstands Gatekeeper Residue Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2016,</strong> <em>138 </em>
                                    (13)
                                     , 4608-4615. <a href="https://doi.org/10.1021/jacs.6b01232" title="DOI URL">https://doi.org/10.1021/jacs.6b01232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.6b01232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.6b01232%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DHow%252Ba%252BKinase%252BInhibitor%252BWithstands%252BGatekeeper%252BResidue%252BMutations%26aulast%3DMondal%26aufirst%3DJagannath%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D02022016%26date%3D22032016%26date%3D06042016%26date%3D08032016%26volume%3D138%26issue%3D13%26spage%3D4608%26epage%3D4615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiao  Jiao</span>, <span class="hlFld-ContribAuthor ">Kei  Murakami</span>, and <span class="hlFld-ContribAuthor ">Kenichiro  Itami</span>  . </span><span class="cited-content_cbyCitation_article-title">Catalytic Methods for Aromatic CâH Amination: An Ideal Strategy for Nitrogen-Based Functional Molecules. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2016,</strong> <em>6 </em>
                                    (2)
                                     , 610-633. <a href="https://doi.org/10.1021/acscatal.5b02417" title="DOI URL">https://doi.org/10.1021/acscatal.5b02417</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.5b02417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.5b02417%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DCatalytic%252BMethods%252Bfor%252BAromatic%252BC%2525E2%252580%252593H%252BAmination%25253A%252BAn%252BIdeal%252BStrategy%252Bfor%252BNitrogen-Based%252BFunctional%252BMolecules%26aulast%3DJiao%26aufirst%3DJiao%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D27102015%26date%3D07122015%26date%3D24122015%26date%3D05022016%26date%3D07122015%26volume%3D6%26issue%3D2%26spage%3D610%26epage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takahiro  Kawakami</span>, <span class="hlFld-ContribAuthor ">Kei  Murakami</span>, and <span class="hlFld-ContribAuthor ">Kenichiro  Itami</span>  . </span><span class="cited-content_cbyCitation_article-title">Catalytic CâH Imidation of Aromatic Cores of Functional Molecules: Ligand-Accelerated Cu Catalysis and Application to Materials- and Biology-Oriented Aromatics. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2015,</strong> <em>137 </em>
                                    (7)
                                     , 2460-2463. <a href="https://doi.org/10.1021/ja5130012" title="DOI URL">https://doi.org/10.1021/ja5130012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja5130012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja5130012%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DCatalytic%252BC%2525E2%252580%252593H%252BImidation%252Bof%252BAromatic%252BCores%252Bof%252BFunctional%252BMolecules%25253A%252BLigand-Accelerated%252BCu%252BCatalysis%252Band%252BApplication%252Bto%252BMaterials-%252Band%252BBiology-Oriented%252BAromatics%26aulast%3DKawakami%26aufirst%3DTakahiro%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D21122014%26date%3D12022015%26date%3D25022015%26date%3D10022015%26volume%3D137%26issue%3D7%26spage%3D2460%26epage%3D2463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naeem  Asad</span>, <span class="hlFld-ContribAuthor ">Thiwanka B.  Samarakoon</span>, <span class="hlFld-ContribAuthor ">Qin  Zang</span>, <span class="hlFld-ContribAuthor ">Joanna K.  Loh</span>, <span class="hlFld-ContribAuthor ">Salim  Javed</span>, and <span class="hlFld-ContribAuthor ">Paul R.  Hanson</span>  . </span><span class="cited-content_cbyCitation_article-title">Rapid, Scalable Assembly of Stereochemically Rich, Mono- and Bicyclic Acyl Sultams. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2014,</strong> <em>16 </em>
                                    (1)
                                     , 82-85. <a href="https://doi.org/10.1021/ol403070w" title="DOI URL">https://doi.org/10.1021/ol403070w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ol403070w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fol403070w%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRapid%25252C%252BScalable%252BAssembly%252Bof%252BStereochemically%252BRich%25252C%252BMono-%252Band%252BBicyclic%252BAcyl%252BSultams%26aulast%3DAsad%26aufirst%3DNaeem%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D24102013%26date%3D06122013%26date%3D03012014%26volume%3D16%26issue%3D1%26spage%3D82%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shun  Zhu</span>, <span class="hlFld-ContribAuthor ">Sue M.  Travis</span>, and <span class="hlFld-ContribAuthor ">Adrian H.  Elcock</span>  . </span><span class="cited-content_cbyCitation_article-title">Accurate Calculation of Mutational Effects on the Thermodynamics of Inhibitor Binding to p38Î± MAP Kinase: A Combined Computational and Experimental Study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Theory and Computation</span><span> <strong>2013,</strong> <em>9 </em>
                                    (7)
                                     , 3151-3164. <a href="https://doi.org/10.1021/ct400104x" title="DOI URL">https://doi.org/10.1021/ct400104x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ct400104x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fct400104x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Theory%2520and%2520Computation%26atitle%3DAccurate%252BCalculation%252Bof%252BMutational%252BEffects%252Bon%252Bthe%252BThermodynamics%252Bof%252BInhibitor%252BBinding%252Bto%252Bp38%2525CE%2525B1%252BMAP%252BKinase%25253A%252BA%252BCombined%252BComputational%252Band%252BExperimental%252BStudy%26aulast%3DZhu%26aufirst%3DShun%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D08022013%26date%3D11062013%26date%3D09072013%26date%3D28052013%26volume%3D9%26issue%3D7%26spage%3D3151%26epage%3D3164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alan B.  Northrup</span>, <span class="hlFld-ContribAuthor ">Matthew H.  Katcher</span>, <span class="hlFld-ContribAuthor ">Michael D.  Altman</span>, <span class="hlFld-ContribAuthor ">Melissa  Chenard</span>, <span class="hlFld-ContribAuthor ">Matthew H.  Daniels</span>, <span class="hlFld-ContribAuthor ">Sujal V.  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Danielle  Falcone</span>, <span class="hlFld-ContribAuthor ">David J.  Guerin</span>, <span class="hlFld-ContribAuthor ">Harold  Hatch</span>, <span class="hlFld-ContribAuthor ">Chaomin  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Lu</span>, <span class="hlFld-ContribAuthor ">Bart  Lutterbach</span>, <span class="hlFld-ContribAuthor ">Timothy J.  Allison</span>, <span class="hlFld-ContribAuthor ">Sangita B.  Patel</span>, <span class="hlFld-ContribAuthor ">John F.  Reilly</span>, <span class="hlFld-ContribAuthor ">Michael  Reutershan</span>, <span class="hlFld-ContribAuthor ">Keith W.  Rickert</span>, <span class="hlFld-ContribAuthor ">Craig  Rosenstein</span>, <span class="hlFld-ContribAuthor ">Stephen M.  Soisson</span>, <span class="hlFld-ContribAuthor ">Alexander A.  Szewczak</span>, <span class="hlFld-ContribAuthor ">Deborah  Walker</span>, <span class="hlFld-ContribAuthor ">Kevin  Wilson</span>, <span class="hlFld-ContribAuthor ">Jonathan R.  Young</span>, <span class="hlFld-ContribAuthor ">Bo-Sheng  Pan</span>, and <span class="hlFld-ContribAuthor ">Christopher J.  Dinsmore</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (6)
                                     , 2294-2310. <a href="https://doi.org/10.1021/jm301619u" title="DOI URL">https://doi.org/10.1021/jm301619u</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301619u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301619u%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%25255B3-%2525281-Methyl-1H-pyrazol-4-yl%252529-5-oxo-5H-benzo%25255B4%25252C5%25255Dcyclohepta%25255B1%25252C2-b%25255Dpyridin-7-yl%25255D-N-%252528pyridin-2-ylmethyl%252529methanesulfonamide%252B%252528MK-8033%252529%25253A%252BA%252BSpecific%252Bc-Met%25252FRon%252BDual%252BKinase%252BInhibitor%252Bwith%252BPreferential%252BAffinity%252Bfor%252Bthe%252BActivated%252BState%252Bof%252Bc-Met%26aulast%3DNorthrup%26aufirst%3DAlan%2BB.%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D02112012%26date%3D18032013%26date%3D28032013%26date%3D04022013%26volume%3D56%26issue%3D6%26spage%3D2294%26epage%3D2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Xiaofen  Pan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Deping  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Yupeng  Li</span>, <span class="hlFld-ContribAuthor ">Donghai  Wen</span>, <span class="hlFld-ContribAuthor ">Huoyou  Long</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yubing  Feng</span>, <span class="hlFld-ContribAuthor ">Xiaoxi  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fengxiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianqi  Liu</span>, <span class="hlFld-ContribAuthor ">Fang  Leng</span>, <span class="hlFld-ContribAuthor ">Xingfen  Lang</span>, <span class="hlFld-ContribAuthor ">Yang  Bai</span>, <span class="hlFld-ContribAuthor ">Miaoqin  She</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Jingxuan  Pan</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster RegionâAbelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (3)
                                     , 879-894. <a href="https://doi.org/10.1021/jm301581y" title="DOI URL">https://doi.org/10.1021/jm301581y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301581y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301581y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BGZD824%252Bas%252Ban%252BOrally%252BBioavailable%252BInhibitor%252BThat%252BTargets%252BPhosphorylated%252Band%252BNonphosphorylated%252BBreakpoint%252BCluster%252BRegion%2525E2%252580%252593Abelson%252B%252528Bcr-Abl%252529%252BKinase%252Band%252BOvercomes%252BClinically%252BAcquired%252BMutation-Induced%252BResistance%252Bagainst%252BImatinib%26aulast%3DRen%26aufirst%3DXiaomei%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D17092012%26date%3D28012013%26date%3D14022013%26date%3D09012013%26volume%3D56%26issue%3D3%26spage%3D879%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takuji  Hatakeyama</span>, <span class="hlFld-ContribAuthor ">Ryuji  Imayoshi</span>, <span class="hlFld-ContribAuthor ">Yuya  Yoshimoto</span>, <span class="hlFld-ContribAuthor ">Sujit K.  Ghorai</span>, <span class="hlFld-ContribAuthor ">Masayoshi  Jin</span>, <span class="hlFld-ContribAuthor ">Hikaru  Takaya</span>, <span class="hlFld-ContribAuthor ">Kazuhiro  Norisuye</span>, <span class="hlFld-ContribAuthor ">Yoshiki  Sohrin</span>, and <span class="hlFld-ContribAuthor ">Masaharu  Nakamura</span>  . </span><span class="cited-content_cbyCitation_article-title">Iron-Catalyzed Aromatic Amination for Nonsymmetrical Triarylamine Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2012,</strong> <em>134 </em>
                                    (50)
                                     , 20262-20265. <a href="https://doi.org/10.1021/ja309845k" title="DOI URL">https://doi.org/10.1021/ja309845k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja309845k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja309845k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DIron-Catalyzed%252BAromatic%252BAmination%252Bfor%252BNonsymmetrical%252BTriarylamine%252BSynthesis%26aulast%3DHatakeyama%26aufirst%3DTakuji%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D05102012%26date%3D04122012%26date%3D19122012%26date%3D26112012%26volume%3D134%26issue%3D50%26spage%3D20262%26epage%3D20265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satoshi  Niijima</span>, <span class="hlFld-ContribAuthor ">Akira  Shiraishi</span>, and <span class="hlFld-ContribAuthor ">Yasushi  Okuno</span>  . </span><span class="cited-content_cbyCitation_article-title">Dissecting Kinase Profiling Data to Predict Activity and Understand Cross-Reactivity of Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2012,</strong> <em>52 </em>
                                    (4)
                                     , 901-912. <a href="https://doi.org/10.1021/ci200607f" title="DOI URL">https://doi.org/10.1021/ci200607f</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ci200607f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fci200607f%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDissecting%252BKinase%252BProfiling%252BData%252Bto%252BPredict%252BActivity%252Band%252BUnderstand%252BCross-Reactivity%252Bof%252BKinase%252BInhibitors%26aulast%3DNiijima%26aufirst%3DSatoshi%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D17122011%26date%3D26032012%26date%3D23042012%26date%3D13032012%26volume%3D52%26issue%3D4%26spage%3D901%26epage%3D912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Werner  Ginzinger</span>, <span class="hlFld-ContribAuthor ">Gerhard  MÃ¼hlgassner</span>, <span class="hlFld-ContribAuthor ">Vladimir B.  Arion</span>, <span class="hlFld-ContribAuthor ">Michael A.  Jakupec</span>, <span class="hlFld-ContribAuthor ">Alexander  Roller</span>, <span class="hlFld-ContribAuthor ">Markus  Galanski</span>, <span class="hlFld-ContribAuthor ">Michael  Reithofer</span>, <span class="hlFld-ContribAuthor ">Walter  Berger</span>, and <span class="hlFld-ContribAuthor ">Bernhard K.  Keppler</span>  . </span><span class="cited-content_cbyCitation_article-title">A SAR Study of Novel Antiproliferative Ruthenium and Osmium Complexes with Quinoxalinone Ligands in Human Cancer Cell Lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (7)
                                     , 3398-3413. <a href="https://doi.org/10.1021/jm3000906" title="DOI URL">https://doi.org/10.1021/jm3000906</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm3000906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm3000906%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BSAR%252BStudy%252Bof%252BNovel%252BAntiproliferative%252BRuthenium%252Band%252BOsmium%252BComplexes%252Bwith%252BQuinoxalinone%252BLigands%252Bin%252BHuman%252BCancer%252BCell%252BLines%26aulast%3DGinzinger%26aufirst%3DWerner%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D20012012%26date%3D27032012%26date%3D12042012%26date%3D15032012%26volume%3D55%26issue%3D7%26spage%3D3398%26epage%3D3413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaohua  Chang</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Duanqing  Pei</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 â Methionine790 Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (6)
                                     , 2711-2723. <a href="https://doi.org/10.1021/jm201591k" title="DOI URL">https://doi.org/10.1021/jm201591k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201591k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BConformationally%252BConstrained%252BInhibitors%252BTargeting%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BThreonine790%252B%2525E2%252586%252592%252BMethionine790%252BMutant%26aulast%3DChang%26aufirst%3DShaohua%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D25112011%26date%3D01032012%26date%3D22032012%26date%3D16022012%26volume%3D55%26issue%3D6%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ioannis S.  Vizirianakis</span>, <span class="hlFld-ContribAuthor ">Maria  Chatzopoulou</span>, <span class="hlFld-ContribAuthor ">Ioannis D.  Bonovolias</span>, <span class="hlFld-ContribAuthor ">Ioannis  Nicolaou</span>, <span class="hlFld-ContribAuthor ">Vassilis J.  Demopoulos</span>, and <span class="hlFld-ContribAuthor ">Asterios S.  Tsiftsoglou</span>  . </span><span class="cited-content_cbyCitation_article-title">Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (19)
                                     , 6779-6810. <a href="https://doi.org/10.1021/jm100189a" title="DOI URL">https://doi.org/10.1021/jm100189a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm100189a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm100189a%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DToward%252Bthe%252BDevelopment%252Bof%252BInnovative%252BBifunctional%252BAgents%252BTo%252BInduce%252BDifferentiation%252Band%252BTo%252BPromote%252BApoptosis%252Bin%252BLeukemia%25253A%252BClinical%252BCandidates%252Band%252BPerspectives%26aulast%3DVizirianakis%26aufirst%3DIoannis%2BS.%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D12022010%26date%3D20072010%26date%3D14102010%26volume%3D53%26issue%3D19%26spage%3D6779%26epage%3D6810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dominic A.  Sloane</span>, <span class="hlFld-ContribAuthor ">Michael Z.  Trikic</span>, <span class="hlFld-ContribAuthor ">Matthew L. H.  Chu</span>, <span class="hlFld-ContribAuthor ">Maria B. A. C.  Lamers</span>, <span class="hlFld-ContribAuthor ">Clive S.  Mason</span>, <span class="hlFld-ContribAuthor ">Ilka  Mueller</span>, <span class="hlFld-ContribAuthor ">Wendy J.  Savory</span>, <span class="hlFld-ContribAuthor ">David H.  Williams</span> and <span class="hlFld-ContribAuthor ">Patrick A.  Eyers</span>  . </span><span class="cited-content_cbyCitation_article-title">Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2010,</strong> <em>5 </em>
                                    (6)
                                     , 563-576. <a href="https://doi.org/10.1021/cb100053q" title="DOI URL">https://doi.org/10.1021/cb100053q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb100053q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb100053q%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DDrug-Resistant%252BAurora%252BA%252BMutants%252Bfor%252BCellular%252BTarget%252BValidation%252Bof%252Bthe%252BSmall%252BMolecule%252BKinase%252BInhibitors%252BMLN8054%252Band%252BMLN8237%26aulast%3DSloane%26aufirst%3DDominic%2BA.%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D05%252003%25202010%26date%3D28%252004%25202010%26date%3D11052010%26date%3D18062010%26date%3D28042010%26volume%3D5%26issue%3D6%26spage%3D563%26epage%3D576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabio  Zuccotto</span>, <span class="hlFld-ContribAuthor ">Elena  Ardini</span>, <span class="hlFld-ContribAuthor ">Elena  Casale</span> and <span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>  . </span><span class="cited-content_cbyCitation_article-title">Through the âGatekeeper Doorâ: Exploiting the Active Kinase Conformation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (7)
                                     , 2681-2694. <a href="https://doi.org/10.1021/jm901443h" title="DOI URL">https://doi.org/10.1021/jm901443h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm901443h%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThrough%252Bthe%252B%2525E2%252580%25259CGatekeeper%252BDoor%2525E2%252580%25259D%25253A%252BExploiting%252Bthe%252BActive%252BKinase%252BConformation%26aulast%3DZuccotto%26aufirst%3DFabio%26date%3D2010%26date%3D2009%26date%3D2009%26date%3D29092009%26date%3D14122009%26date%3D08042010%26volume%3D53%26issue%3D7%26spage%3D2681%26epage%3D2694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernd  Kuhn</span>, <span class="hlFld-ContribAuthor ">Peter  Mohr</span> and <span class="hlFld-ContribAuthor ">Martin  Stahl</span>. </span><span class="cited-content_cbyCitation_article-title">Intramolecular Hydrogen Bonding in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (6)
                                     , 2601-2611. <a href="https://doi.org/10.1021/jm100087s" title="DOI URL">https://doi.org/10.1021/jm100087s</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm100087s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm100087s%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIntramolecular%252BHydrogen%252BBonding%252Bin%252BMedicinal%252BChemistry%26aulast%3DKuhn%26aufirst%3DBernd%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D20012010%26date%3D22022010%26date%3D25032010%26volume%3D53%26issue%3D6%26spage%3D2601%26epage%3D2611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caterina  Carmi</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavazzoni</span>, <span class="hlFld-ContribAuthor ">Stefano  Vezzosi</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Bordi</span>, <span class="hlFld-ContribAuthor ">Federica  Vacondio</span>, <span class="hlFld-ContribAuthor ">Claudia  Silva</span>, <span class="hlFld-ContribAuthor ">Silvia  Rivara</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Roberta R.  Alfieri</span>, <span class="hlFld-ContribAuthor ">Silvia  La Monica</span>, <span class="hlFld-ContribAuthor ">Maricla  Galetti</span>, <span class="hlFld-ContribAuthor ">Andrea  Ardizzoni</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span> and <span class="hlFld-ContribAuthor ">Marco  Mor</span>  . </span><span class="cited-content_cbyCitation_article-title">Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (5)
                                     , 2038-2050. <a href="https://doi.org/10.1021/jm901558p" title="DOI URL">https://doi.org/10.1021/jm901558p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm901558p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm901558p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BIrreversible%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%252Bby%252BChemical%252BModulation%252Bof%252Bthe%252BCysteine-Trap%252BPortion%26aulast%3DCarmi%26aufirst%3DCaterina%26date%3D2010%26date%3D2010%26date%3D2009%26date%3D21102009%26date%3D12022010%26date%3D11032010%26volume%3D53%26issue%3D5%26spage%3D2038%26epage%3D2050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Morphy</span>. </span><span class="cited-content_cbyCitation_article-title">Selectively Nonselective Kinase Inhibition: Striking the Right Balance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2010,</strong> <em>53 </em>
                                    (4)
                                     , 1413-1437. <a href="https://doi.org/10.1021/jm901132v" title="DOI URL">https://doi.org/10.1021/jm901132v</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm901132v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm901132v%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelectively%252BNonselective%252BKinase%252BInhibition%25253A%252BStriking%252Bthe%252BRight%252BBalance%26aulast%3DMorphy%26aufirst%3DRichard%26date%3D2010%26date%3D2009%26date%3D2009%26date%3D30072009%26date%3D27102009%26date%3D25022010%26volume%3D53%26issue%3D4%26spage%3D1413%26epage%3D1437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ratika  Krishnamurty</span> and <span class="hlFld-ContribAuthor ">Dustin J.  Maly</span>. </span><span class="cited-content_cbyCitation_article-title">Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2010,</strong> <em>5 </em>
                                    (1)
                                     , 121-138. <a href="https://doi.org/10.1021/cb9002656" title="DOI URL">https://doi.org/10.1021/cb9002656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb9002656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb9002656%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DBiochemical%252BMechanisms%252Bof%252BResistance%252Bto%252BSmall-Molecule%252BProtein%252BKinase%252BInhibitors%26aulast%3DKrishnamurty%26aufirst%3DRatika%26date%3D2010%26date%3D2010%26date%3D2010%26date%3D2009%26date%3D03%252001%25202010%26date%3D27%252010%25202009%26date%3D03%252001%25202010%26date%3D15012010%26date%3D03012010%26volume%3D5%26issue%3D1%26spage%3D121%26epage%3D138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">MatthÃ¤us  Getlik</span>, <span class="hlFld-ContribAuthor ">Christian  GrÃ¼tter</span>, <span class="hlFld-ContribAuthor ">Jeffrey R.  Simard</span>, <span class="hlFld-ContribAuthor ">Sabine  KlÃ¼ter</span>, <span class="hlFld-ContribAuthor ">Matthias  Rabiller</span>, <span class="hlFld-ContribAuthor ">Haridas B.  Rode</span>, <span class="hlFld-ContribAuthor ">Armin  Robubi</span> and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2009,</strong> <em>52 </em>
                                    (13)
                                     , 3915-3926. <a href="https://doi.org/10.1021/jm9002928" title="DOI URL">https://doi.org/10.1021/jm9002928</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm9002928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm9002928%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHybrid%252BCompound%252BDesign%252BTo%252BOvercome%252Bthe%252BGatekeeper%252BT338M%252BMutation%252Bin%252BcSrc%26aulast%3DGetlik%26aufirst%3DMatth%25C3%25A4us%26date%3D2009%26date%3D2009%26date%3D2009%26date%3D8%252003%25202009%26date%3D22052009%26date%3D09072009%26volume%3D52%26issue%3D13%26spage%3D3915%26epage%3D3926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yahya  Absalan</span>, <span class="hlFld-ContribAuthor ">Nazanin Noroozi  Shad</span>, <span class="hlFld-ContribAuthor ">Mostafa  Gholizadeh</span>, <span class="hlFld-ContribAuthor ">Ghodrat  Mahmoudi</span>, <span class="hlFld-ContribAuthor ">Hossein Sabet  Sarvestani</span>, <span class="hlFld-ContribAuthor ">Pavel  Strashnov</span>, <span class="hlFld-ContribAuthor ">Khashayar  Ghandi</span>, <span class="hlFld-ContribAuthor ">Olga  Kovalchukova</span>. </span><span class="cited-content_cbyCitation_article-title">Schiff bases-titanium (III) & (IV) complex compounds: Novel photocatalysts in Buchwald-Hartwig CâN cross-coupling reaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Photochemistry and Photobiology A: Chemistry</span><span> <strong>2021,</strong> <em>417 </em>, 113346. <a href="https://doi.org/10.1016/j.jphotochem.2021.113346" title="DOI URL">https://doi.org/10.1016/j.jphotochem.2021.113346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jphotochem.2021.113346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jphotochem.2021.113346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Photochemistry%2520and%2520Photobiology%2520A%253A%2520Chemistry%26atitle%3DSchiff%252Bbases-titanium%252B%252528III%252529%252B%252526%252B%252528IV%252529%252Bcomplex%252Bcompounds%25253A%252BNovel%252Bphotocatalysts%252Bin%252BBuchwald-Hartwig%252BC%2525E2%252580%252593N%252Bcross-coupling%252Breaction%26aulast%3DAbsalan%26aufirst%3DYahya%26date%3D2021%26volume%3D417%26spage%3D113346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kang M.  Kim</span>, <span class="hlFld-ContribAuthor ">Kang Min  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Copper Catalyzed
              N
              âArylation of Amines in Ionic Liquid Using 1âAryltriazenes as Aryl Surrogates. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (11)
                                     , 2709-2715. <a href="https://doi.org/10.1002/slct.202100180" title="DOI URL">https://doi.org/10.1002/slct.202100180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202100180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202100180%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DCopper%252BCatalyzed%252BN%252B%2525E2%252580%252590Arylation%252Bof%252BAmines%252Bin%252BIonic%252BLiquid%252BUsing%252B1%2525E2%252580%252590Aryltriazenes%252Bas%252BAryl%252BSurrogates%26aulast%3DKim%26aufirst%3DKang%2BM.%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D11%26spage%3D2709%26epage%3D2715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiefei  Wu</span>, <span class="hlFld-ContribAuthor ">Zexi  Pan</span>, <span class="hlFld-ContribAuthor ">Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">A one-pot synthesis of 2-aminothiazoles via the coupling of ketones and thiourea using I
              2
              /dimethyl sulfoxide as a catalytic oxidative system. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2021,</strong> <em>45 </em>
                                    (1-2)
                                     , 89-94. <a href="https://doi.org/10.1177/1747519820930961" title="DOI URL">https://doi.org/10.1177/1747519820930961</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1747519820930961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1747519820930961%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DA%252Bone-pot%252Bsynthesis%252Bof%252B2-aminothiazoles%252Bvia%252Bthe%252Bcoupling%252Bof%252Bketones%252Band%252Bthiourea%252Busing%252BI%252B2%252B%25252Fdimethyl%252Bsulfoxide%252Bas%252Ba%252Bcatalytic%252Boxidative%252Bsystem%26aulast%3DZhang%26aufirst%3DQian%26date%3D2021%26date%3D2020%26volume%3D45%26issue%3D1-2%26spage%3D89%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lars J.  Wesenberg</span>, <span class="hlFld-ContribAuthor ">Erika  Diehl</span>, <span class="hlFld-ContribAuthor ">Till J. B.  ZÃ¤hringer</span>, <span class="hlFld-ContribAuthor ">Carolin  DÃ¶rr</span>, <span class="hlFld-ContribAuthor ">Dieter  Schollmeyer</span>, <span class="hlFld-ContribAuthor ">Akihiro  Shimizu</span>, <span class="hlFld-ContribAuthor ">Junâichi  Yoshida</span>, <span class="hlFld-ContribAuthor ">Ute A.  Hellmich</span>, <span class="hlFld-ContribAuthor ">Siegfried R.  Waldvogel</span>. </span><span class="cited-content_cbyCitation_article-title">MetalâFree Twofold Electrochemical CâH Amination of Activated Arenes: Application to Medicinally Relevant Precursor Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Chemistry â A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (72)
                                     , 17574-17580. <a href="https://doi.org/10.1002/chem.202003852" title="DOI URL">https://doi.org/10.1002/chem.202003852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202003852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202003852%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DMetal%2525E2%252580%252590Free%252BTwofold%252BElectrochemical%252BC%2525E2%252588%252592H%252BAmination%252Bof%252BActivated%252BArenes%25253A%252BApplication%252Bto%252BMedicinally%252BRelevant%252BPrecursor%252BSynthesis%26aulast%3DWesenberg%26aufirst%3DLars%2BJ.%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D72%26spage%3D17574%26epage%3D17580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">XinâYang  Liu</span>, <span class="hlFld-ContribAuthor ">Hao  Liu</span>, <span class="hlFld-ContribAuthor ">XianâZhang  Liao</span>, <span class="hlFld-ContribAuthor ">Lin  Dong</span>, <span class="hlFld-ContribAuthor ">FenâEr  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Fused Polycyclic 4âAnilinoquinazolines and
              N
              âQuinazolineâIndoles
              via
              Selective CâH Bond Activation. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (24)
                                     , 5645-5652. <a href="https://doi.org/10.1002/adsc.202000895" title="DOI URL">https://doi.org/10.1002/adsc.202000895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000895%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DSynthesis%252Bof%252BFused%252BPolycyclic%252B4%2525E2%252580%252590Anilinoquinazolines%252Band%252BN%252B%2525E2%252580%252590Quinazoline%2525E2%252580%252590Indoles%252Bvia%252BSelective%252BC%2525E2%252588%252592H%252BBond%252BActivation%26aulast%3DLiu%26aufirst%3DXin%25E2%2580%2590Yang%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D24%26spage%3D5645%26epage%3D5652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guolin  Luo</span>, <span class="hlFld-ContribAuthor ">Yanxia  Ma</span>, <span class="hlFld-ContribAuthor ">Xintong  Liang</span>, <span class="hlFld-ContribAuthor ">Guoquan  Xie</span>, <span class="hlFld-ContribAuthor ">Yingqi  Luo</span>, <span class="hlFld-ContribAuthor ">Dailong  Zha</span>, <span class="hlFld-ContribAuthor ">Sheng  Wang</span>, <span class="hlFld-ContribAuthor ">Lihong  Yu</span>, <span class="hlFld-ContribAuthor ">Xuehua  Zheng</span>, <span class="hlFld-ContribAuthor ">Wenhao  Wu</span>, <span class="hlFld-ContribAuthor ">Chao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104356. <a href="https://doi.org/10.1016/j.bioorg.2020.104356" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104356</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104356%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bevaluation%252Bof%252Bnovel%252B5-methylpyrazolo%25255B1%25252C5-a%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotential%252Bc-Met%252Binhibitors%26aulast%3DLuo%26aufirst%3DGuolin%26date%3D2020%26volume%3D104%26spage%3D104356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingguang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yunyun  Wang</span>, <span class="hlFld-ContribAuthor ">Jia  Wang</span>, <span class="hlFld-ContribAuthor ">Zhaogang  Liu</span>, <span class="hlFld-ContribAuthor ">Jingmiao  Shi</span>, <span class="hlFld-ContribAuthor ">Mingxin  Li</span>, <span class="hlFld-ContribAuthor ">Yongqiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Shifa  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2020,</strong> <em>68 </em>
                                    (10)
                                     , 971-980. <a href="https://doi.org/10.1248/cpb.c20-00411" title="DOI URL">https://doi.org/10.1248/cpb.c20-00411</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c20-00411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c20-00411%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252Bthe%252BQuinazoline%252BDerivatives%252Bas%252BL858R%25252FT790M%25252FC797S%252BTriple%252BMutant%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DZhang%26aufirst%3DMingguang%26date%3D2020%26volume%3D68%26issue%3D10%26spage%3D971%26epage%3D980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tarek S.  Mansour</span>, <span class="hlFld-ContribAuthor ">Ranga R.  Pallepati</span>, <span class="hlFld-ContribAuthor ">Vishnu  Basetti</span>. </span><span class="cited-content_cbyCitation_article-title">Potent dual EGFR/Her4 tyrosine kinase inhibitors containing novel (1,2-dithiolan-4-yl)acetamides. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (16)
                                     , 127288. <a href="https://doi.org/10.1016/j.bmcl.2020.127288" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127288</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127288%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPotent%252Bdual%252BEGFR%25252FHer4%252Btyrosine%252Bkinase%252Binhibitors%252Bcontaining%252Bnovel%252B%2525281%25252C2-dithiolan-4-yl%252529acetamides%26aulast%3DMansour%26aufirst%3DTarek%2BS.%26date%3D2020%26volume%3D30%26issue%3D16%26spage%3D127288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lianqi  Sun</span>, <span class="hlFld-ContribAuthor ">Chenxi  Wang</span>, <span class="hlFld-ContribAuthor ">Xinyue  Hu</span>, <span class="hlFld-ContribAuthor ">Yanbin  Wu</span>, <span class="hlFld-ContribAuthor ">Zhi  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhuorong  Li</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Chen</span>, <span class="hlFld-ContribAuthor ">Laixing  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and evaluations of the antiproliferative activity and aqueous solubility of novel carbazole sulfonamide derivatives as antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103766. <a href="https://doi.org/10.1016/j.bioorg.2020.103766" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103766</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103766%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bevaluations%252Bof%252Bthe%252Bantiproliferative%252Bactivity%252Band%252Baqueous%252Bsolubility%252Bof%252Bnovel%252Bcarbazole%252Bsulfonamide%252Bderivatives%252Bas%252Bantitumor%252Bagents%26aulast%3DSun%26aufirst%3DLianqi%26date%3D2020%26volume%3D99%26spage%3D103766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fang  Hao</span>, <span class="hlFld-ContribAuthor ">Xin  Wang</span>, <span class="hlFld-ContribAuthor ">Linfang  Huang</span>, <span class="hlFld-ContribAuthor ">Wei  Xiong</span>, <span class="hlFld-ContribAuthor ">Pingle  Liu</span>, <span class="hlFld-ContribAuthor ">Hean  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">One-step catalytic amination of naphthalene to naphthylamine with exceptional yield. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2020,</strong> <em>22 </em>
                                    (9)
                                     , 2744-2749. <a href="https://doi.org/10.1039/D0GC00633E" title="DOI URL">https://doi.org/10.1039/D0GC00633E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0GC00633E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0GC00633E%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DOne-step%252Bcatalytic%252Bamination%252Bof%252Bnaphthalene%252Bto%252Bnaphthylamine%252Bwith%252Bexceptional%252Byield%26aulast%3DHao%26aufirst%3DFang%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D9%26spage%3D2744%26epage%3D2749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuma  Aoki</span>, <span class="hlFld-ContribAuthor ">Takahiro  Toyoda</span>, <span class="hlFld-ContribAuthor ">Hiroto  Kawasaki</span>, <span class="hlFld-ContribAuthor ">Hikaru  Takaya</span>, <span class="hlFld-ContribAuthor ">Akhilesh K.  Sharma</span>, <span class="hlFld-ContribAuthor ">Keiji  Morokuma</span>, <span class="hlFld-ContribAuthor ">Masaharu  Nakamura</span>. </span><span class="cited-content_cbyCitation_article-title">IronâCatalyzed Chemoselective CâN Coupling Reaction: A ProtectingâGroupâFree Amination of Aryl Halides Bearing Amino or Hydroxy Groups. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>9 </em>
                                    (3)
                                     , 372-376. <a href="https://doi.org/10.1002/ajoc.201900641" title="DOI URL">https://doi.org/10.1002/ajoc.201900641</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201900641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201900641%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DIron%2525E2%252580%252590Catalyzed%252BChemoselective%252BC%2525E2%252588%252592N%252BCoupling%252BReaction%25253A%252BA%252BProtecting%2525E2%252580%252590Group%2525E2%252580%252590Free%252BAmination%252Bof%252BAryl%252BHalides%252BBearing%252BAmino%252Bor%252BHydroxy%252BGroups%26aulast%3DAoki%26aufirst%3DYuma%26date%3D2020%26date%3D2019%26volume%3D9%26issue%3D3%26spage%3D372%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mauro  Angiolini</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 363-393. <a href="https://doi.org/10.1002/9781118681121.ch16" title="DOI URL">https://doi.org/10.1002/9781118681121.ch16</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118681121.ch16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118681121.ch16%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BRole%252Bof%252BStructural%252BBiology%252Bin%252BKinase%252BInhibitor%252BDrug%252BDiscovery%252BSuccess%26aulast%3DAngiolini%26aufirst%3DMauro%26date%3D2020%26date%3D2020%26spage%3D363%26epage%3D393%26pub%3DWiley%26atitle%3DStructural%252BBiology%252Bin%252BDrug%252BDiscovery%26aulast%3DRenaud%26aufirst%3DJean%25E2%2580%2590Paul%26date%3D2020%26date%3D2020%26volume%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">LÃ­dia Moreira  Lima</span>, <span class="hlFld-ContribAuthor ">Maria LetÃ­cia  de Castro Barbosa</span>, <span class="hlFld-ContribAuthor ">Daniel Nascimento  do Amaral</span>, <span class="hlFld-ContribAuthor ">Eliezer J.  Barreiro</span>. </span><span class="cited-content_cbyCitation_article-title">Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 155-201. <a href="https://doi.org/10.1007/7355_2020_95" title="DOI URL">https://doi.org/10.1007/7355_2020_95</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_95%26sid%3Dliteratum%253Aachs%26atitle%3DCase%252BStudy%252Bon%252BReceptor%252BTyrosine%252BKinases%252BEGFR%25252C%252BVEGFR%25252C%252Band%252BPDGFR%26aulast%3DLima%26aufirst%3DL%25C3%25ADdia%2BMoreira%26date%3D2020%26date%3D2020%26spage%3D155%26epage%3D201%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sushmita</span>, <span class="hlFld-ContribAuthor ">Trapti  Aggarwal</span>, <span class="hlFld-ContribAuthor ">Norio  Shibata</span>, <span class="hlFld-ContribAuthor ">Akhilesh K.  Verma</span>. </span><span class="cited-content_cbyCitation_article-title">TripleâBond Directed Csp
              2
              âN Bond Formation with
              N
              âFluorobenzenesulfonimide as Aminating Source: OneâStep Transformation of Aldehydes into Amines. </span><span class="cited-content_cbyCitation_journal-name">Chemistry â A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (70)
                                     , 16063-16067. <a href="https://doi.org/10.1002/chem.201903495" title="DOI URL">https://doi.org/10.1002/chem.201903495</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201903495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201903495%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DTriple%2525E2%252580%252590Bond%252BDirected%252BCsp%252B2%252B%2525E2%252588%252592N%252BBond%252BFormation%252Bwith%252BN%252B%2525E2%252580%252590Fluorobenzenesulfonimide%252Bas%252BAminating%252BSource%25253A%252BOne%2525E2%252580%252590Step%252BTransformation%252Bof%252BAldehydes%252Binto%252BAmines%26aulast%3DSushmita%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D70%26spage%3D16063%26epage%3D16067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shiv  Chand</span>, <span class="hlFld-ContribAuthor ">Saurabh  Kumar</span>, <span class="hlFld-ContribAuthor ">Rahul  Singh</span>, <span class="hlFld-ContribAuthor ">Krishna Nand  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">A Practical Copper Catalyzed
              N
              âArylation of Amines Using Aryl Triazenes as Aryl Source. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (2)
                                     , 718-721. <a href="https://doi.org/10.1002/slct.201803356" title="DOI URL">https://doi.org/10.1002/slct.201803356</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201803356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201803356%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DA%252BPractical%252BCopper%252BCatalyzed%252BN%252B%2525E2%252580%252590Arylation%252Bof%252BAmines%252BUsing%252BAryl%252BTriazenes%252Bas%252BAryl%252BSource%26aulast%3DChand%26aufirst%3DShiv%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D2%26spage%3D718%26epage%3D721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tatjana  Kovacevic</span>, <span class="hlFld-ContribAuthor ">Milan  Mesic</span>, <span class="hlFld-ContribAuthor ">Amir  Avdagic</span>, <span class="hlFld-ContribAuthor ">Miroslav  Zegarac</span>. </span><span class="cited-content_cbyCitation_article-title">An alternative synthesis of the non-small cell lung carcinoma drug afatinib. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (47)
                                     , 4180-4182. <a href="https://doi.org/10.1016/j.tetlet.2018.10.026" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.10.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.10.026%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DAn%252Balternative%252Bsynthesis%252Bof%252Bthe%252Bnon-small%252Bcell%252Blung%252Bcarcinoma%252Bdrug%252Bafatinib%26aulast%3DKovacevic%26aufirst%3DTatjana%26date%3D2018%26volume%3D59%26issue%3D47%26spage%3D4180%26epage%3D4182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prasanjit  Ghosh</span>, <span class="hlFld-ContribAuthor ">Sajal  Das</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand Free Approach for the Copper(II)âMediated CâNH
              2
              Arylation of 4âQuinolone Derivatives Under Ambient Condition. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2018,</strong> <em>3 </em>
                                    (30)
                                     , 8624-8627. <a href="https://doi.org/10.1002/slct.201801756" title="DOI URL">https://doi.org/10.1002/slct.201801756</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201801756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201801756%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DLigand%252BFree%252BApproach%252Bfor%252Bthe%252BCopper%252528II%252529%2525E2%252580%252590Mediated%252BC%2525E2%252580%252590NH%252B2%252BArylation%252Bof%252B4%2525E2%252580%252590Quinolone%252BDerivatives%252BUnder%252BAmbient%252BCondition%26aulast%3DGhosh%26aufirst%3DPrasanjit%26date%3D2018%26date%3D2018%26volume%3D3%26issue%3D30%26spage%3D8624%26epage%3D8627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anton  Wiebe</span>, <span class="hlFld-ContribAuthor ">Tile  Gieshoff</span>, <span class="hlFld-ContribAuthor ">Sabine  MÃ¶hle</span>, <span class="hlFld-ContribAuthor ">Eduardo  Rodrigo</span>, <span class="hlFld-ContribAuthor ">Michael  Zirbes</span>, <span class="hlFld-ContribAuthor ">Siegfried R.  Waldvogel</span>. </span><span class="cited-content_cbyCitation_article-title">Elektrifizierung der organischen Synthese. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (20)
                                     , 5694-5721. <a href="https://doi.org/10.1002/ange.201711060" title="DOI URL">https://doi.org/10.1002/ange.201711060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201711060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201711060%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DElektrifizierung%252Bder%252Borganischen%252BSynthese%26aulast%3DWiebe%26aufirst%3DAnton%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D20%26spage%3D5694%26epage%3D5721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anton  Wiebe</span>, <span class="hlFld-ContribAuthor ">Tile  Gieshoff</span>, <span class="hlFld-ContribAuthor ">Sabine  MÃ¶hle</span>, <span class="hlFld-ContribAuthor ">Eduardo  Rodrigo</span>, <span class="hlFld-ContribAuthor ">Michael  Zirbes</span>, <span class="hlFld-ContribAuthor ">Siegfried R.  Waldvogel</span>. </span><span class="cited-content_cbyCitation_article-title">Electrifying Organic Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (20)
                                     , 5594-5619. <a href="https://doi.org/10.1002/anie.201711060" title="DOI URL">https://doi.org/10.1002/anie.201711060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201711060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201711060%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DElectrifying%252BOrganic%252BSynthesis%26aulast%3DWiebe%26aufirst%3DAnton%26date%3D2018%26date%3D2018%26volume%3D57%26issue%3D20%26spage%3D5594%26epage%3D5619" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Longjia  Yan</span>, <span class="hlFld-ContribAuthor ">Hui  Wang</span>, <span class="hlFld-ContribAuthor ">Yunpeng  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Li</span>, <span class="hlFld-ContribAuthor ">Yazhong  Pei</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structureâactivity relationship study of diaryl[d,f][1,3]diazepines as potential anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2018,</strong> <em>22 </em>
                                    (2)
                                     , 323-333. <a href="https://doi.org/10.1007/s11030-017-9805-0" title="DOI URL">https://doi.org/10.1007/s11030-017-9805-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-017-9805-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-017-9805-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bstudy%252Bof%252Bdiaryl%25255Bd%25252Cf%25255D%25255B1%25252C3%25255Ddiazepines%252Bas%252Bpotential%252Banti-cancer%252Bagents%26aulast%3DYan%26aufirst%3DLongjia%26date%3D2018%26date%3D2018%26volume%3D22%26issue%3D2%26spage%3D323%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Majid M.  Heravi</span>, <span class="hlFld-ContribAuthor ">Zohreh  Kheilkordi</span>, <span class="hlFld-ContribAuthor ">Vahideh  Zadsirjan</span>, <span class="hlFld-ContribAuthor ">Masumeh  Heydari</span>, <span class="hlFld-ContribAuthor ">Masoumeh  Malmir</span>. </span><span class="cited-content_cbyCitation_article-title">Buchwald-Hartwig reaction: An overview. </span><span class="cited-content_cbyCitation_journal-name">Journal of Organometallic Chemistry</span><span> <strong>2018,</strong> <em>861 </em>, 17-104. <a href="https://doi.org/10.1016/j.jorganchem.2018.02.023" title="DOI URL">https://doi.org/10.1016/j.jorganchem.2018.02.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jorganchem.2018.02.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jorganchem.2018.02.023%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Organometallic%2520Chemistry%26atitle%3DBuchwald-Hartwig%252Breaction%25253A%252BAn%252Boverview%26aulast%3DHeravi%26aufirst%3DMajid%2BM.%26date%3D2018%26volume%3D861%26spage%3D17%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.P.N.  Sudhan</span>, <span class="hlFld-ContribAuthor ">R. Nasir  Ahmed</span>, <span class="hlFld-ContribAuthor ">H.  Kiyani</span>, <span class="hlFld-ContribAuthor ">S. Sheik  Mansoor</span>. </span><span class="cited-content_cbyCitation_article-title">Ionic liquid 1-butyl-3-methylimidazolium bromide: A green reaction media for the efficient synthesis of 3-methyl-1,4-diphenyl-1,4,5,7-tetrahydro-pyrazolo[3,4- d ]pyrimidine-6-ones/thiones using phthalimide- N -sulfonic acid as catalyst. </span><span class="cited-content_cbyCitation_journal-name">Journal of Saudi Chemical Society</span><span> <strong>2018,</strong> <em>22 </em>
                                    (3)
                                     , 269-278. <a href="https://doi.org/10.1016/j.jscs.2016.07.001" title="DOI URL">https://doi.org/10.1016/j.jscs.2016.07.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jscs.2016.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jscs.2016.07.001%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Saudi%2520Chemical%2520Society%26atitle%3DIonic%252Bliquid%252B1-butyl-3-methylimidazolium%252Bbromide%25253A%252BA%252Bgreen%252Breaction%252Bmedia%252Bfor%252Bthe%252Befficient%252Bsynthesis%252Bof%252B3-methyl-1%25252C4-diphenyl-1%25252C4%25252C5%25252C7-tetrahydro-pyrazolo%25255B3%25252C4-%252Bd%252B%25255Dpyrimidine-6-ones%25252Fthiones%252Busing%252Bphthalimide-%252BN%252B-sulfonic%252Bacid%252Bas%252Bcatalyst%26aulast%3DSudhan%26aufirst%3DS.P.N.%26date%3D2018%26volume%3D22%26issue%3D3%26spage%3D269%26epage%3D278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sabine  MÃ¶hle</span>, <span class="hlFld-ContribAuthor ">Sebastian  Herold</span>, <span class="hlFld-ContribAuthor ">Frank  Richter</span>, <span class="hlFld-ContribAuthor ">Hartmut  Nefzger</span>, <span class="hlFld-ContribAuthor ">Siegfried R.  Waldvogel</span>. </span><span class="cited-content_cbyCitation_article-title">Twofold Electrochemical Amination of Naphthalene and Related Arenes. </span><span class="cited-content_cbyCitation_journal-name">ChemElectroChem</span><span> <strong>2017,</strong> <em>4 </em>
                                    (9)
                                     , 2196-2210. <a href="https://doi.org/10.1002/celc.201700476" title="DOI URL">https://doi.org/10.1002/celc.201700476</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/celc.201700476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcelc.201700476%26sid%3Dliteratum%253Aachs%26jtitle%3DChemElectroChem%26atitle%3DTwofold%252BElectrochemical%252BAmination%252Bof%252BNaphthalene%252Band%252BRelated%252BArenes%26aulast%3DM%25C3%25B6hle%26aufirst%3DSabine%26date%3D2017%26date%3D2017%26volume%3D4%26issue%3D9%26spage%3D2196%26epage%3D2210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Antineoplastic and Immunomodulating Agents (L). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-56. <a href="https://doi.org/10.1002/14356007.a05_001.pub3" title="DOI URL">https://doi.org/10.1002/14356007.a05_001.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.a05_001.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.a05_001.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DAntineoplastic%252Band%252BImmunomodulating%252BAgents%252B%252528L%252529%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2017%26date%3D2017%26spage%3D1%26epage%3D56%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yao  Yin</span>, <span class="hlFld-ContribAuthor ">Jian  Xie</span>, <span class="hlFld-ContribAuthor ">Feng-Qing  Huang</span>, <span class="hlFld-ContribAuthor ">Lian-Wen  Qi</span>, <span class="hlFld-ContribAuthor ">Bo  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-Catalyzed Remote CâH Amination of Quinolines with
              N
              -Fluorobenzenesulfonimide. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2017,</strong> <em>359 </em>
                                    (6)
                                     , 1037-1042. <a href="https://doi.org/10.1002/adsc.201600947" title="DOI URL">https://doi.org/10.1002/adsc.201600947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201600947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201600947%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DCopper-Catalyzed%252BRemote%252BC%2525E2%252588%252592H%252BAmination%252Bof%252BQuinolines%252Bwith%252BN%252B-Fluorobenzenesulfonimide%26aulast%3DYin%26aufirst%3DYao%26date%3D2017%26date%3D2016%26volume%3D359%26issue%3D6%26spage%3D1037%26epage%3D1042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Siva Reddy</span>, <span class="hlFld-ContribAuthor ">K.  Ranjith Reddy</span>, <span class="hlFld-ContribAuthor ">D.  Nageswar Rao</span>, <span class="hlFld-ContribAuthor ">Chaitanya K.  Jaladanki</span>, <span class="hlFld-ContribAuthor ">Prasad V.  Bharatam</span>, <span class="hlFld-ContribAuthor ">Patrick Y. S.  Lam</span>, <span class="hlFld-ContribAuthor ">Parthasarathi  Das</span>. </span><span class="cited-content_cbyCitation_article-title">Copper(
              ii
              )-catalyzed ChanâLam cross-coupling: chemoselective N-arylation of aminophenols. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (4)
                                     , 801-806. <a href="https://doi.org/10.1039/C6OB02444K" title="DOI URL">https://doi.org/10.1039/C6OB02444K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6OB02444K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6OB02444K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DCopper%252528%252Bii%252B%252529-catalyzed%252BChan%2525E2%252580%252593Lam%252Bcross-coupling%25253A%252Bchemoselective%252BN-arylation%252Bof%252Baminophenols%26aulast%3DSiva%2BReddy%26aufirst%3DA.%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D4%26spage%3D801%26epage%3D806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianyi  Wang</span>, <span class="hlFld-ContribAuthor ">Qing  Chen</span>, <span class="hlFld-ContribAuthor ">Mian  Wang</span>, <span class="hlFld-ContribAuthor ">Cheng  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">The opening/closure of the P-loop and hinge of BCR-ABL1 decodes the low/high bioactivities of dasatinib and axitinib. </span><span class="cited-content_cbyCitation_journal-name">Physical Chemistry Chemical Physics</span><span> <strong>2017,</strong> <em>19 </em>
                                    (33)
                                     , 22444-22453. <a href="https://doi.org/10.1039/C7CP03443A" title="DOI URL">https://doi.org/10.1039/C7CP03443A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CP03443A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CP03443A%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysical%2520Chemistry%2520Chemical%2520Physics%26atitle%3DThe%252Bopening%25252Fclosure%252Bof%252Bthe%252BP-loop%252Band%252Bhinge%252Bof%252BBCR-ABL1%252Bdecodes%252Bthe%252Blow%25252Fhigh%252Bbioactivities%252Bof%252Bdasatinib%252Band%252Baxitinib%26aulast%3DWang%26aufirst%3DJianyi%26date%3D2017%26date%3D2017%26volume%3D19%26issue%3D33%26spage%3D22444%26epage%3D22453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kun  Tong</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Liu</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Shouyun  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Visible-Light-Induced Direct Oxidative CâH Amidation of Heteroarenes with Sulfonamides. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - A European Journal</span><span> <strong>2016,</strong> <em>22 </em>
                                    (44)
                                     , 15669-15673. <a href="https://doi.org/10.1002/chem.201604014" title="DOI URL">https://doi.org/10.1002/chem.201604014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201604014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201604014%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520A%2520European%2520Journal%26atitle%3DVisible-Light-Induced%252BDirect%252BOxidative%252BC%2525E2%252588%252592H%252BAmidation%252Bof%252BHeteroarenes%252Bwith%252BSulfonamides%26aulast%3DTong%26aufirst%3DKun%26date%3D2016%26date%3D2016%26volume%3D22%26issue%3D44%26spage%3D15669%26epage%3D15673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">SaadatÂ U.  Aleem</span>, <span class="hlFld-ContribAuthor ">George  Georghiou</span>, <span class="hlFld-ContribAuthor ">RalphÂ E.  Kleiner</span>, <span class="hlFld-ContribAuthor ">KipÂ E.  Guja</span>, <span class="hlFld-ContribAuthor ">BarbaraÂ P.  Craddock</span>, <span class="hlFld-ContribAuthor ">Agatha  Lyczek</span>, <span class="hlFld-ContribAuthor ">AlixÂ I.  Chan</span>, <span class="hlFld-ContribAuthor ">Miguel  Garcia-Diaz</span>, <span class="hlFld-ContribAuthor ">W.Â Todd  Miller</span>, <span class="hlFld-ContribAuthor ">DavidÂ R.  Liu</span>, <span class="hlFld-ContribAuthor ">MarkusÂ A.  Seeliger</span>. </span><span class="cited-content_cbyCitation_article-title">Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2016,</strong> <em>23 </em>
                                    (9)
                                     , 1103-1112. <a href="https://doi.org/10.1016/j.chembiol.2016.07.017" title="DOI URL">https://doi.org/10.1016/j.chembiol.2016.07.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2016.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2016.07.017%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DStructural%252Band%252BBiochemical%252BBasis%252Bfor%252BIntracellular%252BKinase%252BInhibition%252Bby%252BSrc-specific%252BPeptidic%252BMacrocycles%26aulast%3DAleem%26aufirst%3DSaadat%25C2%25A0U.%26date%3D2016%26volume%3D23%26issue%3D9%26spage%3D1103%26epage%3D1112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Moll</span>, <span class="hlFld-ContribAuthor ">Paul W.  Finn</span>, <span class="hlFld-ContribAuthor ">Lydia E.  Kavraki</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-guided selection of specificity determining positions in the human Kinome. </span><span class="cited-content_cbyCitation_journal-name">BMC Genomics</span><span> <strong>2016,</strong> <em>17 </em>
                                    (S4)
                                     <a href="https://doi.org/10.1186/s12864-016-2790-3" title="DOI URL">https://doi.org/10.1186/s12864-016-2790-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12864-016-2790-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12864-016-2790-3%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Genomics%26atitle%3DStructure-guided%252Bselection%252Bof%252Bspecificity%252Bdetermining%252Bpositions%252Bin%252Bthe%252Bhuman%252BKinome%26aulast%3DMoll%26aufirst%3DMark%26date%3D2016%26date%3D2016%26volume%3D17%26issue%3DS4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Wang</span>, <span class="hlFld-ContribAuthor ">Xue  Wu</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Jiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianli  Liu</span>, <span class="hlFld-ContribAuthor ">Zhongxing  Song</span>, <span class="hlFld-ContribAuthor ">Zhishu  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (11)
                                     , 2589-2593. <a href="https://doi.org/10.1016/j.bmcl.2016.04.032" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.04.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.04.032%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DFacile%252Band%252Befficient%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B4-anilinoquinazoline%252Bderivatives%252Bas%252BEGFR%252Binhibitors%26aulast%3DWang%26aufirst%3DZheng%26date%3D2016%26volume%3D26%26issue%3D11%26spage%3D2589%26epage%3D2593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Enrico  Glaab</span>. </span><span class="cited-content_cbyCitation_article-title">Building a virtual ligand screening pipeline using free software: a survey. </span><span class="cited-content_cbyCitation_journal-name">Briefings in Bioinformatics</span><span> <strong>2016,</strong> <em>17 </em>
                                    (2)
                                     , 352-366. <a href="https://doi.org/10.1093/bib/bbv037" title="DOI URL">https://doi.org/10.1093/bib/bbv037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bib/bbv037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbib%2Fbbv037%26sid%3Dliteratum%253Aachs%26jtitle%3DBriefings%2520in%2520Bioinformatics%26atitle%3DBuilding%252Ba%252Bvirtual%252Bligand%252Bscreening%252Bpipeline%252Busing%252Bfree%252Bsoftware%25253A%252Ba%252Bsurvey%26aulast%3DGlaab%26aufirst%3DEnrico%26date%3D2016%26date%3D2015%26volume%3D17%26issue%3D2%26spage%3D352%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinbao  Xiang</span>, <span class="hlFld-ContribAuthor ">Crystal  Leung</span>, <span class="hlFld-ContribAuthor ">Zhuoqi  Zhang</span>, <span class="hlFld-ContribAuthor ">Cassie  Hu</span>, <span class="hlFld-ContribAuthor ">Chao  Geng</span>, <span class="hlFld-ContribAuthor ">Lili  Liu</span>, <span class="hlFld-ContribAuthor ">Lang  Yi</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Li</span>, <span class="hlFld-ContribAuthor ">James  Berenson</span>, <span class="hlFld-ContribAuthor ">Xu  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of 2-Alkylthio-4-(
              N
              -substituted sulfonamide)pyrimidine Hydroxamic Acids as Anti-myeloma Agents. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>87 </em>
                                    (3)
                                     , 472-477. <a href="https://doi.org/10.1111/cbdd.12678" title="DOI URL">https://doi.org/10.1111/cbdd.12678</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12678%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252B2-Alkylthio-4-%252528%252BN%252B-substituted%252Bsulfonamide%252529pyrimidine%252BHydroxamic%252BAcids%252Bas%252BAnti-myeloma%252BAgents%26aulast%3DXiang%26aufirst%3DJinbao%26date%3D2016%26date%3D2015%26volume%3D87%26issue%3D3%26spage%3D472%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Ni</span>, <span class="hlFld-ContribAuthor ">Li  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Chinese Medical Journal</span><span> <strong>2016,</strong> <em>129 </em>
                                    (3)
                                     , 332-340. <a href="https://doi.org/10.4103/0366-6999.174484" title="DOI URL">https://doi.org/10.4103/0366-6999.174484</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4103/0366-6999.174484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4103%2F0366-6999.174484%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Medical%2520Journal%26atitle%3DEvaluation%252Bof%252BThree%252BSmall%252BMolecular%252BDrugs%252Bfor%252BTargeted%252BTherapy%252Bto%252BTreat%252BNonsmall%252BCell%252BLung%252BCancer%26aulast%3DNi%26aufirst%3DJun%26date%3D2016%26volume%3D129%26issue%3D3%26spage%3D332%26epage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. V.  Koroleva</span>, <span class="hlFld-ContribAuthor ">Zh. I.  Ignatovich</span>, <span class="hlFld-ContribAuthor ">Yu. V.  Sinyutich</span>, <span class="hlFld-ContribAuthor ">K. N.  Gusak</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>52 </em>
                                    (2)
                                     , 139-177. <a href="https://doi.org/10.1134/S1070428016020019" title="DOI URL">https://doi.org/10.1134/S1070428016020019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428016020019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428016020019%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAminopyrimidine%252Bderivatives%252Bas%252Bprotein%252Bkinases%252Binhibitors.%252BMolecular%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiologic%252Bactivity%26aulast%3DKoroleva%26aufirst%3DE.%2BV.%26date%3D2016%26date%3D2016%26volume%3D52%26issue%3D2%26spage%3D139%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alka  Sharma</span>, <span class="hlFld-ContribAuthor ">Vijay  Luxami</span>, <span class="hlFld-ContribAuthor ">Kamaldeep  Paul</span>. </span><span class="cited-content_cbyCitation_article-title">Csp
              2
              -O and C-C Bond Formation via Pd-Catalyzed Coupling Reaction of 2,4-Dichloroquinazoline. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2016,</strong> <em>53 </em>
                                    (1)
                                     , 241-248. <a href="https://doi.org/10.1002/jhet.2330" title="DOI URL">https://doi.org/10.1002/jhet.2330</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.2330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.2330%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DCsp%252B2%252B-O%252Band%252BC-C%252BBond%252BFormation%252Bvia%252BPd-Catalyzed%252BCoupling%252BReaction%252Bof%252B2%25252C4-Dichloroquinazoline%26aulast%3DSharma%26aufirst%3DAlka%26date%3D2016%26date%3D2015%26volume%3D53%26issue%3D1%26spage%3D241%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maud  Antoine</span>, <span class="hlFld-ContribAuthor ">Tilmann  Schuster</span>, <span class="hlFld-ContribAuthor ">Irene  Seipelt</span>, <span class="hlFld-ContribAuthor ">Babette  Aicher</span>, <span class="hlFld-ContribAuthor ">Michael  Teifel</span>, <span class="hlFld-ContribAuthor ">Eckhard  GÃ¼nther</span>, <span class="hlFld-ContribAuthor ">Matthias  Gerlach</span>, <span class="hlFld-ContribAuthor ">Pascal  Marchand</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient synthesis of novel disubstituted pyrido[3,4-b]pyrazines for the design of protein kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2016,</strong> <em>7 </em>
                                    (2)
                                     , 224-229. <a href="https://doi.org/10.1039/C5MD00424A" title="DOI URL">https://doi.org/10.1039/C5MD00424A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5MD00424A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5MD00424A%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DEfficient%252Bsynthesis%252Bof%252Bnovel%252Bdisubstituted%252Bpyrido%25255B3%25252C4-b%25255Dpyrazines%252Bfor%252Bthe%252Bdesign%252Bof%252Bprotein%252Bkinase%252Binhibitors%26aulast%3DAntoine%26aufirst%3DMaud%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D2%26spage%3D224%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinbao  Xiang</span>, <span class="hlFld-ContribAuthor ">Zhuoqi  Zhang</span>, <span class="hlFld-ContribAuthor ">Renzhong  Fu</span>, <span class="hlFld-ContribAuthor ">Robert J.  Ternansky</span>, <span class="hlFld-ContribAuthor ">Patricia L.  Gladstone</span>, <span class="hlFld-ContribAuthor ">Amy L.  Allan</span>, <span class="hlFld-ContribAuthor ">Fernando  Donate</span>, <span class="hlFld-ContribAuthor ">Graham  Parry</span>, <span class="hlFld-ContribAuthor ">Jose  Juarez</span>, <span class="hlFld-ContribAuthor ">Andrew P.  Mazar</span>, <span class="hlFld-ContribAuthor ">Xu  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">The discovery of kinase inhibitors by a combination of diversity-oriented synthesis and selective screening. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2016,</strong> <em>7 </em>
                                    (10)
                                     , 1946-1951. <a href="https://doi.org/10.1039/C6MD00351F" title="DOI URL">https://doi.org/10.1039/C6MD00351F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6MD00351F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6MD00351F%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DThe%252Bdiscovery%252Bof%252Bkinase%252Binhibitors%252Bby%252Ba%252Bcombination%252Bof%252Bdiversity-oriented%252Bsynthesis%252Band%252Bselective%252Bscreening%26aulast%3DXiang%26aufirst%3DJinbao%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D10%26spage%3D1946%26epage%3D1951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Liu</span>, <span class="hlFld-ContribAuthor ">Tian  Luan</span>, <span class="hlFld-ContribAuthor ">Jian  Kong</span>, <span class="hlFld-ContribAuthor ">Ying  Zhang</span>, <span class="hlFld-ContribAuthor ">Hai-Feng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Anti-Tumor Activities of 4-Anilinoquinoline Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (1)
                                     , 21. <a href="https://doi.org/10.3390/molecules21010021" title="DOI URL">https://doi.org/10.3390/molecules21010021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21010021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21010021%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BAnti-Tumor%252BActivities%252Bof%252B4-Anilinoquinoline%252BDerivatives%26aulast%3DLiu%26aufirst%3DDan%26date%3D2016%26date%3D2015%26volume%3D21%26issue%3D1%26spage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Long</span>, <span class="hlFld-ContribAuthor ">Wenge  Qiu</span>, <span class="hlFld-ContribAuthor ">Chongwei  Guo</span>, <span class="hlFld-ContribAuthor ">Chuanqiang  Li</span>, <span class="hlFld-ContribAuthor ">Liyun  Song</span>, <span class="hlFld-ContribAuthor ">Guangmei  Bai</span>, <span class="hlFld-ContribAuthor ">Guizhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong  He</span>. </span><span class="cited-content_cbyCitation_article-title">A Copper-Based Metal-Organic Framework as an Efficient and Reusable Heterogeneous Catalyst for Ullmann and Goldberg Type CâN Coupling Reactions. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2015,</strong> <em>20 </em>
                                    (12)
                                     , 21178-21192. <a href="https://doi.org/10.3390/molecules201219756" title="DOI URL">https://doi.org/10.3390/molecules201219756</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules201219756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules201219756%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DA%252BCopper-Based%252BMetal-Organic%252BFramework%252Bas%252Ban%252BEfficient%252Band%252BReusable%252BHeterogeneous%252BCatalyst%252Bfor%252BUllmann%252Band%252BGoldberg%252BType%252BC%2525E2%252580%252593N%252BCoupling%252BReactions%26aulast%3DLong%26aufirst%3DWei%26date%3D2015%26date%3D2015%26volume%3D20%26issue%3D12%26spage%3D21178%26epage%3D21192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Moll</span>, <span class="hlFld-ContribAuthor ">Paul W.  Finn</span>, <span class="hlFld-ContribAuthor ">Lydia E.  Kavraki</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-guided selection of Specificity Determining Positions in the human kinome. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 21-28. <a href="https://doi.org/10.1109/BIBM.2015.7359650" title="DOI URL">https://doi.org/10.1109/BIBM.2015.7359650</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1109/BIBM.2015.7359650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1109%2FBIBM.2015.7359650%26sid%3Dliteratum%253Aachs%26atitle%3DStructure-guided%252Bselection%252Bof%252BSpecificity%252BDetermining%252BPositions%252Bin%252Bthe%252Bhuman%252Bkinome%26aulast%3DMoll%26aufirst%3DMark%26date%3D2015%26spage%3D21%26epage%3D28%26pub%3DIEEE%26atitle%3D2015%252BIEEE%252BInternational%252BConference%252Bon%252BBioinformatics%252Band%252BBiomedicine%252B%252528BIBM%252529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siyuan  Yin</span>, <span class="hlFld-ContribAuthor ">Liliang  Zhou</span>, <span class="hlFld-ContribAuthor ">Jinsheng  Lin</span>, <span class="hlFld-ContribAuthor ">Lingjing  Xue</span>, <span class="hlFld-ContribAuthor ">Can  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological activities of novel oxazolo[4,5- g ]quinazolin-2(1H)-one derivatives as EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>101 </em>, 462-475. <a href="https://doi.org/10.1016/j.ejmech.2015.07.008" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.07.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.07.008%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bactivities%252Bof%252Bnovel%252Boxazolo%25255B4%25252C5-%252Bg%252B%25255Dquinazolin-2%2525281H%252529-one%252Bderivatives%252Bas%252BEGFR%252Binhibitors%26aulast%3DYin%26aufirst%3DSiyuan%26date%3D2015%26volume%3D101%26spage%3D462%26epage%3D475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cong-min  Kang</span>, <span class="hlFld-ContribAuthor ">Dong-qing  Liu</span>, <span class="hlFld-ContribAuthor ">Xin-ying  Wang</span>, <span class="hlFld-ContribAuthor ">Ri-lei  Yu</span>, <span class="hlFld-ContribAuthor ">Ying-tao  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">The unbinding studies of vascular endothelial growth factor receptor-2 protein tyrosine kinase type II inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2015,</strong> <em>59 </em>, 130-135. <a href="https://doi.org/10.1016/j.jmgm.2015.04.011" title="DOI URL">https://doi.org/10.1016/j.jmgm.2015.04.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2015.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2015.04.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DThe%252Bunbinding%252Bstudies%252Bof%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor-2%252Bprotein%252Btyrosine%252Bkinase%252Btype%252BII%252Binhibitors%26aulast%3DKang%26aufirst%3DCong-min%26date%3D2015%26volume%3D59%26spage%3D130%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuzhen  Wang</span>, <span class="hlFld-ContribAuthor ">Weiquan  Xie</span>, <span class="hlFld-ContribAuthor ">Duowei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhigang  Peng</span>, <span class="hlFld-ContribAuthor ">Yan  Zheng</span>, <span class="hlFld-ContribAuthor ">Nan  Liu</span>, <span class="hlFld-ContribAuthor ">Wen  Dai</span>, <span class="hlFld-ContribAuthor ">Yang  Wang</span>, <span class="hlFld-ContribAuthor ">Zongqiang  Wang</span>, <span class="hlFld-ContribAuthor ">Yong  Yang</span>, <span class="hlFld-ContribAuthor ">Yijun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2015,</strong> <em>6 </em>
                                    (14)
                                     , 12128-12140. <a href="https://doi.org/10.18632/oncotarget.3665" title="DOI URL">https://doi.org/10.18632/oncotarget.3665</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.3665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.3665%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DDiscovery%252Bof%252Ba%252Bsmall%252Bmolecule%252Btargeting%252BSET-PP2A%252Binteraction%252Bto%252Bovercome%252BBCR-ABLT315I%252Bmutation%252Bof%252Bchronic%252Bmyeloid%252Bleukemia%26aulast%3DWang%26aufirst%3DShuzhen%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D14%26spage%3D12128%26epage%3D12140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott M.  Norberg</span>, <span class="hlFld-ContribAuthor ">Sujana  Movva</span>. </span><span class="cited-content_cbyCitation_article-title">Role of Genetic and Molecular Profiling in Sarcomas. </span><span class="cited-content_cbyCitation_journal-name">Current Treatment Options in Oncology</span><span> <strong>2015,</strong> <em>16 </em>
                                    (5)
                                     <a href="https://doi.org/10.1007/s11864-015-0339-3" title="DOI URL">https://doi.org/10.1007/s11864-015-0339-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11864-015-0339-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11864-015-0339-3%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Treatment%2520Options%2520in%2520Oncology%26atitle%3DRole%252Bof%252BGenetic%252Band%252BMolecular%252BProfiling%252Bin%252BSarcomas%26aulast%3DNorberg%26aufirst%3DScott%2BM.%26date%3D2015%26date%3D2015%26volume%3D16%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ke  Gao</span>, <span class="hlFld-ContribAuthor ">Hideki  Yorimitsu</span>, <span class="hlFld-ContribAuthor ">Atsuhiro  Osuka</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Amination of Aryl Sulfides with Aliphatic Amines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2015,</strong> <em>2015 </em>
                                    (12)
                                     , 2678-2682. <a href="https://doi.org/10.1002/ejoc.201500226" title="DOI URL">https://doi.org/10.1002/ejoc.201500226</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201500226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201500226%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPalladium-Catalyzed%252BAmination%252Bof%252BAryl%252BSulfides%252Bwith%252BAliphatic%252BAmines%26aulast%3DGao%26aufirst%3DKe%26date%3D2015%26date%3D2015%26volume%3D2015%26issue%3D12%26spage%3D2678%26epage%3D2682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Zhou</span>, <span class="hlFld-ContribAuthor ">Wenfang  Xu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Drug Discoveries & Therapeutics</span><span> <strong>2015,</strong> <em>9 </em>
                                    (3)
                                     , 147-155. <a href="https://doi.org/10.5582/ddt.2015.01001" title="DOI URL">https://doi.org/10.5582/ddt.2015.01001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5582/ddt.2015.01001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5582%2Fddt.2015.01001%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discoveries%2520%2526%2520Therapeutics%26atitle%3DHistone%252Bdeacetylase%252Binhibitors%252Bmerged%252Bwith%252Bprotein%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DZhou%26aufirst%3DNan%26date%3D2015%26volume%3D9%26issue%3D3%26spage%3D147%26epage%3D155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deping  Wang</span>, <span class="hlFld-ContribAuthor ">Daizhi  Kuang</span>, <span class="hlFld-ContribAuthor ">Fuxing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Shunhua  Ning</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand free copper-catalyzed N-arylation of heteroarylamines. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2014,</strong> <em>55 </em>
                                    (51)
                                     , 7121-7123. <a href="https://doi.org/10.1016/j.tetlet.2014.11.002" title="DOI URL">https://doi.org/10.1016/j.tetlet.2014.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2014.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2014.11.002%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DLigand%252Bfree%252Bcopper-catalyzed%252BN-arylation%252Bof%252Bheteroarylamines%26aulast%3DWang%26aufirst%3DDeping%26date%3D2014%26volume%3D55%26issue%3D51%26spage%3D7121%26epage%3D7123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yankun  Duan</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Yongheng  Chen</span>, <span class="hlFld-ContribAuthor ">Xue-gong  Fan</span>, . </span><span class="cited-content_cbyCitation_article-title">c-Src Binds to the Cancer Drug Ruxolitinib with an Active Conformation. </span><span class="cited-content_cbyCitation_journal-name">PLoS ONE</span><span> <strong>2014,</strong> <em>9 </em>
                                    (9)
                                     , e106225. <a href="https://doi.org/10.1371/journal.pone.0106225" title="DOI URL">https://doi.org/10.1371/journal.pone.0106225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0106225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0106225%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520ONE%26atitle%3Dc-Src%252BBinds%252Bto%252Bthe%252BCancer%252BDrug%252BRuxolitinib%252Bwith%252Ban%252BActive%252BConformation%26aulast%3DDuan%26aufirst%3DYankun%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D9%26spage%3De106225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tomohiro  Sugahara</span>, <span class="hlFld-ContribAuthor ">Kei  Murakami</span>, <span class="hlFld-ContribAuthor ">Hideki  Yorimitsu</span>, <span class="hlFld-ContribAuthor ">Atsuhiro  Osuka</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Amination of Aryl Sulfides with Anilines. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2014,</strong> <em>126 </em>
                                    (35)
                                     , 9483-9487. <a href="https://doi.org/10.1002/ange.201404355" title="DOI URL">https://doi.org/10.1002/ange.201404355</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201404355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201404355%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DPalladium-Catalyzed%252BAmination%252Bof%252BAryl%252BSulfides%252Bwith%252BAnilines%26aulast%3DSugahara%26aufirst%3DTomohiro%26date%3D2014%26date%3D2014%26volume%3D126%26issue%3D35%26spage%3D9483%26epage%3D9487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tomohiro  Sugahara</span>, <span class="hlFld-ContribAuthor ">Kei  Murakami</span>, <span class="hlFld-ContribAuthor ">Hideki  Yorimitsu</span>, <span class="hlFld-ContribAuthor ">Atsuhiro  Osuka</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Amination of Aryl Sulfides with Anilines. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2014,</strong> <em>53 </em>
                                    (35)
                                     , 9329-9333. <a href="https://doi.org/10.1002/anie.201404355" title="DOI URL">https://doi.org/10.1002/anie.201404355</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201404355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201404355%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DPalladium-Catalyzed%252BAmination%252Bof%252BAryl%252BSulfides%252Bwith%252BAnilines%26aulast%3DSugahara%26aufirst%3DTomohiro%26date%3D2014%26date%3D2014%26volume%3D53%26issue%3D35%26spage%3D9329%26epage%3D9333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Clive  McCarthy</span>, <span class="hlFld-ContribAuthor ">Edward  Walker</span>. </span><span class="cited-content_cbyCitation_article-title">Tropomyosin receptor kinase inhibitors: a patent update 2009 â 2013. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (7)
                                     , 731-744. <a href="https://doi.org/10.1517/13543776.2014.910195" title="DOI URL">https://doi.org/10.1517/13543776.2014.910195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.910195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.910195%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DTropomyosin%252Breceptor%252Bkinase%252Binhibitors%25253A%252Ba%252Bpatent%252Bupdate%252B2009%252B%2525E2%252580%252593%252B2013%26aulast%3DMcCarthy%26aufirst%3DClive%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D7%26spage%3D731%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenta  Shimizu</span>, <span class="hlFld-ContribAuthor ">Yasunori  Minami</span>, <span class="hlFld-ContribAuthor ">Osamu  Goto</span>, <span class="hlFld-ContribAuthor ">Hideyuki  Ikehira</span>, <span class="hlFld-ContribAuthor ">Tamejiro  Hiyama</span>. </span><span class="cited-content_cbyCitation_article-title">Silicon-based CâN Cross-coupling Reaction. </span><span class="cited-content_cbyCitation_journal-name">Chemistry Letters</span><span> <strong>2014,</strong> <em>43 </em>
                                    (4)
                                     , 438-440. <a href="https://doi.org/10.1246/cl.131075" title="DOI URL">https://doi.org/10.1246/cl.131075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1246/cl.131075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1246%2Fcl.131075%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520Letters%26atitle%3DSilicon-based%252BC%2525E2%252580%252593N%252BCross-coupling%252BReaction%26aulast%3DShimizu%26aufirst%3DKenta%26date%3D2014%26volume%3D43%26issue%3D4%26spage%3D438%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pablo  Carbonell</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Trosset</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming drug resistance through in silico prediction. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today: Technologies</span><span> <strong>2014,</strong> <em>11 </em>, 101-107. <a href="https://doi.org/10.1016/j.ddtec.2014.03.012" title="DOI URL">https://doi.org/10.1016/j.ddtec.2014.03.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ddtec.2014.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ddtec.2014.03.012%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technologies%26atitle%3DOvercoming%252Bdrug%252Bresistance%252Bthrough%252Bin%252Bsilico%252Bprediction%26aulast%3DCarbonell%26aufirst%3DPablo%26date%3D2014%26volume%3D11%26spage%3D101%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Si-Ning  Li</span>, <span class="hlFld-ContribAuthor ">Huan-Qiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor inhibitors: a patent review (2010 â present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (3)
                                     , 309-321. <a href="https://doi.org/10.1517/13543776.2014.871527" title="DOI URL">https://doi.org/10.1517/13543776.2014.871527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.871527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.871527%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Ba%252Bpatent%252Breview%252B%2525282010%252B%2525E2%252580%252593%252Bpresent%252529%26aulast%3DLi%26aufirst%3DSi-Ning%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D3%26spage%3D309%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Protein Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 1-26. <a href="https://doi.org/10.1002/14356007.r22_r01" title="DOI URL">https://doi.org/10.1002/14356007.r22_r01</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.r22_r01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.r22_r01%26sid%3Dliteratum%253Aachs%26atitle%3DProtein%252BKinase%252BInhibitors%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2014%26date%3D2014%26spage%3D1%26epage%3D26%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard B.  Silverman</span>, <span class="hlFld-ContribAuthor ">Mark W.  Holladay</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Resistance and Drug Synergism. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 333-356. <a href="https://doi.org/10.1016/B978-0-12-382030-3.00007-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-382030-3.00007-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-382030-3.00007-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-382030-3.00007-6%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%252BResistance%252Band%252BDrug%252BSynergism%26aulast%3DSilverman%26aufirst%3DRichard%2BB.%26date%3D2014%26spage%3D333%26epage%3D356%26pub%3DElsevier%26atitle%3DThe%252BOrganic%252BChemistry%252Bof%252BDrug%252BDesign%252Band%252BDrug%252BAction%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fiona P.  Bailey</span>, <span class="hlFld-ContribAuthor ">Veselin I.  Andreev</span>, <span class="hlFld-ContribAuthor ">Patrick A.  Eyers</span>. </span><span class="cited-content_cbyCitation_article-title">The Resistance Tetrad. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 117-146. <a href="https://doi.org/10.1016/B978-0-12-397918-6.00005-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-397918-6.00005-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-397918-6.00005-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-397918-6.00005-7%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BResistance%252BTetrad%26aulast%3DBailey%26aufirst%3DFiona%2BP.%26date%3D2014%26spage%3D117%26epage%3D146%26pub%3DElsevier%26atitle%3DProtein%252BKinase%252BInhibitors%252Bin%252BResearch%252Band%252BMedicine%26date%3D2014%26volume%3D548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">He Ping  Yan</span>, <span class="hlFld-ContribAuthor ">Gui Ping  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of 7 - (3 - (substituted-phenoxy) propoxy) Quinazoline Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Advanced Materials Research</span><span> <strong>2013,</strong> <em>781-784 </em>, 1003-1006. <a href="https://doi.org/10.4028/www.scientific.net/AMR.781-784.1003" title="DOI URL">https://doi.org/10.4028/www.scientific.net/AMR.781-784.1003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4028/www.scientific.net/AMR.781-784.1003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4028%2Fwww.scientific.net%2FAMR.781-784.1003%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Materials%2520Research%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252B7%252B-%252B%2525283%252B-%252B%252528substituted-phenoxy%252529%252Bpropoxy%252529%252BQuinazoline%252BDerivatives%26aulast%3DYan%26aufirst%3DHe%2BPing%26date%3D2013%26date%3D2013%26volume%3D781-784%26spage%3D1003%26epage%3D1006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Drew H.  Bryant</span>, <span class="hlFld-ContribAuthor ">Mark  Moll</span>, <span class="hlFld-ContribAuthor ">Paul W.  Finn</span>, <span class="hlFld-ContribAuthor ">Lydia E.  Kavraki</span>, . </span><span class="cited-content_cbyCitation_article-title">Combinatorial Clustering of Residue Position Subsets Predicts Inhibitor Affinity across the Human Kinome. </span><span class="cited-content_cbyCitation_journal-name">PLoS Computational Biology</span><span> <strong>2013,</strong> <em>9 </em>
                                    (6)
                                     , e1003087. <a href="https://doi.org/10.1371/journal.pcbi.1003087" title="DOI URL">https://doi.org/10.1371/journal.pcbi.1003087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pcbi.1003087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pcbi.1003087%26sid%3Dliteratum%253Aachs%26jtitle%3DPLoS%2520Computational%2520Biology%26atitle%3DCombinatorial%252BClustering%252Bof%252BResidue%252BPosition%252BSubsets%252BPredicts%252BInhibitor%252BAffinity%252Bacross%252Bthe%252BHuman%252BKinome%26aulast%3DBryant%26aufirst%3DDrew%2BH.%26date%3D2013%26date%3D2013%26volume%3D9%26issue%3D6%26spage%3De1003087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Napat  Songtawee</span>, <span class="hlFld-ContribAuthor ">M. Paul  Gleeson</span>, <span class="hlFld-ContribAuthor ">Kiattawee  Choowongkomon</span>. </span><span class="cited-content_cbyCitation_article-title">Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2013,</strong> <em>19 </em>
                                    (2)
                                     , 497-509. <a href="https://doi.org/10.1007/s00894-012-1559-0" title="DOI URL">https://doi.org/10.1007/s00894-012-1559-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-012-1559-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-012-1559-0%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DComputational%252Bstudy%252Bof%252BEGFR%252Binhibition%25253A%252Bmolecular%252Bdynamics%252Bstudies%252Bon%252Bthe%252Bactive%252Band%252Binactive%252Bprotein%252Bconformations%26aulast%3DSongtawee%26aufirst%3DNapat%26date%3D2013%26date%3D2012%26volume%3D19%26issue%3D2%26spage%3D497%26epage%3D509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mostafa M.  Hamed</span>, <span class="hlFld-ContribAuthor ">Dalal A.  Abou El Ella</span>, <span class="hlFld-ContribAuthor ">Adam B.  Keeton</span>, <span class="hlFld-ContribAuthor ">Gary A.  Piazza</span>, <span class="hlFld-ContribAuthor ">Matthias  Engel</span>, <span class="hlFld-ContribAuthor ">Rolf W.  Hartmann</span>, <span class="hlFld-ContribAuthor ">Ashraf H.  Abadi</span>. </span><span class="cited-content_cbyCitation_article-title">Quinazoline and tetrahydropyridothieno[2,3-d]pyrimidine derivatives as irreversible EGFR tyrosine kinase inhibitors: influence of the position 4 substituent. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2013,</strong> <em>4 </em>
                                    (8)
                                     , 1202. <a href="https://doi.org/10.1039/c3md00118k" title="DOI URL">https://doi.org/10.1039/c3md00118k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c3md00118k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc3md00118k%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DQuinazoline%252Band%252Btetrahydropyridothieno%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Birreversible%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%25253A%252Binfluence%252Bof%252Bthe%252Bposition%252B4%252Bsubstituent%26aulast%3DHamed%26aufirst%3DMostafa%2BM.%26date%3D2013%26volume%3D4%26issue%3D8%26spage%3D1202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akira  Takagi</span>, <span class="hlFld-ContribAuthor ">Takashi  Ikawa</span>, <span class="hlFld-ContribAuthor ">Kozumo  Saito</span>, <span class="hlFld-ContribAuthor ">Shigeaki  Masuda</span>, <span class="hlFld-ContribAuthor ">Toyohiro  Ito</span>, <span class="hlFld-ContribAuthor ">Shuji  Akai</span>. </span><span class="cited-content_cbyCitation_article-title">ortho-Selective nucleophilic addition of amines to 3-borylbenzynes: synthesis of multisubstituted anilines by the triple role of the boryl group. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2013,</strong> <em>11 </em>
                                    (46)
                                     , 8145. <a href="https://doi.org/10.1039/c3ob41787e" title="DOI URL">https://doi.org/10.1039/c3ob41787e</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c3ob41787e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc3ob41787e%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3Dortho-Selective%252Bnucleophilic%252Baddition%252Bof%252Bamines%252Bto%252B3-borylbenzynes%25253A%252Bsynthesis%252Bof%252Bmultisubstituted%252Banilines%252Bby%252Bthe%252Btriple%252Brole%252Bof%252Bthe%252Bboryl%252Bgroup%26aulast%3DTakagi%26aufirst%3DAkira%26date%3D2013%26volume%3D11%26issue%3D46%26spage%3D8145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D. Nageswar  Rao</span>, <span class="hlFld-ContribAuthor ">Sk.  Rasheed</span>, <span class="hlFld-ContribAuthor ">S.  Aravinda</span>, <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>, <span class="hlFld-ContribAuthor ">Parthasarathi  Das</span>. </span><span class="cited-content_cbyCitation_article-title">Base and ligand free copper-catalyzed N-arylation of 2-amino-N-heterocycles with boronic acids in air. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2013,</strong> <em>3 </em>
                                    (29)
                                     , 11472. <a href="https://doi.org/10.1039/c3ra40735g" title="DOI URL">https://doi.org/10.1039/c3ra40735g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c3ra40735g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc3ra40735g%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DBase%252Band%252Bligand%252Bfree%252Bcopper-catalyzed%252BN-arylation%252Bof%252B2-amino-N-heterocycles%252Bwith%252Bboronic%252Bacids%252Bin%252Bair%26aulast%3DRao%26aufirst%3DD.%2BNageswar%26date%3D2013%26volume%3D3%26issue%3D29%26spage%3D11472" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingyi  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Bai</span>, <span class="hlFld-ContribAuthor ">Rui  Xie</span>, <span class="hlFld-ContribAuthor ">Liping  Sun</span>, <span class="hlFld-ContribAuthor ">Kejiang  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Development and strategies of VEGFR-2/KDR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2012,</strong> <em>4 </em>
                                    (14)
                                     , 1839-1852. <a href="https://doi.org/10.4155/fmc.12.121" title="DOI URL">https://doi.org/10.4155/fmc.12.121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.12.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.12.121%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Band%252Bstrategies%252Bof%252BVEGFR-2%25252FKDR%252Binhibitors%26aulast%3DHuang%26aufirst%3DLingyi%26date%3D2012%26volume%3D4%26issue%3D14%26spage%3D1839%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shirin  Safaei</span>, <span class="hlFld-ContribAuthor ">Iraj  Mohammadpoor-Baltork</span>, <span class="hlFld-ContribAuthor ">Ahmad Reza  Khosropour</span>, <span class="hlFld-ContribAuthor ">Majid  Moghadam</span>, <span class="hlFld-ContribAuthor ">Shahram  Tangestaninejad</span>, <span class="hlFld-ContribAuthor ">Valiollah  Mirkhani</span>. </span><span class="cited-content_cbyCitation_article-title">Regioselective multi-component synthesis of 1H-pyrazolo[3,4-d]pyrimidine-6(7H)-thiones. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2012,</strong> <em>16 </em>
                                    (3)
                                     , 591-600. <a href="https://doi.org/10.1007/s11030-012-9391-0" title="DOI URL">https://doi.org/10.1007/s11030-012-9391-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-012-9391-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-012-9391-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DRegioselective%252Bmulti-component%252Bsynthesis%252Bof%252B1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidine-6%2525287H%252529-thiones%26aulast%3DSafaei%26aufirst%3DShirin%26date%3D2012%26date%3D2012%26volume%3D16%26issue%3D3%26spage%3D591%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Jiang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Baohui  Qi</span>, <span class="hlFld-ContribAuthor ">Haiyan  Tao</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel 2-(2-arylmethylene)hydrazinyl-4-aminoquinazoline derivatives as potent antitumor agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>54 </em>, 534-541. <a href="https://doi.org/10.1016/j.ejmech.2012.05.039" title="DOI URL">https://doi.org/10.1016/j.ejmech.2012.05.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2012.05.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2012.05.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B2-%2525282-arylmethylene%252529hydrazinyl-4-aminoquinazoline%252Bderivatives%252Bas%252Bpotent%252Bantitumor%252Bagents%26aulast%3DJiang%26aufirst%3DNan%26date%3D2012%26volume%3D54%26spage%3D534%26epage%3D541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carmela  Napolitano</span>, <span class="hlFld-ContribAuthor ">Viraja R.  Palwai</span>, <span class="hlFld-ContribAuthor ">Leif A.  Eriksson</span>, <span class="hlFld-ContribAuthor ">Paul V.  Murphy</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, kinase activity and molecular modeling of a resorcylic acid lactone incorporating an amide and a trans-enone in the macrocycle. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2012,</strong> <em>68 </em>
                                    (27-28)
                                     , 5533-5540. <a href="https://doi.org/10.1016/j.tet.2012.04.082" title="DOI URL">https://doi.org/10.1016/j.tet.2012.04.082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2012.04.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2012.04.082%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DSynthesis%25252C%252Bkinase%252Bactivity%252Band%252Bmolecular%252Bmodeling%252Bof%252Ba%252Bresorcylic%252Bacid%252Blactone%252Bincorporating%252Ban%252Bamide%252Band%252Ba%252Btrans-enone%252Bin%252Bthe%252Bmacrocycle%26aulast%3DNapolitano%26aufirst%3DCarmela%26date%3D2012%26volume%3D68%26issue%3D27-28%26spage%3D5533%26epage%3D5540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Norman</span>, <span class="hlFld-ContribAuthor ">Dorin  Toader</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Ferguson</span>. </span><span class="cited-content_cbyCitation_article-title">Structural approaches to obtain kinase selectivity. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2012,</strong> <em>33 </em>
                                    (5)
                                     , 273-278. <a href="https://doi.org/10.1016/j.tips.2012.03.005" title="DOI URL">https://doi.org/10.1016/j.tips.2012.03.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2012.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2012.03.005%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DStructural%252Bapproaches%252Bto%252Bobtain%252Bkinase%252Bselectivity%26aulast%3DNorman%26aufirst%3DRichard%2BA.%26date%3D2012%26volume%3D33%26issue%3D5%26spage%3D273%26epage%3D278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">George  Georghiou</span>, <span class="hlFld-ContribAuthor ">Ralph E  Kleiner</span>, <span class="hlFld-ContribAuthor ">Michael  Pulkoski-Gross</span>, <span class="hlFld-ContribAuthor ">David R  Liu</span>, <span class="hlFld-ContribAuthor ">Markus A  Seeliger</span>. </span><span class="cited-content_cbyCitation_article-title">Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2012,</strong> <em>8 </em>
                                    (4)
                                     , 366-374. <a href="https://doi.org/10.1038/nchembio.792" title="DOI URL">https://doi.org/10.1038/nchembio.792</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nchembio.792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnchembio.792%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DHighly%252Bspecific%25252C%252Bbisubstrate-competitive%252BSrc%252Binhibitors%252Bfrom%252BDNA-templated%252Bmacrocycles%26aulast%3DGeorghiou%26aufirst%3DGeorge%26date%3D2012%26date%3D2012%26volume%3D8%26issue%3D4%26spage%3D366%26epage%3D374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinbao  Xiang</span>, <span class="hlFld-ContribAuthor ">Hanghang  Li</span>, <span class="hlFld-ContribAuthor ">Kai  Yang</span>, <span class="hlFld-ContribAuthor ">Lang  Yi</span>, <span class="hlFld-ContribAuthor ">Yongnan  Xu</span>, <span class="hlFld-ContribAuthor ">Qun  Dang</span>, <span class="hlFld-ContribAuthor ">Xu  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of novel 4H-pyrimido[1,6-a]pyrimidines via a one-pot three-component condensation. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2012,</strong> <em>16 </em>
                                    (1)
                                     , 173-181. <a href="https://doi.org/10.1007/s11030-011-9345-y" title="DOI URL">https://doi.org/10.1007/s11030-011-9345-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-011-9345-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-011-9345-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%252Bof%252Bnovel%252B4H-pyrimido%25255B1%25252C6-a%25255Dpyrimidines%252Bvia%252Ba%252Bone-pot%252Bthree-component%252Bcondensation%26aulast%3DXiang%26aufirst%3DJinbao%26date%3D2012%26date%3D2011%26volume%3D16%26issue%3D1%26spage%3D173%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carina  Neto</span>, <span class="hlFld-ContribAuthor ">CÃ©lia  Fernandes</span>, <span class="hlFld-ContribAuthor ">Maria Cristina  Oliveira</span>, <span class="hlFld-ContribAuthor ">Lurdes  Gano</span>, <span class="hlFld-ContribAuthor ">Filipa  Mendes</span>, <span class="hlFld-ContribAuthor ">Torsten  Kniess</span>, <span class="hlFld-ContribAuthor ">Isabel  Santos</span>. </span><span class="cited-content_cbyCitation_article-title">Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents. </span><span class="cited-content_cbyCitation_journal-name">Nuclear Medicine and Biology</span><span> <strong>2012,</strong> <em>39 </em>
                                    (2)
                                     , 247-260. <a href="https://doi.org/10.1016/j.nucmedbio.2011.09.001" title="DOI URL">https://doi.org/10.1016/j.nucmedbio.2011.09.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nucmedbio.2011.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nucmedbio.2011.09.001%26sid%3Dliteratum%253Aachs%26jtitle%3DNuclear%2520Medicine%2520and%2520Biology%26atitle%3DRadiohalogenated%252B4-anilinoquinazoline-based%252BEGFR-TK%252Binhibitors%252Bas%252Bpotential%252Bcancer%252Bimaging%252Bagents%26aulast%3DNeto%26aufirst%3DCarina%26date%3D2012%26volume%3D39%26issue%3D2%26spage%3D247%26epage%3D260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinbao  Xiang</span>, <span class="hlFld-ContribAuthor ">Chao  Geng</span>, <span class="hlFld-ContribAuthor ">Lang  Yi</span>, <span class="hlFld-ContribAuthor ">Qun  Dang</span>, <span class="hlFld-ContribAuthor ">Xu  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of highly substituted 2,3-dihydropyrimido[4,5-d]pyrimidin-4(1H)-ones from 4,6-dichloro-5-formylpyrimidine, amines and aldehydes. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2011,</strong> <em>15 </em>
                                    (4)
                                     , 839-847. <a href="https://doi.org/10.1007/s11030-011-9314-5" title="DOI URL">https://doi.org/10.1007/s11030-011-9314-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-011-9314-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-011-9314-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%252Bof%252Bhighly%252Bsubstituted%252B2%25252C3-dihydropyrimido%25255B4%25252C5-d%25255Dpyrimidin-4%2525281H%252529-ones%252Bfrom%252B4%25252C6-dichloro-5-formylpyrimidine%25252C%252Bamines%252Band%252Baldehydes%26aulast%3DXiang%26aufirst%3DJinbao%26date%3D2011%26date%3D2011%26volume%3D15%26issue%3D4%26spage%3D839%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Antineoplastic Agents, 1. Nonhormonal. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2011,</strong>,<a href="https://doi.org/10.1002/14356007.a05_001.pub2" title="DOI URL">https://doi.org/10.1002/14356007.a05_001.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.a05_001.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.a05_001.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DAntineoplastic%252BAgents%25252C%252B1.%252BNonhormonal%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2011%26date%3D2011%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm8010542&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm8010542%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2009.52.issue-6&amp;citedByCount=124&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="âtrueâ" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of kinase inhibitors marketed in the U.S. as of August 2008.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Crystal structure of Abl in the active form bound to dasatinib (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GQG">2GQG</a>.pdb) in ribbon depiction. The top part, mostly in white, is the N-terminal lobe. The C-terminal lobe at the bottom is shown in yellow. The hinge region connecting the two lobes is colored orange, and dashed yellow lines show the hydrogen-bonding interactions of dasatinib to the hinge region. Also shown is the hydrogen bond of the inhibitor to the gatekeeper residue Thr315 (magenta carbons). Helix C at the back of the binding site is colored green, and the P loop is shown in purple. The activation loop (pink) and the DFG motif (red) are fully resolved in this structure. The catalytic lysine (cyan carbons) is in proximity to the glutamic acid (white carbons) from helix C, allowing the formation of a salt bridge, as expected in the active form.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding site comparisons of active and inactive forms of different kinases. (a) The Abl active form in complex with dasatinib (2GQG.pdb). The phenylalanine of the DFG motif (green carbons) is shown to point away from the binding site and is buried in the interior of the protein. (b) The Abl DFG-out inactive form in complex with imatinib (1IEP.pdb). The phenylalanine of the DFG motif is shown in pink carbons and points into the binding pocket. (c) Rotation of â¼90 degrees of (b) to highlight the depth of the DFG-out pocket (surface representation). (d) Helix-C-out inactive form of EGFR (1XKK.pdb). The catalytic lysine (cyan carbons) is far removed from Helix Câs glutamic acid (white carbons). (e) Helix-C movement from active (cyan helix) to inactive form (green helix) from an overlay of the Abl (2GQG.pdb, helix in) and EGFR (1XKK.pdb, helix out). (a)â(c) show the catalytic lysine (cyan carbons) and the salt bridge formed with the glutamic acid from Helix C (white carbons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Preclinical and clinical phase inhibitors of bcr-Abl.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Preclinical and clinical investigational inhibitors of EGFR kinase.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Protein crystallographic complex of EGFR in the active form with gefitinib (<a href="https://" class="ext-link">2ITY</a>.pdb). The central ring interacts with Met 793 of the hinge (gray carbons) with a single hydrogen bond. The DFG motif is shown in pink carbons. The locations of key mutant residues are shown. Glycine 719 (green carbons) lies in the P-loop, and Thr 790 (gatekeeper, magenta carbons) forms part of the binding pocket. Leu 858, which is part of the activation loop (cyan carbons), does not interact with the inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0001.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Kinase domain mutations identified in EGFR, ABL, and PDGF and c-Kit. Mutants that activate the kinase or cause resistance by activating the kinase are shown in magenta. Mutants that lead to resistance either directly or in conjunction with an activating mutant are shown in bold blue. Although not directly linked to resistance mutations, activating mutations of b-Raf are also shown emphasizing the patterns arising in the resistance mutants.<a onclick="showRef(event, 'ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref114 ref115">(114, 115)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Close-up of binding site of Abl bound to imatinib (<a href="https://" class="ext-link">1IEP</a>.pdb). Hydrogen bonding interactions of imatinib to the hinge region (Met 318 in gray carbons) and T315 (magenta carbons) are indicated. Several drug-resistant mutation sites are shown. Gly321, in the front of the binding, is shown in purple carbons, and the P-loop residue L248 is shown in orange carbons. Also shown is Glu255 (cyan carbons) and its proximity to Lys247 (magenta carbons) and Tyr 257 (white carbons). (b) Close-up of the hydrophobic enclosure of imatinib (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP">1IEP</a>.pdb). The hinge-region hydrogen bond to Met 318 is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Crystal structure of an analogue of <b>4</b> in complex with Abl, highlighting its distance from the gatekeeper residue T315 (magenta carbons, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QOH">2QOH</a>.pdb) and the Ile 315 mutant (cyan carbons, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z60">2Z60</a>.pdb).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Lapatinib bound to the C-helix-out inactive form of EGFR kinase (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>.pdb). Threonine 790 (magenta carbons) makes a favorable interaction with the fluorophenyl group of the inhibitor. The DFG motif is shown in pink carbons. Glycine 719 (green carbons) lies in the P-loop and forms part of the binding cleft. The significant change in conformation of the DFG motif (compare to Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>) causes Leu 858 (cyan carbons) to be directed toward the binding region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/medium/jm-2008-010542_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <b>8</b> bound to the T790M mutant of EGFR (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV">2JIV</a>.pdb). Cysteine 797 (green carbons) forms a covalent bond to the inhibitor (purple carbons).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-6/jm8010542/production/images/large/jm-2008-010542_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm8010542&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21428" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21428" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 115 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x"> (</span><span class="NLM_issue">5600</span><span class="NLM_x">) </span> <span class="NLM_fpage">1912</span><span class="NLM_x">â</span> <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&issue=5600&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0li677uG9HnkEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26issue%3D5600%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">LaRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eder, J. P.</span><span> </span><span class="NLM_article-title">Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1013</span><span class="NLM_x">â</span> <span class="NLM_lpage">1028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=1013-1028&issue=7&author=P.+M.+LaRussoauthor=J.+P.+Eder&title=Therapeutic+potential+of+novel+selective-spectrum+kinase+inhibitors+in+oncology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaRusso%26aufirst%3DP.%2BM.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26atitle%3DTherapeutic%2520potential%2520of%2520novel%2520selective-spectrum%2520kinase%2520inhibitors%2520in%2520oncology%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26issue%3D7%26spage%3D1013%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Liao, J. J.-L.</span><span> </span><span class="NLM_article-title">Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">409</span><span class="NLM_x">â</span> <span class="NLM_lpage">424</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0608107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=409-424&issue=3&author=J.+J.-L.+Liao&title=Molecular+recognition+of+protein+kinase+binding+pockets+for+design+of+potent+and+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many kinase inhibitors have failed in preclin. or clin. development because of the lack of such selectivity that induces intolerable side effects, mostly because the catalytic cleft is highly conserved in sequence and conformation.  Systematic anal. of the crystal structures of protein kinases can offer insight into the design of highly selective kinase inhibitors to overcome these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDTl2SBUfbbVg90H21EOLACvtfcHk0liZghkWnONGQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D&md5=77542d3ba589bd834a0d2b97a24eea05</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm0608107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608107%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.-L.%26atitle%3DMolecular%2520recognition%2520of%2520protein%2520kinase%2520binding%2520pockets%2520for%2520design%2520of%2520potent%2520and%2520selective%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D3%26spage%3D409%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Liao, J. J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, R. C.</span><span> </span><span class="NLM_article-title">Targeting protein multiple conformations: a structure-based strategy for kinase drug design</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1394</span><span class="NLM_x">â</span> <span class="NLM_lpage">1407</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.2174%2F156802607781696783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17692028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1394-1407&author=J.+J.-L.+Liaoauthor=R.+C.+Andrews&title=Targeting+protein+multiple+conformations%3A+a+structure-based+strategy+for+kinase+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting protein multiple conformations: a structure-based strategy for kinase drug design</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou; Andrews, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1394-1407</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Multiple conformations of a protein kinase target offer an opportunity to design small-mol. inhibitors with distinct but clin. useful profiles.  This article analyzes and classifies the binding pockets in the kinase catalytic cleft in different conformational states.  Targeting kinase multiple conformations as an emerging strategy in the field is exemplified with important small-mol. agents in the clinic.  The structure-based anal. in the paper provides a rationale for thwarting the development of drug-resistant mutations in antikinase therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWOkJq0JBN2rVg90H21EOLACvtfcHk0liZghkWnONGQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1SmtbrF&md5=db6aa8c76bf20857cfe31c71625ffa9e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F156802607781696783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802607781696783%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.-L.%26aulast%3DAndrews%26aufirst%3DR.%2BC.%26atitle%3DTargeting%2520protein%2520multiple%2520conformations%253A%2520a%2520structure-based%2520strategy%2520for%2520kinase%2520drug%2520design%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1394%26epage%3D1407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paetel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">11011</span><span class="NLM_x">â</span> <span class="NLM_lpage">11016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&issue=31&author=T.+A.+Carterauthor=L.+M.+Dodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=W.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrfardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Paetelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DDodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrfard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPaetel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26issue%3D31%26spage%3D11011%26epage%3D11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Strategies to overcome resistance to targeted protein kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1001</span><span class="NLM_x">â</span> <span class="NLM_lpage">1010</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1001-1010&issue=12&author=H.+Daubauthor=K.+Spechtauthor=A.+Ullrich&title=Strategies+to+overcome+resistance+to+targeted+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DSpecht%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DStrategies%2520to%2520overcome%2520resistance%2520to%2520targeted%2520protein%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D12%26spage%3D1001%26epage%3D1010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resitance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">786</span><span class="NLM_x">â</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&issue=8&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resitance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lh47bFItWGv0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resitance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D8%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Dowell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">Chasing mutations in the epidermal growth factor in lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">830</span><span class="NLM_x">â</span> <span class="NLM_lpage">832</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMe058033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15728818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFChsrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=830-832&issue=8&author=J.+E.+Dowellauthor=J.+D.+Minna&title=Chasing+mutations+in+the+epidermal+growth+factor+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Chasing mutations in the epidermal growth factor in lung cancer</span></div><div class="casAuthors">Dowell, Jonathan E.; Minna, John D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">830-832</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDSz54eHP5KbVg90H21EOLACvtfcHk0lh47bFItWGv0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFChsrk%253D&md5=4f73d92d2b699d0ad2004e0b60ca78e7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMe058033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe058033%26sid%3Dliteratum%253Aachs%26aulast%3DDowell%26aufirst%3DJ.%2BE.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DChasing%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520in%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26issue%3D8%26spage%3D830%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">293</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">â</span> <span class="NLM_lpage">880</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=876-880&author=M.+E.+Gorreauthor=M.+Mohammedauthor=K.+Ellwoodauthor=N.+Hsuauthor=R.+L.+Paquetteauthor=P.+N.+Raoauthor=C.+L.+Sawyers&title=Clinical+resistance+to+STI-571+cancer+therapy+caused+by+BCR-ABL+gene+mutation+or+amplification"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DMohammed%26aufirst%3DM.%26aulast%3DEllwood%26aufirst%3DK.%26aulast%3DHsu%26aufirst%3DN.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DRao%26aufirst%3DP.%2BN.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DClinical%2520resistance%2520to%2520STI-571%2520cancer%2520therapy%2520caused%2520by%2520BCR-ABL%2520gene%2520mutation%2520or%2520amplification%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D876%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyland, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A., J</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">316</span><span class="NLM_x"> (</span><span class="NLM_issue">5827</span><span class="NLM_x">) </span> <span class="NLM_fpage">1039</span><span class="NLM_x">â</span> <span class="NLM_lpage">1043</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=1039-1043&issue=5827&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=T.+Misudomiauthor=Y.+Songauthor=C.+Hylandauthor=J.+O.+Parkauthor=N.+Lindemanauthor=C.-M.+Galeauthor=X.+Zhaoauthor=J.+Christensenauthor=T.+Kosakaauthor=A.%2C+J+Holmesauthor=A.+M.+Rogersauthor=F.+Cappuzzoauthor=T.+Mokauthor=C.+Leeauthor=B.+E.+Johnsonauthor=L.+C.+Cantleyauthor=P.+A.+Janne&title=MET+amplification+leads+to+gefitinib+resistance+in+lung+cancer+by+activating+ERBB3+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DMisudomi%26aufirst%3DT.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHyland%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DHolmes%26aufirst%3DA.%252C%2BJ%26aulast%3DRogers%26aufirst%3DA.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DMET%2520amplification%2520leads%2520to%2520gefitinib%2520resistance%2520in%2520lung%2520cancer%2520by%2520activating%2520ERBB3%2520signaling%26jtitle%3DScience%26date%3D2007%26volume%3D316%26issue%3D5827%26spage%3D1039%26epage%3D1043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">4392</span><span class="NLM_x">â</span> <span class="NLM_lpage">4399</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1158%2F1078-0432.CCR-08-0117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18628453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4392-4399&issue=14&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Therapeutic+options+against+BCR-ABL1+T315I-positive+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4399</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease.  Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib.  Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid.  This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket.  To expedite the identification of strategies to override the resistance imposed by the T315I mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1.  Recent insights gained regarding the structural biol. of T315I have led to the development of a variety of compds. against this mutant.  We herein summarize the most clin. promising anti-T315I therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplJ8bpmJXGkrVg90H21EOLACvtfcHk0ljuUftElNCqGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D&md5=01688b0795daf1ca29c7ad4a98e3977b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0117%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DTherapeutic%2520options%2520against%2520BCR-ABL1%2520T315I-positive%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26issue%3D14%26spage%3D4392%26epage%3D4399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamaru, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">â</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnm0596-561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=8616716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&author=B.+J.+Drukerauthor=S.+Tamaruauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span></div><div class="casAuthors">Druker, Brian J.; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shane; Zimmermann, Jurg; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">The Bcr-Abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease.  A compd., designed to inhibit the Abl protein tyrosine kinase (CGP 57148), was evaluated for its effects on cells contg. the Bcr-Abl fusion protein.  Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compd.  In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the no. of Bcr-Abl colonies formed but no inhibition of normal colony formation.  This compd. may be useful in the treatment of Bcr-Abl-pos. leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzXj-25AHOrVg90H21EOLACvtfcHk0ljuUftElNCqGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D&md5=1dc111cc883a1ed29964ae2c88c88cb9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnm0596-561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0596-561%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamaru%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Boschelli, D. H.</span><span> </span><span class="NLM_article-title">Bcr-Abl kinase inhibitors</span> <span class="citation_source-journal">Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">â</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1007%2F7355_2006_008" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=407-444&author=D.+H.+Boschelli&title=Bcr-Abl+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2F7355_2006_008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F7355_2006_008%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26atitle%3DBcr-Abl%2520kinase%2520inhibitors%26jtitle%3DTop.%2520Med.%2520Chem.%26date%3D2007%26volume%3D1%26spage%3D407%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dneprovskaia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebansky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McPherson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moorthy, S. S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathak, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, B.</span><span> </span><span class="NLM_article-title">Inhibitors of ABL and the ABL-T315I mutation</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">â</span> <span class="NLM_lpage">921</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.2174%2F156802608784911635" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18673174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=905-921&author=G.+Noronhaauthor=J.+Caoauthor=C.+P.+Chowauthor=E.+Dneprovskaiaauthor=R.+M.+Fineauthor=J.+Hoodauthor=X.+Kangauthor=B.+Klebanskyauthor=D.+Lohseauthor=C.+C.+Makauthor=A.+McPhersonauthor=S.+S.+P.+Moorthyauthor=V.+P.+Pathakauthor=J.+Renickauthor=R.+Sollauthor=B.+Zeng&title=Inhibitors+of+ABL+and+the+ABL-T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of ABL and the ABL-T315I mutation</span></div><div class="casAuthors">Noronha, Glenn; Cao, Jianguo; Chow, Chun P.; Dneprovskaia, Elena; Fine, Richard M.; Hood, John; Kang, Xinshan; Klebansky, Boris; Lohse, Dan; Mak, Chi Ching; McPherson, Andrew; Palanki, Moorthy S. S.; Pathak, Ved P.; Renick, Joel; Soll, Richard; Zeng, Binqi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">905-921</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) is a hematol. stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells.  Abelson tyrosine kinase (ABL) is a non-receptor tyrosine kinase involved in cell growth and proliferation and is usually under tight control.  However, 95% of CML patients have the ABL gene from chromosome 9 fused with the breakpoint cluster (BCR) gene from chromosome 22, resulting in a short chromosome known as the Philadelphia chromosome.  This Philadelphia chromosome is responsible for the prodn. of BCR-ABL, a constitutively active tyrosine kinase that causes uncontrolled cellular proliferation.  An ABL inhibitor, imatinib, was approved by the FDA for the treatment of CML, and is currently used as first line therapy.  However, a high percentage of clin. relapse has been obsd. due to long term treatment with imatinib.  A majority of these relapsed patients have several point mutations at and around the ATP binding pocket of the ABL kinase domain in BCR-ABL.  To address the resistance of mutated BCR-ABL to imatinib, 2nd generation inhibitors such as dasatinib, and nilotinib were developed.  These compds. were approved for the treatment of CML patients who are resistant to imatinib.  All of the BCR-ABL mutants are inhibited by the 2nd generation inhibitors with the exception of the T3151 mutant.  Several 3rd generation inhibitors such as AP24534, VX-680 (MK-0457), PHA-739358, PPY-A, XL-228, SGX-70393, FTY720 and TG101113 are being developed to target the T3151 mutation.  The early results from these compds. are encouraging and it is anticipated that physicians will have addnl. drugs at their disposal for the treatment of patients with the mutated BCR-ABL-T315I.  The success of these inhibitors has greater implication not only in CML, but also in other diseases driven by kinases where the mutated gatekeeper residue plays a major role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCjbrW8rt8HbVg90H21EOLACvtfcHk0ljuUftElNCqGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVantL8%253D&md5=c61dc3941c9fd71ddd4ed02732e80998</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F156802608784911635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784911635%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DC.%2BP.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DFine%26aufirst%3DR.%2BM.%26aulast%3DHood%26aufirst%3DJ.%26aulast%3DKang%26aufirst%3DX.%26aulast%3DKlebansky%26aufirst%3DB.%26aulast%3DLohse%26aufirst%3DD.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DMcPherson%26aufirst%3DA.%26aulast%3DMoorthy%26aufirst%3DS.%2BS.%2BP.%26aulast%3DPathak%26aufirst%3DV.%2BP.%26aulast%3DRenick%26aufirst%3DJ.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DB.%26atitle%3DInhibitors%2520of%2520ABL%2520and%2520the%2520ABL-T315I%2520mutation%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D905%26epage%3D921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarijian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Flying under the radar: the new wave of BCR-ABL inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">834</span><span class="NLM_x">â</span> <span class="NLM_lpage">848</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=834-848&issue=10&author=A.+Quintas-Cardamaauthor=H.+Kantarijianauthor=J.+Cortes&title=Flying+under+the+radar%3A+the+new+wave+of+BCR-ABL+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarijian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFlying%2520under%2520the%2520radar%253A%2520the%2520new%2520wave%2520of%2520BCR-ABL%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D10%26spage%3D834%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Chan, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullick, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, M. E.</span><span> </span><span class="NLM_article-title">Mutations of the epidermal growth factor receptor in non-small cell lung cancerâsearch and destroy</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">â</span> <span class="NLM_lpage">23</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=17-23&author=S.+K.+Chanauthor=W.+J.+Gullickauthor=M.+E.+Hill&title=Mutations+of+the+epidermal+growth+factor+receptor+in+non-small+cell+lung+cancer%E2%80%94search+and+destroy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BK.%26aulast%3DGullick%26aufirst%3DW.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BE.%26atitle%3DMutations%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520non-small%2520cell%2520lung%2520cancer%25E2%2580%2594search%2520and%2520destroy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D17%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shigematsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">Mutations and addiction to EGFR: the Achilles âhealâ of lung cancers</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">481</span><span class="NLM_x">â</span> <span class="NLM_lpage">486</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=481-486&issue=10&author=A.+F.+Gazdarauthor=H.+Shigematsuauthor=J.+Herzauthor=J.+D.+Minna&title=Mutations+and+addiction+to+EGFR%3A+the+Achilles+%E2%80%9Cheal%E2%80%9D+of+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DShigematsu%26aufirst%3DH.%26aulast%3DHerz%26aufirst%3DJ.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DMutations%2520and%2520addiction%2520to%2520EGFR%253A%2520the%2520Achilles%2520%25E2%2580%259Cheal%25E2%2580%259D%2520of%2520lung%2520cancers%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2004%26volume%3D10%26issue%3D10%26spage%3D481%26epage%3D486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protopopov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glatt, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">7817</span><span class="NLM_x">â</span> <span class="NLM_lpage">7822</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=7817-7822&issue=20&author=H.+Jiauthor=X.+Zhaoauthor=Y.+Yuzaauthor=T.+Shimamuraauthor=D.+Liauthor=A.+Protopopovauthor=B.+L.+Jungauthor=K.+McNamaraauthor=H.+Xiaauthor=K.+A.+Glattauthor=R.+K.+Thomasauthor=H.+Sasakiauthor=J.+W.+Hornerauthor=M.+J.+Eckauthor=C.+M.+Discafaniauthor=E.+Maherauthor=G.+I.+Shapiroauthor=M.+Meyersonauthor=K.-K.+Wong&title=Epidermal+growth+factor+receptor+variant+III+mutations+in+lung+tumorigenesis+and+sensitivity+to+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DProtopopov%26aufirst%3DA.%26aulast%3DJung%26aufirst%3DB.%2BL.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DXia%26aufirst%3DH.%26aulast%3DGlatt%26aufirst%3DK.%2BA.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DHorner%26aufirst%3DJ.%2BW.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DMaher%26aufirst%3DE.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520variant%2520III%2520mutations%2520in%2520lung%2520tumorigenesis%2520and%2520sensitivity%2520to%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26issue%3D20%26spage%3D7817%26epage%3D7822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in patients with non-small cell lung cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7525</span><span class="NLM_x">â</span> <span class="NLM_lpage">7529</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=7525-7529&issue=17&author=B.+E.+Johnsonauthor=P.+Janne&title=Epidermal+growth+factor+receptor+mutations+in+patients+with+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DJanne%26aufirst%3DP.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520patients%2520with%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D17%26spage%3D7525%26epage%3D7529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatual, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">2129</span><span class="NLM_x">â</span> <span class="NLM_lpage">2139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&issue=21&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatualauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lhEKj2Dzl8AcQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatual%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26issue%3D21%26spage%3D2129%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">â</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0ljNkpbroMUmNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reily, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from ânever smokersâ and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">â</span> <span class="NLM_lpage">13311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+I.+Reilyauthor=R.+Somwarauthor=M.+F.+Zakowski&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%9Cnever+smokers%E2%80%9D+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DReily%26aufirst%3DG.%2BI.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%259Cnever%2520smokers%25E2%2580%259D%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sargent, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Molecular basis for sunitinib efficacy and future clinical development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">734</span><span class="NLM_x">â</span> <span class="NLM_lpage">745</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=734-745&issue=9&author=S.+Faivreauthor=G.+Demetriauthor=W.+Sargentauthor=E.+Raymond&title=Molecular+basis+for+sunitinib+efficacy+and+future+clinical+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DDemetri%26aufirst%3DG.%26aulast%3DSargent%26aufirst%3DW.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DMolecular%2520basis%2520for%2520sunitinib%2520efficacy%2520and%2520future%2520clinical%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26issue%3D9%26spage%3D734%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1116</span><span class="NLM_x">â</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&issue=7&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=T.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D7%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span> </span><span class="NLM_article-title">Design and discovery of small molecules targeting Raf-1 kinase</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x"> (</span><span class="NLM_issue">25</span><span class="NLM_x">) </span> <span class="NLM_fpage">2269</span><span class="NLM_x">â</span> <span class="NLM_lpage">2278</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.2174%2F1381612023393125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12369855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XnvVGntrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=2269-2278&issue=25&author=T.+Lowingerauthor=B.+Riedlauthor=J.+Dumasauthor=R.+A.+Smith&title=Design+and+discovery+of+small+molecules+targeting+Raf-1+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design and discovery of small molecules targeting raf-1 kinase</span></div><div class="casAuthors">Lowinger, Timothy B.; Riedl, Bernd; Dumas, Jacques; Smith, Roger A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2269-2278</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review.  Raf kinase, an enzyme which acts downstream in the Ras signaling pathway, is involved in cancerous cell proliferation.  Thus, small mol. inhibitors of Raf kinase activity may be important agents for the treatment of cancer.  A novel class of Raf-1 inhibitors was discovered, using a combination of medicinal and combinatorial chem. approaches.  This effort culminated in the identification of the clin. candidate BAY 43-9006, currently undergoing Phase I clin. trials.  The present review summarizes the medicinal chem. development of ureas as highly potent inhibitors of Raf-1 kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqviNIBK_IYW7Vg90H21EOLACvtfcHk0ljNkpbroMUmNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnvVGntrk%253D&md5=a62445c3fb50083175ee4863ae84f6ce</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F1381612023393125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612023393125%26sid%3Dliteratum%253Aachs%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26atitle%3DDesign%2520and%2520discovery%2520of%2520small%2520molecules%2520targeting%2520Raf-1%2520kinase%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2002%26volume%3D8%26issue%3D25%26spage%3D2269%26epage%3D2278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Huse, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">The conformational plasticity of protein kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">275</span><span class="NLM_x">â</span> <span class="NLM_lpage">282</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS0092-8674%2802%2900741-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12015977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=275-282&issue=3&author=M.+Huseauthor=J.+Kuriyan&title=The+conformational+plasticity+of+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The conformational plasticity of protein kinases</span></div><div class="casAuthors">Huse, Morgan; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">275-282</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review with 48 refs.  Protein kinases operate in a large no. of distinct signaling pathways, where the tight regulation of their catalytic activity is crucial to the development and maintenance of eukaryotic organisms.  The catalytic domains of different kinases adopt strikingly similar structures when they are active.  By contrast, crystal structures of inactive kinases have revealed a marked plasticity in the kinase domain that allows the adoption of distinct conformations in response to interactions with specific regulatory domains or proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJrn7F3h4ej7Vg90H21EOLACvtfcHk0lhjeJ_TbPesNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvV2lsLw%253D&md5=cd56edae94ad239f2ce7a5d6c8930cbb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2802%2900741-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252802%252900741-9%26sid%3Dliteratum%253Aachs%26aulast%3DHuse%26aufirst%3DM.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DThe%2520conformational%2520plasticity%2520of%2520protein%2520kinases%26jtitle%3DCell%26date%3D2002%26volume%3D109%26issue%3D3%26spage%3D275%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">358</span><span class="NLM_x">â</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&issue=7&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lhjeJ_TbPesNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26issue%3D7%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Masterson, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascioni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traaseth, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veglia, G.</span><span> </span><span class="NLM_article-title">Allosteric cooperativity in protein kinase A</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">506</span><span class="NLM_x">â</span> <span class="NLM_lpage">511</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=506-511&issue=2&author=L.+R.+Mastersonauthor=A.+Mascioniauthor=N.+J.+Traasethauthor=S.+S.+Taylorauthor=G.+Veglia&title=Allosteric+cooperativity+in+protein+kinase+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMasterson%26aufirst%3DL.%2BR.%26aulast%3DMascioni%26aufirst%3DA.%26aulast%3DTraaseth%26aufirst%3DN.%2BJ.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DVeglia%26aufirst%3DG.%26atitle%3DAllosteric%2520cooperativity%2520in%2520protein%2520kinase%2520A%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26issue%3D2%26spage%3D506%26epage%3D511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Vajpai, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grzesiek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jahnke, W.</span><span> </span><span class="NLM_article-title">Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x"> (</span><span class="NLM_issue">26</span><span class="NLM_x">) </span> <span class="NLM_fpage">18292</span><span class="NLM_x">â</span> <span class="NLM_lpage">18302</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=18292-18302&issue=26&author=N.+Vajpaiauthor=A.+Straussauthor=G.+Fendrichauthor=S.+W.+Cowan-Jacobauthor=P.+W.+Manleyauthor=S.+Grzesiekauthor=W.+Jahnke&title=Solution+conformations+and+dynamics+of+ABL+kinase-inhibitor+complexes+determined+by+NMR+substantiate+the+different+binding+modes+of+imatinib%2Fnilotinib+and+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVajpai%26aufirst%3DN.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DGrzesiek%26aufirst%3DS.%26aulast%3DJahnke%26aufirst%3DW.%26atitle%3DSolution%2520conformations%2520and%2520dynamics%2520of%2520ABL%2520kinase-inhibitor%2520complexes%2520determined%2520by%2520NMR%2520substantiate%2520the%2520different%2520binding%2520modes%2520of%2520imatinib%252Fnilotinib%2520and%2520dasatinib%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26issue%3D26%26spage%3D18292%26epage%3D18302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Dorsey, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jove, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span> </span><span class="NLM_article-title">The pyrido[2,3-<i>d</i>]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">3127</span><span class="NLM_x">â</span> <span class="NLM_lpage">3131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=3127-3131&issue=12&author=J.+F.+Dorseyauthor=R.+Joveauthor=A.+J.+Krakerauthor=J.+Wu&title=The+pyrido%5B2%2C3-d%5Dpyrimidine+derivative+PD180970+inhibits+p210Bcr-Abl+tyrosine+kinase+and+induces+apoptosis+of+K562+leukemic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DJ.%2BF.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DThe%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520derivative%2520PD180970%2520inhibits%2520p210Bcr-Abl%2520tyrosine%2520kinase%2520and%2520induces%2520apoptosis%2520of%2520K562%2520leukemic%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26issue%3D12%26spage%3D3127%26epage%3D3131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartl, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, C. W.</span><span> </span><span class="NLM_article-title">Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-<i>d</i>]pyrimidine tyrosine kinase inhibitors</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">885</span><span class="NLM_x">â</span> <span class="NLM_lpage">898</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=885-898&issue=7&author=A.+J.+Krakerauthor=B.+G.+Hartlauthor=A.+M.+Amarauthor=M.+R.+Barvianauthor=H.+D.+H.+Showalterauthor=C.+W.+Moore&title=Biochemical+and+cellular+effects+of+c-Src+kinase-selective+pyrido%5B2%2C3-d%5Dpyrimidine+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DHartl%26aufirst%3DB.%2BG.%26aulast%3DAmar%26aufirst%3DA.%2BM.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DMoore%26aufirst%3DC.%2BW.%26atitle%3DBiochemical%2520and%2520cellular%2520effects%2520of%2520c-Src%2520kinase-selective%2520pyrido%255B2%252C3-d%255Dpyrimidine%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2000%26volume%3D60%26issue%3D7%26spage%3D885%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, O. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennisi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakcey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuck, L.</span><span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">66452</span><span class="NLM_x">â</span> <span class="NLM_lpage">66659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=66452-66659&author=E.+R.+Woodauthor=A.+T.+Tuesdaleauthor=O.+B.+McDonaldauthor=D.+Yanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lakceyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilbmerauthor=L.+Shewchuck&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTuesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLakcey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilbmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuck%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D66452%26epage%3D66659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">â</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lj8dUIRx7kdeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gureasko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">â</span> <span class="NLM_lpage">1149</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2Fj.cell.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=16777603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=1137-1149&author=X.+Zhangauthor=J.+Gureaskoauthor=H.+Shenauthor=P.+A.+Coleauthor=J.+Kuriyan&title=An+allosteric+mechanism+for+activation+of+the+kinase+domain+of+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span></div><div class="casAuthors">Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1137-1149</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition.  We find that the EGFR kinase domain can be activated by increasing its local concn. or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation.  This suggests that the kinase domain is intrinsically auto-inhibited, and an intermol. interaction promotes its activation.  Using further mutational anal. and crystallog. we demonstrate that the auto-inhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs).  EGFR activation results from the formation of an asym. dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes.  The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRAzLF-wK7Vg90H21EOLACvtfcHk0lj8dUIRx7kdeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D&md5=f7b6795851425346f588cbd682125c93</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGureasko%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DAn%2520allosteric%2520mechanism%2520for%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D1137%26epage%3D1149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickin, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">450</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">â</span> <span class="NLM_lpage">745</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnature05998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18046415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKmtbrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2007&pages=741-745&author=X.+Zhangauthor=K.+A.+Pickinauthor=R.+Boseauthor=N.+Juraauthor=P.+A.+Coleauthor=J.+Kuriyan&title=Inhibition+of+the+EGF+receptor+by+binding+of+MIG6+to+an+activating+kinase+domain+interface"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface</span></div><div class="casAuthors">Zhang, Xuewu; Pickin, Kerry A.; Bose, Ron; Jura, Natalia; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">7170</span>),
    <span class="NLM_cas:pages">741-744</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy.  Crit. for activation is the formation of an asym. dimer by the intracellular kinase domains, in which the carboxy-terminal lobe (C lobe) of one kinase domain induces an active conformation in the other.  The cytoplasmic protein MIG6 (mitogen-induced gene 6; also known as ERRFI1) interacts with and inhibits the kinase domains of EGFR and ERBB2 (refs).  Crystal structures of complexes between the EGFR kinase domain and a fragment of MIG6 show that a â¼25-residue epitope (segment 1) from MIG6 binds to the distal surface of the C lobe of the kinase domain.  Biochem. and cell-based analyses confirm that this interaction contributes to EGFR inhibition by blocking the formation of the activating dimer interface.  A longer MIG6 peptide that is extended C terminal to segment 1 has increased potency as an inhibitor of the activated EGFR kinase domain, while retaining a crit. dependence on segment 1.  We show that signaling by EGFR mols. that contain constitutively active kinase domains still requires formation of the asym. dimer, underscoring the importance of dimer interface blockage in MIG6-mediated inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2aM4ZGKQTr7Vg90H21EOLACvtfcHk0lj8dUIRx7kdeQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKmtbrP&md5=788822e6303a35eddea3e032875c57d7</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnature05998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05998%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DPickin%26aufirst%3DK.%2BA.%26aulast%3DBose%26aufirst%3DR.%26aulast%3DJura%26aufirst%3DN.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520the%2520EGF%2520receptor%2520by%2520binding%2520of%2520MIG6%2520to%2520an%2520activating%2520kinase%2520domain%2520interface%26jtitle%3DNature%26date%3D2007%26volume%3D450%26spage%3D741%26epage%3D745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Levinson, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchment, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koldobskiy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karplus, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">A Src-like inactive conformation in the Abl tyrosine kinase domain</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">753</span><span class="NLM_x">â</span> <span class="NLM_lpage">767</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=753-767&issue=5&author=N.+M.+Levinsonauthor=O.+Kuchmentauthor=K.+Shenauthor=M.+A.+Youngauthor=M.+Koldobskiyauthor=M.+Karplusauthor=P.+A.+Coleauthor=J.+Kuriyan&title=A+Src-like+inactive+conformation+in+the+Abl+tyrosine+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLevinson%26aufirst%3DN.%2BM.%26aulast%3DKuchment%26aufirst%3DO.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DKoldobskiy%26aufirst%3DM.%26aulast%3DKarplus%26aufirst%3DM.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DA%2520Src-like%2520inactive%2520conformation%2520in%2520the%2520Abl%2520tyrosine%2520kinase%2520domain%26jtitle%3DPLoS%2520Biol.%26date%3D2006%26volume%3D4%26issue%3D5%26spage%3D753%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coa, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">â</span> <span class="NLM_lpage">311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2Fj.str.2007.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17355866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=299-311&author=M.+A.+Seeligerauthor=B.+Nagarauthor=F.+Frankauthor=X.+Coaauthor=M.+N.+Hendersonauthor=J.+Kuriyan&title=c-Src+binds+to+the+cancer+drug+imatinib+with+an+inactive+Abl%2Fc-Kit+conformation+and+a+distributed+thermodynamic+penalty"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty</span></div><div class="casAuthors">Seeliger, Markus A.; Nagar, Bhushan; Frank, Filipp; Cao, Xiaoxian; Henderson, M. Nidanie; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">299-311</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor.  Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src.  The crystal structure of the c-Src kinase domain in complex with imatinib closely resembles that of Ablâ¢imatinib and c-Kitâ¢imatinib, and differs significantly from the inactive "Src/CDK" conformation of the Src family kinases.  Attempts to increase the affinity of c-Src for imatinib by swapping residues with the corresponding residues in Abl have not been successful, suggesting that the thermodn. penalty for adoption of the imatinib-binding conformation by c-Src is distributed over a broad region of the structure.  Two mutations that are expected to destabilize the inactive Src/CDK conformation increase drug sensitivity 15-fold, suggesting that the free-energy balance between different inactive states is a key to imatinib binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2SQGjjXdg1LVg90H21EOLACvtfcHk0liI8M8bhkAT7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisleisbY%253D&md5=ddfbcf06d91b408ca5fb25af9774c334</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2007.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2007.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DFrank%26aufirst%3DF.%26aulast%3DCoa%26aufirst%3DX.%26aulast%3DHenderson%26aufirst%3DM.%2BN.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3Dc-Src%2520binds%2520to%2520the%2520cancer%2520drug%2520imatinib%2520with%2520an%2520inactive%2520Abl%252Fc-Kit%2520conformation%2520and%2520a%2520distributed%2520thermodynamic%2520penalty%26jtitle%3DStructure%26date%3D2007%26volume%3D15%26spage%3D299%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayahshi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmood, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Hashem, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronson, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">â</span> <span class="NLM_lpage">495</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2006&pages=485-495&author=H.+Jiauthor=D.+Liauthor=L.+Chenauthor=T.+Shimamuraauthor=S.+Kobayahshiauthor=K.+McNamaraauthor=U.+Mahmoodauthor=A.+Mitchellauthor=Y.+Sunauthor=R.+Al-Hashemauthor=L.+R.+Chirieacauthor=R.+Paderaauthor=R.+T.+Bronsonauthor=W.+Kimauthor=P.+Janneauthor=G.+I.+Shapiroauthor=D.+G.+Tenenauthor=B.+E.+Johnsonauthor=R.+Weisslederauthor=N.+E.+Sharplessauthor=K.-K.+Wong&title=The+impact+of+human+EGFR+kinase+domain+mutations+on+lung+tumorigenesis+and+in+vivo+sensitivity+to+EGFR-targeted+therapies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKobayahshi%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DK.%26aulast%3DMahmood%26aufirst%3DU.%26aulast%3DMitchell%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAl-Hashem%26aufirst%3DR.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DKim%26aufirst%3DW.%26aulast%3DJanne%26aufirst%3DP.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DSharpless%26aufirst%3DN.%2BE.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DThe%2520impact%2520of%2520human%2520EGFR%2520kinase%2520domain%2520mutations%2520on%2520lung%2520tumorigenesis%2520and%2520in%2520vivo%2520sensitivity%2520to%2520EGFR-targeted%2520therapies%26jtitle%3DCancer%2520Cell%26date%3D2006%26volume%3D9%26spage%3D485%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Modugno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soncini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosettani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I Abl mutant in complex with the Aurora kinase inhibitor PHA-739358</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7987</span><span class="NLM_x">â</span> <span class="NLM_lpage">7990</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=7987-7990&issue=17&author=M.+Modugnoauthor=E.+Casaleauthor=C.+Sonciniauthor=P.+Rosettaniauthor=R.+Colomboauthor=R.+Lupiauthor=L.+Rusconiauthor=D.+Fancelliauthor=P.+Carpinelliauthor=A.+D.+Cameronauthor=A.+Isacchiauthor=J.+Moll&title=Crystal+structure+of+the+T315I+Abl+mutant+in+complex+with+the+Aurora+kinase+inhibitor+PHA-739358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DModugno%26aufirst%3DM.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DRosettani%26aufirst%3DP.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DA.%2BD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520Abl%2520mutant%2520in%2520complex%2520with%2520the%2520Aurora%2520kinase%2520inhibitor%2520PHA-739358%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D17%26spage%3D7987%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Young, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">1007</span><span class="NLM_x">â</span> <span class="NLM_lpage">1014</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1007-1014&issue=2&author=M.+A.+Youngauthor=N.+P.+Shahauthor=L.+H.+Chaoauthor=M.+Seeligerauthor=Z.+V.+Milanovauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhartauthor=C.+L.+Sawyersauthor=J.+Kuriyan&title=Structure+of+the+kinase+domain+of+an+imatinib-resistant+Abl+mutant+in+complex+with+the+Aurora+kinase+inhibitor+VX-680"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DChao%26aufirst%3DL.%2BH.%26aulast%3DSeeliger%26aufirst%3DM.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520kinase%2520domain%2520of%2520an%2520imatinib-resistant%2520Abl%2520mutant%2520in%2520complex%2520with%2520the%2520Aurora%2520kinase%2520inhibitor%2520VX-680%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26issue%3D2%26spage%3D1007%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parillon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I mutant of Abl kinase</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">171</span><span class="NLM_x">â</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1111%2Fj.1747-0285.2007.00556.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17718712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=171-181&issue=3&author=T.+Zhouauthor=L.+Parillonauthor=F.+Liauthor=Y.+Wangauthor=J.+Keatsauthor=S.+Lamoreauthor=Q.+Xuauthor=W.+Shakespeareauthor=D.+Dalgarnoauthor=X.+Zhu&title=Crystal+structure+of+the+T315I+mutant+of+Abl+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the T315I mutant of Abl kinase</span></div><div class="casAuthors">Zhou, Tianjun; Parillon, Lois; Li, Feng; Wang, Yihan; Keats, Jeff; Lamore, Sarah; Xu, Qihong; Shakespeare, William; Dalgarno, David; Zhu, Xiaotian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a disease characterized by the presence of a constitutively activated chimeric tyrosine kinase protein Bcr-Abl.  However, drug resistance often occurs at later stages of the disease, principally because of the occurrence of mutations in the kinase domain.  Second generation Bcr-Abl inhibitors, such as dasatinib and nilotinib are capable of inhibiting many imatinib-resistant forms of the kinase but not the form in which threonine is mutated to isoleucine at the gatekeeper position (T315I).  In this study, we present the crystal structure of the kinase domain of the c-Abl T315I mutant, as well as the wild-type form, in complex with a pyrrolopyridine inhibitor, PPY-A.  The side chain of Ile315 is accommodated in the Abl T315I mutant structure without large conformational changes proximal to the site of mutation.  In contrast to other inhibitors, such as imatinib and dasatinib, PPY-A does not occupy the hydrophobic pocket behind the gate-keeper residue.  This binding mode, coupled with augmented contacts with the glycine-rich loop, appears to be crit. for its ability to override the T315I mutation.  The data presented here may provide structural guidance for the design of clin. useful inhibitors of Bcr-Abl T315I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcbSxFWWpadbVg90H21EOLACvtfcHk0liMBFrhrooSFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F&md5=b15c60121b02e33d71783db3abd5ce72</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00556.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00556.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DLamore%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DShakespeare%26aufirst%3DW.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520mutant%2520of%2520Abl%2520kinase%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26issue%3D3%26spage%3D171%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">â</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0liMBFrhrooSFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Beghini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cairoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larizza, L.</span><span> </span><span class="NLM_article-title">In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation</span> <span class="citation_source-journal">Blood Cells, Mol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">262</span><span class="NLM_x">â</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1006%2Fbcmd.1998.0191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=9714703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADyaK1cXltl2ntbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1998&pages=262-270&issue=2&author=A.+Beghiniauthor=R.+Cairoliauthor=E.+Morraauthor=L.+Larizza&title=In+vivo+differentiation+of+mast+cells+from+acute+myeloid+leukemia+blasts+carrying+a+novel+activating+ligand-independent+C-kit+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation</span></div><div class="casAuthors">Beghini, Alessandro; Cairoli, Roberto; Morra, Enrica; Larizza, Lidia</div><div class="citationInfo"><span class="NLM_cas:title">Blood Cells, Molecules & Diseases</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">262-270</span>CODEN:
                <span class="NLM_cas:coden">BCMDFX</span>;
        ISSN:<span class="NLM_cas:issn">1079-9796</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The primary role of protooncogene c-kit in mast cell differentiation is supported by the development of mast cells from CD34+/CD117+ (c-kit) myeloid precursors.  Growth factor independence, neoplastic transformation and differentiation of mast cells were found in assocn. with c-kit activating mutations in both murine and human mastocytoma and mast cell diseases.  We have identified a novel c-kit mutation (D816Y) in peripheral blood mononuclear cells from a patient with AML (M2), massive presence of mast cells in bone marrow and rapid progression of the disease.  The mutation, a GâT transversion at nt 2467 of the c-kit gene resulting in Asp816âTyr substitution, corresponds to the D814Y and D817Y mutations identified and characterized in the murine P815 mastocytoma and the rat RBL-2H3 mast cell leukemia cell lines.  The absence of SCF transcripts that we found by RT-PCR in the patient's blasts indicates that, also in humans, this activating mutation leads to SCF independent growth.  The expression of the mutant allele on Kit signaling may by further enhanced by trisomy of chromosome 4 (carrying the c-kit gene) in the patient's blasts.  From these findings it is concluded that mast cells could be generated from a leukemic CD34/CD117-pos. clone, that combines the antigenic expression of mast cell precursor to the growth and differentiation factor-independence which was derived by the c-kit D816Y mutation.  (c) 1998 The Blood Cells Foundation, La Jolla, CA, USA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdKER3DbokJLVg90H21EOLACvtfcHk0liMBFrhrooSFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltl2ntbo%253D&md5=e9c69dc1b7dcc192411a9f3612927274</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1006%2Fbcmd.1998.0191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbcmd.1998.0191%26sid%3Dliteratum%253Aachs%26aulast%3DBeghini%26aufirst%3DA.%26aulast%3DCairoli%26aufirst%3DR.%26aulast%3DMorra%26aufirst%3DE.%26aulast%3DLarizza%26aufirst%3DL.%26atitle%3DIn%2520vivo%2520differentiation%2520of%2520mast%2520cells%2520from%2520acute%2520myeloid%2520leukemia%2520blasts%2520carrying%2520a%2520novel%2520activating%2520ligand-independent%2520C-kit%2520mutation%26jtitle%3DBlood%2520Cells%252C%2520Mol.%2520Dis.%26date%3D1998%26volume%3D24%26issue%3D2%26spage%3D262%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Chompret, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannengiesser, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrois, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tursz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenoir, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bressac-De Paillerets, B.</span><span> </span><span class="NLM_article-title">PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">318</span><span class="NLM_x">â</span> <span class="NLM_lpage">321</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=318-321&issue=1&author=A.+Chompretauthor=C.+Kannengiesserauthor=M.+Barroisauthor=P.+Terrierauthor=P.+Dahanauthor=T.+Turszauthor=G.+M.+Lenoirauthor=B.+Bressac-De+Paillerets&title=PDGFRA+germline+mutation+in+a+family+with+multiple+cases+of+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChompret%26aufirst%3DA.%26aulast%3DKannengiesser%26aufirst%3DC.%26aulast%3DBarrois%26aufirst%3DM.%26aulast%3DTerrier%26aufirst%3DP.%26aulast%3DDahan%26aufirst%3DP.%26aulast%3DTursz%26aufirst%3DT.%26aulast%3DLenoir%26aufirst%3DG.%2BM.%26aulast%3DBressac-De%2BPaillerets%26aufirst%3DB.%26atitle%3DPDGFRA%2520germline%2520mutation%2520in%2520a%2520family%2520with%2520multiple%2520cases%2520of%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DGastroenterology%26date%3D2004%26volume%3D126%26issue%3D1%26spage%3D318%26epage%3D321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duensing, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">PDGFRA activating mutations in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x"> (</span><span class="NLM_issue">5607</span><span class="NLM_x">) </span> <span class="NLM_fpage">708</span><span class="NLM_x">â</span> <span class="NLM_lpage">710</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=708-710&issue=5607&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=A.+Duensingauthor=L.+McGreeveyauthor=C.+J.+Chenauthor=N.+Josephauthor=S.+Singerauthor=D.+J.+Griffithauthor=A.+Haleyauthor=A.+Townauthor=G.+D.+Demetriauthor=C.+D.+Fletcherauthor=J.+A.+Fletcher&title=PDGFRA+activating+mutations+in+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDuensing%26aufirst%3DA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DGriffith%26aufirst%3DD.%2BJ.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DPDGFRA%2520activating%2520mutations%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D2003%26volume%3D299%26issue%3D5607%26spage%3D708%26epage%3D710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohacek, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">9244</span><span class="NLM_x">â</span> <span class="NLM_lpage">9249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=9244-9249&issue=24&author=M.+Azamauthor=V.+Nardiauthor=W.+C.+Shakespeareauthor=C.+A.+Metcalfauthor=R.+S.+Bohacekauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=P.+Slizauthor=D.+R.+Veachauthor=W.+G.+Bornmannauthor=B.+Clarksonauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=G.+Q.+Daley&title=Activity+of+dual+SRC-ABL+inhibitors+highlights+the+role+of+BCR%2FABL+kinase+dynamics+in+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DNardi%26aufirst%3DV.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivity%2520of%2520dual%2520SRC-ABL%2520inhibitors%2520highlights%2520the%2520role%2520of%2520BCR%252FABL%2520kinase%2520dynamics%2520in%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26issue%3D24%26spage%3D9244%26epage%3D9249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Rosee, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lahaye, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanfstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gschaidmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hehlmann, R.</span><span> </span><span class="NLM_article-title">Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2190</span><span class="NLM_x">â</span> <span class="NLM_lpage">2196</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=2190-2196&issue=11&author=A.+Hochhausauthor=S.+Kreilauthor=A.+S.+Corbinauthor=P.+La+Roseeauthor=M.+C.+Mullerauthor=T.+Lahayeauthor=B.+Hanfsteinauthor=C.+Schochauthor=N.+C.+Crossauthor=U.+Bergerauthor=H.+Gschaidmeierauthor=B.+J.+Drukerauthor=R.+Hehlmann&title=Molecular+and+chromosomal+mechanisms+of+resistance+to+imatinib+%28STI571%29+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DKreil%26aufirst%3DS.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DLa%2BRosee%26aufirst%3DP.%26aulast%3DMuller%26aufirst%3DM.%2BC.%26aulast%3DLahaye%26aufirst%3DT.%26aulast%3DHanfstein%26aufirst%3DB.%26aulast%3DSchoch%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DBerger%26aufirst%3DU.%26aulast%3DGschaidmeier%26aufirst%3DH.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DHehlmann%26aufirst%3DR.%26atitle%3DMolecular%2520and%2520chromosomal%2520mechanisms%2520of%2520resistance%2520to%2520imatinib%2520%2528STI571%2529%2520therapy%26jtitle%3DLeukemia%26date%3D2002%26volume%3D16%26issue%3D11%26spage%3D2190%26epage%3D2196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Roumiantsev, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasher, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Etten, R. A.</span><span> </span><span class="NLM_article-title">Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x"> (</span><span class="NLM_issue">16</span><span class="NLM_x">) </span> <span class="NLM_fpage">10700</span><span class="NLM_x">â</span> <span class="NLM_lpage">10705</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=10700-10705&issue=16&author=S.+Roumiantsevauthor=N.+P.+Shahauthor=M.+E.+Gorreauthor=J.+Nicollauthor=B.+B.+Brasherauthor=C.+L.+Sawyersauthor=R.+A.+Van+Etten&title=Clinical+resistance+to+the+kinase+inhibitor+STI-571+in+chronic+myeloid+leukemia+by+mutation+of+Tyr-253+in+the+Abl+kinase+domain+P-loop"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRoumiantsev%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DNicoll%26aufirst%3DJ.%26aulast%3DBrasher%26aufirst%3DB.%2BB.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVan%2BEtten%26aufirst%3DR.%2BA.%26atitle%3DClinical%2520resistance%2520to%2520the%2520kinase%2520inhibitor%2520STI-571%2520in%2520chronic%2520myeloid%2520leukemia%2520by%2520mutation%2520of%2520Tyr-253%2520in%2520the%2520Abl%2520kinase%2520domain%2520P-loop%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2002%26volume%3D99%26issue%3D16%26spage%3D10700%26epage%3D10705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">117</span><span class="NLM_x">â</span> <span class="NLM_lpage">125</span><div class="note"><p class="first last">[Comment]</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&issue=2&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+kinase+domain+mutations+confer+polyclonal+resistance+to+the+tyrosine+kinase+inhibitor+imatinib+%28STI571%29+in+chronic+phase+and+blast+crisis+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520confer%2520polyclonal%2520resistance%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520%2528STI571%2529%2520in%2520chronic%2520phase%2520and%2520blast%2520crisis%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26issue%3D2%26spage%3D117%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">OâHare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia</span> <span class="citation_source-journal">Clin. Lymphoma Myeloma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 3</span><span class="NLM_x">) </span> <span class="NLM_fpage">S120</span><span class="NLM_x">â</span> <span class="NLM_lpage">S130</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=S120-S130&issue=Suppl.+3&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=M.+W.+Deininger&title=Bcr-Abl+kinase+domain+mutations+and+the+unsettled+problem+of+Bcr-AblT315I%3A+looking+into+the+future+of+controlling+drug+resistance+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DBcr-Abl%2520kinase%2520domain%2520mutations%2520and%2520the%2520unsettled%2520problem%2520of%2520Bcr-AblT315I%253A%2520looking%2520into%2520the%2520future%2520of%2520controlling%2520drug%2520resistance%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Lymphoma%2520Myeloma%26date%3D2007%26volume%3D7%26issue%3DSuppl.%25203%26spage%3DS120%26epage%3DS130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Soverini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colarossi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gnani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poerio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacobucci, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amabile, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abruzzese, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlandi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radaelli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciccone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiribelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">di Lorenzo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caracciolo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izzo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pane, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leukemia, G. W. P. o. C. M.</span><span> </span><span class="NLM_article-title">Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">7374</span><span class="NLM_x">â</span> <span class="NLM_lpage">7379</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1158%2F1078-0432.CCR-06-1516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17189410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCrtr%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=7374-7379&issue=24&author=S.+Soveriniauthor=S.+Colarossiauthor=A.+Gnaniauthor=G.+Rostiauthor=F.+Castagnettiauthor=A.+Poerioauthor=I.+Iacobucciauthor=M.+Amabileauthor=E.+Abruzzeseauthor=E.+Orlandiauthor=F.+Radaelliauthor=F.+Cicconeauthor=M.+Tiribelliauthor=R.+di+Lorenzoauthor=C.+Caraccioloauthor=B.+Izzoauthor=F.+Paneauthor=G.+Saglioauthor=M.+Baccaraniauthor=G.+Martinelliauthor=G.+W.+P.+o.+C.+M.+Leukemia&title=Contribution+of+ABL+kinase+domain+mutations+to+imatinib+resistance+in+different+subsets+of+Philadelphia-positive+patients%3A+by+the+GIMEMA+Working+Party+on+Chronic+Myeloid+Leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia</span></div><div class="casAuthors">Soverini, Simona; Colarossi, Sabrina; Gnani, Alessandra; Rosti, Gianantonio; Castagnetti, Fausto; Poerio, Angela; Iacobucci, Ilaria; Amabile, Marilina; Abruzzese, Elisabetta; Orlandi, Ester; Radaelli, Franca; Ciccone, Fabrizio; Tiribelli, Mario; di Lorenzo, Roberto; Caracciolo, Clementina; Izzo, Barbara; Pane, Fabrizio; Saglio, Giuseppe; Baccarani, Michele; Martinelli, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7374-7379</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-pos. (Ph+) leukemia patients.  Exptl. Design: Using denaturing high-performance liq. chromatog. and sequencing, we screened for ABL kinase domain mutations in 370 Ph+ patients with evidence of hematol. or cytogenetic resistance to imatinib.  Results: Mutations were found in 127 of 297 (43%) evaluable patients.  Mutations were found in 27% of chronic-phase patients (14% treated with imatinib frontline; 31% treated with imatinib post-IFN failure), 52% of accelerated-phase patients, 75% of myeloid blast crisis patients, and 83% of lymphoid blast crisis/Ph+ acute lymphoblastic leukemia (ALL) patients.  Mutations were assocd. in 30% of patients with primary resistance (44% hematol. and 28% cytogenetic) and in 57% of patients with acquired resistance (23% patients who lost cytogenetic response; 55% patients who lost hematol. response; and 87% patients who progressed to accelerated phase/blast crisis).  P-loop and T315I mutations were particularly frequent in advanced-phase chronic myeloid leukemia and Ph+ ALL patients, and often accompanied progression from chronic phase to accelerated phase/blast crisis.  Conclusions: We conclude that (a) amino acid substitutions at seven residues (M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V) account for 85% of all resistance-assocd. mutations; (b) the search for mutations is important both in case of imatinib failure and in case of loss of response at the hematol. or cytogenetic level; (c) advanced-phase chronic myeloid leukemia and Ph+ ALL patients have a higher likelihood of developing imatinib-resistant mutations; and (d) the presence of either P-loop or T315I mutations in imatinib-treated patients should warn the clinician to reconsider the therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSQP35u9vcXbVg90H21EOLACvtfcHk0lgpyr29QZrHXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCrtr%252FK&md5=52440d8b2a968324b30fec90669cd442</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1516%26sid%3Dliteratum%253Aachs%26aulast%3DSoverini%26aufirst%3DS.%26aulast%3DColarossi%26aufirst%3DS.%26aulast%3DGnani%26aufirst%3DA.%26aulast%3DRosti%26aufirst%3DG.%26aulast%3DCastagnetti%26aufirst%3DF.%26aulast%3DPoerio%26aufirst%3DA.%26aulast%3DIacobucci%26aufirst%3DI.%26aulast%3DAmabile%26aufirst%3DM.%26aulast%3DAbruzzese%26aufirst%3DE.%26aulast%3DOrlandi%26aufirst%3DE.%26aulast%3DRadaelli%26aufirst%3DF.%26aulast%3DCiccone%26aufirst%3DF.%26aulast%3DTiribelli%26aufirst%3DM.%26aulast%3Ddi%2BLorenzo%26aufirst%3DR.%26aulast%3DCaracciolo%26aufirst%3DC.%26aulast%3DIzzo%26aufirst%3DB.%26aulast%3DPane%26aufirst%3DF.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DLeukemia%26aufirst%3DG.%2BW.%2BP.%2Bo.%2BC.%2BM.%26atitle%3DContribution%2520of%2520ABL%2520kinase%2520domain%2520mutations%2520to%2520imatinib%2520resistance%2520in%2520different%2520subsets%2520of%2520Philadelphia-positive%2520patients%253A%2520by%2520the%2520GIMEMA%2520Working%2520Party%2520on%2520Chronic%2520Myeloid%2520Leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26issue%3D24%26spage%3D7374%26epage%3D7379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">4236</span><span class="NLM_x">â</span> <span class="NLM_lpage">4243</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12154025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=4236-4243&issue=15&author=B.+Nagarauthor=W.+G.+Bornmannauthor=P.+Pellicenaauthor=T.+Schindlerauthor=D.+R.+Veachauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Crystal+structures+of+the+kinase+domain+of+c-Abl+in+complex+with+the+small+molecule+inhibitors+PD173955+and+imatinib+%28STI-571%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)</span></div><div class="casAuthors">Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4236-4243</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia.  Small mol. inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia.  We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, imatinib (also known as STI-571 and Gleevec) and PD173955 (Parke-Davis).  Both compds. bind to the canonical ATP-binding site of the kinase domain, but they do so in different ways.  As shown previously in a crystal structure of Abl bound to a smaller variant of STI-571, STI-571 captures a specific inactive conformation of the activation loop of Abl in which the loop mimics bound peptide substrate.  In contrast, PD173955 binds to a conformation of Abl in which the activation loop resembles that of an active kinase.  The structure suggests that PD173955 would be insensitive to whether the conformation of the activation loop corresponds to active kinases or to that seen in the STI-571 complex.  In vitro kinase assays confirm that this is the case and indicate that PD173955 is at least 10-fold more inhibitory than STI-571.  The structures suggest that PD173955 achieves its greater potency over STI-571 by being able to target multiple forms of Abl (active or inactive), whereas STI-571 requires a specific inactive conformation of Abl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-5qYZHMOZCrVg90H21EOLACvtfcHk0lgpyr29QZrHXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFeltLY%253D&md5=843213cd6038ed82a0e43dce56e81a91</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DCrystal%2520structures%2520of%2520the%2520kinase%2520domain%2520of%2520c-Abl%2520in%2520complex%2520with%2520the%2520small%2520molecule%2520inhibitors%2520PD173955%2520and%2520imatinib%2520%2528STI-571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26issue%3D15%26spage%3D4236%26epage%3D4243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1109</span><span class="NLM_x">â</span> <span class="NLM_lpage">1118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnsmb.1486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18794843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1109-1118&issue=10&author=M.+Azamauthor=M.+A.+Seeligerauthor=N.+S.+Grayauthor=J.+Kuriyanauthor=G.+Q.+Daley&title=Activation+of+tyrosine+kinases+by+mutation+of+the+gatekeeper+threonine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span></div><div class="casAuthors">Azam, Mohammad; Seeliger, Markus A.; Gray, Nathanael S.; Kuriyan, John; Daley, George Q.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1109-1118</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinases targeted by small-mol. inhibitors develop resistance through mutation of the 'gatekeeper' threonine residue of the active site.  Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth factor receptor-Î± and -Î², and epidermal growth factor receptor activates the kinase and promotes malignant transformation of BaF3 cells.  Structural anal. reveals that a network of hydrophobic interactions - the hydrophobic spine - characteristic of the active kinase conformation is stabilized by the gatekeeper substitution.  Substitution of glycine for the residues constituting the spine disrupts the hydrophobic connectivity and inactivates the kinase.  Furthermore, a small-mol. inhibitor (compd. 14) that maximizes complementarity with the dismantled spine inhibits the gatekeeper mutation of BCR-ABL-T315I.  These results demonstrate that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases and provide structural insights to guide the development of next-generation inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEoZTY5SkbALVg90H21EOLACvtfcHk0lgpyr29QZrHXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM&md5=4afc4e5a0850a4510ced3fa5fbda97fa</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1486%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivation%2520of%2520tyrosine%2520kinases%2520by%2520mutation%2520of%2520the%2520gatekeeper%2520threonine%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2008%26volume%3D15%26issue%3D10%26spage%3D1109%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haste, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyck, L. F.</span><span> </span><span class="NLM_article-title">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">17783</span><span class="NLM_x">â</span> <span class="NLM_lpage">17788</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1073%2Fpnas.0607656103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17095602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=17783-17788&author=A.+P.+Kornevauthor=N.+M.+Hasteauthor=S.+S.+Taylorauthor=L.+F.+Eyck&title=Surface+comparison+of+active+and+inactive+protein+kinases+identifies+a+conserved+activation+mechanism"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</span></div><div class="casAuthors">Kornev, Alexandr P.; Haste, Nina M.; Taylor, Susan S.; Ten Eyck, Lynn F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">17783-17788</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The surface comparison of different serine-threonine and tyrosine kinases reveals a set of 30 residues whose spatial positions are highly conserved.  The comparison between active and inactive conformations identified the residues whose positions are the most sensitive to activation.  Based on these results, we propose a model of protein kinase activation.  This model explains how the presence of a phosphate group in the activation loop dets. the position of the catalytically important aspartate in the Asp-Phe-Gly (DFG) motif.  According to the model, the most important feature of the activation is a "spine" formation that is dynamically assembled in all active kinases.  The spine is comprised of four hydrophobic residues that we detected in a set of 23 eukaryotic and prokaryotic kinases.  It spans the mol. and plays a coordinating role in activated kinases.  The spine is disordered in the inactive kinases and can explain how stabilization of the whole mol. is achieved upon phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwv4ByA5owH7Vg90H21EOLACvtfcHk0lgpyr29QZrHXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KnurfJ&md5=f474acffd8b17d8352ac9f6fc9bbbf8f</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0607656103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0607656103%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DHaste%26aufirst%3DN.%2BM.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DEyck%26aufirst%3DL.%2BF.%26atitle%3DSurface%2520comparison%2520of%2520active%2520and%2520inactive%2520protein%2520kinases%2520identifies%2520a%2520conserved%2520activation%2520mechanism%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D17783%26epage%3D17788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halgren, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanschagrin, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainz, D. T.</span><span> </span><span class="NLM_article-title">Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for proteinâligand complexes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">6177</span><span class="NLM_x">â</span> <span class="NLM_lpage">6196</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm051256o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6177-6196&issue=21&author=R.+A.+Friesnerauthor=R.+B.+Murphyauthor=M.+P.+Repaskyauthor=L.+L.+Fryeauthor=J.+R.+Greenwoodauthor=T.+A.+Halgrenauthor=P.+C.+Sanschagrinauthor=D.+T.+Mainz&title=Extra+precision+glide%3A+docking+and+scoring+incorporating+a+model+of+hydrophobic+enclosure+for+protein%E2%88%92ligand+complexes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm051256o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051256o%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DSanschagrin%26aufirst%3DP.%2BC.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26atitle%3DExtra%2520precision%2520glide%253A%2520docking%2520and%2520scoring%2520incorporating%2520a%2520model%2520of%2520hydrophobic%2520enclosure%2520for%2520protein%25E2%2588%2592ligand%2520complexes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D21%26spage%3D6177%26epage%3D6196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">31</span><span class="NLM_x">) </span> <span class="NLM_fpage">11011</span><span class="NLM_x">â</span> <span class="NLM_lpage">11016</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&issue=31&author=T.+A.+Carterauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=W.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Patelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26issue%3D31%26spage%3D11011%26epage%3D11016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">OâHare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4500</span><span class="NLM_x">â</span> <span class="NLM_lpage">4505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4500-4505&issue=11&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=T.+Jiaauthor=P.+W.+Manleyauthor=J.+Mestanauthor=S.+W.+Cowan-Jacobauthor=F.+Y.+Leeauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=In+vitro+activity+of+Bcr-Abl+inhibitors+AMN107+and+BMS-354825+against+clinically+relevant+imatinib-resistant+Abl+kinase+domain+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DJia%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bcr-Abl%2520inhibitors%2520AMN107%2520and%2520BMS-354825%2520against%2520clinically%2520relevant%2520imatinib-resistant%2520Abl%2520kinase%2520domain%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26issue%3D11%26spage%3D4500%26epage%3D4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">le Coutre, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottmann, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gattermann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apperley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abruzzese, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâBrien, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuliczkowski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahon, F.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gobbi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwong, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">1834</span><span class="NLM_x">â</span> <span class="NLM_lpage">1839</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=1834-1839&issue=4&author=P.+le+Coutreauthor=O.+G.+Ottmannauthor=F.+Gilesauthor=D.-W.+Kimauthor=J.+Cortesauthor=N.+Gattermannauthor=J.+F.+Apperleyauthor=R.+A.+Larsonauthor=E.+Abruzzeseauthor=S.+G.+O%E2%80%99Brienauthor=K.+Kuliczkowskiauthor=A.+Hochhausauthor=F.-X.+Mahonauthor=G.+Saglioauthor=M.+Gobbiauthor=Y.-L.+Kwongauthor=M.+Baccaraniauthor=T.+Hughesauthor=G.+Martinelliauthor=J.+P.+Radichauthor=M.+Zhengauthor=Y.+Shouauthor=H.+Kantarjian&title=Nilotinib+%28formerly+AMN107%29%2C+a+highly+selective+BCR-ABL+tyrosine+kinase+inhibitor%2C+is+active+in+patients+with+imatinib-resistant+or+-intolerant+accelerated-phase+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dle%2BCoutre%26aufirst%3DP.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DGattermann%26aufirst%3DN.%26aulast%3DApperley%26aufirst%3DJ.%2BF.%26aulast%3DLarson%26aufirst%3DR.%2BA.%26aulast%3DAbruzzese%26aufirst%3DE.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BG.%26aulast%3DKuliczkowski%26aufirst%3DK.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DMahon%26aufirst%3DF.-X.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DGobbi%26aufirst%3DM.%26aulast%3DKwong%26aufirst%3DY.-L.%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DT.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DShou%26aufirst%3DY.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DNilotinib%2520%2528formerly%2520AMN107%2529%252C%2520a%2520highly%2520selective%2520BCR-ABL%2520tyrosine%2520kinase%2520inhibitor%252C%2520is%2520active%2520in%2520patients%2520with%2520imatinib-resistant%2520or%2520-intolerant%2520accelerated-phase%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26issue%3D4%26spage%3D1834%26epage%3D1839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">OâHare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holme, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jessen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burley, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">5507</span><span class="NLM_x">â</span> <span class="NLM_lpage">5512</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=5507-5512&issue=14&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=J.+W.+Tynerauthor=A.+S.+Corbinauthor=M.+J.+Wongauthor=S.+Buchananauthor=K.+Holmeauthor=K.+A.+Jessenauthor=C.+Tangauthor=H.+A.+Lewisauthor=R.+D.+Romeroauthor=S.+K.+Burleyauthor=M.+W.+Deininger&title=SGX393+inhibits+the+CML+mutant+Bcr-AblT315I+and+preempts+in+vitro+resistance+when+combined+with+nilotinib+or+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWong%26aufirst%3DM.%2BJ.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DHolme%26aufirst%3DK.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLewis%26aufirst%3DH.%2BA.%26aulast%3DRomero%26aufirst%3DR.%2BD.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DSGX393%2520inhibits%2520the%2520CML%2520mutant%2520Bcr-AblT315I%2520and%2520preempts%2520in%2520vitro%2520resistance%2520when%2520combined%2520with%2520nilotinib%2520or%2520dasatinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26issue%3D14%26spage%3D5507%26epage%3D5512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Harrington, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebbington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajose-Adeogun, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hercend, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diu-Hercend, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golec, J. M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. M.</span><span> </span><span class="NLM_article-title">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">262</span><span class="NLM_x">â</span> <span class="NLM_lpage">267</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnm1003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=14981513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=262-267&issue=3&author=E.+A.+Harringtonauthor=D.+Bebbingtonauthor=J.+Mooreauthor=R.+K.+Rasmussenauthor=A.+O.+Ajose-Adeogunauthor=T.+Nakayamaauthor=J.+A.+Grahamauthor=C.+Demurauthor=T.+Hercendauthor=A.+Diu-Hercendauthor=M.+Suauthor=J.+M.+C.+Golecauthor=K.+M.+Miller&title=VX-680%2C+a+potent+and+selective+small-molecule+inhibitor+of+the+Aurora+kinases%2C+suppresses+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo</span></div><div class="casAuthors">Harrington, Elizabeth A.; Bebbington, David; Moore, Jeff; Rasmussen, Richele K.; Ajose-Adeogun, Abi O.; Nakayama, Tomoko; Graham, Joanne A.; Demur, Cecile; Hercend, Thierry; Diu-Hercend, Anita; Su, Michael; Golec, Julian M. C.; Miller, Karen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-267</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Aurora kinases are essential for the regulation of chromosome segregation and cytokinesis during mitosis.  Aberrant expression and activity of these kinases occur in a wide range of human tumors, and lead to aneuploidy and tumorigenesis.  Here we report the discovery of a highly potent and selective small-mol. inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types.  This compd. causes profound inhibition of tumor growth in a variety of in vivo xenograft models, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses.  Our data indicate that Aurora kinase inhibition provides a new approach for the treatment of multiple human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgm1YUgqkWLVg90H21EOLACvtfcHk0lhl9nrOetgn8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1Wnur4%253D&md5=954ba274e280d8d08a7f2e331011432d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnm1003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1003%26sid%3Dliteratum%253Aachs%26aulast%3DHarrington%26aufirst%3DE.%2BA.%26aulast%3DBebbington%26aufirst%3DD.%26aulast%3DMoore%26aufirst%3DJ.%26aulast%3DRasmussen%26aufirst%3DR.%2BK.%26aulast%3DAjose-Adeogun%26aufirst%3DA.%2BO.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DJ.%2BA.%26aulast%3DDemur%26aufirst%3DC.%26aulast%3DHercend%26aufirst%3DT.%26aulast%3DDiu-Hercend%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DGolec%26aufirst%3DJ.%2BM.%2BC.%26aulast%3DMiller%26aufirst%3DK.%2BM.%26atitle%3DVX-680%252C%2520a%2520potent%2520and%2520selective%2520small-molecule%2520inhibitor%2520of%2520the%2520Aurora%2520kinases%252C%2520suppresses%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26issue%3D3%26spage%3D262%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skaggs, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branford, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">2562</span><span class="NLM_x">â</span> <span class="NLM_lpage">2569</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=2562-2569&issue=9&author=N.+P.+Shahauthor=B.+J.+Skaggsauthor=S.+Branfordauthor=T.+P.+Hughesauthor=J.+M.+Nicollauthor=R.+L.+Paquetteauthor=C.+L.+Sawyers&title=Sequential+ABL+kinase+inhibitor+therapy+selects+for+compound+drug-resistant+BCR-ABL+mutations+with+altered+oncogenic+potency"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DSkaggs%26aufirst%3DB.%2BJ.%26aulast%3DBranford%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DSequential%2520ABL%2520kinase%2520inhibitor%2520therapy%2520selects%2520for%2520compound%2520drug-resistant%2520BCR-ABL%2520mutations%2520with%2520altered%2520oncogenic%2520potency%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26issue%3D9%26spage%3D2562%26epage%3D2569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, S. J.</span><span> </span><span class="NLM_article-title">MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">500</span><span class="NLM_x">â</span> <span class="NLM_lpage">502</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=500-502&issue=2&author=F.+J.+Gilesauthor=J.+Cortesauthor=D.+Jonesauthor=D.+Bergstromauthor=H.+Kantarjianauthor=S.+J.+Freedman&title=MK-0457%2C+a+novel+kinase+inhibitor%2C+is+active+in+patients+with+chronic+myeloid+leukemia+or+acute+lymphocytic+leukemia+with+the+T315I+BCR-ABL+mutation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DBergstrom%26aufirst%3DD.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFreedman%26aufirst%3DS.%2BJ.%26atitle%3DMK-0457%252C%2520a%2520novel%2520kinase%2520inhibitor%252C%2520is%2520active%2520in%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520or%2520acute%2520lymphocytic%2520leukemia%2520with%2520the%2520T315I%2520BCR-ABL%2520mutation%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26issue%3D2%26spage%3D500%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Gumireddy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1992</span><span class="NLM_x">â</span> <span class="NLM_lpage">1997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=1992-1997&issue=6&author=K.+Gumireddyauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=P.+Johnauthor=A.+D.+Kangauthor=K.+A.+Robellauthor=M.+V.+R.+Reddyauthor=E.+P.+Reddy&title=A+non-ATP-competitive+inhibitor+of+BCR-ABL+overrides+imatinib+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DJohn%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DA.%2BD.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DReddy%26aufirst%3DM.%2BV.%2BR.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520non-ATP-competitive%2520inhibitor%2520of%2520BCR-ABL%2520overrides%2520imatinib%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26issue%3D6%26spage%3D1992%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Miettinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlomo-Rikala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasota, J.</span><span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors: recent advances in understanding of their biology</span> <span class="citation_source-journal">Hum. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1213</span><span class="NLM_x">â</span> <span class="NLM_lpage">1220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS0046-8177%2899%2990040-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=10534170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FgtFOgtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1999&pages=1213-1220&issue=10&author=M.+Miettinenauthor=M.+Sarlomo-Rikalaauthor=J.+Lasota&title=Gastrointestinal+stromal+tumors%3A+recent+advances+in+understanding+of+their+biology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumors: recent advances in understanding of their biology</span></div><div class="casAuthors">Miettinen M; Sarlomo-Rikala M; Lasota J</div><div class="citationInfo"><span class="NLM_cas:title">Human pathology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1213-20</span>
        ISSN:<span class="NLM_cas:issn">0046-8177</span>.
    </div><div class="casAbstract">Gastrointestinal stromal tumor (GIST) is the preferred term for mesenchymal tumors specific for the gastrointestinal tract (60% in stomach, 30% small intestine, 10% elsewhere).  GISTs include most tumors previously designated as leiomyoma, cellular leiomyoma, leiomyoblastoma, and leiomyosarcoma.  However, in the esophagus, leiomyoma is the most common mesenchymal tumor.  GISTs are composed of spindle (70%) or epithelioid (30%) cells, and 10%-30% are malignant showing intra-abdominal spread or liver metastases.  They are immunohistochemically positive for c-kit (CD117), CD34, and sometimes for actin but are almost always negative for desmin and S100-protein.  The malignant GISTs especially show activating mutations in the c-kit gene.  GISTs and gastrointestinal autonomic nerve tumors (GANT) overlap.  The cell of origin is not fully understood, but resemblance to the interstitial cells of Cajal, expression of some smooth muscle markers, and occurrence outside of the GI-tract suggest origin from multipotential cells that can differentiate into Cajal and smooth muscle cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyWL-Bn3fJXO3MPKNEWB5RfW6udTcc2eafisK6zK-j17ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FgtFOgtQ%253D%253D&md5=694517ed6b6ea7e57bd91895fc5c1c6c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0046-8177%2899%2990040-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0046-8177%252899%252990040-0%26sid%3Dliteratum%253Aachs%26aulast%3DMiettinen%26aufirst%3DM.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DLasota%26aufirst%3DJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors%253A%2520recent%2520advances%2520in%2520understanding%2520of%2520their%2520biology%26jtitle%3DHum.%2520Pathol.%26date%3D1999%26volume%3D30%26issue%3D10%26spage%3D1213%26epage%3D1220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Hirota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isozaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishiguro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhammad Tunio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuzawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, Y.</span><span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x"> (</span><span class="NLM_issue">5350</span><span class="NLM_x">) </span> <span class="NLM_fpage">577</span><span class="NLM_x">â</span> <span class="NLM_lpage">580</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&issue=5350&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+Muhammad+Tunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%2BTunio%26aufirst%3DG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26issue%3D5350%26spage%3D577%26epage%3D580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlomo-Rikala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tervahartiala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">1052</span><span class="NLM_x">â</span> <span class="NLM_lpage">1056</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJM200104053441404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=11287975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1052-1056&issue=14&author=H.+Joensuuauthor=P.+J.+Robertsauthor=M.+Sarlomo-Rikalaauthor=L.+C.+Anderssonauthor=P.+Tervahartialaauthor=D.+Tuvesonauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=S.+Dimitrijevicauthor=B.+Drukerauthor=G.+D.+Demetri&title=Effect+of+the+tyrosine+kinase+inhibitor+STI571+in+a+patient+with+a+metastatic+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1052-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYZ86Vmj15i5otVjB3IRIyfW6udTcc2ebtLrZTEwpRjrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3gvVekuw%253D%253D&md5=d361debf544b136b28889449118225e3</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441404%26sid%3Dliteratum%253Aachs%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSarlomo-Rikala%26aufirst%3DM.%26aulast%3DAndersson%26aufirst%3DL.%2BC.%26aulast%3DTervahartiala%26aufirst%3DP.%26aulast%3DTuveson%26aufirst%3DD.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEffect%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%2520STI571%2520in%2520a%2520patient%2520with%2520a%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26issue%3D14%26spage%3D1052%26epage%3D1056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Verweij, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casali, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalcberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeCesne, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blay, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issels, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Oosterom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogendoorn, P. C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Glabbeke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertulli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I.</span><span> </span><span class="NLM_article-title">Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x"> (</span><span class="NLM_issue">9440</span><span class="NLM_x">) </span> <span class="NLM_fpage">1127</span><span class="NLM_x">â</span> <span class="NLM_lpage">1134</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=1127-1134&issue=9440&author=J.+Verweijauthor=P.+G.+Casaliauthor=J.+Zalcbergauthor=A.+LeCesneauthor=P.+Reichardtauthor=J.-Y.+Blayauthor=R.+Isselsauthor=A.+van+Oosteromauthor=P.+C.+W.+Hogendoornauthor=M.+Van+Glabbekeauthor=R.+Bertulliauthor=I.+Judson&title=Progression-free+survival+in+gastrointestinal+stromal+tumours+with+high-dose+imatinib%3A+randomised+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DZalcberg%26aufirst%3DJ.%26aulast%3DLeCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DIssels%26aufirst%3DR.%26aulast%3Dvan%2BOosterom%26aufirst%3DA.%26aulast%3DHogendoorn%26aufirst%3DP.%2BC.%2BW.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBertulli%26aufirst%3DR.%26aulast%3DJudson%26aufirst%3DI.%26atitle%3DProgression-free%2520survival%2520in%2520gastrointestinal%2520stromal%2520tumours%2520with%2520high-dose%2520imatinib%253A%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26issue%3D9440%26spage%3D1127%26epage%3D1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span> </span><span class="NLM_article-title">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">472</span><span class="NLM_x">â</span> <span class="NLM_lpage">480</span><div class="note"><p class="first last">[see Comment]</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMoa020461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12181401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=472-480&issue=7&author=G.+D.+Demetriauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=A.+D.+Van+den+Abbeeleauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=M.+C.+Heinrichauthor=D.+A.+Tuvesonauthor=S.+Singerauthor=M.+Janicekauthor=J.+A.+Fletcherauthor=S.+G.+Silvermanauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=B.+Kieseauthor=B.+Pengauthor=S.+Dimitrijevicauthor=B.+J.+Drukerauthor=C.+Corlessauthor=C.+D.+Fletcherauthor=H.+Joensuu&title=Efficacy+and+safety+of+imatinib+mesylate+in+advanced+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span></div><div class="casAuthors">Demetri, George D.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D. M.; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Constitutive activation of KIT receptor tyrosine kinase is crit. in the pathogenesis of gastrointestinal stromal tumors.  Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclin. models and preliminary clin. studies to have activity against such tumors.  We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor.  We assessed antitumor response and the safety and tolerability of the drug.  Pharmacokinetics were assessed in a subgroup of patients.  A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily.  Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for tech. reasons, response could not be evaluated in 7 patients (4.8 percent).  No patient had a complete response to the treatment.  The median duration of response had not been reached after a median follow-up of 24 wk after the onset of response.  Early resistance to imatinib was noted in 20 patients (13.6 percent).  Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common.  Gastrointestinal or intraabdominal hemorrhage occurred in approx. 5 percent of patients.  There were no significant differences in toxic effects or response between the two doses.  Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.  Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.  Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVE0HpuuKXXrVg90H21EOLACvtfcHk0liIQJWFgmm3JQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D&md5=95c9ea076dd2b0e053ae2061cb3f5d24</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020461%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DJanicek%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSilverman%26aufirst%3DS.%2BG.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520imatinib%2520mesylate%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26issue%3D7%26spage%3D472%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheibe, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. P.</span><span> </span><span class="NLM_article-title">Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x"> (</span><span class="NLM_issue">30</span><span class="NLM_x">) </span> <span class="NLM_fpage">31655</span><span class="NLM_x">â</span> <span class="NLM_lpage">31663</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1074%2Fjbc.M403319200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15123710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=31655-31663&issue=30&author=C.+D.+Molauthor=D.+R.+Douganauthor=T.+R.+Schneiderauthor=R.+J.+Skeneauthor=M.+L.+Krausauthor=D.+N.+Scheibeauthor=G.+P.+Snellauthor=H.+Zouauthor=B.-C.+Sangauthor=K.+P.+Wilson&title=Structural+basis+for+the+autoinhibition+and+STI-571+inhibition+of+c-Kit+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase</span></div><div class="casAuthors">Mol, Clifford D.; Dougan, Douglas R.; Schneider, Thomas R.; Skene, Robert J.; Kraus, Michelle L.; Scheibe, Daniel N.; Snell, Gyorgy P.; Zou, Hua; Sang, Bi-Ching; Wilson, Keith P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">31655-31663</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers.  The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known.  We report the 1.9-Ã resoln. crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase.  Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure.  A 1.6-Ã crystal structure of c-Kit in complex with STI-571 (Imatinib or Gleevec) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state.  Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWJsKx1IzXQbVg90H21EOLACvtfcHk0liIQJWFgmm3JQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D&md5=df6065a62b44e4c2e6b020da0f797ab4</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403319200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403319200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKraus%26aufirst%3DM.%2BL.%26aulast%3DScheibe%26aufirst%3DD.%2BN.%26aulast%3DSnell%26aufirst%3DG.%2BP.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSang%26aufirst%3DB.-C.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520for%2520the%2520autoinhibition%2520and%2520STI-571%2520inhibition%2520of%2520c-Kit%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26issue%3D30%26spage%3D31655%26epage%3D31663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Antonescu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koryotowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leversha, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desantis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span> </span><span class="NLM_article-title">Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4182</span><span class="NLM_x">â</span> <span class="NLM_lpage">4190</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1158%2F1078-0432.CCR-04-2245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15930355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=4182-4190&issue=11&author=C.+R.+Antonescuauthor=P.+Besmerauthor=T.+Guoauthor=K.+Arkunauthor=G.+Homauthor=B.+Koryotowskiauthor=M.+A.+Levershaauthor=P.+D.+Jeffreyauthor=D.+Desantisauthor=S.+Singerauthor=M.+F.+Brennanauthor=R.+G.+Makiauthor=R.+P.+DeMatteo&title=Acquired+resistance+to+imatinib+in+gastrointestinal+stromal+tumor+occurs+through+secondary+gene+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation</span></div><div class="casAuthors">Antonescu, Cristina R.; Besmer, Peter; Guo, Tianhua; Arkun, Knarik; Hom, Glory; Koryotowski, Beata; Leversha, Margaret A.; Jeffrey, Philip D.; Desantis, Diann; Singer, Samuel; Brennan, Murray F.; Maki, Robert G.; DeMatteo, Ronald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4182-4190</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GIST) have an activating mutation in either KIT or PDGFRA.  Imatinib is a selective tyrosine kinase inhibitor and achieves a partial response or stable disease in about 80% of patients with metastatic GIST.  It is now clear that some patients with GIST develop resistance to imatinib during chronic therapy.  To identify the mechanism of resistance, we studied 31 patients with GIST who were treated with imatinib and then underwent surgical resection.  There were 13 patients who were nonresistant to imatinib, 3 with primary resistance, and 15 with acquired resistance after initial benefit from the drug.  There were no secondary mutations in KIT or PDGFRA in the nonresistant or primary resistance groups.  In contrast, secondary mutations were found in 7 of 15 (46%) patients with acquired resistance, each of whom had a primary mutation in KIT exon 11.  Most secondary mutations were located in KIT exon 17.  KIT phosphorylation was heterogeneous and did not correlate with clin. response to imatinib or mutation status.  That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOQf6NfYqwnrVg90H21EOLACvtfcHk0lgVzfddkcLCdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1GksLw%253D&md5=f0f8000b2c362c7d1dcc74a2a7aaa067</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-2245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-2245%26sid%3Dliteratum%253Aachs%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DArkun%26aufirst%3DK.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DKoryotowski%26aufirst%3DB.%26aulast%3DLeversha%26aufirst%3DM.%2BA.%26aulast%3DJeffrey%26aufirst%3DP.%2BD.%26aulast%3DDesantis%26aufirst%3DD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DBrennan%26aufirst%3DM.%2BF.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26atitle%3DAcquired%2520resistance%2520to%2520imatinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520occurs%2520through%2520secondary%2520gene%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26issue%3D11%26spage%3D4182%26epage%3D4190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Chen, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trent, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuller, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramdas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prieto, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyedeji, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feig, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macapinlac, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hittelman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier, M. L.</span><span> </span><span class="NLM_article-title">A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">5913</span><span class="NLM_x">â</span> <span class="NLM_lpage">5919</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=5913-5919&issue=17&author=L.+L.+Chenauthor=J.+C.+Trentauthor=E.+F.+Wuauthor=G.+N.+Fullerauthor=L.+Ramdasauthor=W.+Zhangauthor=A.+K.+Raymondauthor=V.+G.+Prietoauthor=C.+O.+Oyedejiauthor=K.+K.+Huntauthor=R.+E.+Pollockauthor=B.+W.+Feigauthor=K.+J.+Hayesauthor=H.+Choiauthor=H.+A.+Macapinlacauthor=W.+Hittelmanauthor=M.+A.+Velascoauthor=S.+Patelauthor=M.+A.+Burgessauthor=R.+S.+Benjaminauthor=M.+L.+Frazier&title=A+missense+mutation+in+KIT+kinase+domain+1+correlates+with+imatinib+resistance+in+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%2BL.%26aulast%3DTrent%26aufirst%3DJ.%2BC.%26aulast%3DWu%26aufirst%3DE.%2BF.%26aulast%3DFuller%26aufirst%3DG.%2BN.%26aulast%3DRamdas%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DRaymond%26aufirst%3DA.%2BK.%26aulast%3DPrieto%26aufirst%3DV.%2BG.%26aulast%3DOyedeji%26aufirst%3DC.%2BO.%26aulast%3DHunt%26aufirst%3DK.%2BK.%26aulast%3DPollock%26aufirst%3DR.%2BE.%26aulast%3DFeig%26aufirst%3DB.%2BW.%26aulast%3DHayes%26aufirst%3DK.%2BJ.%26aulast%3DChoi%26aufirst%3DH.%26aulast%3DMacapinlac%26aufirst%3DH.%2BA.%26aulast%3DHittelman%26aufirst%3DW.%26aulast%3DVelasco%26aufirst%3DM.%2BA.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DBurgess%26aufirst%3DM.%2BA.%26aulast%3DBenjamin%26aufirst%3DR.%2BS.%26aulast%3DFrazier%26aufirst%3DM.%2BL.%26atitle%3DA%2520missense%2520mutation%2520in%2520KIT%2520kinase%2520domain%25201%2520correlates%2520with%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26issue%3D17%26spage%3D5913%26epage%3D5919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Nishida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishitani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirota, S.</span><span> </span><span class="NLM_article-title">Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">799</span><span class="NLM_x">â</span> <span class="NLM_lpage">804</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1111%2Fj.1349-7006.2008.00727.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18294292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsFyls7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2008&pages=799-804&issue=4&author=T.+Nishidaauthor=T.+Kandaauthor=A.+Nishitaniauthor=T.+Takahashiauthor=K.+Nakajimaauthor=T.+Ishikawaauthor=S.+Hirota&title=Secondary+mutations+in+the+kinase+domain+of+the+KIT+gene+are+predominant+in+imatinib-resistant+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor</span></div><div class="casAuthors">Nishida, Toshirou; Kanda, Tatsuo; Nishitani, Akiko; Takahashi, Tsuyoshi; Nakajima, Kiyokazu; Ishikawa, Takashi; Hirota, Seiichi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">799-804</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">Although imatinib showed high activity for advanced gastrointestinal stromal tumor (GIST) and improved the prognosis of GIST patients, resistance to the drug appears with prolonged use.  Mechanisms of acquired resistance are still under investigation.  In the present study, the authors carried out histol. and genetic anal. of 45 secondary resistant lesions obtained from 25 Japanese GIST patients treated with imatinib.  All resistant lesions showed viable tumor cells expressing KIT protein, whereas imatinib-sensitive lesions did not.  All pre-imatinib samples have KIT mutations either in exon 9 (n = 3) or exon 11 (n = 22), identified in the KIT gene of corresponding resistant tumors.  In addn. to primary mutations, 33 out of 45 tumors (73%) showed secondary KIT mutations in the kinase domain of the KIT gene.  Secondary mutations are missense mutations and are mostly located in the kinase domains of the same allele to the primary mutations (cis-position).  Resistant lesions showed monoclonal development of tumor cells.  Taken together, addnl. cis-positioned mutations in the kinase domains are a major cause of secondary resistance to imatinib in Japanese GIST patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7QYQriMQeU7Vg90H21EOLACvtfcHk0lgVzfddkcLCdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsFyls7w%253D&md5=5b18ed82560702b3b9b2111149d8e44a</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.00727.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.00727.x%26sid%3Dliteratum%253Aachs%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DKanda%26aufirst%3DT.%26aulast%3DNishitani%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DNakajima%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DHirota%26aufirst%3DS.%26atitle%3DSecondary%2520mutations%2520in%2520the%2520kinase%2520domain%2520of%2520the%2520KIT%2520gene%2520are%2520predominant%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DCancer%2520Sci.%26date%3D2008%26volume%3D99%26issue%3D4%26spage%3D799%26epage%3D804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Wardelmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkelbach-Bruse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pauls, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speidel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BÃ¼ttner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bihl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leutner, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinicke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohenberger, P.</span><span> </span><span class="NLM_article-title">Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">249</span><span class="NLM_x">â</span> <span class="NLM_lpage">251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS1470-2045%2805%2970097-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15811621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlWjtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=249-251&issue=4&author=E.+Wardelmannauthor=N.+Thomasauthor=S.+Merkelbach-Bruseauthor=K.+Paulsauthor=N.+Speidelauthor=R.+B%C3%BCttnerauthor=H.+Bihlauthor=C.+C.+Leutnerauthor=T.+Heinickeauthor=P.+Hohenberger&title=Acquired+resistance+to+imatinib+in+gastrointestinal+stromal+tumours+caused+by+multiple+KIT+mutations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations</span></div><div class="casAuthors">Wardelmann, Eva; Thomas, Nadja; Merkelbach-Bruse, Sabine; Pauls, Katharina; Speidel, Nicola; Buettner, Reinhard; Bihl, Heiner; Leutner, Claudia C.; Heinicke, Thomas; Hohenberger, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">249-251</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The acquired imatinib resistance in two patients with gastrointestinal stromal tumors is discussed.  The study showed that imatinib treatment of gastrointestinal stromal tumors might lead to secondary resistance because of newly acquired KIT mutations affecting different synchronous codons and exons in different tumor manifestations of the same patient.  More studies on the heterogeneity of acquired KIT mutations are needed to improve understanding of the biol. of metastatic lesions of gastrointestinal stromal tumors during imatinib treatment.  Results might affect the development of alternate therapeutic strategies in patients with progressive gastrointestinal stromal tumors.  Strategies might include surgical resection of single, progressive lesions as well as introduction of new mol.-targeted substances such as SU11248, another multitargeted tyrosine kinase-inhibitor that might overcome imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnW8mBAlLQc7Vg90H21EOLACvtfcHk0ljsW54sY1hYJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlWjtLY%253D&md5=1d30e96167153da54cd9388ce440b9ba</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2805%2970097-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252805%252970097-8%26sid%3Dliteratum%253Aachs%26aulast%3DWardelmann%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DN.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DPauls%26aufirst%3DK.%26aulast%3DSpeidel%26aufirst%3DN.%26aulast%3DB%25C3%25BCttner%26aufirst%3DR.%26aulast%3DBihl%26aufirst%3DH.%26aulast%3DLeutner%26aufirst%3DC.%2BC.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DHohenberger%26aufirst%3DP.%26atitle%3DAcquired%2520resistance%2520to%2520imatinib%2520in%2520gastrointestinal%2520stromal%2520tumours%2520caused%2520by%2520multiple%2520KIT%2520mutations%26jtitle%3DLancet%2520Oncol.%26date%3D2005%26volume%3D6%26issue%3D4%26spage%3D249%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Bickenbach, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcox, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veerapong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindler, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posner, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noffsinger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roggin, K. K.</span><span> </span><span class="NLM_article-title">A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy</span> <span class="citation_source-journal">J. Gastrointest. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">758</span><span class="NLM_x">â</span> <span class="NLM_lpage">766</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1007%2Fs11605-007-0150-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17417711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A280%3ADC%252BD2szkslOhsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=758-766&issue=6&author=K.+Bickenbachauthor=R.+Wilcoxauthor=J.+Veerapongauthor=H.+L.+Kindlerauthor=M.+C.+Posnerauthor=A.+Noffsingerauthor=K.+K.+Roggin&title=A+review+of+resistance+patterns+and+phenotypic+changes+in+gastrointestinal+stromal+tumors+following+imatinib+mesylate+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy</span></div><div class="casAuthors">Bickenbach Kai; Wilcox Rebecca; Veerapong Jula; Kindler Hedy Lee; Posner Mitchell C; Noffsinger Amy; Roggin Kevin King</div><div class="citationInfo"><span class="NLM_cas:title">Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">758-66</span>
        ISSN:<span class="NLM_cas:issn">1091-255X</span>.
    </div><div class="casAbstract">Gastrointestinal stromal tumors are neoplastic lesions that arise from the interstitial cells of Cajal and are associated with somatic mutations in the tyrosine kinase receptor, KIT.  The only known curative therapy is complete surgical resection.  Unfortunately, postsurgical recurrence rates exceed 50% and most tumors are resistant to standard chemotherapy and radiation.  Imatinib mesylate, a novel tyrosine kinase inhibitor, holds promise as a potential adjuvant therapy to prevent recurrence and improve long-term survival.  However, as resistance data emerge, it appears that a potential "escape pathway" may originate from secondary mutations in the KIT receptor.  This paper reviews the historical clinical experience with imatinib mesylate and discusses resistance patterns following targeted therapy.  We highlight this review with an interesting case report that illustrates unique phenotypic tumoral changes associated with imatinib mesylate resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsZ3-xUqAauq-9TkgmBqTqfW6udTcc2eZltex6_kppILntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szkslOhsA%253D%253D&md5=1c343754f90366f8931ecab054ffcd28</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1007%2Fs11605-007-0150-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11605-007-0150-y%26sid%3Dliteratum%253Aachs%26aulast%3DBickenbach%26aufirst%3DK.%26aulast%3DWilcox%26aufirst%3DR.%26aulast%3DVeerapong%26aufirst%3DJ.%26aulast%3DKindler%26aufirst%3DH.%2BL.%26aulast%3DPosner%26aufirst%3DM.%2BC.%26aulast%3DNoffsinger%26aufirst%3DA.%26aulast%3DRoggin%26aufirst%3DK.%2BK.%26atitle%3DA%2520review%2520of%2520resistance%2520patterns%2520and%2520phenotypic%2520changes%2520in%2520gastrointestinal%2520stromal%2520tumors%2520following%2520imatinib%2520mesylate%2520therapy%26jtitle%3DJ.%2520Gastrointest.%2520Surg.%26date%3D2007%26volume%3D11%26issue%3D6%26spage%3D758%26epage%3D766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Guo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agaram, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAdamo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMatteo, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">16</span><span class="NLM_x">) </span> <span class="NLM_fpage">4874</span><span class="NLM_x">â</span> <span class="NLM_lpage">4881</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1158%2F1078-0432.CCR-07-0484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17699867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4874-4881&issue=16&author=T.+Guoauthor=N.+P.+Agaramauthor=G.+C.+Wongauthor=G.+Homauthor=D.+D%E2%80%99Adamoauthor=R.+G.+Makiauthor=G.+K.+Schwartzauthor=D.+Veachauthor=B.+D.+Clarksonauthor=S.+Singerauthor=R.+P.+DeMatteoauthor=P.+Besmerauthor=C.+R.+Antonescu&title=Sorafenib+inhibits+the+imatinib-resistant+KITT670I+gatekeeper+mutation+in+gastrointestinal+stromal+tumor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor</span></div><div class="casAuthors">Guo, Tianhua; Agaram, Narasimhan P.; Wong, Grace C.; Hom, Glory; D'Adamo, David; Maki, Robert G.; Schwartz, Gary K.; Veach, Darren; Clarkson, Bayard D.; Singer, Samuel; DeMatteo, Ronald P.; Besmer, Peter; Antonescu, Cristina R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4874-4881</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Resistance is commonly acquired in patients with metastatic gastrointestinal stromal tumor who are treated with imatinib mesylate, often due to the development of secondary mutations in the KIT kinase domain.  We sought to investigate the efficacy of second-line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and nilotinib, against the commonly obsd. imatinib-resistant KIT mutations (KITV654A, KITT670I, KITD820Y, and KITN822K) expressed in the Ba/F3 cellular system.  EXPTL. DESIGN: In vitro drug screening of stable Ba/F3 KIT mutants recapitulating the genotype of imatinib-resistant patients harboring primary and secondary KIT mutations was investigated.  Comparison was made to imatinib-sensitive Ba/F3 KIT mutant cells as well as Ba/F3 cells expressing only secondary KIT mutations.  The efficacy of drug treatment was evaluated by proliferation and apoptosis assays, in addn. to biochem. inhibition of KIT activation.  RESULTS: Sorafenib was potent against all imatinib-resistant Ba/F3 KIT double mutants tested, including the gatekeeper secondary mutation KITWK557-8del/T670I, which was resistant to other kinase inhibitors.  Although all three drugs tested decreased cell proliferation and inhibited KIT activation against exon 13 (KITV560del/V654A) and exon 17 (KITV559D/D820Y) double mutants, nilotinib did so at lower concns.  CONCLUSIONS: Our results emphasize the need for tailored salvage therapy in imatinib-refractory gastrointestinal stromal tumors according to individual mol. mechanisms of resistance.  The Ba/F3 KITWK557-8del/T670I cells were sensitive only to sorafenib inhibition, whereas nilotinib was more potent on imatinib-resistant KITV560del/V654A and KITV559D/D820Y mutant cells than dasatinib and sorafenib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqllTJoDeevKbVg90H21EOLACvtfcHk0ljsW54sY1hYJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGmtLw%253D&md5=f1643671ada85f1bcd05faa04cd88b52</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0484%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DAgaram%26aufirst%3DN.%2BP.%26aulast%3DWong%26aufirst%3DG.%2BC.%26aulast%3DHom%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DClarkson%26aufirst%3DB.%2BD.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DDeMatteo%26aufirst%3DR.%2BP.%26aulast%3DBesmer%26aufirst%3DP.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DSorafenib%2520inhibits%2520the%2520imatinib-resistant%2520KITT670I%2520gatekeeper%2520mutation%2520in%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26issue%3D16%26spage%3D4874%26epage%3D4881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Nagata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worobec, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdhury, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannenbaum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, D. D.</span><span> </span><span class="NLM_article-title">Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">10560</span><span class="NLM_x">â</span> <span class="NLM_lpage">10564</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=10560-10564&issue=23&author=H.+Nagataauthor=A.+S.+Worobecauthor=C.+K.+Ohauthor=B.+A.+Chowdhuryauthor=S.+Tannenbaumauthor=Y.+Suzukiauthor=D.+D.+Metcalfe&title=Identification+of+a+point+mutation+in+the+catalytic+domain+of+the+protooncogene+c-kit+in+peripheral+blood+mononuclear+cells+of+patients+who+have+mastocytosis+with+an+associated+hematologic+disorder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagata%26aufirst%3DH.%26aulast%3DWorobec%26aufirst%3DA.%2BS.%26aulast%3DOh%26aufirst%3DC.%2BK.%26aulast%3DChowdhury%26aufirst%3DB.%2BA.%26aulast%3DTannenbaum%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26atitle%3DIdentification%2520of%2520a%2520point%2520mutation%2520in%2520the%2520catalytic%2520domain%2520of%2520the%2520protooncogene%2520c-kit%2520in%2520peripheral%2520blood%2520mononuclear%2520cells%2520of%2520patients%2520who%2520have%2520mastocytosis%2520with%2520an%2520associated%2520hematologic%2520disorder%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1995%26volume%3D92%26issue%3D23%26spage%3D10560%26epage%3D10564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanning, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">561</span><span class="NLM_x">â</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnm0596-561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=8616716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1996&pages=561-566&issue=5&author=B.+J.+Drukerauthor=S.+Tamuraauthor=E.+Buchdungerauthor=S.+Ohnoauthor=G.+M.+Segalauthor=S.+Fanningauthor=J.+Zimmermannauthor=N.+B.+Lydon&title=Effects+of+a+selective+inhibitor+of+the+Abl+tyrosine+kinase+on+the+growth+of+Bcr-Abl+positive+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</span></div><div class="casAuthors">Druker, Brian J.; Tamura, Shu; Buchdunger, Elisabeth; Ohno, Sayuri; Segal, Gerald M.; Fanning, Shane; Zimmermann, Jurg; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">The Bcr-Abl oncogene, present in 95% of patients with chronic myelogenous leukemia (CML), has been implicated as the cause of this disease.  A compd., designed to inhibit the Abl protein tyrosine kinase (CGP 57148), was evaluated for its effects on cells contg. the Bcr-Abl fusion protein.  Cellular proliferation and tumor formation by Bcr-Abl-expressing cells were specifically inhibited by this compd.  In colony-forming assays of peripheral blood or bone marrow from patients with CML, there was a 92-98% decrease in the no. of Bcr-Abl colonies formed but no inhibition of normal colony formation.  This compd. may be useful in the treatment of Bcr-Abl-pos. leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjzXj-25AHOrVg90H21EOLACvtfcHk0lgqEoo6I9PyLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xislyhs70%253D&md5=1dc111cc883a1ed29964ae2c88c88cb9</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnm0596-561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0596-561%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTamura%26aufirst%3DS.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DSegal%26aufirst%3DG.%2BM.%26aulast%3DFanning%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DEffects%2520of%2520a%2520selective%2520inhibitor%2520of%2520the%2520Abl%2520tyrosine%2520kinase%2520on%2520the%2520growth%2520of%2520Bcr-Abl%2520positive%2520cells%26jtitle%3DNat.%2520Med.%26date%3D1996%26volume%3D2%26issue%3D5%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cioffi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno-Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Abl proteinâtyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">139</span><span class="NLM_x">â</span> <span class="NLM_lpage">145</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=10991971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnt1ygur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2000&pages=139-145&issue=1&author=E.+Buchdungerauthor=C.+L.+Cioffiauthor=N.+Lawauthor=D.+Stoverauthor=S.+Ohno-Jonesauthor=B.+J.+Drukerauthor=N.+B.+Lydon&title=Abl+protein%E2%88%92tyrosine+kinase+inhibitor+STI571+inhibits+in+vitro+signal+transduction+mediated+by+c-kit+and+platelet-derived+growth+factor+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors</span></div><div class="casAuthors">Buchdunger, Elisabeth; Cioffi, Catherine L.; Law, Norman; Stover, David; Ohno-Jones, Sayuri; Druker, Brian J.; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">139-145</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">STI571 (formerly known as CGP 57148B) is a protein-tyrosine kinase inhibitor that is currently in clin. trials for the treatment of chronic myelogenous leukemia.  STI571 selectively inhibits the Abl and platelet-derived growth factor (PDGF) receptor tyrosine kinases in vitro and blocks cellular proliferation and tumor growth of Bcr-abl- or v-abl-expressing cells.  We have further investigated the profile of STI571 against related receptor tyrosine kinases.  STI571 was found to potently inhibit the kinase activity of the Î±- and Î²-PDGF receptors and the receptor for stem cell factor, but not the closely related c-Fms, Flt-3, Kdr, Flt-1, and Tek tyrosine kinases.  Addnl., no inhibition of c-Met or nonreceptor tyrosine kinases such as Src and Jak-2 has been obsd.  In cell-based assays, STI571 selectively inhibited PDGF and stem cell factor-mediated cellular signaling, including ligand-stimulated receptor autophosphorylation, inositol phosphate formation, and mitogen-activated protein kinase activation and proliferation.  These results expand the profile of STI571 and suggest that in addn. to chronic myelogenous leukemia, STI571 may have clin. potential in the treatment of diseases that involve abnormal activation of c-Kit or PDGF receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogymen0UOTarVg90H21EOLACvtfcHk0lgqEoo6I9PyLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnt1ygur4%253D&md5=b15a49df360ae0d00c34f7cc5d3b0fe8</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCioffi%26aufirst%3DC.%2BL.%26aulast%3DLaw%26aufirst%3DN.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DOhno-Jones%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DAbl%2520protein%25E2%2588%2592tyrosine%2520kinase%2520inhibitor%2520STI571%2520inhibits%2520in%2520vitro%2520signal%2520transduction%2520mediated%2520by%2520c-kit%2520and%2520platelet-derived%2520growth%2520factor%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D295%26issue%3D1%26spage%3D139%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Shimizu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâBrien, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjoblom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietras, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heldin, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumanski, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostman, A.</span><span> </span><span class="NLM_article-title">The dermatofibrosarcoma protuberans-associated collagen type IÎ±1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x"> (</span><span class="NLM_issue">15</span><span class="NLM_x">) </span> <span class="NLM_fpage">3719</span><span class="NLM_x">â</span> <span class="NLM_lpage">3723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=3719-3723&issue=15&author=A.+Shimizuauthor=K.+P.+O%E2%80%99Brienauthor=T.+Sjoblomauthor=K.+Pietrasauthor=E.+Buchdungerauthor=V.+P.+Collinsauthor=C.-H.+Heldinauthor=J.+P.+Dumanskiauthor=A.+Ostman&title=The+dermatofibrosarcoma+protuberans-associated+collagen+type+I%CE%B11%2Fplatelet-derived+growth+factor+%28PDGF%29+B-chain+fusion+gene+generates+a+transforming+protein+that+is+processed+to+functional+PDGF-BB"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShimizu%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%2BP.%26aulast%3DSjoblom%26aufirst%3DT.%26aulast%3DPietras%26aufirst%3DK.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCollins%26aufirst%3DV.%2BP.%26aulast%3DHeldin%26aufirst%3DC.-H.%26aulast%3DDumanski%26aufirst%3DJ.%2BP.%26aulast%3DOstman%26aufirst%3DA.%26atitle%3DThe%2520dermatofibrosarcoma%2520protuberans-associated%2520collagen%2520type%2520I%25CE%25B11%252Fplatelet-derived%2520growth%2520factor%2520%2528PDGF%2529%2520B-chain%2520fusion%2520gene%2520generates%2520a%2520transforming%2520protein%2520that%2520is%2520processed%2520to%2520functional%2520PDGF-BB%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26issue%3D15%26spage%3D3719%26epage%3D3723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Simon, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedeutour, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirvent, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosgeorge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minoletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coindre, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terrier-Lacombe, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandahl, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craver, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sozzi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turc-Carel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâBrien, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kedra, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fransson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilbaud, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumanski, J. P.</span><span> </span><span class="NLM_article-title">Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">95</span><span class="NLM_x">â</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fng0197-95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=8988177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFGksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1997&pages=95-98&issue=1&author=M.+P.+Simonauthor=F.+Pedeutourauthor=N.+Sirventauthor=J.+Grosgeorgeauthor=F.+Minolettiauthor=J.+M.+Coindreauthor=M.+J.+Terrier-Lacombeauthor=N.+Mandahlauthor=R.+D.+Craverauthor=N.+Blinauthor=G.+Sozziauthor=C.+Turc-Carelauthor=K.+P.+O%E2%80%99Brienauthor=D.+Kedraauthor=I.+Franssonauthor=C.+Guilbaudauthor=J.+P.+Dumanski&title=Deregulation+of+the+platelet-derived+growth+factor+B-chain+gene+via+fusion+with+collagen+gene+COL1A1+in+dermatofibrosarcoma+protuberans+and+giant-cell+fibroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma</span></div><div class="casAuthors">Simon, Marie-Pierre; Pedeutour, Florence; Sirvent, Nicolas; Grosgeorge, Josiane; Minoletti, Fabiola; Coindre, Jean-Michel; Terrier-Lacombe, Marie-Jose; Mandahl, Nils; Craver, Randall D.; Blin, Nikolaus; Sozzi, Gabriella; Turc-Carel, Claude; O'Brien, Kevin P.; Kedra, Darek; Fransson, Ingegerd; Guilbaud, Cecille; Dumanski, Jan P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-98</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Dermatofibrosarcoma protuberans (DP), an infiltrative skin tumor of intermediate malignancy, presents specific features such as reciprocal translocations t(17;22)(q22;q13) and supernumerary ring chromosomes derived from the t(17;22).  In this report, the breakpoints from translocations and rings in DP and its juvenile form, giant cell fibroblastoma (GCF), were characterized on the genomic and RNA level.  These rearrangements fuse the platelet-derived growth factor B-chain (PDGFB, c-sis proto-oncogene) and the collagen type I Î±1 (COL1A1) genes.  PDGFB has transforming activity and is a potent mitogen for a no. of cell types, but its role in oncogenic processes is not fully understood.  COL1A1 is major constituent of the connective tissue matrix.  Neither PDGFB nor COL1A1 have so far been implicated in any tumor translocations.  These gene fusions delete exon 1 of PDGFB, and release this growth factor from its normal regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6UEUQtHNyobVg90H21EOLACvtfcHk0lgAX7uTPK1kzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFGksg%253D%253D&md5=72435d32b5bfc28567d91488f9c5767a</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fng0197-95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0197-95%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DM.%2BP.%26aulast%3DPedeutour%26aufirst%3DF.%26aulast%3DSirvent%26aufirst%3DN.%26aulast%3DGrosgeorge%26aufirst%3DJ.%26aulast%3DMinoletti%26aufirst%3DF.%26aulast%3DCoindre%26aufirst%3DJ.%2BM.%26aulast%3DTerrier-Lacombe%26aufirst%3DM.%2BJ.%26aulast%3DMandahl%26aufirst%3DN.%26aulast%3DCraver%26aufirst%3DR.%2BD.%26aulast%3DBlin%26aufirst%3DN.%26aulast%3DSozzi%26aufirst%3DG.%26aulast%3DTurc-Carel%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DK.%2BP.%26aulast%3DKedra%26aufirst%3DD.%26aulast%3DFransson%26aufirst%3DI.%26aulast%3DGuilbaud%26aufirst%3DC.%26aulast%3DDumanski%26aufirst%3DJ.%2BP.%26atitle%3DDeregulation%2520of%2520the%2520platelet-derived%2520growth%2520factor%2520B-chain%2520gene%2520via%2520fusion%2520with%2520collagen%2520gene%2520COL1A1%2520in%2520dermatofibrosarcoma%2520protuberans%2520and%2520giant-cell%2520fibroblastoma%26jtitle%3DNat.%2520Genet.%26date%3D1997%26volume%3D15%26issue%3D1%26spage%3D95%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Sjoblom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boureux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronnstrand, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heldin, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghysdael, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ostman, A.</span><span> </span><span class="NLM_article-title">Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">50</span><span class="NLM_x">) </span> <span class="NLM_fpage">7055</span><span class="NLM_x">â</span> <span class="NLM_lpage">7062</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1999&pages=7055-7062&issue=50&author=T.+Sjoblomauthor=A.+Boureuxauthor=L.+Ronnstrandauthor=C.+H.+Heldinauthor=J.+Ghysdaelauthor=A.+Ostman&title=Characterization+of+the+chronic+myelomonocytic+leukemia+associated+TEL-PDGF+beta+R+fusion+protein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSjoblom%26aufirst%3DT.%26aulast%3DBoureux%26aufirst%3DA.%26aulast%3DRonnstrand%26aufirst%3DL.%26aulast%3DHeldin%26aufirst%3DC.%2BH.%26aulast%3DGhysdael%26aufirst%3DJ.%26aulast%3DOstman%26aufirst%3DA.%26atitle%3DCharacterization%2520of%2520the%2520chronic%2520myelomonocytic%2520leukemia%2520associated%2520TEL-PDGF%2520beta%2520R%2520fusion%2520protein%26jtitle%3DOncogene%26date%3D1999%26volume%3D18%26issue%3D50%26spage%3D7055%26epage%3D7062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Jousset, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boureux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quang, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oury, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusanter-Fourt, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghysdael, J.</span><span> </span><span class="NLM_article-title">A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">69</span><span class="NLM_x">â</span> <span class="NLM_lpage">82</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=69-82&issue=1&author=C.+Joussetauthor=C.+Carronauthor=A.+Boureuxauthor=C.+T.+Quangauthor=C.+Ouryauthor=I.+Dusanter-Fourtauthor=M.+Charonauthor=J.+Levinauthor=O.+Bernardauthor=J.+Ghysdael&title=A+domain+of+TEL+conserved+in+a+subset+of+ETS+proteins+defines+a+specific+oligomerization+interface+essential+to+the+mitogenic+properties+of+the+TEL-PDGFR+beta+oncoprotein"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJousset%26aufirst%3DC.%26aulast%3DCarron%26aufirst%3DC.%26aulast%3DBoureux%26aufirst%3DA.%26aulast%3DQuang%26aufirst%3DC.%2BT.%26aulast%3DOury%26aufirst%3DC.%26aulast%3DDusanter-Fourt%26aufirst%3DI.%26aulast%3DCharon%26aufirst%3DM.%26aulast%3DLevin%26aufirst%3DJ.%26aulast%3DBernard%26aufirst%3DO.%26aulast%3DGhysdael%26aufirst%3DJ.%26atitle%3DA%2520domain%2520of%2520TEL%2520conserved%2520in%2520a%2520subset%2520of%2520ETS%2520proteins%2520defines%2520a%2520specific%2520oligomerization%2520interface%2520essential%2520to%2520the%2520mitogenic%2520properties%2520of%2520the%2520TEL-PDGFR%2520beta%2520oncoprotein%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26issue%3D1%26spage%3D69%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Apperley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardembas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melo, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell-Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chase, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chessells, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombat, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearden, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahon, F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolova, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olavarria, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultheis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. M.</span><span> </span><span class="NLM_article-title">Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">481</span><span class="NLM_x">â</span> <span class="NLM_lpage">487</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMoa020150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12181402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=481-487&issue=7&author=J.+F.+Apperleyauthor=M.+Gardembasauthor=J.+V.+Meloauthor=R.+Russell-Jonesauthor=B.+J.+Bainauthor=E.+J.+Baxterauthor=A.+Chaseauthor=J.+M.+Chessellsauthor=M.+Colombatauthor=C.+E.+Deardenauthor=S.+Dimitrijevicauthor=F.+X.+Mahonauthor=D.+Marinauthor=Z.+Nikolovaauthor=E.+Olavarriaauthor=S.+Silbermanauthor=B.+Schultheisauthor=N.+C.+Crossauthor=J.+M.+Goldman&title=Response+to+imatinib+mesylate+in+patients+with+chronic+myeloproliferative+diseases+with+rearrangements+of+the+platelet-derived+growth+factor+receptor+beta"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta</span></div><div class="casAuthors">Apperley, Jane F.; Gardembas, Martine; Melo, Junia V.; Russell-Jones, Robin; Bain, Barbara J.; Baxter, E. Joanna; Chase, Andrew; Chessells, Judith M.; Colombat, Marie; Dearden, Claire E.; Dimitrijevic, Sasa; Mahon, Francois-X.; Marin, David; Nikolova, Zariana; Olavarria, Eduardo; Silberman, Sandra; Schultheis, Beate; Cross, Nicholas C. P.; Goldman, John M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">481-487</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A small proportion of patients with chronic myeloproliferative diseases have constitutive activation of the gene for platelet-derived growth factor receptor beta (PDGFRB), which encodes a receptor tyrosine kinase.  The gene is located on chromosome 5q33, and the activation is usually caused by a t(5;12)(q33;p13) translocation assocd. with an ETV6-PDGFRB fusion gene.  The tyrosine kinase inhibitor imatinib mesylate specifically inhibits ABL, PDGFR, and KIT kinases and has impressive clin. efficacy in BCR-ABL-pos. chronic myeloid leukemia.  We treated four patients who had chronic myeloproliferative diseases and chromosomal translocations involving 5q33 with imatinib mesylate (400 mg daily).  Three of the four patients presented with leukocytosis and eosinophilia; their leukemia cells carried the ETV6-PDGFRB fusion gene.  The fourth patient had leukocytosis, eosinophilia, and a t(5;12) translocation involving PDGFRB and an unknown partner gene; he also had extensive raised, ulcerated skin lesions that had been present for a long time.  In all four patients, a normal blood count was achieved within four weeks after treatment began.  In the patient with skin disease, the lesions began to resolve shortly after treatment began.  The t(5;12) translocation was undetectable by 12 wk in three patients and by 36 wk in the fourth patient.  In the three patients with the ETV6-PDGFRB fusion gene, the transcript level decreased, and in one patient, it became undetectable by 36 wk.  All responses were durable at 9 to 12 mo of follow-up.  Imatinib mesylate induces durable responses in patients with chronic myeloproliferative diseases assocd. with activation of PDGFRB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEEKR95RMc8bVg90H21EOLACvtfcHk0lgAX7uTPK1kzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7g%253D&md5=2c03b388677f674f278544d6e9aa0698</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020150%26sid%3Dliteratum%253Aachs%26aulast%3DApperley%26aufirst%3DJ.%2BF.%26aulast%3DGardembas%26aufirst%3DM.%26aulast%3DMelo%26aufirst%3DJ.%2BV.%26aulast%3DRussell-Jones%26aufirst%3DR.%26aulast%3DBain%26aufirst%3DB.%2BJ.%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DChase%26aufirst%3DA.%26aulast%3DChessells%26aufirst%3DJ.%2BM.%26aulast%3DColombat%26aufirst%3DM.%26aulast%3DDearden%26aufirst%3DC.%2BE.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DMahon%26aufirst%3DF.%2BX.%26aulast%3DMarin%26aufirst%3DD.%26aulast%3DNikolova%26aufirst%3DZ.%26aulast%3DOlavarria%26aufirst%3DE.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DSchultheis%26aufirst%3DB.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DGoldman%26aufirst%3DJ.%2BM.%26atitle%3DResponse%2520to%2520imatinib%2520mesylate%2520in%2520patients%2520with%2520chronic%2520myeloproliferative%2520diseases%2520with%2520rearrangements%2520of%2520the%2520platelet-derived%2520growth%2520factor%2520receptor%2520beta%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26issue%3D7%26spage%3D481%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awan, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixon, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhanwar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C. R.</span><span> </span><span class="NLM_article-title">Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">623</span><span class="NLM_x">â</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1002%2Fijc.10535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12209598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFKhu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=623-626&issue=6&author=R.+G.+Makiauthor=R.+A.+Awanauthor=R.+H.+Dixonauthor=S.+Jhanwarauthor=C.+R.+Antonescu&title=Differential+sensitivity+to+imatinib+of+2+patients+with+metastatic+sarcoma+arising+from+dermatofibrosarcoma+protuberans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans</span></div><div class="casAuthors">Maki, Robert G.; Awan, Rashid A.; Dixon, Richard H.; Jhanwar, Suresh; Antonescu, Cristina R.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">623-626</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Dermatofibrosarcoma protuberans (DFSP) is a rare superficial sarcoma usually affecting the trunk, with significant risk of local recurrence.  It is characterized by the presence of ring chromosomes or chromosomal translocations fusing the promoter of the collagen gene COLIAI to the platelet-derived growth factor Î²-chain gene PDGFB, increasing the prodn. of PDGF locally and promoting autocrine or paracrine tumor growth.  Fewer than 5% of patients with DFSP develop metastatic sarcoma, with a poor subsequent prognosis.  Imatinib (STI-571) was developed as an inhibitor of the PDGF receptor tyrosine kinase and has proven clin. activity against chronic myelogenous leukemia (expressing bcr-abl) and gastrointestinal stromal tumors (expressing c-kit).  We describe 2 patients with metastatic and unresectable metastases from DFSP treated with imatinib.  After confirmation of neg. CD117 status of 2 sarcomas arising from DFSP, patients were given imatinib 400 mg po qd and assessed at regular intervals for their tolerance and response to therapy.  One patient had a transient response, then progressed rapidly and died of disease.  Another patient showed a partial response to therapy after 2 mo, with resoln. of superior vena cava syndrome and shrinking of metastatic lung lesions.  His response is ongoing after 6 mo of therapy.  These clin. data confirm findings from models of DFSP and support the use of imatinib in the rare setting of metastatic DFSP.  Imatinib may be useful for patients with locally advanced DFSP, when other options for local therapy are limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlU-Gnkx4EW7Vg90H21EOLACvtfcHk0lj0RN8qMkoX1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFKhu70%253D&md5=1efca6a46aa9fb897ad05997f8e41d55</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1002%2Fijc.10535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10535%26sid%3Dliteratum%253Aachs%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DAwan%26aufirst%3DR.%2BA.%26aulast%3DDixon%26aufirst%3DR.%2BH.%26aulast%3DJhanwar%26aufirst%3DS.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26atitle%3DDifferential%2520sensitivity%2520to%2520imatinib%2520of%25202%2520patients%2520with%2520metastatic%2520sarcoma%2520arising%2520from%2520dermatofibrosarcoma%2520protuberans%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D100%26issue%3D6%26spage%3D623%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Rubin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuetze, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eary, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norwood, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conrad, E. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruckner, J. D.</span><span> </span><span class="NLM_article-title">Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">3586</span><span class="NLM_x">â</span> <span class="NLM_lpage">3591</span><div class="note"><p class="first last">[see Comment]</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1200%2FJCO.2002.01.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12202658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVynsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=3586-3591&issue=17&author=B.+P.+Rubinauthor=S.+M.+Schuetzeauthor=J.+F.+Earyauthor=T.+H.+Norwoodauthor=S.+Mirzaauthor=E.+U.+Conradauthor=J.+D.+Bruckner&title=Molecular+targeting+of+platelet-derived+growth+factor+B+by+imatinib+mesylate+in+a+patient+with+metastatic+dermatofibrosarcoma+protuberans"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Targeting of Platelet-Derived Growth Factor B by Imatinib Mesylate in a Patient With Metastatic Dermatofibrosarcoma Protuberans</span></div><div class="casAuthors">Rubin, Brian P.; Schuetze, Scott M.; Eary, Janet F.; Norwood, Thomas H.; Mirza, Sohail; Conrad, Ernest U.; Bruckner, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3586-3591</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Dermatofibrosarcoma protuberans is caused by activation of the platelet-derived growth factor B (PDGFB) receptor, a transmembrane tyrosine kinase.  We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate.  A patient with unresectable, metastatic dermatofibrosarcoma protuberans received imatinib mesylate (400 mg bid).  Response to therapy was assessed by [18F]fluorodeoxyglucose (FDG) positron emission tomog., magnetic, resonance imaging, and histopathol. and immunohistochem. evaluation.  The patient was treated for 4 mo with imatinib mesylate.  The hypermetabolic uptake of FDG fell to background levels within 2 wk of treatment, and the tumor vol. shrank by over 75% during the 4 mo of therapy, allowing for resection of the mass.  There was no residual viable tumor in the resected specimen, indicating a complete histol. response to treatment with imatinib mesylate.  Thus, imatinib mesylate is highly active in dermatofibrosarcoma protuberans.  The dramatic response seen in this patient demonstrates that inhibition of PDGFB receptor tyrosine kinase activity can significantly impact viability of at least one type of solid tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTXFGgToc-cbVg90H21EOLACvtfcHk0lj0RN8qMkoX1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVynsr8%253D&md5=578d0d1487ba94e613492c71c0d70ad0</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.01.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.01.027%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DSchuetze%26aufirst%3DS.%2BM.%26aulast%3DEary%26aufirst%3DJ.%2BF.%26aulast%3DNorwood%26aufirst%3DT.%2BH.%26aulast%3DMirza%26aufirst%3DS.%26aulast%3DConrad%26aufirst%3DE.%2BU.%26aulast%3DBruckner%26aufirst%3DJ.%2BD.%26atitle%3DMolecular%2520targeting%2520of%2520platelet-derived%2520growth%2520factor%2520B%2520by%2520imatinib%2520mesylate%2520in%2520a%2520patient%2520with%2520metastatic%2520dermatofibrosarcoma%2520protuberans%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26issue%3D17%26spage%3D3586%26epage%3D3591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Baccarani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cilloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaviani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merante, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiribelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buccisano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testoni, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vivo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giugliano, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacobucci, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soverini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rancati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astolfi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pane, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span> </span><span class="NLM_article-title">The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study</span> <span class="citation_source-journal">Haematologica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1173</span><span class="NLM_x">â</span> <span class="NLM_lpage">1179</span><div class="note"><p class="first last">[see Comment]</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2007&pages=1173-1179&issue=9&author=M.+Baccaraniauthor=D.+Cilloniauthor=M.+Rondoniauthor=E.+Ottavianiauthor=F.+Messaauthor=S.+Meranteauthor=M.+Tiribelliauthor=F.+Buccisanoauthor=N.+Testoniauthor=E.+Gottardiauthor=A.+de+Vivoauthor=E.+Giuglianoauthor=I.+Iacobucciauthor=S.+Paoliniauthor=S.+Soveriniauthor=G.+Rostiauthor=F.+Rancatiauthor=C.+Astolfiauthor=F.+Paneauthor=G.+Saglioauthor=G.+Martinelli&title=The+efficacy+of+imatinib+mesylate+in+patients+with+FIP1L1-PDGFRalpha-positive+hypereosinophilic+syndrome.+Results+of+a+multicenter+prospective+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaccarani%26aufirst%3DM.%26aulast%3DCilloni%26aufirst%3DD.%26aulast%3DRondoni%26aufirst%3DM.%26aulast%3DOttaviani%26aufirst%3DE.%26aulast%3DMessa%26aufirst%3DF.%26aulast%3DMerante%26aufirst%3DS.%26aulast%3DTiribelli%26aufirst%3DM.%26aulast%3DBuccisano%26aufirst%3DF.%26aulast%3DTestoni%26aufirst%3DN.%26aulast%3DGottardi%26aufirst%3DE.%26aulast%3Dde%2BVivo%26aufirst%3DA.%26aulast%3DGiugliano%26aufirst%3DE.%26aulast%3DIacobucci%26aufirst%3DI.%26aulast%3DPaolini%26aufirst%3DS.%26aulast%3DSoverini%26aufirst%3DS.%26aulast%3DRosti%26aufirst%3DG.%26aulast%3DRancati%26aufirst%3DF.%26aulast%3DAstolfi%26aufirst%3DC.%26aulast%3DPane%26aufirst%3DF.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DMartinelli%26aufirst%3DG.%26atitle%3DThe%2520efficacy%2520of%2520imatinib%2520mesylate%2520in%2520patients%2520with%2520FIP1L1-PDGFRalpha-positive%2520hypereosinophilic%2520syndrome.%2520Results%2520of%2520a%2520multicenter%2520prospective%2520study%26jtitle%3DHaematologica%26date%3D2007%26volume%3D92%26issue%3D9%26spage%3D1173%26epage%3D1179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Jovanovic, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Score, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waghorn, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cilloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottardi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metzgeroth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erben, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popp, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochhaus, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche-Lestienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preudhomme, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apperley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rondoni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaviani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brito-Babapulle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saglio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hehlmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimwade, D.</span><span> </span><span class="NLM_article-title">Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4635</span><span class="NLM_x">â</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=4635-4640&issue=11&author=J.+V.+Jovanovicauthor=J.+Scoreauthor=K.+Waghornauthor=D.+Cilloniauthor=E.+Gottardiauthor=G.+Metzgerothauthor=P.+Erbenauthor=H.+Poppauthor=C.+Walzauthor=A.+Hochhausauthor=C.+Roche-Lestienneauthor=C.+Preudhommeauthor=E.+Solomonauthor=J.+Apperleyauthor=M.+Rondoniauthor=E.+Ottavianiauthor=G.+Martinelliauthor=F.+Brito-Babapulleauthor=G.+Saglioauthor=R.+Hehlmannauthor=N.+C.+Crossauthor=A.+Reiterauthor=D.+Grimwade&title=Low-dose+imatinib+mesylate+leads+to+rapid+induction+of+major+molecular+responses+and+achievement+of+complete+molecular+remission+in+FIP1L1-PDGFRA-positive+chronic+eosinophilic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJovanovic%26aufirst%3DJ.%2BV.%26aulast%3DScore%26aufirst%3DJ.%26aulast%3DWaghorn%26aufirst%3DK.%26aulast%3DCilloni%26aufirst%3DD.%26aulast%3DGottardi%26aufirst%3DE.%26aulast%3DMetzgeroth%26aufirst%3DG.%26aulast%3DErben%26aufirst%3DP.%26aulast%3DPopp%26aufirst%3DH.%26aulast%3DWalz%26aufirst%3DC.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DRoche-Lestienne%26aufirst%3DC.%26aulast%3DPreudhomme%26aufirst%3DC.%26aulast%3DSolomon%26aufirst%3DE.%26aulast%3DApperley%26aufirst%3DJ.%26aulast%3DRondoni%26aufirst%3DM.%26aulast%3DOttaviani%26aufirst%3DE.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DBrito-Babapulle%26aufirst%3DF.%26aulast%3DSaglio%26aufirst%3DG.%26aulast%3DHehlmann%26aufirst%3DR.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DReiter%26aufirst%3DA.%26aulast%3DGrimwade%26aufirst%3DD.%26atitle%3DLow-dose%2520imatinib%2520mesylate%2520leads%2520to%2520rapid%2520induction%2520of%2520major%2520molecular%2520responses%2520and%2520achievement%2520of%2520complete%2520molecular%2520remission%2520in%2520FIP1L1-PDGFRA-positive%2520chronic%2520eosinophilic%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26issue%3D11%26spage%3D4635%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Antoniu, S. A.</span><span> </span><span class="NLM_article-title">Imatinib mesylate for the treatment of hypereosinophilic syndromes</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">980</span><span class="NLM_x">â</span> <span class="NLM_lpage">984</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17117585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlWhtLrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=980-984&issue=11&author=S.+A.+Antoniu&title=Imatinib+mesylate+for+the+treatment+of+hypereosinophilic+syndromes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib mesylate for the treatment of hypereosinophilic syndromes</span></div><div class="casAuthors">Antoniu, Sabina A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (Thomson Scientific)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">980-984</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">1472-4472</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  Hypereosinophilic syndromes (HES) define several distinct entities, all of which show blood and tissue hypereosinophilia and end-organ secondary manifestations.  From a clin. and pathogenic perspective, the best characterized are the myeloproliferative and lymphoproliferative variants.  While there are several therapies available for the treatment of HES, such as corticosteroids, IFNÎ± and cytotoxic agents, there remains a high incidence of side effects and inconsistent efficacy.  Abnormal tyrosine kinase resulting from the FIP1L1-PDGFRA fusion gene is found in many patients with myeloproliferative variant, and is currently best targeted therapeutically with imatinib mesylate, a tyrosine kinase inhibitor.  However, complete hematol. remissions obtained with this compd. in patients without this defect suggest that it could be effective in other subtypes of HES.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp730dr9vDkDLVg90H21EOLACvtfcHk0limRVg_6DIxCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlWhtLrN&md5=4c5bf1e609e1f85a37bb4a2632711f3b</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAntoniu%26aufirst%3DS.%2BA.%26atitle%3DImatinib%2520mesylate%2520for%2520the%2520treatment%2520of%2520hypereosinophilic%2520syndromes%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2006%26volume%3D7%26issue%3D11%26spage%3D980%26epage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ault, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrajoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierda, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rios, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letvak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaled, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">4714</span><span class="NLM_x">â</span> <span class="NLM_lpage">4716</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=4714-4716&issue=12&author=J.+Cortesauthor=P.+Aultauthor=C.+Kollerauthor=D.+Thomasauthor=A.+Ferrajoliauthor=W.+Wierdaauthor=M.+B.+Riosauthor=L.+Letvakauthor=E.+S.+Kaledauthor=H.+Kantarjian&title=Efficacy+of+imatinib+mesylate+in+the+treatment+of+idiopathic+hypereosinophilic+syndrome"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DAult%26aufirst%3DP.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DWierda%26aufirst%3DW.%26aulast%3DRios%26aufirst%3DM.%2BB.%26aulast%3DLetvak%26aufirst%3DL.%26aulast%3DKaled%26aufirst%3DE.%2BS.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DEfficacy%2520of%2520imatinib%2520mesylate%2520in%2520the%2520treatment%2520of%2520idiopathic%2520hypereosinophilic%2520syndrome%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26issue%3D12%26spage%3D4714%26epage%3D4716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porrata, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tazelaar, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witzig, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">3391</span><span class="NLM_x">â</span> <span class="NLM_lpage">3397</span><div class="note"><p class="first last">[see Comment]</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3391-3397&issue=9&author=A.+Pardananiauthor=T.+Reederauthor=L.+F.+Porrataauthor=C.+Y.+Liauthor=H.+D.+Tazelaarauthor=E.+J.+Baxterauthor=T.+E.+Witzigauthor=N.+C.+Crossauthor=A.+Tefferi&title=Imatinib+therapy+for+hypereosinophilic+syndrome+and+other+eosinophilic+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DReeder%26aufirst%3DT.%26aulast%3DPorrata%26aufirst%3DL.%2BF.%26aulast%3DLi%26aufirst%3DC.%2BY.%26aulast%3DTazelaar%26aufirst%3DH.%2BD.%26aulast%3DBaxter%26aufirst%3DE.%2BJ.%26aulast%3DWitzig%26aufirst%3DT.%2BE.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DImatinib%2520therapy%2520for%2520hypereosinophilic%2520syndrome%2520and%2520other%2520eosinophilic%2520disorders%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26issue%3D9%26spage%3D3391%26epage%3D3397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Ault, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaled, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate</span> <span class="citation_source-journal">Leukemia Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">881</span><span class="NLM_x">â</span> <span class="NLM_lpage">884</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS0145-2126%2802%2900046-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12127565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsVOmsb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=881-884&issue=9&author=P.+Aultauthor=J.+Cortesauthor=C.+Kollerauthor=E.+S.+Kaledauthor=H.+Kantarjian&title=Response+of+idiopathic+hypereosinophilic+syndrome+to+treatment+with+imatinib+mesylate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate</span></div><div class="casAuthors">Ault, Patricia; Cortes, Jorge; Koller, Charles; Kaled, Elizabeth S.; Kantarjian, Hagop</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">881-884</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Idiopathic hypereosinophilic syndrome (HES) is a rare hematol. disorder characterized by persistent eosinophilia with organ involvement.  Patients with HES have a poor prognosis, but the disease course can be heterogeneous.  Treatment of HES has included corticosteroids, chemotherapeutic agents such as cyclophosphamide, vincristine, hydroxyurea, and most recently interferon-Î± (IFN-Î±) which has shown long-term beneficial effects.  The authors herein report on a patient with HES who had disease resistant to steroids, and chemotherapy with 2-chlorodeoxyadenosine and cytarabine, but who had a significant response after only 8 days of treatment with imatinib mesylate 100 mg daily.  The possible mechanism of response is discussed.  This observation may lead to a better understanding of the pathophysiol. of HES, and may provide a new form of effective therapy for the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9MzLHL00PR7Vg90H21EOLACvtfcHk0limRVg_6DIxCQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsVOmsb8%253D&md5=4893d0e27bbb4a3158d1b4de7e0aba6a</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2FS0145-2126%2802%2900046-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0145-2126%252802%252900046-2%26sid%3Dliteratum%253Aachs%26aulast%3DAult%26aufirst%3DP.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DKaled%26aufirst%3DE.%2BS.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DResponse%2520of%2520idiopathic%2520hypereosinophilic%2520syndrome%2520to%2520treatment%2520with%2520imatinib%2520mesylate%26jtitle%3DLeukemia%2520Res.%26date%3D2002%26volume%3D26%26issue%3D9%26spage%3D881%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Gleich, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiferman, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterfield, J. H.</span><span> </span><span class="NLM_article-title">Treatment of hypereosinophilic syndrome with imatinib mesilate</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x"> (</span><span class="NLM_issue">9317</span><span class="NLM_x">) </span> <span class="NLM_fpage">1577</span><span class="NLM_x">â</span> <span class="NLM_lpage">1578</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2002&pages=1577-1578&issue=9317&author=G.+J.+Gleichauthor=K.+M.+Leifermanauthor=A.+Pardananiauthor=A.+Tefferiauthor=J.+H.+Butterfield&title=Treatment+of+hypereosinophilic+syndrome+with+imatinib+mesilate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGleich%26aufirst%3DG.%2BJ.%26aulast%3DLeiferman%26aufirst%3DK.%2BM.%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DButterfield%26aufirst%3DJ.%2BH.%26atitle%3DTreatment%2520of%2520hypereosinophilic%2520syndrome%2520with%2520imatinib%2520mesilate%26jtitle%3DLancet%26date%3D2002%26volume%3D359%26issue%3D9317%26spage%3D1577%26epage%3D1578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotlib, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stover, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legare, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kutok, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrier, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenberghe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoef, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boogaerts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wlodarska, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marynen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coutre, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">348</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1201</span><span class="NLM_x">â</span> <span class="NLM_lpage">1214</span><div class="note"><p class="first last">[see Comment]</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMoa025217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12660384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVCqtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=1201-1214&issue=13&author=J.+Coolsauthor=D.+J.+DeAngeloauthor=J.+Gotlibauthor=E.+H.+Stoverauthor=R.+D.+Legareauthor=J.+Cortesauthor=J.+Kutokauthor=J.+Clarkauthor=I.+Galinskyauthor=J.+D.+Griffinauthor=N.+C.+Crossauthor=A.+Tefferiauthor=J.+Maloneauthor=R.+Alamauthor=S.+L.+Schrierauthor=J.+Schmidauthor=M.+Roseauthor=P.+Vandenbergheauthor=G.+Verhoefauthor=M.+Boogaertsauthor=I.+Wlodarskaauthor=H.+Kantarjianauthor=P.+Marynenauthor=S.+E.+Coutreauthor=R.+Stoneauthor=D.+G.+Gilliland&title=A+tyrosine+kinase+created+by+fusion+of+the+PDGFRA+and+FIP1L1+genes+as+a+therapeutic+target+of+imatinib+in+idiopathic+hypereosinophilic+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome</span></div><div class="casAuthors">Cools, Jan; Daniel, Ph. D.; DeAngelo, J.; Gotlib, Jason; Stover, Elizabeth H.; Phil, M.; Legare, Robert D.; Cortes, Jorges; Lutok, Jeffrey; Clark, Jennifer; Galinsky, Ilene; Griffin, James D.; Cross, Nicholas, C. P.; Tefferi, Ayalew; Malone, James; Alam, Fafeul; Schrier, Stanley L.; Schmid, Janet; Rose, Michal; Vandenberghe, Peter; Verhoef, Gregor; Boogaerts, Marc; Wlodarska, Iwona; Kantarjian, Hagop; Marynen, Peter; Coutre, Steven E.; Stone, Richard; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1201-1214</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia assocd. with organ dysfunction.  It is of unknown cause.  Recent reports of responses to imatinib in patients with the syndrome suggested that an activated kinase such as ABL, platelet-derived growth factor receptor (PDGFR), or KIT, all of which are inhibited by imatinib, might be the cause.  We treated 11 patients with the hypereosinophilic syndrome with imatinib and identified the mol. basis for the response.  Nine of the 11 patients treated with imatinib had responses lasting more than three months in which the eosinophil count returned to normal.  One such patient had a complex chromosomal abnormality, leading to the identification of a fusion of the Fip1H-like 1 (FIP1L1) gene to the PDGFRÎ± (PDGFRA) gene generated by an interstitial deletion on chromosome 4q12.  FIP1L1-PDGFRÎ± is a constitutively activated tyrosine kinase that transforms hematopoietic cells and is inhibited by imatinib (50% inhibitory concn., 3.2 nM).  The FIP1L1-PDGFRA fusion gene was subsequently detected in 9 of 16 patients with the syndrome and in 5 of the 9 patients with responses to imatinib that lasted more than three months.  Relapse in one patient correlated with the appearance of a T674I mutation in PDGFRA that confers resistance to imatinib.  The hypereosinophilic syndrome may result from a novel fusion tyrosine kinase-FIP1L1-PDGFRÎ±-that is a consequence of an interstitial chromosomal deletion.  The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRÎ± is the target of imatinib.  Our data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ae4JFIom8LVg90H21EOLACvtfcHk0lgMIeGH2Pbtgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVCqtrY%253D&md5=1f0cc5760c701bf0ae35bcb7c0727d65</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa025217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa025217%26sid%3Dliteratum%253Aachs%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DGotlib%26aufirst%3DJ.%26aulast%3DStover%26aufirst%3DE.%2BH.%26aulast%3DLegare%26aufirst%3DR.%2BD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKutok%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DCross%26aufirst%3DN.%2BC.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DMalone%26aufirst%3DJ.%26aulast%3DAlam%26aufirst%3DR.%26aulast%3DSchrier%26aufirst%3DS.%2BL.%26aulast%3DSchmid%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DM.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DVerhoef%26aufirst%3DG.%26aulast%3DBoogaerts%26aufirst%3DM.%26aulast%3DWlodarska%26aufirst%3DI.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMarynen%26aufirst%3DP.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DA%2520tyrosine%2520kinase%2520created%2520by%2520fusion%2520of%2520the%2520PDGFRA%2520and%2520FIP1L1%2520genes%2520as%2520a%2520therapeutic%2520target%2520of%2520imatinib%2520in%2520idiopathic%2520hypereosinophilic%2520syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26issue%3D13%26spage%3D1201%26epage%3D1214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ERBB receptors and cancer: the complexity of targeted inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">341</span><span class="NLM_x">â</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&issue=5&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lgMIeGH2Pbtgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26issue%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Dowell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">Chasing mutations in the epidermal growth factor in lung cancer</span> <span class="citation_source-journal">New Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">830</span><span class="NLM_x">â</span> <span class="NLM_lpage">832</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1056%2FNEJMe058033" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2007&pages=830-832&author=J.+E.+Dowellauthor=J.+D.+Minna&title=Chasing+mutations+in+the+epidermal+growth+factor+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1056%2FNEJMe058033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe058033%26sid%3Dliteratum%253Aachs%26aulast%3DDowell%26aufirst%3DJ.%2BE.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DChasing%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520in%2520lung%2520cancer%26jtitle%3DNew%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D352%26spage%3D830%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reily, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_elocation-id">e73</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&issue=3&author=W.+Paoauthor=K.+A.+Politiauthor=G.+I.+Reilyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DReily%26aufirst%3DG.%2BI.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Nat. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">â</span> <span class="NLM_lpage">7670</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1073%2Fpnas.0502860102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15897464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span></div><div class="casAuthors">Kwak, Eunice L.; Sordella, Raffaella; Bell, Daphne W.; Godin-Heymann, Nadia; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Driscoll, David R.; Fidias, Panos; Lynch, Thomas J.; Rabindran, Sridhar K.; McGinnis, John P.; Wissner, Allan; Sharma, Sreenath V.; Isselbacher, Kurt J.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7665-7670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva).  Some recurrent tumors have a common secondary mutation in the EGFR kinase domain, T790M, conferring drug resistance, but in other cases the mechanism underlying acquired resistance is unknown.  In studying multiple sites of recurrent NSCLCs, the authors detected T790M in only a small percentage of tumor cells.  To identify addnl. mechanisms of acquired resistance to gefitinib, the authors used NSCLC cells harboring an activating EGFR mutation to generate multiple resistant clones in vitro.  These drug-resistant cells demonstrate continued dependence on EGFR and ERBB2 signaling for their viability and have not acquired secondary EGFR mutations.  However, they display increased internalization of ligand-activated EGFR, consistent with altered receptor trafficking.  Although gefitinib-resistant clones are cross-resistant to related anilinoquinazolines, they demonstrate sensitivity to a class of irreversible inhibitors of EGFR.  These inhibitors also show effective inhibition of signaling by T790M-mutant EGFR and killing of NSCLC cells with the T790M mutation.  Both mechanisms of gefitinib resistance are therefore circumvented by irreversible tyrosine kinase inhibitors.  Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5BSM8yaZe7Vg90H21EOLACvtfcHk0lhd6HdH5PEOCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D&md5=f3fb866c3673fd4dff8a3f0a8c9be65b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502860102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502860102%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Nat.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Kumar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petri, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span> </span><span class="NLM_article-title">Structure and clinical relevance fo the epidermal growth factor receptor in human cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">1742</span><span class="NLM_x">â</span> <span class="NLM_lpage">1751</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1200%2FJCO.2007.12.1178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18375904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWhs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=1742-1751&issue=10&author=A.+Kumarauthor=E.+T.+Petriauthor=B.+Halmosauthor=T.+J.+Boggon&title=Structure+and+clinical+relevance+fo+the+epidermal+growth+factor+receptor+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and clinical relevance of the epidermal growth factor receptor in human cancer</span></div><div class="casAuthors">Kumar, Amit; Petri, Edward T.; Halmos, Balazs; Boggon, Titus J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1742-1751</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To review the recent advances in the at.-level understanding of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK).  We aim to highlight the current and future importance of these studies for the understanding and treatment of malignancies where EGFR-TK is improperly activated.  Methods: The anal. was conducted on published crystal structures deposited in the Protein Data Bank (www.pdb.org) using the program O.  Results: In this review we emphasize how recent EGFR kinase domain crystal structures can explain the mechanisms of activation for L858R and other EGFR-TK mutations, and compare these distinct activating mechanisms with those recently described for the wild-type EGFR.  We suggest an at.-level mechanism for the poor efficacy of lapatinib against tumors with activating EGFR kinase domain point mutations compared with the efficacy of gefitinib and erlotinib, and demonstrate how structural insights help our understanding of acquired resistance to these agents.  We also highlight how these new mol.-level structural data are expected to affect the development of EGFR-TK targeted small mol. kinase inhibitors.  Conclusion: There are now more crystal structures published for the EGFR-TK domain than for any other TK.  This wealth of crystallog. information is beginning to describe the mechanisms by which proper regulation of EGFR-TK is lost in disease.  These crystal structures are beginning to show how small mols. inhibit EGFR-TK activity and will aid development of EGFR-TK mutant targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7kmKpTtoyyLVg90H21EOLACvtfcHk0lhd6HdH5PEOCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWhs7w%253D&md5=c0879a268b217c8d32573c36c08b9aa0</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1200%2FJCO.2007.12.1178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2007.12.1178%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DPetri%26aufirst%3DE.%2BT.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26atitle%3DStructure%2520and%2520clinical%2520relevance%2520fo%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520human%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26issue%3D10%26spage%3D1742%26epage%3D1751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x"> (</span><span class="NLM_issue">48</span><span class="NLM_x">) </span> <span class="NLM_fpage">46265</span><span class="NLM_x">â</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&issue=48&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Ã resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0lhd6HdH5PEOCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26issue%3D48%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Michalczyk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baviller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">3482</span><span class="NLM_x">â</span> <span class="NLM_lpage">3488</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3482-3488&issue=7&author=A.+Michalczykauthor=S.+Kluterauthor=H.+B.+Rodeauthor=J.+R.+Simardauthor=C.+Grutterauthor=M.+Bavillerauthor=D.+Rauh&title=Structural+insights+into+how+irreversible+inhibitors+can+overcome+drug+resistance+in+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMichalczyk%26aufirst%3DA.%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DBaviller%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStructural%2520insights%2520into%2520how%2520irreversible%2520inhibitors%2520can%2520overcome%2520drug%2520resistance%2520in%2520EGFR%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26issue%3D7%26spage%3D3482%26epage%3D3488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">The development of HKI-272 and related compounds for the treatment of cancer</span> <span class="citation_source-journal">Arch. Pharm. Chem. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">â</span> <span class="NLM_lpage">477</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1002%2Fardp.200800009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18493974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2008&pages=465-477&author=A.+Wissnerauthor=T.+S.+Mansour&title=The+development+of+HKI-272+and+related+compounds+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">The development of HKI-272 and related compounds for the treatment of cancer</span></div><div class="casAuthors">Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">465-477</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The development of HKI-272 and EKB-569 for the treatment of cancer is described.  These compds. function as irreversible inhibitors of some members of the ErbB family of receptor tyrosine kinases.  In particular, they target epidermal growth factor receptor (EGFR, also known as ErbB-1) and human epidermal growth factor receptor-2 (HER2, also known as ErbB-2).  Both, HKI-272 and EKB-569 are 4-anilino-3-cyano quinoline derivs. that contain a 4-(dimethylamino)crotonamide Michael-acceptor group at the 6-position.  These compds. inhibit the function of the target enzymes by forming a covalent interaction with a conserved cysteine residue located in the kinase domains of these proteins.  The potential advantages of using irreversible inhibitors for this purpose are discussed.  We summarize the recent findings concerning some somatic mutations in EGFR and their relevance with respect to the irreversible inhibitors.  In particular, we highlight the findings that these irreversible inhibitors retain activity against tumors that have acquired a resistance to the reversible binding inhibitors gefitinib and erlotinib.  The promising interim clin. trial results for HKI-272 and EKB-569 in treating colon, lung, and breast cancers are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCSokM42ZhprVg90H21EOLACvtfcHk0li6PHPRtFHAMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKnsb7E&md5=2e46d99ca74e297e6a7e860634bf096d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fardp.200800009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.200800009%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DThe%2520development%2520of%2520HKI-272%2520and%2520related%2520compounds%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DArch.%2520Pharm.%2520Chem.%2520Life%2520Sci.%26date%3D2008%26volume%3D341%26spage%3D465%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">HKI-272 in non-small cell lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4593</span><span class="NLM_x">â</span> <span class="NLM_lpage">4596</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1158%2F1078-0432.CCR-07-0369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=17671147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlKjsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4593-4596&author=K.-K.+Wong&title=HKI-272+in+non-small+cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">HKI-272 in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15, Pt. 2</span>),
    <span class="NLM_cas:pages">4593s-4596s</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Somatic mutations in the kinase domain of the epidermal growth factor receptor (EGFR) gene are found in â¼10% of lung adenocarcinomas sequenced in the United States and in â¼30% sequenced in Asia.  These mutations are assocd. with sensitivity to the EGFR inhibitors gefitinib and erlotinib.  Many patients who initially respond to erlotinib or gefitinib subsequently relapse.  Studies have identified EGFR T790M mutations in tumors from patients who initially responded and then relapsed.  The T790M mutation, when combined in vitro with treatment-sensitizing EGFR mutations, permits the continued growth of tumor cells in the presence of erlotinib and gefitinib.  HKI-272 is an irreversible EGFR/HER/ErbB inhibitor that has been shown to inhibit the growth of T790M mutant cells in vitro in human lung cancer cell lines and in murine cells transfected with sensitizing EGFR mutations.  A phase I HKI-272 monotherapy trial in patients with solid tumors is close to completion.  Preliminary analyses of the trial, presented at the 2006 annual meeting of American Society of Clin. Oncol., showed that HKI-272 can achieve stable disease control for over 6 mo in some patients with non-small cell lung cancer that has progressed after treatment with gefitinib or erlotinib.  A phase II trial of HKI-272 in non-small cell lung cancer patients has been initiated.  HKI-272 might offer benefits to non-small cell lung cancer patients who have relapsed after an initial response to erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk5KWthnzz7LVg90H21EOLACvtfcHk0li6PHPRtFHAMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlKjsrw%253D&md5=24d09e44614f8286aa7b590ee86320e0</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0369%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DHKI-272%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4593%26epage%3D4596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">â</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS0163-7258%2802%2900194-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12191617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=253-261&author=W.+A.+Denny&title=Irreversible+inhibitors+of+the+erbB+family+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span></div><div class="casAuthors">Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">253-261</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The erbB family of transmembrane receptor tyrosine kinases initiates a large no. of cellular signaling pathways.  Their over-expression in human tumors correlates with poor prognosis, and they have become important targets for drug development.  The 4-anilinoquinazolines are potent and selective ATP site inhibitors of these enzymes, esp. erbB1 (epidermal growth factor receptor).  Structure-activity studies for binding at the ATP site are narrow, consistent with homol. and crystal structure-binding models.  Combinations of small lipophilic groups at the 3'-position of the aniline and electron-donating groups at the 6- or 7-positions of the quinazoline result in extremely potent (picomolar) reversible inhibitors, several of which are in clin. trial.  Observation that the erbB family of enzymes contains a unique Cys residue (Cys773) close to the ATP-binding site prompted the development of irreversible inhibitors, the most successful being 6-acrylamides and related butynamides, which show significantly improved in vivo antitumor activity compared with closely related reversibly binding compds.  Solubilizing side chains can be placed either at the terminus of the alkylating unit or at the quinazoline C-7, and examples of both types are in clin. trial.  Both reversible and irreversible inhibitors synergize with a variety of DNA-damaging anticancer drugs, and it is likely that the greatest impact of these agents will be in combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwN71GFZA09rVg90H21EOLACvtfcHk0li6PHPRtFHAMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D&md5=7937e2efbf606734ae781554e7c26d15</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900194-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900194-8%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520erbB%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D93%26spage%3D253%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Bridges, A. J.</span><span> </span><span class="NLM_article-title">The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">825</span><span class="NLM_x">â</span> <span class="NLM_lpage">843</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFWqtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1999&pages=825-843&author=A.+J.+Bridges&title=The+rationale+and+strategy+used+to+develop+a+series+of+highly+potent%2C+irreversible%2C+inhibitors+of+the+epidermal+growth+factor+receptor+family+of+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the Epidermal Growth Factor receptor family of tyrosine kinases</span></div><div class="casAuthors">Bridges, A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">825-843</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review with 122 refs.  The Epidermal Growth Factor receptor (EGFr) was one of the first oncogenes identified, and it, or its ligands Epidermal Growth Factor (EGF) and Transforming Growth Factor Î± (TGFÎ±) are overexpressed in most clin. tumors.  As EGF and TGFÎ± are potent mitogens, it appeared that inhibition of EGFr signaling would be a viable anti-proliferative strategy.  Screening found several classes of EGFr inhibitor, one of which, the indolinethiones was developed.  The SAR, in common with that of other first generation tyrosine kinase (TK) inhibitors was flat, and potency was poor.  Rescreening in presence of a thiol, to remove chem. reactive species, identified only two leads, a pyridopyrimidine and a quinazoline.  These were developed into a very broad class of EGFr inhibitors, with great potency and selectivity for EGFr, but poor physicochem. properties, and little if any in vivo anti-tumor activity.  Meanwhile the complex role of other members of the EGFr TK family in oncogenesis, was becoming apparent, suggesting that the whole EGFr family should be inhibited.  The difficulty of finding potent compds. with acceptable pharmacokinetics also suggested that irreversible inhibitors of the TK might produce better in vivo profiles.  Modeling suggested that the unusual Cys773 residue might be reached from the 6/7-positions of quinazoline and pyridopyrimidine inhibitors.  Inhibitors with acrylamides at these positions proved to be irreversible alkylating agents for both EGFr and erbB-2 with cellular inhibitory activities in the low nanomolar range, and very potent in vivo antitumor activity.  Optimized inhibitors had exceptionally potent oral antitumor activity, with negligible cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCfxlExE175LVg90H21EOLACvtfcHk0li6PHPRtFHAMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFWqtb8%253D&md5=36f387aecf4c6e676591383bf25a10ca</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520rationale%2520and%2520strategy%2520used%2520to%2520develop%2520a%2520series%2520of%2520highly%2520potent%252C%2520irreversible%252C%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520family%2520of%2520tyrosine%2520kinases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D1999%26volume%3D6%26spage%3D825%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span> </span><span class="NLM_article-title">4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor (EGF-R) kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3244</span><span class="NLM_x">â</span> <span class="NLM_lpage">3256</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000206a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3244-3256&author=A.+Wissnerauthor=D.+M.+Bergerauthor=D.+H.+Boschelliauthor=M.+B.+J.+Floydauthor=L.+M.+Greenbergerauthor=B.+C.+Gruberauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=R.+Nilakantanauthor=M.+F.+Reichauthor=R.+Shenauthor=H.-R.+Tsouauthor=E.+Upeslacisauthor=Y.-F.+Wangauthor=B.+Wuauthor=F.+Yeauthor=N.+Zhang&title=4-Anilino-6%2C7-dialkoxyquinoline-3-carbonitrile+inhibitors+of+epidermal+growth+factor+receptor+%28EGF-R%29+kinase+and+their+bioisosteric+relationship+to+the+4-anilino-6%2C7-dialkoxyquinazoline+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fjm000206a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000206a%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DD.%2BM.%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%2BJ.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DUpeslacis%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DN.%26atitle%3D4-Anilino-6%252C7-dialkoxyquinoline-3-carbonitrile%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGF-R%2529%2520kinase%2520and%2520their%2520bioisosteric%2520relationship%2520to%2520the%25204-anilino-6%252C7-dialkoxyquinazoline%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3244%26epage%3D3256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x"> (</span><span class="NLM_issue">34</span><span class="NLM_x">) </span> <span class="NLM_fpage">4702</span><span class="NLM_x">â</span> <span class="NLM_lpage">4711</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&issue=34&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+G.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=M.+Solcaauthor=H.+Greulichauthor=K.-K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BG.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DM.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26issue%3D34%26spage%3D4702%26epage%3D4711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">2070</span><span class="NLM_x">â</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&issue=6&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lg0RAnfhCqugg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26issue%3D6%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Chemical Approaches for Making âInactive-Conformationâ Kinase Inhibitors</span>. Presented at the 236th National Meeting of the American Chemical Society, Philadelphia, PA,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=N.+S.+Gray&title=Chemical+Approaches+for+Making+%E2%80%9CInactive-Conformation%E2%80%9D+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DChemical%2520Approaches%2520for%2520Making%2520%25E2%2580%259CInactive-Conformation%25E2%2580%259D%2520Kinase%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Gajiwala, K. S.; Wu, J.; Lunney, E.; Demetri, G.</span><span> </span><span class="NLM_article-title">Novel Mechanisms of Drug Resistance in KIT Mutants from Patients with Gastrointestinal Stromal Tumors: Structural Biology of Wild-Type and Mutated Proteins</span>. Presented at the 236th National Meeting of the American Chemical Society, Philadelphia, PA,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=K.+S.+Gajiwala&author=J.+Wu&author=E.+Lunney&author=G.+Demetri&title=Novel+Mechanisms+of+Drug+Resistance+in+KIT+Mutants+from+Patients+with+Gastrointestinal+Stromal+Tumors%3A+Structural+Biology+of+Wild-Type+and+Mutated+Proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26atitle%3DNovel%2520Mechanisms%2520of%2520Drug%2520Resistance%2520in%2520KIT%2520Mutants%2520from%2520Patients%2520with%2520Gastrointestinal%2520Stromal%2520Tumors%253A%2520Structural%2520Biology%2520of%2520Wild-Type%2520and%2520Mutated%2520Proteins%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Zunder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houseman, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apsel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110alpha</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">180</span><span class="NLM_x">â</span> <span class="NLM_lpage">192</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=180-192&author=E.+R.+Zunderauthor=Z.+A.+Knightauthor=B.+T.+Housemanauthor=B.+Apselauthor=K.+M.+Shokat&title=Discovery+of+drug-resistant+and+drug-sensitizing+mutations+in+the+oncogenic+PI3K+isoform+p110alpha"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DHouseman%26aufirst%3DB.%2BT.%26aulast%3DApsel%26aufirst%3DB.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DDiscovery%2520of%2520drug-resistant%2520and%2520drug-sensitizing%2520mutations%2520in%2520the%2520oncogenic%2520PI3K%2520isoform%2520p110alpha%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D14%26spage%3D180%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Latek, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR_ABL</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">831</span><span class="NLM_x">â</span> <span class="NLM_lpage">843</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2003&pages=831-843&author=M.+Azamauthor=R.+R.+Latekauthor=G.+Q.+Daley&title=Mechanisms+of+autoinhibition+and+STI-571%2Fimatinib+resistance+revealed+by+mutagenesis+of+BCR_ABL"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DLatek%26aufirst%3DR.%2BR.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DMechanisms%2520of%2520autoinhibition%2520and%2520STI-571%252Fimatinib%2520resistance%2520revealed%2520by%2520mutagenesis%2520of%2520BCR_ABL%26jtitle%3DCell%26date%3D2003%26volume%3D112%26spage%3D831%26epage%3D843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">von Bubnoff, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Kuip, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulitzky, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sander, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seipel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peschel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duyster, J.</span><span> </span><span class="NLM_article-title">A cell-based screeen for resistance of Bcr-Abl-positive leukemia identieifs the mutation pattern for PD166326, an alternative Abl kinase inhibitor</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">1652</span><span class="NLM_x">â</span> <span class="NLM_lpage">1659</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=1652-1659&author=N.+von+Bubnoffauthor=D.+R.+Veachauthor=H.+van+der+Kuipauthor=W.+E.+Aulitzkyauthor=J.+Sanderauthor=P.+Seipelauthor=W.+G.+Bornmannauthor=C.+Peschelauthor=B.+Clarksonauthor=J.+Duyster&title=A+cell-based+screeen+for+resistance+of+Bcr-Abl-positive+leukemia+identieifs+the+mutation+pattern+for+PD166326%2C+an+alternative+Abl+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BBubnoff%26aufirst%3DN.%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3Dvan%2Bder%2BKuip%26aufirst%3DH.%26aulast%3DAulitzky%26aufirst%3DW.%2BE.%26aulast%3DSander%26aufirst%3DJ.%26aulast%3DSeipel%26aufirst%3DP.%26aulast%3DBornmann%26aufirst%3DW.%2BG.%26aulast%3DPeschel%26aufirst%3DC.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DDuyster%26aufirst%3DJ.%26atitle%3DA%2520cell-based%2520screeen%2520for%2520resistance%2520of%2520Bcr-Abl-positive%2520leukemia%2520identieifs%2520the%2520mutation%2520pattern%2520for%2520PD166326%252C%2520an%2520alternative%2520Abl%2520kinase%2520inhibitor%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D1652%26epage%3D1659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Girdler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sessa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patercoli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musacchoi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span> </span><span class="NLM_article-title">Molecular basis of drug resistance in Aurora kinases</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">552</span><span class="NLM_x">â</span> <span class="NLM_lpage">562</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2Fj.chembiol.2008.04.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=18559266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1alurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=552-562&issue=6&author=F.+Girdlerauthor=F.+Sessaauthor=S.+Patercoliauthor=F.+Villaauthor=A.+Musacchoiauthor=S.+Taylor&title=Molecular+basis+of+drug+resistance+in+Aurora+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis of Drug Resistance in Aurora Kinases</span></div><div class="casAuthors">Girdler, Fiona; Sessa, Fabio; Patercoli, Simona; Villa, Fabrizio; Musacchio, Andrea; Taylor, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">552-562</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Aurora kinases have emerged as potential targets in cancer therapy, and several drugs are currently undergoing preclin. and clin. validation.  Whether clin. resistance to these drugs can arise is unclear.  The authors exploited a hypermutagenic cancer cell line to select mutations conferring resistance to a well-studied Aurora inhibitor, ZM447439.  All resistant clones contained dominant point mutations in Aurora B.  Three mutations map to residues in the ATP-binding pocket that are distinct from the "gatekeeper" residue.  The mutants retain wild-type catalytic activity and were resistant to all of the Aurora inhibitors tested.  The studies predict that drug-resistant Aurora B mutants are likely to arise during clin. treatment.  Furthermore, because the plasticity of the ATP-binding pocket renders Aurora B insensitive to multiple inhibitors, the observations indicate that the drug-resistant Aurora B mutants should be exploited as novel drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRp7zrCOdSOrVg90H21EOLACvtfcHk0lioZPhMOsRp2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1alurg%253D&md5=f272cd07a8371961b728c410ee987b1a</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.04.013%26sid%3Dliteratum%253Aachs%26aulast%3DGirdler%26aufirst%3DF.%26aulast%3DSessa%26aufirst%3DF.%26aulast%3DPatercoli%26aufirst%3DS.%26aulast%3DVilla%26aufirst%3DF.%26aulast%3DMusacchoi%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DS.%26atitle%3DMolecular%2520basis%2520of%2520drug%2520resistance%2520in%2520Aurora%2520kinases%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26issue%3D6%26spage%3D552%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Project, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of b-Raf</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">â</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+G.+Projectauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+b-Raf"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lioZPhMOsRp2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DProject%26aufirst%3DC.%2BG.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520b-Raf%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailtland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the BRAF gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">â</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Fjm8010542&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Fjm8010542&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Fjm8010542&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Mailtlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lioZPhMOsRp2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMailtland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GQG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GQG','PDB','2GQG'); return false;">PDB: 2GQG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1IEP','PDB','1IEP'); return false;">PDB: 1IEP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QOH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QOH','PDB','2QOH'); return false;">PDB: 2QOH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z60" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z60','PDB','2Z60'); return false;">PDB: 2Z60</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK','PDB','1XKK'); return false;">PDB: 1XKK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV','PDB','2JIV'); return false;">PDB: 2JIV</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm8010542&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Fjm8010542%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2009.52.issue-6" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm8010542" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a736dcefc238c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
